研究者基本情報

• 博士(薬学), 北海道大学

• https://researchmap.jp/read0073955

• https://jglobal.jst.go.jp/detail?JGLOBAL_ID=200901069601066929

• 200901069601066929

• 生物薬剤学
• 薬物動態学

• ライフサイエンス, 医療薬学

• 学士課程, 薬学部
• 修士課程, 生命科学院
• 博士課程, 生命科学院

研究活動情報

• Linezolid-Induced Serotonin Release from QGP-1 Cells.
  Takezo Tsutsumi; Hitoshi Kashiwagi; Shungo Imai; Yuki Sato; Shunsuke Nashimoto; Mitsuru Sugawara; Yoh Takekuma
  Drug research, 2026年03月02日, ［国際誌］
  英語, 研究論文（学術雑誌）, Nausea and vomiting are commonly reported side effects of long-term linezolid therapy, which is indispensable for tuberculosis and osteoarticular infections. Since the mechanism underlying the development of nausea and vomiting during linezolid treatment is unknown, this study aimed to explore the mechanisms by focusing on the monoamine oxidase-inhibiting effect of linezolid.In vitro serotonin release assays were performed using QGP-1 cells as a surrogate for enterochromaffin cells exposed to linezolid, the monoamine oxidase inhibitor clorgyline, and the known emetogenic agent cisplatin. Serotonin concentrations in the solutions were measured using an enzyme-linked immunosorbent assay. Clorgyline and cisplatin were administered simultaneously with linezolid to elucidate the serotonin release mechanism and confirm the synergistic effects. The intracellular Ca2+assays using Fura‑2 were also performed to assess whether serotonin release is mediated by Ca2+‑dependent exocytosis.Linezolid exposure significantly increased serotonin release from QGP-1 cells in concentration- and time-dependent manners. Serotonin release also increased in the clorgyline exposure group, and the release of serotonin in the linezolid/clorgyline co-exposure group was higher than that in the single-exposure groups. In contrast, no significant serotonin release or synergistic effects were observed in the cisplatin/linezolid-exposed groups. The Ca2+assays demonstrated that linezolid exposure did not change intracellular Ca2+levels.Serotonin release was observed when QGP-1 cells were exposed to linezolid, an effect similar to that observed with the potent monoamine oxidase A inhibitor clorgyline. Furthermore, the Ca2+assays indicated that linezolid‑induced serotonin release occurs independently of Ca2+‑dependent exocytosis.
• Impact of baseline regular magnesium oxide administration on chemotherapy-induced constipation during cisplatin-containing treatment.
  Yoshitaka Saito; Yoh Takekuma; Jun Sakakibara-Konishi; Yasushi Shimizu; Ichiro Kinoshita; Mitsuru Sugawara
  International journal of clinical oncology, 31, 2, 336, 346, 2026年02月, ［国内誌］
  英語, 研究論文（学術雑誌）, PURPOSE: Chemotherapy-induced constipation frequently occurs with cisplatin-containing treatments, partly because of concomitant neurokinin 1 and serotonin 3 receptor antagonists. We have clinically observed that patients with baseline regular laxative administration, most of whom were on magnesium oxide, exhibited less chemotherapy-induced constipation than those without, and assessed its impact on symptom development in real-world cisplatin-containing treatment. METHODS: Patients with lung cancer receiving cisplatin-containing treatment (n = 240) were divided into a control group without baseline laxative administration and a magnesium group with baseline regular magnesium oxide administration and retrospectively evaluated. The primary endpoint was evaluation of the incidence of grade ≥ 2 constipation during the first 7 days following treatment initiation. RESULTS: Incidence of grade ≥ 2 constipation was 82.5% in the control group and 50.0% in the magnesium group, which was significantly less in the magnesium group (P < 0.0001). The incidence of all-grade symptoms was also significantly lower in the magnesium group than in the control group (67.5% vs. 84.5%, P = 0.02). Additionally, the administration of new laxatives was less common in the magnesium group (P = 0.007). Multivariable logistic regression analysis suggested that baseline administration of magnesium oxide is a preventive factor for grade ≥ 2 constipation. Furthermore, patients receiving 2 g daily magnesium oxide at baseline developed significantly less grade ≥ 2 constipation than those with < 2 g (19.1% and 84.2%, respectively, P < 0.0001). CONCLUSION: The present study suggests that patients with baseline regular magnesium oxide administration exhibit less chemotherapy-induced constipation than those without the administration in cisplatin-containing treatments.
• Evaluating the potential to predict chemotherapy-induced nausea and vomiting in carboplatin-containing treatment based on symptoms induced by prior cisplatin-containing treatment.
  Yoshitaka Saito; Takuya Watanabe; Yoh Takekuma; Jun Sakakibara-Konishi; Yasushi Shimizu; Ichiro Kinoshita; Mitsuru Sugawara
  Scientific reports, 16, 1, 5817, 5817, 2026年01月20日, ［国際誌］
  英語, 研究論文（学術雑誌）, Chemotherapy-induced nausea and vomiting (CINV) is a serious adverse effect of cisplatin (CDDP)- and carboplatin (CBDCA)-containing treatments. In this study, we aimed to assess the potential to predict CINV in subsequent CBDCA-containing chemotherapy based on symptoms induced by prior CDDP-containing treatments. Patients with thoracic cancer who received CDDP followed by CBDCA treatments (n = 52) were divided into a control group, including patients with total control (TC) of CINV during prior CDDP-containing treatment period, and a CINV-experience group, including patients who did not achieve TC of CINV during the CDDP-containing treatment period. Patients were retrospectively evaluated. The TC rates during all evaluation periods (0-120 h) were significantly lower in the CINV-experience group than in the control group (45.5% and 86.7%, respectively, P = 0.002), which met the primary endpoint. The incidence rates of all-grade nausea and anorexia were also significantly higher in the CINV-experience group. In conclusion, our study suggests that CINV prediction in subsequent CBDCA-containing treatment based on the symptoms induced by prior CDDP-containing treatment is achievable.
• Preventive effect of hot compress on phlebitis during cisplatin and Vinorelbine treatment for non-small cell lung cancer.
  Osamu Taniguchi; Yoshitaka Saito; Tatsuhiko Sakamoto; Jun Sakakibara-Konishi; Yoh Takekuma; Mitsuru Sugawara
  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 34, 2, 107, 107, 2026年01月19日, ［国際誌］
  英語, 研究論文（学術雑誌）, BACKGROUND: Vinorelbine (VNR) is a key chemotherapeutic agent for treating non-small cell lung cancer (NSCLC). However, peripheral venous administration frequently induces phlebitis in 20-50% of patients. A previous study showed that applying a hot compress during VNR was effective in patients who had already developed symptoms. Therefore, this method was applied to all patients receiving VNR via peripheral venous administration at Hokkaido University Hospital. Herein, we aimed to evaluate the prophylactic efficacy of hot compresses for VNR-induced phlebitis in real-world settings. METHODS: Patients with NSCLC who received cisplatin (CDDP) + VNR (n = 92) were retrospectively evaluated. Patients were divided into a hot compress group, which included patients who received hot compresses during VNR administration, and a control group that did not receive hot compresses. The primary endpoint was the frequency of phlebitis during the first cycle between the groups. RESULTS: Hot compress significantly reduced the frequency of phlebitis during the first cycle (47.3% and 18.9% in the control and hot compress groups, respectively; P = 0.008) and on day 8 of the first cycle (38.2% and 10.8%; P = 0.004), with primary endpoint accomplishment. Furthermore, symptom reduction using hot compresses was confirmed among patients who received VNR on day 8 via a different arm from that administered on day 1 (31.6% vs. 3.0%, P = 0.002). Additionally, the onset of the first occurrence of VNR-induced phlebitis was significantly delayed (P = 0.008). CONCLUSION: Hot compresses significantly reduced the frequency of VNR-induced phlebitis in patients with NSCLC receiving CDDP + VNR.
• Successful re-administration after nano-liposomal irinotecan-induced severe hypersensitivity reaction: a case report.
  Ryota Kanno; Yoshitaka Saito; Yoh Takekuma; Kazuaki Harada; Yoshito Komatsu; Mitsuru Sugawara
  Journal of pharmaceutical health care and sciences, 11, 1, 110, 110, 2025年12月22日, ［国際誌］
  英語, 研究論文（学術雑誌）, BACKGROUND: Nano-liposomal irinotecan (nal-IRI) combined with 5-fluorouracil (5-FU) and levofolinate has been reported to extend the survival of patients with pancreatic cancer and represents an effective second-line treatment. Nal-IRI encapsulates IRI in liposomes modified with polyethylene glycol (PEGylation), which can lead to infusion reactions. Hypersensitivity reactions (HSR) to chemotherapeutic agents include both allergic and infusion reactions, which are difficult to distinguish. Severe HSR can be fatal; however, discontinuation of the suspected drug directly affects the treatment strategy. We report a case of severe HSR during the first nal-IRI administration, in which treatment was successfully continued with supportive management. CASE PRESENTATION: A woman in her early 80s with metastatic pancreatic cancer received nal-IRI + 5-FU + levofolinate as second-line treatment. Five minutes after the initiation of the first nal-IRI infusion, the patient developed a tightening sensation in the head, respiratory distress, convulsions, and loss of consciousness, with percutaneous oxygen saturation dropping to the 80% range. The nal-IRI infusion was immediately discontinued, and emergency management was initiated with intravenous infusion of hydrocortisone, famotidine, d-chlorpheniramine maleate, and oxygen administration, resulting in symptom improvement. Given the limited treatment options for metastatic pancreatic cancer and the patient's strong desire to continue therapy, we decided to re-administer the regimen with intensified management, increasing dexamethasone to 19.8 mg and adding famotidine 20 mg and d-chlorpheniramine maleate 5 mg. Furthermore, we adopted a three-step dose-escalation method. The infusion was started at one-third of the standard rate, increased to two-thirds after 30 min, and finally adjusted to the full rate after another 30 min, after confirming the absence of HSR symptoms. Consequently, the patient did not exhibit any signs of HSR, and the same administration method was continued for 11 cycles until disease progression. CONCLUSIONS: The novelty of this report lies in presenting, for the first time, the detailed course and process by which treatment was successfully continued in a patient experiencing severe HSR upon initial nal-IRI administration, through enhanced supportive care tailored to the characteristics of the drug and stepwise dose adjustment.
• Corrigendum to "Quantitative analysis of communication changes in online medication counseling using the Roter Interaction System" [Res Soc Adm Pharm 20 (2024) 36-42].
  Ayako Mori; Izumi Kato; Katsuya Narumi; Yoh Takekuma; Hitoshi Kashiwagi; Yuki Sato; Mitsuru Sugawara; Masaki Kobayashi
  Research in social & administrative pharmacy : RSAP, 2025年12月19日, ［国際誌］
  英語
• Evaluation of factors associated with clinically problematic hiccups in cisplatin-containing treatment with dexamethasone and neurokinin 1 receptor antagonists.
  Yoshitaka Saito; Yoh Takekuma; Jun Sakakibara-Konishi; Yasushi Shimizu; Ichiro Kinoshita; Mitsuru Sugawara
  International journal of clinical oncology, 30, 12, 2504, 2511, 2025年12月, ［査読有り］, ［最終著者］, ［国内誌］
  英語, 研究論文（学術雑誌）, BACKGROUND: Chemotherapy-induced hiccups are one of the frequently appearing adverse events. Previous reports have suggested that cisplatin (CDDP) combined with dexamethasone and neurokinin 1 (NK1) receptor antagonists is particularly associated with these symptoms. Consequently, we aimed to identify additional factors involved in the development of problematic hiccups during the real-world treatment. METHODS: Patients with thoracic cancer first receiving CDDP-containing treatment (≥ 75 mg/m2) with dexamethasone, palonosetron, and aprepitant were retrospectively assessed (n = 286). The primary endpoint was the evaluation of risk factors for grade ≥ 2 hiccups during the first cycle. Secondary endpoints were the evaluation of factors for all-grade symptoms and the efficacy of rescue medication. RESULTS: The incidence of grade ≥ 2 hiccups was 32.9%, with all-grade symptoms of 44.8%. Grade 3 severe hiccups were observed in 5.2% of the patients. Most patients (96.8%) received metoclopramide as first-line treatment, and the efficacy of the first medication was confirmed in 59.6% of patients. Multivariate logistic regression analyses identified male sex, baseline hypoalbuminemia, and concomitant bevacizumab as significant risk factors for grade ≥ 2 problematic hiccups (adjusted odds ratio with 95% confidence interval 10.32 [4.38-24.32], P < 0.0001 for males; 2.41 [1.06-5.50], P = 0.04 for hypoalbuminemia; and 3.42 [1.25-9.36], P = 0.02 for concomitant bevacizumab). Moreover, male sex was identified as a singular risk factor for all-grade symptoms (7.94 [4.14-15.22], P < 0.0001). CONCLUSION: Our study revealed that male sex, hypoalbuminemia, and concomitant bevacizumab use were significant risk factors for clinically problematic hiccups in patients receiving CDDP-containing treatment along with dexamethasone and NK1 receptor inhibitors for thoracic cancer.
• 睡眠薬使用に関する院内ガイドライン改訂に合わせた不眠時指示薬変更の効果
  熊井 正貴; 金森 怜; 植田 孝介; 沖 洋充; 武隈 洋; 菅原 満
  北海道病院薬剤師会誌, 109, 7, 10, (一社)北海道病院薬剤師会, 2025年11月
  日本語
• Evaluation of factors associated with drug fever following gemcitabine and nanoparticle albumin-bound paclitaxel treatment for pancreatic cancer.
  Yoshitaka Saito; Yoh Takekuma; Yoshito Komatsu; Mitsuru Sugawara
  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 33, 11, 1006, 1006, 2025年11月01日, ［査読有り］, ［最終著者］, ［国際誌］
  英語, 研究論文（学術雑誌）, PURPOSE: Gemcitabine (GEM) + nanoparticle albumin-bound paclitaxel (nab-PTX) is an effective treatment for advanced pancreatic cancer. However, drug fever is a frequently observed adverse effect of GEM, and PTX can also induce symptoms. This study aimed to identify factors for drug fever in the real-world treatment of pancreatic cancer with GEM + nab-PTX. METHODS: We retrospectively assessed patients with pancreatic cancer who received GEM + nab-PTX (n = 386). The primary endpoint was the identification of factor(s) associated with the incidence of drug fever following the first administration. We also assessed symptoms between specific patient groups. RESULTS: The incidence of drug fever following the first GEM + nab-PTX treatment was 12.7%. The median onset time was day 3 (range: 1-4) with a symptom duration of 1 (1-6) day. Unresectable setting (adjusted odds ratio [95% confidence interval]: 3.35 [1.35-8.32], P = 0.009) and elevated baseline C-reactive protein (CRP) levels (≥ 1.0 mg/dL) (3.55 [1.80-6.98], P = 0.0002) were identified as risk factors using the multivariable logistic regression analysis. Patients receiving regular antipyretic treatment with non-steroidal anti-inflammatory drugs (NSAIDs) and/or acetaminophen had a lower risk (0.42 [0.20-0.87], P = 0.02). No difference was observed in the impact of the type of antipyretics on drug fever between NSAIDs and acetaminophen. CONCLUSION: An unresectable disease status and high baseline CRP levels are risk factors for drug-induced fever, while patients receiving regular antipyretics are at lower risk of developing these symptoms during real-world treatment of pancreatic cancer with GEM + nab-PTX.
• Baseline hypoalbuminemia enhances regorafenib-induced problematic fatigue development in real-world metastatic colorectal cancer treatment.
  Yoshitaka Saito; Yoh Takekuma; Yoshito Komatsu; Mitsuru Sugawara
  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 33, 11, 990, 990, 2025年10月29日, ［査読有り］, ［最終著者］, ［国際誌］
  英語, 研究論文（学術雑誌）, PURPOSE: Regorafenib, a multikinase inhibitor for treating metastatic colorectal cancer (mCRC), induces fatigue in 40-50% of administered patients, including approximately 10% of grade ≥ 3 cases. Additionally, hypoalbuminemia is associated with cancer- and chemotherapy-induced fatigue and frequently observed in patients with advanced cancers. This study aimed to assess the impact of baseline hypoalbuminemia on the development of clinically problematic fatigue in a real-world regorafenib treatment for mCRC. METHODS: Patients with mCRC who underwent regorafenib (n = 102) were divided into the control (baseline serum albumin levels ≥ 3.5 g/dL) and hypoalbuminemia (baseline serum albumin levels < 3.5 g/dL) groups, and retrospectively evaluated. The primary endpoint was comparison of grade ≥ 2 fatigue incidence during all treatment cycles. We also assessed the impact of grade ≥ 2 symptoms on the treatment efficacy. RESULTS: Incidence of grade ≥ 2 fatigue in all treatment cycles in the hypoalbuminemia group was 41.7%, which was significantly higher than that in the control group (14.1%, P = 0.008). In addition, grade ≥ 2 fatigue within the first cycle was significantly more confirmed in the hypoalbuminemia group than in the control group (37.5% vs. 11.5%, P = 0.01). Additionally, patients with early grade ≥ 2 fatigue within 14 days from treatment initiation had a significantly shorter time to treatment failure or overall survival than those without the symptoms. CONCLUSION: Patients with baseline hypoalbuminemia developed clinically problematic fatigue after regorafenib monotherapy for mCRC. Because regorafenib is a later-line mCRC treatment, successful management of emerging fatigue is crucial and requires further evaluation.
• Factors associated with taxane-associated acute pain syndrome in pancreatic cancer patients receiving gemcitabine and nab-paclitaxel.
  Yoshitaka Saito; Yoh Takekuma; Yoshito Komatsu; Mitsuru Sugawara
  Discover oncology, 16, 1, 1967, 1967, 2025年10月27日, ［査読有り］, ［最終著者］, ［国際誌］
  英語, 研究論文（学術雑誌）, PURPOSE: Taxane-associated acute pain syndrome (T-APS) is a common adverse event in patients treated with gemcitabine (GEM) + nanoparticle albumin-bound paclitaxel (nab-PTX) for pancreatic cancer. As several T-APS risk factors, such as age, cancer type, and taxane dose or formulation, differ between pancreatic cancer and other malignancies in previous studies, we aimed to identify factors associated with T-APS in a real-world setting of GEM + nab-PTX treatment for pancreatic cancer. METHODS: We retrospectively analyzed 394 patients with pancreatic cancer receiving GEM + nab-PTX. The primary endpoint was the identification of factors associated with all-grade T-APS. Symptom incidence was also compared across specific patient groups. RESULTS: T-APS occurred in 26.1% of patients after the first GEM + nab-PTX administration (grade 1: 21.6%; grade 2: 4.6%). Among patients with T-APS, 39.8% received medication, with more than two-thirds reporting symptom relief. Multivariable logistic regression analyses identified body mass index (BMI) ≥ 25 kg/m2 as a risk factor and baseline use of mild analgesics (non-steroidal anti-inflammatory drugs [NSAIDs] and/or acetaminophen) as a preventive factor (adjusted odds ratio, 2.98; 95% confidence interval, 1.68-5.31; P = 0.0002 for BMI, 0.48; 0.26-0.89; P = 0.02 for mild analgesics). A subgroup analysis comparing baseline NSAIDs and acetaminophen in patients receiving mild analgesic monotherapy showed no significant difference (P = 0.49). CONCLUSION: Our study identified BMI ≥ 25 kg/m2 as a risk factor and baseline use of mild analgesics as a preventive factor for T-APS development in a real-world GEM + nab-PTX regimen for pancreatic cancer.
• Impact of baseline hypoalbuminemia on peripheral edema induced by gemcitabine and nab-paclitaxel for pancreatic cancer treatment.
  Yoshitaka Saito; Yoh Takekuma; Yoshito Komatsu; Mitsuru Sugawara
  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 33, 11, 938, 938, 2025年10月13日, ［査読有り］, ［最終著者］, ［国際誌］
  英語, 研究論文（学術雑誌）, BACKGROUND: Gemcitabine (GEM) + nanoparticle albumin-bound paclitaxel (nab-PTX), which is effective in treating pancreatic cancer, frequently induces peripheral edema. Hypoalbuminemia causes generalized peripheral edema and occasionally occurs in patients with cancer, but reports evaluating its interaction with chemotherapy-induced symptoms are lacking. Therefore, we aimed to assess the effect of baseline hypoalbuminemia on peripheral edema following real-world GEM + nab-PTX therapy. METHODS: Patients with pancreatic cancer receiving GEM + nab-PTX (n = 212) were divided into a hypoalbuminemia group (serum albumin levels < 3.5 g/dL), and a control group without hypoalbuminemia, and retrospectively evaluated. The primary endpoint was the incidence of grade ≥ 2 peripheral edema within 6 months of treatment initiation. RESULTS: The incidence of grade ≥ 2 peripheral edema within 6 months was 5.7% in the control group and 22.6% in the hypoalbuminemia group, with a significant difference (P = 0.0009), meeting the primary endpoint. The onset time of grade ≥ 2 peripheral edema was significantly earlier in the hypoalbuminemia group than in the control group (P = 0.0003). In contrast, the incidence of all-grade symptoms was 20.1% in the control group and 30.2% in the hypoalbuminemia group, which was not significantly different (P = 0.13). These results were confirmed in the propensity score-matched population. Multivariate Cox proportional hazard regression analyses showed that baseline hypoalbuminemia was a significant risk factor for grade ≥ 2 peripheral edema (adjusted hazard ratio, 3.84; 95% confidence interval, 1.60-9.23; P = 0.003). CONCLUSION: Our study revealed that patients with baseline hypoalbuminemia who received GEM + nab-PTX therapy for pancreatic cancer developed problematic peripheral edema.
• Younger age as a risk factor for rash development in pemetrexed and carboplatin treatment with dexamethasone prophylaxis.
  Yoshitaka Saito; Osamu Taniguchi; Yoh Takekuma; Jun Sakakibara-Konishi; Yasushi Shimizu; Ichiro Kinoshita; Mitsuru Sugawara
  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 33, 11, 932, 932, 2025年10月11日, ［査読有り］, ［最終著者］, ［国際誌］
  英語, 研究論文（学術雑誌）, PURPOSE: Carboplatin (CBDCA) plus pemetrexed (PEM) is one of the most effective regimens for treating thoracic cancer. Rash, which is mainly caused by PEM, occurs in 15-30% of patients. Dexamethasone administration for 3 days is recommended to manage rash, chemotherapy-induced nausea, and vomiting in this regimen. However, the nature of the PEM-induced rashes is not fully understood. Consequently, we aimed to identify the risk factors associated with rash development under dexamethasone prophylaxis in CBDCA + PEM treatment. METHODS: Patients with thoracic cancer who underwent CBDCA + PEM treatment (n = 133) were retrospectively assessed. The primary endpoint of the present study was to identify the risk factor(s) for the incidence of all-grade rash in the first cycle. Factors affecting the incidence during all treatment cycles were also evaluated. RESULTS: The incidence of all-grade rash in the first cycle was 24.1%, including 16.5% for grade 1, 5.3% for grade 2, and 2.3% for grade 3, respectively. Moreover, that in all cycles, it was 27.1%, with 18.8% for grade 1, 6.0% for grade 2, and 2.3% for grade 3. Multivariate logistic regression analyses identified that age < 65 years was the singular independent risk factor for rash development in the first and all cycles (adjusted odds ratio, 2.79; 95% confidence interval, 1.17-6.67; p = 0.02 for the first cycle, 3.03, 1.29-7.09; p = 0.01 for all cycles). CONCLUSION: Our study revealed that patients aged < 65 years were at a significantly higher risk of rash development during CBDCA + PEM chemotherapy with dexamethasone prophylaxis than patients ≥ 65 years of age.
• Temporal effects of empirical round-up of serum creatinine on the accuracy of estimated kidney function after critical illness.
  R Mikami; S Imai; M Hayakawa; H Kashiwagi; Y Sato; S Nashimoto; M Sugawara; Y Takekuma
  Die Pharmazie, 80, 9, 93, 101, 2025年10月01日, ［国際誌］
  英語, 研究論文（学術雑誌）, This study aimed to evaluate the temporal effect of a serum creatinine (SCr) correction intervention in critically ill patients with daily muscle wasting. A total of 5,355 critical care days in 574 patients with creatinine clearance (Clcr) and glomerular filtration rate (GFR) measured and estimated simultaneously were included. The primary endpoint was the difference in accuracy over time of the estimated Clcr/GFR relative to the measured Clcr. The CG equation was used to estimate Clcr, and the MDRD and CKD-EPI-equations were used to estimate GFR. Estimated Clcr(round-up)/GFR(round-up) indicates the estimated Clcr/GFR calculated using the rounded up value if SCr was <0.6 mg/dL. Bias was analyzed using Bland-Altman analysis, correlation using Spearman's rank correlation coefficient, and accuracy using percentage within 30% of the measured Clcr (P30). The CKD-EPI equation showed a large underestimation bias in the early period, whereas the CG and MDRD equations indicated large overestimation biases in the later period. Round-up correction increased the underestimation bias in the early period of the CG(round-up) and MDRD(round-up) equations, but decreased the overestimation bias in the later period. The limits of agreements for the CG(round-up) and MDRD(round-up) equations were narrower, although not consistently acceptable. The correlations were stronger for the CG(round-up) and MDRD(round-up) equations. Accuracy did not improve with the corrective intervention. Conclusion: SCr round-up correction increased the underestimation of kidney function in the early phase, but mitigated overestimation in the later phase. The limits of agreement remained unacceptable, and the accuracy did not improve.
• 未分画ヘパリンモニタリングにおけるAPTTと抗Xa活性の不一致に対する腎機能の影響 探索的後ろ向き観察研究
  三上 龍生; 早川 峰司; 今井 俊吾; 斉藤 智誉; 佐藤 夕紀; 柏木 仁; 梨本 俊亮; 菅原 満; 武隈 洋
  日本腎臓病薬物療法学会誌, 14, 特別号, S172, S172, (一社)日本腎臓病薬物療法学会, 2025年09月
  日本語
• Temporal effects of errors in estimating kidney function after critical illness on drug dosing categories.
  Ryusei Mikami; Shungo Imai; Mineji Hayakawa; Kento Sabashi; Hitoshi Kashiwagi; Yuki Sato; Shunsuke Nashimoto; Mitsuru Sugawara; Yoh Takekuma
  British journal of clinical pharmacology, 2025年08月26日, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, AIMS: This study aimed to clarify how the trajectories of the Cockcroft-Gault (CG), Modification of Diet in Renal Disease (MDRD) and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations differ from measured creatinine clearance (Clcr) and to determine their impact on drug dosing categories in critically ill patients. METHODS: We used data from 5355 days following critical illness to estimate the trajectories of the above-mentioned kidney function equations using a linear mixed model. In addition, we determined whether the CG, MDRD and CKD-EPI equations would change drug dosing categories (<15, 15-29, 30-59, 60-89, 90-119, 120-149, or ≥150 mL/min) over time compared with that observed using measured Clcr. RESULTS: The rate of change relative to baseline in measured Clcr remained almost unchanged during the 28 days of observation (-0.02 [95% confidence interval, CI: -0.19-0.14] mL/min/1.73 m2/day). In contrast, all indirect kidney function estimating equations showed a time-dependent increase in the rate of change, which was largest for the CG equation, followed by the MDRD and CKD-EPI equations (+2.00 [95% CI: 1.89-2.12], +1.50 [95% CI: 1.34-1.67] and +0.77 [95% CI: 0.61-0.93] mL/min/1.73 m2/day, respectively). More than half of the CG, MDRD and CKD-EPI equations showed discrepancies with the measured Clcr and drug dosing categories, with underestimation in the early phases and overestimation in the later phases being more common. CONCLUSION: Creatinine-based indirect kidney function estimation equations increased over time, indicating erroneous drug dosing categories on over half of the critical care days.
• The effect of sacubitril/valsartan on urinary C-peptide excretion and endogenous insulin secretory capacity in a patient with type 2 diabetes: a case report.
  Shun Onodera; Masashi Miyamae; Issei Higuchi; Shunsuke Nashimoto; Akinobu Nakamura; Mitsuru Sugawara; Yoh Takekuma
  Journal of pharmaceutical health care and sciences, 11, 1, 75, 75, 2025年08月17日, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, BACKGROUND: The evaluation of endogenous insulin secretory capacity is important in the selection of diabetes treatment. C-peptide, which is secreted in equivalent amounts as insulin, is a versatile test for this evaluation. Urinary C-peptide is widely used because it is less invasive. Sacubitril/valsartan, used to treat hypertension and chronic heart failure, has been reported to increase urinary C-peptide levels; however, its effect on endogenous insulin secretion remains unknown. In this report, we present a case in which insulin secretory capacity was evaluated according to a glucagon stimulation test in addition to urinary C-peptide levels in a patient receiving sacubitril/valsartan. CASE PRESENTATION: A male patient in his 50s with type 2 diabetes and hypertension, without renal dysfunction, was treated with sacubitril/valsartan. The results of the glucagon stimulation test showed a C-peptide change of 2.28, and the C-peptide index on the same day was 1.25, indicating normal endogenous insulin secretory capacity. In contrast, 24-h urinary C-peptide excretion was abnormally high at 615.2 µg/day. After discontinuation of sacubitril/valsartan, urinary C-peptide excretion decreased over time (615.2 to 369.0 µg/day), but blood glucose levels did not increase during this period. CONCLUSIONS: In this case, 24-h urinary C-peptide excretion was abnormally elevated despite preserved endogenous insulin secretory capacity, as assessed by the glucagon stimulation test. Although this observation is based on a single case and cannot be generalized, it suggests that sacubitril/valsartan may interfere with the interpretation of urinary C-peptide levels. Therefore, in such clinical contexts, dynamic tests such as the glucagon stimulation test may serve as a useful adjunct to avoid potential overestimation of insulin secretory capacity when relying solely on urinary C-peptide levels.
• Celecoxib has less aggravating effect on cisplatin-induced nephrotoxicity in comparison with non-selective cyclooxygenase inhibitors: a retrospective multi-institutional study.
  Keisuke Okamoto; Yoshitaka Saito; Kenta Takahashi; Yoh Takekuma; Jun Sakakibara-Konishi; Katsuya Narumi; Mitsuru Sugawara; Masaki Kobayashi
  International journal of clinical oncology, 30, 9, 1757, 1763, 2025年07月07日, ［査読有り］, ［国内誌］
  英語, 研究論文（学術雑誌）, BACKGROUND: Cisplatin (CDDP)-induced nephrotoxicity (CIN) is one of its most serious adverse effects. Although we previously demonstrated that celecoxib, a cyclooxygenase (COX)-2 selective inhibitor, attenuates CIN in a basic study, there are no reports that have evaluated its clinical impact on CIN. Therefore, we aimed to determine the effect of celecoxib on CIN compared with that of non-selective COX inhibitors. METHODS: Patients with lung cancer receiving CDDP (≥ 60 mg/m2)-containing regimens with regular administration of loxoprofen or naproxen (COX-1 group), or celecoxib were evaluated in this retrospective, multi-institutional study. The primary endpoint was the evaluation of CIN incidence in all treatment cycles between the groups. In addition, the variance in creatinine clearance (CCr) and the incidence of gastrointestinal adverse effects were evaluated. RESULTS: CIN occurred in 24.2% of patients in the COX-1 group (n = 33) and 0% of those in the celecoxib group (n = 15) in all cycles, showing a significant difference (P = 0.04). In addition, the variance in CCr was significantly smaller in the celecoxib group than in the COX-1 group in all cycles, as well as at the primary endpoint (P = 0.02). However, there was no difference in the incidence of CIN or variance in CCr in the first cycle between the two groups. The incidences of nausea, vomiting, and anorexia were similar between the groups, implying a similar amount of oral hydration. CONCLUSION: These findings suggest that celecoxib is less aggravating on CIN than non-selective COX inhibitors.
• Temporary hypocalcemia induced by cetuximab sarotalocan without hypomagnesemia in a patient with hypoparathyroidism: a novel case report.
  Moeko Kado; Yoshitaka Saito; Tatsuhiko Sakamoto; Takayoshi Suzuki; Yoh Takekuma; Mitsuru Sugawara
  Journal of pharmaceutical health care and sciences, 11, 1, 58, 58, 2025年07月04日, ［査読有り］, ［責任著者］, ［国際誌］
  英語, 研究論文（学術雑誌）, BACKGROUND: Cetuximab sarotalocan, which utilizes the light-activatable dye IRDye700Dx conjugated with cetuximab, is a first-in-class drug based on photoimmunotherapy for treating recurrent head and neck squamous cell carcinoma. Cetuximab frequently induces hypomagnesemia and secondary hypocalcemia. Herein, we report a case of independent hypocalcemia without hypomagnesemia during treatment and discuss symptom progression. CASE PRESENTATION: A female patient with left epipharyngeal cancer, hypothyroidism, and hypoparathyroidism was treated with cetuximab and sarotalocan. On day 3, serum-adjusted calcium levels decreased from 9.6 to 7.4 mg/dL, increased to 8.2 mg/dL on day 9, and further increased to 8.8 mg/dL on day 27; serum magnesium levels were not evaluated. After the second administration, serum-adjusted calcium levels decreased two days later, fluctuating between 7.6 and 8.1 mg/dL for three weeks. Serum magnesium levels were within the normal range, with no significant variation detected during the second cycle. A similar symptom course was observed during the third cycle. The patient received enteral nutrition daily with 424.8-1,038.4 mg of calcium, with daily adjustment during the administration, except on day 2. She received peripheral intravenous nutrition for several days after tumor illumination. Concomitant medications did not appear to affect serum calcium levels. Considering the case process and previous reports, we hypothesized that concomitant hypoparathyroidism, in addition to reduced calcium intake due to the treatment, may have contributed to the observed reduction. CONCLUSIONS: Hypocalcemia without hypomagnesemia can occur in patients with hypoparathyroidism receiving near-infrared photoimmunotherapy with cetuximab sarotalocan. The precise mechanisms and epidemiological features warrant further investigations.
• Optimization of voriconazole dosage via population pharmacokinetic analysis based on the albumin-bilirubin (ALBI) score of patients with liver dysfunction.
  Shunsuke Nashimoto; Mitsuru Sugawara; Yoh Takekuma
  Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 31, 8, 102766, 102766, 2025年07月02日, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, INTRODUCTION: Voriconazole (VRCZ) is an antifungal agent used to treat refractory fungal infections. Its dosage is adjusted based on the individual liver function. In this study, we aimed to establish a population pharmacokinetic analysis model based on the albumin-bilirubin (ALBI) score to objectively assess the liver function using only albumin and total bilirubin levels as covariates. METHODS: In total, 126 plasma samples of 16 patients with liver dysfunction who received oral VRCZ between 2012 and 2022 were analyzed in this study. Phoenix NLME software was used for population pharmacokinetic analysis, and Monte Carlo simulations were performed to determine the optimal dosing regimen to achieve the target blood VRCZ concentration. RESULTS: Blood VRCZ concentration was described using a 1-compartment model with lag time. In the final model, objective function was significantly decreased upon ALBI score incorporation into clearance. Monte Carlo simulations showed that the optimal dosing schedules were 100 mg twice daily, 75 mg twice daily, and 50 mg twice daily for ALBI scores of -3, -2, and -1, respectively. Notably, for an ALBI score of 0, target blood VRCZ concentration was exceeded, even a dosing regimen of 50 mg twice daily. CONCLUSION: To the best of our knowledge, this study is the first to incorporate the ALBI score into a population pharmacokinetic model for VRCZ. Our simulation results suggest that the maintenance dose should be reduced based on the ALBI score. Furthermore, our findings highlight the potential use of the ALBI score for optimal drug dosage design.
• Impact of baseline proteinuria on progression-free survival after regorafenib treatment for metastatic colorectal cancer.
  Yoshitaka Saito; Yoh Takekuma; Yoshito Komatsu; Mitsuru Sugawara
  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 33, 5, 443, 443, 2025年05月02日, ［査読有り］, ［最終著者］, ［国際誌］
  英語, 研究論文（学術雑誌）, PURPOSE: Regorafenib improves the survival of patients with metastatic colorectal cancer (mCRC). However, proteinuria frequently occurs in regorafenib treatment, and development of severe hypertension, which is closely related to proteinuria, is associated with better treatment outcomes. We previously reported that patients with baseline proteinuria exhibit regorafenib-induced problematic symptoms. In this study, we aimed to assess the effect of baseline proteinuria on the treatment efficacy of regorafenib for mCRC. METHODS: Patients with mCRC receiving regorafenib (n = 100) were categorized into control (without baseline proteinuria) and pre-existing proteinuria (baseline grades 1-2) groups and retrospectively evaluated. The primary endpoint was the progression-free survival (PFS). RESULTS: Patients in the pre-existing proteinuria group exhibited significantly worse PFS than those in the control group (median with 95% confidence interval [CI] = 51 (46-56) and 56 (49-81) days, respectively; P = 0.04). Overall survival and disease control rate were lower in the pre-existing proteinuria group than in the control group although the difference was not statistically significant (P = 0.11 and 0.10, respectively). Similar results were obtained in the propensity score-matched population. Multivariate Cox hazard regression analyses revealed that baseline pre-existing proteinuria was associated with poor PFS (adjusted hazard ratio = 1.67; 95% CI = 1.03-2.72; P = 0.04). Additionally, ratio of drug suspension duration during all treatment cycles was higher in patients with pre-existing proteinuria than those without symptoms. CONCLUSION: Our results suggest that patients with baseline proteinuria experience poor PFS following regorafenib treatment for mCRC, although we should consider the clinical significance of the difference.
• イリノテカン誘発性コリン症状に対する抗コリン薬単回予防投与の症状コントロール不良因子の探索
  渡辺 拓也; 齋藤 佳敬; 武隈 洋; 清水 康; 木下 一郎; 小松 嘉人; 菅原 満
  日本臨床腫瘍薬学会雑誌, 41, 137, 137, (一社)日本臨床腫瘍薬学会, 2025年05月
  日本語
• 非小細胞肺がん患者におけるドセタキセル誘発性浮腫の要因分析
  山下 慎介; 齋藤 佳敬; 今井 俊吾; 柏木 仁; 佐藤 夕紀; 梨本 俊亮; 榊原 純; 清水 康; 木下 一郎; 武隈 洋; 菅原 満
  日本臨床腫瘍薬学会雑誌, 41, 139, 139, (一社)日本臨床腫瘍薬学会, 2025年05月
  日本語
• アミノ酸トランスポーターSNAT4を介したエンドサイトーシスによる基質修飾リポソームの取り込み
  松山 琳空; 佐藤 夕紀; 藤田 聡; 丸山 真吾; 梨本 俊亮; 柏木 仁; 武隈 洋; 菅原 満
  日本薬剤学会年会講演要旨集, 40年会, 130, 130, (公社)日本薬剤学会, 2025年05月
  日本語
• Dexamethasone dose-dependently attenuates docetaxel-induced peripheral neuropathy in breast cancer treatment.
  Ryota Kanno; Yoshitaka Saito; Yoh Takekuma; Masato Takahashi; Tomohiro Oshino; Mitsuru Sugawara
  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 33, 5, 360, 360, 2025年04月07日, ［査読有り］, ［最終著者］, ［国際誌］
  英語, 研究論文（学術雑誌）, PURPOSE: Peripheral neuropathy is one of the most problematic adverse effects of docetaxel. We previously reported that dexamethasone (DEX) prevents taxane-associated acute pain syndrome (T-APS) in a dose-dependent manner, which might be a partial manifestation of chemotherapy-induced peripheral neuropathy (CIPN), in breast cancer treatment. Therefore, this study examined the dose-dependent prophylactic efficacy of DEX against CIPN. METHODS: Female patients with breast cancer receiving docetaxel-containing treatments (75 mg/m2) were divided into two groups according to DEX dosage on days 2-4; an 8 mg group (n = 56) and a 4 mg group (n = 28) and retrospectively evaluated. The primary endpoint in this study was defined as the development of grade ≥ 2 CIPN during 4 cycles of the treatment. RESULTS: The incidence of grade ≥ 2 CIPN was 32.1% in the 4 mg group and 10.7% in the 8 mg group and was significantly lower in the 8 mg group (P = 0.03). The incidence of all-grade CIPN was lower in the 8 mg group than in the control group, although the difference was not statistically significant (P = 0.06). Onset time of all-grade and grade ≥ 2 CIPN in the 8 mg group was significantly delayed compared to that in the 4 mg group (P = 0.003 and 0.01, respectively). Additionally, 8 mg/day of DEX was identified as a preventive factor for all-grade CIPN, although the evaluation of grade ≥ 2 symptoms was not possible. CONCLUSION: Our study found that DEX attenuated docetaxel-induced CIPN in a dose-dependent manner during real-world breast cancer treatment. Further studies are needed to develop better CIPN management strategies.
• グラム陽性球菌による骨・関節感染症に対するリネゾリドの第一選択薬としての有効性調査
  新沼 悠介; 石黒 信久; 鏡 圭介; 菅原 満; 武隈 洋
  日本感染症学会総会・学術講演会・日本化学療法学会学術集会合同学会プログラム・抄録集, 99回・73回, O, 007, 日本感染症学会・日本化学療法学会, 2025年04月
  日本語
• Evaluation of nausea induced by trifluridine/tipiracil in metastatic colorectal cancer treatment.
  Yoshitaka Saito; Yoh Takekuma; Yoshito Komatsu; Mitsuru Sugawara
  Journal of chemotherapy (Florence, Italy), 1, 8, 2025年03月20日, ［査読有り］, ［最終著者］, ［国際誌］
  英語, 研究論文（学術雑誌）, Trifluridine/tipiracil (FTD/TPI) frequently induces chemotherapy-induced nausea and vomiting (CINV). As evidence of factors associated with CINV in oral chemotherapeutic agents is limited, we aimed to assess factors for nausea development in a real-world FTD/TPI-containing treatment for metastatic colorectal cancer (mCRC). Patients with mCRC receiving FTD/TPI with or without bevacizumab (n = 104) were retrospectively evaluated. Nausea occurred in 40.4% of the patients, and the severity was grade 1 for 23.1%, grade 2 for 15.4%, and grade 3 for 1.9%. Multivariable logistic regression analysis suggested that female sex (adjusted odds ratio 2.74, 95% confidence interval 1.02-7.33, p = 0.045) and concomitant bevacizumab (2.68, 1.13-6.37, p = 0.03) were independent risk factors for all-grade nausea during the first cycle as a primary endpoint. Particularly, among patients with FTD/TPI monotherapy, females significantly exhibited nausea compared to males. Our study revealed that concomitant bevacizumab and female sex are independent risk factors for nausea in FTD/TPI-containing treatment for mCRC.
• Identification of risk factors related to problematic peripheral neuropathy development in gemcitabine and nab-paclitaxel treatment for pancreatic cancer.
  Yoshitaka Saito; Yoh Takekuma; Yoshito Komatsu; Mitsuru Sugawara
  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 33, 4, 263, 263, 2025年03月10日, ［査読有り］, ［最終著者］, ［国際誌］
  英語, 研究論文（学術雑誌）, PURPOSE: Chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse effect in patients treated with gemcitabine (GEM) and nanoparticle albumin-bound paclitaxel (nab-PTX) for pancreatic cancer, negatively impacting their quality of life. This study aimed to identify risk factors for significant CIPN development in a real-world setting of GEM + nab-PTX treatment to inform effective management strategies. METHODS: Patients with unresectable pancreatic cancer who received GEM + nab-PTX (n = 140) were retrospectively assessed. The primary endpoint was to identify the risk factor(s) associated with the development of problematic grade ≥ 2 CIPN within six months of treatment initiation. We also evaluated factors associated with all-grade CIPN and compared CIPN incidence across specific patient groups. RESULTS: The incidence of grade ≥ 2 CIPN was 35.0%, with 63.6% of patients experiencing symptoms of any grade. Multivariate Cox proportional hazard regression analysis identified baseline preexisting neuropathy as an independent risk factor for developing grade ≥ 2 CIPN (adjusted hazard ratio 4.03, 95% confidence interval 1.82-8.96, P = 0.0006). Conversely, dose modification of nab-PTX at or within 4 weeks of treatment initiation emerged as a protective factor (0.45, 0.22-0.91, P = 0.03). Additionally, the cumulative incidence of grade ≥ 2 CIPN was significantly lower and delayed in patients who underwent dose modification within 4 weeks compared to those who did not in the population with preexisting neuropathy (P = 0.01). CONCLUSION: Baseline preexisting neuropathy significantly increases the risk, while early dose modification of nab-PTX serves as a protective factor against developing grade ≥ 2 CIPN in patients receiving GEM + nab-PTX treatment for pancreatic cancer.
• Validity and Utility of a Risk Prediction Model for Wound Infection After Lower Third Molar Surgery
  Akira Yamagami; Katsuya Narumi; Yoshitaka Saito; Ayako Furugen; Shungo Imai; Keisuke Okamoto; Yoshimasa Kitagawa; Yoichi Ohiro; Ryo Takagi; Yoh Takekuma; Mitsuru Sugawara; Masaki Kobayashi
  Oral Diseases, Wiley, 2025年01月10日, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, ABSTRACT
  
  Objectives
  
  To externally validate a clinical prediction model for surgical site infection (SSI) after lower third molar (L3M) surgery and evaluate its clinical usefulness.
  
  Methods
  
  We conducted a retrospective cohort study of patients who underwent L3M surgery at Hokkaido University Hospital. The study was designed to evaluate the historical and methodological transportability. Clinical usefulness was evaluated using decision curve analysis on the data of the non‐antibiotic‐treated patients.
  
  Results
  
  We obtained 2543 validation cohorts from April 2020 to March 2023, and 640 non‐antibiotic cohorts from July 2010 to September 2023. The incidences of SSI after L3M surgery were 5.3% (135/2543) and 7.7% (49/640) in the validation and non‐antibiotic cohorts, respectively. The discrimination ability of the prediction model was acceptable for the external validation cohort (c‐statistic: 0.67; 95% CI: 0.62–0.71) and adequate for the non‐antibiotic cohort (c‐statistic: 0.72; 95% CI: 0.63–0.79). In both cohorts, the model showed excellent calibration between the observed and predicted probabilities. Decision curve analysis showed increased net benefit across a range of meaningful risk thresholds.
  
  Conclusion
  
  A simple risk prediction model for SSI after L3M surgery demonstrated clinical transportability and usefulness. This model may help surgeons/clinicians determine the appropriateness of prophylactic antibiotics administration for patients in L3M surgery.
• Evaluation of Transport Activity Using Mouse Jejunal Epithelial Cell Monolayer Culture System.
  Yoshiki Sasagawa; Riho Kamishima; Hitoshi Kashiwagi; Yuki Sato; Shunsuke Nashimoto; Yoh Takekuma; Mitsuru Sugawara
  Biological & pharmaceutical bulletin, 48, 8, 1199, 1206, 2025年, ［査読有り］, ［最終著者, 責任著者］, ［国内誌］
  英語, 研究論文（学術雑誌）, Caco-2 cells, derived from colorectal cancer cells, are generally used to evaluate drug absorption in the gastrointestinal tract. However, differences between Caco-2 and normal intestinal cells have been observed. Cells cultured directly from crypts are maintained in their biological state. Therefore, we developed a rapid and easy method of monolayer culture of epithelial cells isolated from the jejunum of mice. We analyzed the usefulness of the jejunal epithelial cell monolayer culture system as a research tool and evaluated changes in the transport activity and mRNA expression of transporters. We focused on P-glycoprotein (P-gp) and peptide transporter 1 (Pept1) as representative transporters expressed in the small intestine. A P-gp inhibitor significantly enhanced the accumulation of Rhodamine 123 (Rho123), a substrate of P-gp, indicating that the transport activity of P-gp could be evaluated. Uptake of glycylsarcosine, a Pept1 substrate, significantly decreased in the presence of the Pept1 inhibitor, indicating that the transport activity of Pept1 could be evaluated. Rho123 accumulation significantly decreased in the group treated with calcitriol, an inducer of P-gp and Cyp3a11, suggesting that changes in P-gp expression could be evaluated. Furthermore, we examined whether mRNA expression levels of transporters and drug-metabolizing enzyme were altered. In the calcitriol-supplemented group, P-gp and Cyp3a11 mRNA levels significantly increased. However, no significant differences were observed in Pept1 mRNA levels. Overall, the jejunal epithelial cell monolayer culture system developed from intestinal tissues is a useful research tool for assessing the transport activities and expression variabilities of transporters.
• Relationship Between Anthracycline-cyclophosphamide Regimens and Docetaxel Monotherapy in Oral Mucositis Development.
  Yoshitaka Saito; Tatsuhiko Sakamoto; Yoh Takekuma; Masato Takahashi; Tomohiro Oshino; Mitsuru Sugawara
  In vivo (Athens, Greece), 39, 4, 2259, 2266, 2025年, ［査読有り］, ［最終著者］, ［国際誌］
  英語, 研究論文（学術雑誌）, BACKGROUND/AIM: We have previously reported that patients experiencing oral mucositis (OM) during anthracycline-cyclophosphamide treatment develop symptoms following subsequent docetaxel-containing chemotherapy for perioperative breast cancer therapy. However, the concomitant use of pertuzumab and trastuzumab with docetaxel has also been suggested as a significant risk factor for OM. This study aimed to further evaluate the direct relationship of OM with anthracycline-cyclophosphamide treatment and docetaxel monotherapy. PATIENTS AND METHODS: Patients with breast cancer who underwent anthracycline-cyclophosphamide treatment followed by docetaxel monotherapy as perioperative therapy (n=63) were divided into control and OM-experience groups based on the absence or presence of OM development during prior anthracycline-cyclophosphamide treatment, and retrospectively evaluated. The primary endpoint was the comparison of all-grade OM incidence in the first docetaxel cycle between the two groups. The incidence of OM and dysgeusia was also assessed across all treatment cycles. RESULTS: The incidence of all-grade OM was 42.9% in the OM-experience group and 9.5% in the control group during the first cycle (p=0.006) and 47.6% and 11.9% across all treatment cycles (p=0.004), thereby achieving the primary endpoint. In contrast, the incidence of grade ≥2 OM in both settings was higher in the OM-experience group than in the control group, although the difference was not statistically significant (14.3% vs. 2.4%, p=0.10 for both settings). Moreover, the incidence of dysgeusia did not differ between the two groups. CONCLUSION: Patients exhibiting OM during prior anthracycline-cyclophosphamide treatment were significantly more likely to develop symptoms during subsequent docetaxel monotherapy for perioperative breast cancer therapy.
• Severe Hypomagnesemia in a Patient Treated Using Carboplatin Co-Administered with Vonoprazan.
  Osamu Taniguchi; Yoshitaka Saito; Yuka Yamaguchi; Midori Sakai; Yasuyuki Ikezawa; Jun Sakakibara-Konishi; Mina Eguchi; Yoh Takekuma; Mitsuru Sugawara
  Case reports in oncology, 18, 1, 151, 158, 2025年, ［査読有り］, ［最終著者, 責任著者］, ［国際誌］
  英語, 研究論文（学術雑誌）, INTRODUCTION: We describe a case of severe hypomagnesemia that occurred during treatment with carboplatin (CBDCA) and nanoparticle albumin-bound paclitaxel (nab-PTX) for lung adenocarcinoma when co-administered with vonoprazan. CASE PRESENTATION: A man in his 70s was diagnosed with stage IIIA lung adenocarcinoma and received CBDCA and nab-PTX as the first-line treatment. The patient had been taking omeprazole 10 mg once daily (for >3 years) for gastroesophageal reflux disease, but it was switched to lansoprazole 15 mg because of hospital's adopted medication. During the first treatment cycle, his serum creatinine levels increased from 1.0 to 1.5 mg/dL, suggesting CBDCA-associated renal impairment. Because of gastric discomfort on day 15 of the second cycle, lansoprazole was switched to vonoprazan 10 mg once daily. On day 23 of the second cycle, he developed torsades de pointes and was hospitalized; severe hypomagnesemia (0.4 mg/dL) was detected to be causing the symptoms. Discontinuation of vonoprazan and a single intravenous infusion of 60 mEq magnesium sulfate raised serum magnesium levels to 3.7 mg/dL, and the arrhythmia disappeared. Mild hypomagnesemia (1.4 mg/dL) reappeared 5 days later, and an additional intravenous infusion of 20 mEq magnesium sulfate with subsequent oral magnesium oxide (1,980 mg/day) resolved the symptoms. CBDCA was discontinued and nab-PTX monotherapy was continued. Vonoprazan was resumed owing to gastric discomfort relapse; however, grade ≥2 hypomagnesemia did not reappear later. CONCLUSIONS: This case highlights the risk of severe hypomagnesemia in patients with CBDCA and vonoprazan co-administration; therefore, regular monitoring of serum magnesium levels during the treatment is crucial.
• Actual Use of Budesonide Enteric-Coated Capsules for Crohn's Disease in Japan: Analysis of Health Insurance Big Data.
  Keiji Yagisawa; Atsuhito Kubota; Shungo Imai; Shunsuke Nashimoto; Yuki Sato; Hitoshi Kashiwagi; Atsuo Maemoto; Mitsuru Sugawara; Yoh Takekuma
  Biological & pharmaceutical bulletin, 48, 1, 33, 38, 2025年, ［査読有り］, ［国内誌］
  英語, 研究論文（学術雑誌）, Using a large health insurance database in Japan, we examined the real-world usage of budesonide enteric-coated capsules (BUD) in treating Crohn's disease. We analyzed data from the Japan Medical Data Center claims database for Crohn's disease patients prescribed BUD from April 2016 to March 2021, focusing on prescription status, adverse events (AEs), monitoring tests, and concomitant medications over 2 years following BUD initiation. Patients were categorized into two groups based on BUD usage duration: ≤1 year and >1 year. Of the 7364 registered patients, 1049 (14.2%) were prescribed BUD. Among the 562 followed for 2 years, 505 (89.9%) used BUD for ≤1 year and 57 (10.1%) for >1 year. Over 70% of the patients used at least one biologic, and more than 20% used at least two. The proportions of new thiopurine initiation were 22 and 9% in the ≤1-year and >1-year groups, respectively (p = 0.0181). We did not identify any obvious increase in AEs from long-term BUD use within the confines of our study design. However, regardless of prescription duration, over half of the patients lacked hepatitis B virus screening, glycated hemoglobin measurement, adrenal function quantification, or bone densitometry. Usage of strong CYP3A4 inhibitors was more frequent among patients in the BUD >1-year group. This study revealed that numerous Japanese patients received long-term BUD prescriptions. Although no apparent increase in AEs from long-term BUD was detected, we identified inadequate monitoring of AEs and drug interactions, as well as insufficient use of steroid-sparing agents.
• Impact of Eye Contact on Communication during Online Medication Counseling: An Analysis Using the Roter Interaction Analysis System.
  Ayako Mori; Izumi Kato; Katsuya Narumi; Yoh Takekuma; Shuhei Ishikawa; Hitoshi Kashiwagi; Yuki Sato; Mitsuru Sugawara; Masaki Kobayashi
  Biological & pharmaceutical bulletin, 48, 1, 17, 22, 2025年, ［査読有り］, ［国内誌］
  英語, 研究論文（学術雑誌）, We have previously used the Roter Interaction Analysis System (RIAS) to analyze differences between online and face-to-face medication counseling. In our previous research, students have commented that the built-in camera on their laptops makes it difficult to make eye contact and communicate effectively. Furthermore, there is a lack of research on the impact of eye contact in online medical communication. Therefore, this study aimed to investigate the effects of eye contact on online medication counseling. Two simulated patients (SPs) and 10 pharmacy students acting as pharmacists were enrolled in this clinical study (ID:2022-001). Participants were divided into 2 groups: one using cameras designed to naturally align eye contact and another using standard device cameras. The dialogues were segmented into meaningful minimal units (utterances), categorized using RIAS according to their nature, and analyzed. Scenarios with aligned eye contact significantly increased the total number of SP utterances and the occurrence and proportion of "Check" utterances by students, confirming their understanding. The increase in the total utterance count of SPs was associated with a corresponding increase in the number of "Agree" utterances indicating agreement and understanding. Thus, eye contact enhances the clarity of patient responses and proactively confirms patient understanding, thereby mitigating the difficulty of assessing comprehension and conducting bidirectional communication online. This study's findings quantitatively suggested that eye contact in online medication counseling enhances proactive engagement in communication for pharmacy students and SPs.
• Comparison of busulfan pharmacokinetics between four-times-daily and once-daily administration in pediatric patients: a preliminary prospective observational trial
  Atsushi Yamaguchi; Shinsuke Hirabayashi; Kazuko Niki; Keisuke Kagami; Yukayo Terashita; Yuko Cho; Atsushi Manabe; Mitsuru Sugawara; Yoh Takekuma
  International Journal of Hematology, 121, 2, 244, 251, Springer Science and Business Media LLC, 2024年12月03日, ［査読有り］, ［国内誌］
  英語, 研究論文（学術雑誌）, Therapeutic drug monitoring (TDM) of busulfan (BU) is useful for achieving the target area under the curve (AUC) because its effective plasma-concentration range is narrow. This preliminary observational study evaluated the pharmacokinetic (PK) parameters of BU administered four times daily or once daily to pediatric patients. The plasma concentrations were measured at both the test dose and first dose, and the doses on day 1 and days 2-4 were determined based on each TDM. A comparison of PK parameters between four-times-daily and once-daily administration was performed for both the test dose and first dose of BU. Of the 11 patients, five received four-times-daily BU and six received once-daily BU. The Vd for once-daily administration was higher than that for four-times-daily administration for the first dose but not for the test dose. The ratio of actual AUC for the first dose to estimated AUC guided by the test dose was lower with once-daily administration than with four-times-daily administration. These results indicate that the PK parameters of BU administered once daily are challenging to predict based on the TDM of the test dose. TDM should be considered on day 1 to achieve the target AUC, especially with once-daily administration.
• Validated UPLC-MS/MS method for quantification of melatonin receptor agonists and dual orexin receptor antagonists in human plasma and breast milk: Application to quantify suvorexant and lemborexant in clinical samples
  Hina Ishikawa; Ayako Furugen; Ayako Nishimura; Takeshi Umazume; Shuhei Ishikawa; Ryoichi Aoyagi; Katsuya Narumi; Keisuke Okamoto; Yoh Takekuma; Mitsuru Sugawara; Masaki Kobayashi
  Journal of Pharmaceutical and Biomedical Analysis, 251, 116432, 116432, Elsevier BV, 2024年12月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, Pharmaceutical care is important for mental health during the perinatal period, which is often characterized by insomnia. In recent years, prescriptions of melatonin receptor agonists (MRAs) and dual orexin receptor antagonists (DORAs) for insomnia have increased; however, their use during the perinatal period has scarcely been reported. In the present study, we developed a UPLC-MS/MS method for the quantification of ramelteon, its metabolite M-II, suvorexant, and lemborexant in human plasma and breast milk to accumulate information on the safety and transfer of MRAs and DORAs into breast milk. Samples of MRAs (ramelteon and M-II) in plasma and breast milk were prepared using liquid-liquid extraction (LLE) with ethyl acetate. For DORAs (suvorexant and lemborexant), LLE with ethyl acetate was applied to plasma samples. For breast milk samples, significant ion suppression was observed for LLE with ethyl acetate. Solid-phase extraction (SPE) cartridges capable of removing phospholipids improved the matrix effects. Finally, protein precipitation with methanol and an SPE cartridge, InertSep® Phospholipid Remover, were selected for breast milk sample preparation. An ACQUITY UPLC BEH C18 column was used for analyte separation. MRAs and DORAs were eluted using isocratic and gradient elution, respectively, and analyzed using electrospray ionization in the positive mode with multiple reaction monitoring. The range of calibration curve for MRAs and DORAs was 0.1-25 and 0.5-50 ng/ml, respectively. Both the plasma and breast milk samples exhibited good linearity over this range. The method was validated by evaluating its accuracy and precision, matrix effect, recovery, carry-over, stability, and dilution integrity. The validated method was successfully applied to clinical samples donated by breastfeeding women and the milk/plasma (M/P) ratio and relative infant dose (RID) of lemborexant (one case) and suvorexant (two cases) were estimated. The M/P ratio of lemborexant was <1, and the RID was 1.05 %. The M/P ratio of suvorexant was <0.1, and RID was 0.11-0.20 %. This method will be useful for future studies evaluating the safety of these drugs during breastfeeding.
• Impact of baseline renal impairment on severe neutropenia development in pemetrexed and carboplatin thoracic cancer treatment.
  Yoshitaka Saito; Osamu Taniguchi; Yoh Takekuma; Jun Sakakibara-Konishi; Yasushi Shimizu; Ichiro Kinoshita; Mitsuru Sugawara
  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 32, 12, 829, 829, 2024年11月27日, ［査読有り］, ［最終著者］, ［国際誌］
  英語, 研究論文（学術雑誌）, BACKGROUND: Carboplatin (CBDCA) plus pemetrexed (PEM) is a commonly-used thoracic cancer treatment. As both CBDCA and PEM are excreted via the kidneys, renal impairment (RI) can lead to severe neutropenia, the most typical adverse event in the treatment. We aimed to determine the impact of baseline RI on the development of severe neutropenia following real-world CBDCA + PEM-containing treatments. METHODS: Patients with thoracic cancer receiving CBDCA + PEM-containing treatments (n = 155) were divided into a control group (baseline creatinine clearance [CCr] ≥ 60 mL/min) and an RI group (baseline CCr < 60 mL/min) and retrospectively evaluated. The primary endpoint was the incidence of severe neutropenia during the first cycle. We also assessed factors associated with the development of severe neutropenia. RESULTS: Severe neutropenia during the first cycle was confirmed in 41.2% of the patients in the RI group, which was significantly higher than that in the control group (20.7%, P = 0.02). Additionally, severe neutropenia during all evaluation periods was also more prevalent in the RI group compared to the control group (47.1% vs. 24.8%, P = 0.02). In contrast, the incidence of severe thrombocytopenia was not different. Multivariate logistic regression analyses identified RI as a risk factor for severe neutropenia (adjusted odds ratio 2.71; 95% confidence interval 1.18-6.21, P = 0.02 for the first cycle; 2.62, 1.17-5.84, P = 0.02 for all evaluation periods). CONCLUSION: Our study revealed that patients with baseline RI exhibited severe neutropenia after CBDCA + PEM-containing treatments.
• Effects of famotidine use during pregnancy: an observational cohort study.
  Ayako Nishimura; Ayako Furugen; Masaki Kobayashi; Yoh Takekuma; Naho Yakuwa; Mikako Goto; Masahiro Hayashi; Atsuko Murashima; Mitsuru Sugawara
  Journal of pharmaceutical health care and sciences, 10, 1, 70, 70, 2024年11月08日, ［査読有り］, ［最終著者, 責任著者］, ［国際誌］
  英語, 研究論文（学術雑誌）, BACKGROUND: Famotidine, a histamine2-receptor antagonist (H2Ras), is widely used to treat and prevent gastrointestinal symptoms during pregnancy. Although several studies have reported the use of H2Ras during pregnancy, limited data on famotidine were included in these reports. Therefore, we analyzed pregnancy outcome data to evaluate the effects of famotidine use during pregnancy on the fetus. METHODS: Pregnancy outcome data were used for females enrolled in two Japanese facilities that provided counseling on drug use during pregnancy between April 1988 and December 2017. For the primary endpoint, the incidence of congenital malformations was calculated from the data of live birth to pregnant women who took famotidine (n = 330) or drugs considered to exert no teratogenic risk (control, n = 1,407) during the first trimester of pregnancy. Considering secondary endpoints, the incidence of obstetric outcomes, including preterm delivery, was calculated from data on the use of famotidine (n = 347) and controls (n = 1,476) during the entire pregnancy. The crude odds ratios (cORs) for the incidence of congenital malformations were calculated using univariate logistic regression analysis, with the control group used as the reference. Adjusted ORs (aORs) were calculated using multivariate logistic regression analysis adjusted for various other factors. RESULTS: The incidences of congenital malformations in the famotidine and control groups were 3.9% and 2.8%, respectively. There was no significant difference between the famotidine and control groups (cOR: 1.40 [95% CI:0.68-2.71], aOR: 1.06 [95% CI:0.51-2.16]). Conversely, the preterm delivery rates were 8.1% and 3.8% in the famotidine and control groups, respectively, indicating a significant difference (cOR: 2.00 [95% CI:1.20-3.27]). However, the multivariate analysis eliminated famotidine use as a confounding factor. CONCLUSIONS: This observational cohort study revealed that exposure to famotidine during the first trimester of pregnancy was not associated with an increased risk of congenital malformations in infants. Although a higher rate of preterm delivery was detected in famotidine users when compared with controls, this could be attributed to confounding factors, such as complications.
• Impact of renal impairment on early development of severe neutropenia with trifluridine/tipiracil treatment for metastatic colorectal cancer.
  Yoshitaka Saito; Yoh Takekuma; Yoshito Komatsu; Mitsuru Sugawara
  Scientific reports, 14, 1, 26990, 26990, 2024年11月06日, ［査読有り］, ［最終著者］, ［国際誌］
  英語, 研究論文（学術雑誌）, Trifluridine/tipiracil (FTD/TPI) with or without bevacizumab is an effective treatment for metastatic colorectal cancer (mCRC). As this agent is mainly excreted via the kidney, we aimed to evaluate the impact of renal impairment (RI) on the early development of severe neutropenia, a dose-limiting toxicity and whose development reflects better treatment outcomes, in patients with mCRC treated with FTD/TPI. Patients with mCRC receiving FTD/TPI ± bevacizumab (n = 100) were divided into the RI group (creatinine clearance [CCr] < 90 mL/min) or control group (CCr ≥ 90 mL/min), and retrospectively evaluated. Severe neutropenia during the first two cycles occurred in 57.6% and 34.2% of patients in the RI and control groups, respectively, which was significantly different (P = 0.03) and met our primary endpoint. Furthermore, the incidence during the first cycle also differed significantly (52.5% in the RI group and 17.1% in the control group, P = 0.0004). Multivariate logistic regression analysis suggested that baseline RI and neutropenia were significant risk factors for early severe neutropenia (adjusted odds ratio and 95% confidence interval: 3.07, 1.24-7.59, P = 0.02 for RI, and 9.76, 1.08-88.11, P = 0.04 for neutropenia). In conclusion, our study suggested that patients with RI can exhibit early severe neutropenia during real-world FTD/TPI treatment for mCRC.
• Development and validation of the prediction score for augmented renal clearance in critically Ill Japanese adults.
  Ryusei Mikami; Shungo Imai; Mineji Hayakawa; Hitoshi Kashiwagi; Yuki Sato; Shunsuke Nashimoto; Mitsuru Sugawara; Yoh Takekuma
  Journal of pharmaceutical health care and sciences, 10, 1, 69, 69, 2024年11月06日, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, BACKGROUND: Augmented renal clearance (ARC) decreases the therapeutic concentration of drugs excreted by the kidneys in critically ill patients. Several ARC prediction models have been developed and validated; however, their usefulness in Japan has not been comprehensively investigated. Thus, we developed a unique ARC prediction model for a Japanese mixed intensive care unit (ICU) population and compared it with existing models. METHODS: This retrospective study enrolled a mixed ICU population in Japan from January 2019 and June 2022. The primary outcome was the development and validation of a model to predict ARC onset based on baseline information at ICU admission. Patients admitted until May 2021 were included in the training set, and external validation was performed on patients admitted thereafter. A multivariate logistic regression model was used to develop an integer-based predictive scoring system for ARC. The new model (the JPNARC score) was externally validated along with the ARC and Augmented Renal Clearance in Trauma Intensive Care (ARCTIC) scores. RESULTS: A total of 2,592 critically ill patients were enrolled initially, with 651 patients finally included after excluding 1,941 patients. The training and validation datasets comprised 456 and 195 patients, respectively. Multivariate analysis was performed to develop the JPNARC score, which incorporated age, sex, serum creatinine, and diagnosis upon ICU admission (trauma or central nervous system disease). The JPNARC score had a larger area under the receiver operating characteristic curve than the ARC and ARCTIC scores in the validation dataset (0.832, 0.633, and 0.740, respectively). CONCLUSIONS: An integer-based scoring system was developed to predict ARC onset in a critically ill Japanese population and showed high predictive performance. New models designed to predict the often-unrecognized ARC phenomenon may aid in the decision-making process for upward drug dosage modifications, especially in resource- and labor-limited settings.
• Reply to Accurate Risk Prediction Model for Surgical Site Infection After Lower Third Molar Surgery.
  Akira Yamagami; Katsuya Narumi; Yoshitaka Saito; Ayako Furugen; Shungo Imai; Yoshimasa Kitagawa; Yoichi Ohiro; Ryo Takagi; Yoh Takekuma; Mitsuru Sugawara; Masaki Kobayashi
  Oral diseases, 2024年11月03日, ［査読有り］, ［国際誌］
  英語
• トラブルシューティングに効果的な電子マニュアルの作成・運用
  小柳 遼; 川岸 亨; 水口 貴史; 山崎 浩二郎; 武隈 洋; 菅原 満
  北海道病院薬剤師会誌, 107, 7, 9, (一社)北海道病院薬剤師会, 2024年11月
  日本語
• Effect of baseline anemia on the efficacy of docetaxel and ramucirumab for advanced non-small cell lung cancer treatment.
  Yoshitaka Saito; Yoh Takekuma; Jun Sakakibara-Konishi; Yasushi Shimizu; Ichiro Kinoshita; Mitsuru Sugawara
  BMC cancer, 24, 1, 1301, 1301, 2024年10月21日, ［査読有り］, ［最終著者］, ［国際誌］
  英語, 研究論文（学術雑誌）, BACKGROUND: Docetaxel (DOC) and ramucirumab (RAM) is one of the most effective regimens for advanced non-small cell lung cancer (NSCLC) treatment. In our previous study, baseline anemia was identified as a preventive factor against the development of severe adverse effects during the first treatment cycle. It was hypothesized that anemia directly promotes tumor angiogenesis, leading to the elevation of RAM efficacy with increased DOC delivery to tumors, while reducing DOC delivery to other organs, potentially mitigating severe adverse effects. If this hypothesis is correct, patients with baseline anemia may have better clinical outcomes than those with normal hemoglobin levels. In this study, we aimed to investigate the effect of baseline anemia on the efficacy of DOC + RAM in treating advanced NSCLC in a real-word setting. METHODS: Patients with advanced NSCLC receiving DOC + RAM (n = 72) were retrospectively assessed. They were categorized into a control group with normal baseline hemoglobin levels and an anemia group with baseline anemia. The primary endpoint was progression-free survival (PFS) evaluation. RESULTS: Patients in the anemia group had a significantly shorter PFS than that of patients in the control group (median PFS: 3.2 and 6.2 months; 95% confidence interval [CI]: 2.2-4.8 and 4.3-9.9 months, respectively;P = 0.008). In addition, the disease control rate in the anemia group was 65.8%, which was significantly lower than that in the control group (93.6%; P = 0.007). Overall survival tended to be shorter in patients with anemia than in controls, although the difference was not statistically significant (P = 0.07). Multivariate Cox hazard analysis suggested that baseline anemia was a singular risk factor for poor PFS (adjusted hazard ratio 1.84, 95% CI 1.08-3.13; P = 0.02). The incidence of severe adverse effects did not differ between the two groups. CONCLUSIONS: This study suggests that the PFS of patients with anemia treated with DOC + RAM for advanced NSCLC is shorter than that of those without the symptoms.
• Clinical research for saliva-based therapeutic drug monitoring of linezolid.
  Yuki Inoue; Hitoshi Kashiwagi; Yuki Sato; Shunsuke Nashimoto; Tsutomu Endo; Masahiko Takahata; Miki Komatsu; Mitsuru Sugawara; Yoh Takekuma
  British journal of clinical pharmacology, 2024年10月10日, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, AIMS: Linezolid is primarily used to treat of methicillin-resistant Staphylococcus aureus and multidrug-resistant tuberculosis infections. Thrombocytopenia due to linezolid usage is a concern, and therapeutic drug monitoring has been reported to be effective in its prevention. Plasma concentrations provide valuable information for treatment decisions; however, collecting plasma samples can be burdensome for both patients and healthcare providers. Therefore, there is interest in saliva as an alternative for monitoring, considering its potential to replace plasma samples. METHODS: Patients hospitalized at Hokkaido University Hospital and Hokkaido Spinal Cord Injury Center between April 2022 and July 2024, who received oral or intravenous linezolid treatment, were enrolled. The concentrations of linezolid were simultaneously measured in plasma and saliva samples. We determined the concentration profiles of linezolid in the saliva and examined the correlation between saliva and plasma linezolid concentrations. RESULTS: Eighteen patients receiving linezolid were enrolled. The average of saliva/plasma (S/P) concentration ratios of linezolid were 1.018. A strong correlation was found between the salivary and plasma concentrations of linezolid (R = .833, P < .001). Notably, in patients receiving intravenous administration of linezolid, the correlation was even more pronounced (R = .885, P < .001). Additionally, when focusing on the S/P ratio of the trough concentrations in the morning and at night, the S/P ratios at night were much closer to 1.0. CONCLUSION: The concentrations of linezolid in plasma and saliva were similar, indicating their potential applicability in clinical settings. The monitoring of linezolid concentrations in saliva has been shown to be particularly suitable for patients receiving intravenous administration.
• Exploring the impact of baseline platelet count on linezolid-induced thrombocytopenia: a retrospective single-center observation study.
  Yuki Inoue; Hitoshi Kashiwagi; Yuki Sato; Shunsuke Nashimoto; Mitsuru Sugawara; Yoh Takekuma
  International journal of clinical pharmacy, 2024年10月04日, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, BACKGROUND: Patients treated with linezolid (LZD) frequently develop thrombocytopenia, and previous studies have identified the risk factors for this condition. However, the relationship between the development of LZD-induced thrombocytopenia and baseline platelet count has varied according to different reports. AIM: To explore the relationship between platelet count and the development of LZD-induced thrombocytopenia. METHOD: Patients who underwent LZD at Hokkaido University Hospital in Japan from September 2008 to March 2023 were included. We collected data on patient characteristics and platelet counts at baseline and during LZD therapy from the electronic medical records. Thrombocytopenia was defined as a decrease in platelet count by 30% or more from baseline, or a platelet level < 100,000/µL. RESULTS: Two hundred and ninety-five patients who received LZD were included in this study, of whom 34.9% developed thrombocytopenia. In the early days of LZD treatment, the thrombocytopenia group showed a nearly 5% decrease in platelet count, while the non-thrombocytopenia group exhibited an increase of over 5%. Additionally, focusing on early onset thrombocytopenia (within 5 days), a baseline platelet count of < 150,000/µL was identified as a risk factor for early thrombocytopenia. Conversely, it was also observed that 24.7% of patients with a baseline platelet count ≥ 150,000/µL still developed early thrombocytopenia. CONCLUSION: Our findings suggest that while a baseline platelet count of < 150,000/µL is a risk factor for the early onset of thrombocytopenia, vigilant monitoring of platelet counts by clinical pharmacists in the early stages of LZD treatment is essential, regardless of baseline platelet levels.
• The crucial relationship between vancomycin minimum inhibitory concentration and therapeutic efficacy against methicillin-resistant coagulase-negative staphylococci.
  Yusuke Niinuma; Keisuke Kagami; Mitsuru Sugawara; Yoh Takekuma
  Journal of chemotherapy (Florence, Italy), 1, 8, 2024年08月26日, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, The area under the curve (AUC)/minimum inhibitory concentration (MIC) ratio was used as an indicator of the clinical efficacy of vancomycin. However, the target AUC/MIC has not been set for methicillin-resistant coagulase-negative staphylococci (MR-CNS), and the effectiveness of vancomycin in strains with high MIC is unknown. Therefore, we aimed to investigate the relationship between the vancomycin MIC and therapeutic efficacy in patients with MR-CNS bacteremia. The primary outcome was the difference in treatment failure rate when the MR-CNS vancomycin MIC was 1 or 2 µg/mL. The treatment failure rate did not significantly differ between the two groups (MIC 1 vs. MIC 2: 27.0% vs. 31.0%; p = 0.779). As a result of multivariate analysis, AUC/MIC0-24 h ≤230 was extracted as risk factor for treatment failure, suggesting the importance of a sufficient initial loading dose and early blood concentration monitoring to increase AUC/MIC0-24 h for successful treatment.
• Association of oral mucositis induced by anthracycline-cyclophosphamide and subsequent docetaxel treatment for perioperative breast cancer.
  Yoshitaka Saito; Yoh Takekuma; Masato Takahashi; Tomohiro Oshino; Mitsuru Sugawara
  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 32, 8, 513, 513, 2024年07月13日, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, PURPOSE: Anthracycline-cyclophosphamide followed by docetaxel-containing chemotherapy is effective for perioperative breast cancer treatment. However, these treatments frequently induce oral mucositis (OM), with an incidence ranging from 20 to 50%. The association of OM development between different chemotherapeutic treatments remains unclear. Consequently, this study aimed to compare OM development during docetaxel-containing chemotherapy between patients with and without OM experience during previous anthracycline-cyclophosphamide treatments to assess the association between OM development and treatment regimens. METHODS: Seventy-two patients with breast cancer receiving anthracycline-cyclophosphamide followed by docetaxel-containing chemotherapy as a perioperative treatment were categorized into the control (no prior OM experience with anthracycline-cyclophosphamide) and OM-experience (OM development during previous treatment) groups and retrospectively evaluated. The primary endpoint was the incidence of all-grade OM in the first docetaxel-containing chemotherapy cycle. Additionally, the incidences of OM and dysgeusia during all treatment cycles and factors associated with the incidence of OM were evaluated. RESULTS: The incidence of all-grade OM in the first cycle was significantly higher in the OM-experience group (54.2%) than in the control group (10.4%; P < 0.0001). Furthermore, its incidence in all treatment cycles was higher in the OM-experience group (66.7%) than in the control group (12.5%, P < 0.0001). However, the incidence of dysgeusia did not differ between the groups. Multivariate logistic regression analysis revealed OM experience during previous anthracycline-cyclophosphamide treatment and concomitant pertuzumab use as independent risk factors for OM development in subsequent docetaxel-containing chemotherapy. CONCLUSION: Our study suggests that patients experiencing OM with anthracycline-cyclophosphamide during perioperative breast cancer treatment exhibit symptoms following subsequent docetaxel-containing chemotherapy.
• Evaluation of the impact of systemic dexamethasone dosage on docetaxel-induced hand-foot syndrome in patients with breast cancer.
  Yoshitaka Saito; Yoh Takekuma; Masato Takahashi; Tomohiro Oshino; Mitsuru Sugawara
  Scientific reports, 14, 1, 14083, 14083, 2024年06月18日, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, Hand-foot syndrome (HFS) is a frequently occurring and treatment-requiring adverse effect of docetaxel. We previously reported that systemic dexamethasone (DEX) prevents the other docetaxel-induced adverse inflammatory effects in a dose-dependent manner. This study aimed to evaluate the dose-dependent efficacy of systemic DEX in attenuating HFS in patients with breast cancer receiving docetaxel. Patients with breast cancer receiving docetaxel (75 mg/m2)-containing regimens (n = 111) were divided into 4 and 8 mg/day DEX groups, with each DEX dose administered on days 2-4, and analyzed retrospectively. Development of all-grade HFS in all treatment cycles was significantly lower in the 8 mg group (50.0%) than in the 4 mg group (73.0%, P = 0.03), with primary endpoint accomplishment. Moreover, its development in the first cycle was also lower in the 8 mg group than in the 4 mg group. These results were confirmed in a propensity score-matched population. Logistic regression analysis suggested higher DEX dosage as an independent preventive factor (adjusted odds ratio 0.35; 95% confidence interval 0.14-0.86, P = 0.02 for all cycles; 0.26, 0.11-0.63, P = 0.003 for the first cycle). Our study suggests that systemic DEX prevents the occurrence of docetaxel-induced HFS in patients with breast cancer in a dose-dependent manner in a real-world setting.
• Development of an Evaluation System Using Intestinal Organoids for Drug Efflux Transport Analysis by an Imaging Approach
  Chihiro Koseki; Takehiko Ishikawa; Yuki Sato; Mikiko Shimada; Yuki Yokoi; Kiminori Nakamura; Naoyuki Honma; Takanori Moriyama; Hitoshi Kashiwagi; Mitsuru Sugawara
  Journal of Pharmaceutical Sciences, Elsevier BV, 2024年06月, ［査読有り］, ［最終著者, 責任著者］, ［国際誌］
  英語, 研究論文（学術雑誌）, There are several in vitro systems that enable evaluation of the absorption direction, but there are few quantitative systems that enable easy evaluation of the excretion direction. Enteroids, organoids derived from intestine, have been frozen and passaged for various research. But it is not clear how the freezing and passaging affect the expression and function of transporters. We investigated the effects of passage and cryopreservation of enteroids. We focused on P-gp (P-glycoprotein) and compared the transfer rates of rhodamine 123 (Rh123) into the lumen of enteroids with and without a P-gp inhibitor. mRNA expression levels did not change significantly before and after passage and cryopreservation. Accumulation of Rh123 in the lumen of enteroids was observed. With some P-gp inhibitors, excretion of Rh123 into the lumen of enteroids was inhibited and the nonexcreted Rh123 accumulated in enteroids epithelial cells. The transfer rate of Rh123 into the lumen of enteroids with a P-gp inhibitor was significantly decreased compared to that of without a P-gp inhibitor. Before and after passage and cryopreservation, the transfer rate was almost the same as that of primary cultured enteroids. We succeeded in easily evaluating whether a component is a substrate of P-gp using enteroids.
• Dolutegravir/lamivudineへの薬剤変更における薬剤師介入の効果
  田澤 佑基; 遠藤 知之; 武隈 洋; 菅原 満
  日本エイズ学会誌, 26, 2, 77, 84, (一社)日本エイズ学会, 2024年05月
  日本語
• Immunoregulatory Effects of Elemental Diet and Its Ingredient, Tryptophan, via Activation of the Aryl Hydrocarbon Receptor in Mice
  Atsuhito Kubota; Shungo Imai; Ryoichi Aoyagi; Wataru Murase; Masaru Terasaki; Mitsuru Sugawara; Yoh Takekuma; Hiroyuki Kojima
  International Journal of Molecular Sciences, 25, 6, 3448, 2024年03月19日, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, Inflammatory bowel disease (IBD) is characterized by chronic intestinal inflammation and its treatment varies widely; however, when inflammation is high, a complete nutrient containing pre-digested elemental diet (ED) is used to preserve the intestinal tract. In this study, we investigated the mechanisms underlying the effectiveness of EDs for IBD using mice. C57BL/6 mice were orally treated with the ED (5 mL/day) and its ingredient L-tryptophan (Trp) (1-100 mg/kg), respectively. Flow cytometry analysis revealed that treatment with the ED and Trp (10 and 100 mg/kg) significantly increased the percentage of splenic CD4+-/CD25+-/Foxp3+ regulatory T cells (Tregs). In the 2% DSS-induced colitis-mouse model, Trp administration (100 mg/kg) led to a significant decrease in TNF-α and increase in IL-10 in the serum as well as a significant decrease in the inflammation score. Furthermore, the aryl hydrocarbon receptor (AhR) agonistic activity, which is a key function of Treg induction, of Trp and 15 Trp metabolites was characterized using a highly sensitive DR-EcoScreen cell assay. Five Trp metabolites, including L-kynurenine, acted as AhR agonists, while Trp did not. Taken together, these results suggest that the ED treatment has a Trp-dependent immunoregulatory effect, and several Trp metabolites that activate the AhR might contribute to induction of remission in patients with IBD.
• Evaluation of the risk factors for the failure of a single prophylactic dose of anticholinergic drugs for irinotecan-induced cholinergic symptoms.
  Takuya Watanabe; Yoshitaka Saito; Yoh Takekuma; Yasushi Shimizu; Ichiro Kinoshita; Yoshito Komatsu; Mitsuru Sugawara
  International journal of clinical pharmacology and therapeutics, 62, 5, 213, 221, 2024年03月03日, ［査読有り］, ［最終著者, 責任著者］, ［国際誌］
  英語, 研究論文（学術雑誌）, OBJECTIVE: Irinotecan (IRI) is an anticancer drug that is frequently used to treat colorectal, gastric, and pancreatic cancers. Its side effects include cholinergic symptoms, such as diarrhea, abdominal pain, nausea, and hyperhidrosis. Anticholinergic medicines are frequently used for treatment or prophylaxis; however, the risk factors for the failure of a single prophylactic anticholinergic administration remain unclear. Moreover, an appropriate anticholinergic drug for prophylaxis remains unknown. Thus, we aimed to identify the risk factors associated with the failure of a single prophylactic dose of anticholinergic drugs for IRI-induced cholinergic symptoms and to evaluate the usefulness of multiple prophylactic doses of anticholinergic drugs. MATERIALS AND METHODS: Patients who underwent IRI treatment for colorectal, gastric, or pancreatic cancer and received prophylactic anticholinergic drugs for IRI-induced cholinergic symptoms (n = 135) were retrospectively evaluated. Univariate and multivariate logistic regression analyses were performed to identify the risk factors for failure of a single prophylactic dose of anticholinergic drugs. We also evaluated the efficacy of multiple prophylactic anticholinergic drug administration. RESULTS: Based on univariate and multivariate analyses, colorectal cancer, female sex, and prophylactic use of scopolamine butyl bromide were identified as risk factors for failure of a single prophylactic dose of anticholinergic drugs. The efficacy of multiple prophylactic doses was confirmed to be 95% of the patients who had a single prophylactic failure due to temporary effect but symptom appearance after a certain period of time (wearing-off). CONCLUSION: We determined that colorectal cancer, female sex, and prophylactic use of scopolamine butyl bromide were risk factors associated with the failure of a single prophylactic dose of anticholinergic drugs, and that multiple prophylactic doses for wearing-off can be a promising method.
• Impact of preexisting proteinuria on the development of regorafenib-induced problematic proteinuria in real-world metastatic colorectal cancer treatment.
  Yoshitaka Saito; Yoh Takekuma; Yoshito Komatsu; Mitsuru Sugawara
  Scientific reports, 14, 1, 5153, 5153, 2024年03月02日, ［査読有り］, ［最終著者］, ［国際誌］
  英語, 研究論文（学術雑誌）, Regorafenib is the first multikinase inhibitor for treating metastatic colorectal cancer (mCRC). Proteinuria is a frequently encountered adverse effect, regardless of prior administration of vascular endothelial growth factor inhibitors. Herein, we aimed to assess the impact of baseline preexisting proteinuria on regorafenib-induced problematic proteinuria during real-world mCRC therapy. Patients with mCRC receiving regorafenib (n = 100) were retrospectively assessed and divided into control and preexisting proteinuria (baseline grade of 1-2) groups. The primary endpoint was the development of grade ≥ 2 (grade ≥ 3 in case of baseline grade 2 patients) proteinuria. Propensity score-matching was performed to confirm the robustness of primary analyses. Defined proteinuria occurred in 30.7 and 57.9% of patients in the control and preexisting proteinuria groups, respectively, with significant differences in the all-patient population (P = 0.01). The preexisting proteinuria group exhibited significant defined proteinuria development within 7 days of regorafenib initiation, grade ≥ 3 symptoms, and treatment suspension owing to proteinuria. Similar results were obtained in the propensity score-matched population. According to multivariate logistic regression analysis, baseline proteinuria was a singular risk factor for defined proteinuria development (adjusted odds ratio; 3.76, 95% confidence interval; 1.45-9.75, P = 0.007). Collectively, our study revealed that patients with preexisting proteinuria develop regorafenib-induced proteinuria degradation.
• Evaluation of Prediabetes in Cisplatin-induced Nephrotoxicity in the Short Hydration Method: A Subgroup Analysis
  YOSHITAKA SAITO; TATSUHIKO SAKAMOTO; MASAKI KOBAYASHI; YOH TAKEKUMA; ISSEI HIGUCHI; KEISUKE OKAMOTO; JUN SAKAKIBARA-KONISHI; YASUSHI SHIMIZU; ICHIRO KINOSHITA; MITSURU SUGAWARA
  In Vivo, 38, 2, 800, 806, Anticancer Research USA Inc., 2024年02月28日, ［査読有り］, ［最終著者］, ［国際誌］
  英語, 研究論文（学術雑誌）, BACKGROUND/AIM: Cisplatin-induced nephrotoxicity (CIN) is one of the most attention-requiring adverse effects. We have reported that diabetes mellitus significantly increases the incidence of CIN in a short hydration method in real-world lung cancer treatment. However, the effect of prediabetes on CIN development remains unclear. This study investigated whether patients with prediabetes exhibit CIN at a greater rate during real-world cisplatin-including treatments as a subgroup analysis. PATIENTS AND METHODS: This retrospective observational study enrolled patients with lung cancer receiving cisplatin treatment (≥75 mg/m2) from May 2014 to January 2021 (n=169). Patients were divided into a prediabetes group (baseline HbA1c 5.7-6.4%) and a control group (baseline HbA1c <5.7%). The primary endpoint of this study was the incidence of CIN in all treatment cycles between the two groups. We also assessed variations in serum creatinine (SCr) levels and creatinine clearance (CCr). RESULTS: CIN occurred in 4.7% of controls and 8.3% of patients with prediabetes in all cycles, with no significant difference (p=0.37). In contrast, variation of SCr levels and CCr was significantly worse in the prediabetes group [median variation level (range) 0.11 mg/dl (-0.11-0.46 mg/dl) and 0.12 mg/dl (-0.02-1.08 mg/d) in controls and prediabetes, p=0.04 for SCr; -12.9 ml/min (-54.1-4.9 ml/min) and -16.3 ml/min (-49.4-3.0 ml/min), p=0.02 for CCr, respectively]. These results were also confirmed during the first cycle of treatment. CONCLUSION: Patients with prediabetes did not develop problematic CIN, although they exhibited significant increases in SCr and decreases in CCr.
• コロナウイルス感染症流行時の病院実習における栄養サポートチーム(NST)実習を遠隔配信で行った場合の教育効果
  巽 道代; 熊谷 聡美; 七戸 俊明; 片山 真育; 武隈 洋; 菅原 満
  薬学教育, 7, 213, 221, (一社)日本薬学教育学会, 2024年01月
  日本語
• 新たなTDM対象抗菌薬の最前線 オキサゾリジノン系抗菌薬のTDM
  武隈 洋; 井上 優希; 菅原 満
  日本化学療法学会雑誌, 72, 1, 61, 61, (公社)日本化学療法学会, 2024年01月
  日本語
• Association Between Multisystem Immune-related Adverse Events and Progression-free Survivals in PD-1/PD-L1 Inhibitor Monotherapy.
  Atsushi Yamaguchi; Yoshitaka Saito; Keisuke Okamoto; Ayako Furugen; Katsuya Narumi; Yoh Takekuma; Jun Sakakibara-Konishi; Yasushi Shimizu; Ichiro Kinoshita; Mitsuru Sugawara; Masaki Kobayashi
  In vivo (Athens, Greece), 38, 6, 2886, 2896, 2024年, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, BACKGROUND/AIM: Immune-related adverse events (irAEs) occur in various organs, and sometimes multiply following treatment with immune checkpoint inhibitors (ICIs). This study aimed to determine the association between the number of irAEs and clinical outcomes. PATIENTS AND METHODS: This was a retrospective study that included patients with lung cancer, melanoma, and head and neck cancer who were treated with anti-programmed cell death (ligand) 1 (PD-1/PD-L1) monotherapy. We evaluated the association between the number of irAEs and progression-free survival (PFS) in the simple Cox regression analysis. To eliminate the immortal-time bias, an additional landmark analysis was performed. RESULTS: In total, 92, 69, and 37 patients were allocated to the no, single, and multisystem irAEs groups, respectively. The multisystem irAEs were associated with better PFS compared to the no irAE group. In contrast, at the 12-week landmark, multisystem irAEs were associated with poor PFS compared to the no irAEs group. Furthermore, the rate of treatment suspension owing to irAEs in the multisystem irAEs group (62.5%) was higher than that in the single irAE group (17.3%) at the 12-week landmark. CONCLUSION: The incidence of multisystem irAEs was associated with improved clinical outcomes in patients with lung cancer, melanoma, and head and neck cancer treated with PD-1/PD-L1 inhibitor monotherapy. However, these results may be influenced by a potential immortal-time bias. When accounting for this bias, the early development of multisystem irAEs within 12 weeks was linked to treatment suspension and poorer clinical outcomes.
• Risk Factor Analysis for Anti-epidermal Growth Factor Receptor Monoclonal Antibody-induced Problematic Skin Toxicities in Patients With Liver Metastatic Colorectal Cancer.
  Yoshitaka Saito; Kazuki Uchiyama; Yoh Takekuma; Yoshito Komatsu; Mitsuru Sugawara
  In vivo (Athens, Greece), 38, 5, 2390, 2398, 2024年, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, BACKGROUND/AIM: We previously reported that patients with metastatic colorectal cancer (mCRC) and baseline liver metastasis are at a higher risk of developing grade ≥2 overall skin toxicities when treated with anti-epidermal growth factor receptor (EGFR) monoclonal antibody. This study aimed to identify additional factors associated with skin toxicities induced by anti-EGFR treatment in patients with liver metastatic CRC. PATIENTS AND METHODS: Patients with liver metastatic CRC who initially received anti-EGFR monoclonal antibody-containing treatment (n=77) were retrospectively assessed. The primary endpoint was to identify the factor(s) responsible for the development of grade ≥2 overall skin toxicities. Additionally, factors for grade ≥2 rash and paronychia were evaluated. RESULTS: The incidence of grade ≥2 overall skin symptoms, rash, and paronychia was 62.3%, 31.2%, and 28.6%, respectively. Multivariate Cox proportional hazard regression analyses revealed that age <65 years and anemia were independent baseline risk factors for grade ≥2 overall skin toxicities (adjusted hazard ratio 2.09, 95% confidence interval=1.10-3.97, p=0.02 for age; 2.36, 1.20-4.61, p=0.01 for anemia). In contrast, combination prophylaxis using systemic minocycline and corticosteroid ointment was a preventive factor (0.47, 0.25-0.88, p=0.02). Males and age <65 years were baseline risk factors for grade ≥2 rash, and combination prophylaxis was identified as a preventive factor. No factors were identified for paronychia. CONCLUSION: Age <65 years and anemia were identified as independent baseline risk factors. Additionally, combination prophylaxis was found to be a preventive factor against anti-EGFR monoclonal antibody-induced grade ≥2 overall skin toxicities in patients with liver metastatic CRC.
• Evaluation of Efficacy of Adding Aprepitant to Palonosetron and Dexamethasone in Carboplatin and Etoposide Therapy.
  Tatsuhiko Sakamoto; Moeko Kado; Yoshitaka Saito; Kazuki Uchiyama; Ryota Kanno; Osamu Taniguchi; Yoh Takekuma; Jun Sakakibara-Konishi; Yasushi Shimizu; Ichiro Kinoshita; Mitsuru Sugawara
  Biological & pharmaceutical bulletin, 47, 6, 1189, 1195, 2024年, ［査読有り］, ［最終著者, 責任著者］, ［国内誌］
  英語, 研究論文（学術雑誌）, Although carboplatin (CBDCA) is classified as a moderately emetogenic agent, the majority of guidelines recommend the use of a neurokinin-1 receptor antagonist in addition to a 5-hydroxytryptamine type 3 receptor antagonist with dexamethasone (DEX) for CBDCA-containing chemotherapy because of its higher emetogenic risk. However, the additional efficacy of aprepitant (APR) in CBDCA-containing treatment remains controversial, and data on multiple-day treatments are limited. Etoposide (ETP) was administered on days 1-3 in the CBDCA + ETP regimen, and it is important to evaluate suitable antiemetic therapy for the regimen. Therefore, we evaluated the efficacy of additional APR in CBDCA + ETP. Patients were divided into two groups and retrospectively evaluated. One was the control group, which was prophylactically administered palonosetron (PALO) and DEX, and the other was the APR group, which received APR orally with PALO and DEX. The primary endpoint was complete response (CR) between the groups. The overall CR rates were 75.0 and 76.4% in the control and APR groups, respectively, with no significant difference (p = 1.00). In the acute phase, it was 88.9 and 97.2%, respectively, and 86.1 and 79.2% in the delayed phase, respectively, without significant differences (p = 0.10 and 0.38, respectively). The incidence and severity of nausea, vomiting, and anorexia were not significantly different between the two groups in the acute and delayed phases. Our findings suggest that combining APR with PALO and DEX does not improve the CR rate in CBDCA + ETP therapy.
• Platelets Affect the Activity of Amino Acid Transporter SNAT4 in HuH-7 Human Hepatoma Cells.
  Hitoshi Kashiwagi; Yuki Sato; Shunsuke Nashimoto; Shungo Imai; Yoh Takekuma; Mitsuru Sugawara
  Biological & pharmaceutical bulletin, 47, 3, 652, 659, 2024年, ［査読有り］, ［責任著者］, ［国内誌］
  英語, 研究論文（学術雑誌）, Platelets have been reported to exert diverse actions besides hemostasis and thrombus formation in the body. However, whether platelets affect transporter activity remains to be determined. In this study, we examined the effects of platelets on the activity of amino acid transporter system A, which is known to be changed by various factors, and we clarified the mechanism by which platelets affect system A activity. Among system A subtypes, we found that sodium-coupled neutral amino acid transporter (SNAT) 4 played a central role in the transport activity of system A in HuH-7 human hepatoma cells. Interestingly, platelets showed a biphasic effect on system A activity: activated platelet supernatants (APS) including the granule contents released from platelets downregulated system A activity at lower concentrations and the downregulation was suppressed at higher concentrations. The downregulation was due to a decrease in the affinity of SNAT4 for its substrate and not a decrease in the SNAT4 abundance on the plasma membrane. In addition, APS did not decrease the expression level of SNAT4 mRNA. On the other hand, platelets did not affect system A activity when the platelet suspension was added to HuH-7 cells. These results indicate that platelets indirectly affect the transport activity of system A by releasing bioactive substances but do not directly affect it by binding to HuH-7 cells.
• Decrease in Mycophenolic Acid Plasma Level by Sacubitril/Valsartan in a Lupus Nephritis Patient: A Case Report.
  Shunsuke Nashimoto; Masashi Miyamae; Issei Higuchi; Michihito Kono; Maria Tada; Tatsuya Atsumi; Mitsuru Sugawara; Yoh Takekuma
  Case reports in nephrology and dialysis, 14, 1, 30, 35, 2024年, ［査読有り］, ［国際誌］
  英語, INTRODUCTION: Mycophenolate mofetil (MMF), an inactive prodrug of mycophenolic acid (MPA), is an immunosuppressive drug used widely in the treatment of lupus nephritis. In this case report, the area under the blood concentration time curve (AUC) of MPA was significantly decreased by the concomitant use of sacubitril/valsartan. CASE PRESENTATION: The patient was a man in his 40s with a diagnosis of lupus nephritis class IVa/c+V. MMF dose was 1.5 g/day at admission, and AUC of MPA on day 14 was 25.1 μg⋅h/mL. Owing to poor blood pressure control, sacubitril/valsartan was initiated at 97/103 mg/day on day 29. On day 37, AUC of MPA was significantly decreased to 8.7 μg⋅h/mL, suggesting drug interaction with the newly initiated sacubitril/valsartan. Sacubitril/valsartan was decreased to 49/51 mg/day, and AUC of MPA on day 67 was 37.6 μg⋅h/mL, achieving the target range. The final MMF dose was set at 1.75 g/day. A possible mechanism of drug interaction between sacubitril/valsartan and MPA involves an organic anion transporting polypeptide (OATP). The inhibition of OATPs by sacubitril may have interrupted the enterohepatic circulation of MPA, resulting in a lower plasma concentration. CONCLUSION: Since lupus nephritis is often associated with hypertension, the drug interaction observed in this report may also occur in other cases. However, it is impossible to conclude that the decrease in plasma MPA levels was due to the concomitant use of sacubitril/valsartan, and more cases and basic findings are needed.
• Significantly Delayed Development of Polyarthritis with Active Tenosynovitis after Possible Temporary Neutropenic Immune-Related Adverse Events Caused by Atezolizumab Treatment: A Novel Case Report.
  Yoshitaka Saito; Yoh Takekuma; Hajime Asahina; Ryo Hisada; Mitsuru Sugawara
  Case reports in oncological medicine, 2024, 1566299, 1566299, 2024年, ［査読有り］, ［最終著者］, ［国際誌］
  英語, Immune checkpoint inhibitors have drastically improved cancer treatment. However, they may induce immune-related adverse events (irAEs). Here, we report a case of significantly delayed rheumatic irAEs (Rh-irAEs) with prior possible temporary neutropenic irAEs in a patient with atezolizumab-treated non-small-cell lung cancer and its management. A man in his sixties received atezolizumab monotherapy as the sixth-line treatment. He experienced an infusion-related reaction (fever) during the first cycle. On day 22 of cycle 2, grade 4 neutropenia suddenly appeared, but it disappeared on the next day. Cycle 3 was initiated after seven days; the patient did not exhibit any symptoms for approximately 500 days. However, on day 534 (day 1 of cycle 21), the patient complained of pain in the shoulders, back, and wrists. On day 644, the shoulder and back pain worsened with obvious swelling of the fingers. We thus suspended treatment and consulted a rheumatologist. A diagnosis of polyarthritis with active tenosynovitis was made based on joint ultrasound and laboratory tests. Prednisolone 15 mg attenuated the symptoms, allowing suspension of analgesics; however, dose reduction from 15 mg/day was difficult because of symptom flares. Finally, iguratimod 25 mg twice daily was initiated on day 764; prednisolone was reduced to 10 mg without flares, and its dosage was slowly reduced to 5 mg/day. Although irAEs exhibit multisystem features, delayed development of polyarthritis with active tenosynovitis after possible temporary neutropenic irAEs is rare. Thus, irAEs need to be monitored for a long time in patients with suspected irAE development even if it appears transiently.
• Comparison of the incidence of nausea and vomiting between linezolid and vancomycin using claims database: a retrospective cohort study.
  Takezo Tsutsumi; Shungo Imai; Kenji Momo; Hitoshi Kashiwagi; Yuki Sato; Mitsuru Sugawara; Yoh Takekuma
  International journal of clinical pharmacy, 46, 2, 421, 428, 2023年12月29日, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, BACKGROUND: Nausea and vomiting during linezolid therapy have been reported as part of safety analyses in clinical trials. We have previously examined the incidence of vomiting during linezolid therapy (18.1%). A previous study conducted at a single hospital showed low external validity. It is necessary to verify whether these results can be reproduced using generalizable data sources. AIM: To evaluate the incidence of nausea and vomiting during linezolid therapy compared with vancomycin using a Japanese claims database. METHOD: Patients administered linezolid or vancomycin were selected from the database between January 2005 and June 2017. The primary endpoint was the comparison of nausea and vomiting between the linezolid and vancomycin groups. We conducted propensity score matching (PSM) to adjust for patient characteristics. To assess risk factors for nausea and vomiting, logistic regression was conducted as the secondary endpoint. We defined nausea and vomiting as the first prescription of antiemetics during linezolid or vancomycin therapy as a surrogate endpoint. RESULTS: In total, 1215 patients were enrolled. After PSM, the number of patients in the linezolid and vancomycin groups was 241. Nausea and vomiting were observed in 11.2% and 5.0% of patients in the linezolid and vancomycin groups, respectively (p < 0.05). Linezolid administration was extracted as a risk factor for nausea and vomiting (odds ratio, 2.09; 95% confidence interval, 1.02-4.30). CONCLUSION: This study clarified the relationship between linezolid and nausea and vomiting using a Japanese claims database. Further studies are required to elucidate the unknown mechanisms of linezolid-induced nausea and vomiting.
• Palonosetron for prevention of delayed chemotherapy-induced nausea and vomiting in pediatric patients: a meta-analysis
  Atsushi Yamaguchi; Yoshitaka Saito; Yoh Takekuma; Mitsuru Sugawara
  Supportive Care in Cancer, 32, 1, 58, 58, Springer Science and Business Media LLC, 2023年12月26日, ［査読有り］, ［責任著者］, ［国際誌］
  英語, 研究論文（学術雑誌）, PURPOSE: Chemotherapy-induced nausea and vomiting (CINV) are common adverse events in patients undergoing emetogenic chemotherapy. Palonosetron, a second-generation 5-hydroxytryptamine-3 receptor antagonist (5-HT3 RA), has demonstrated non-inferiority to first-generation 5-HT3 RAs for CINV in pediatric patients. Although palonosetron has a long half-life and prolonged antiemetic action, its efficacy against delayed CINV in pediatric patients is not well understood. Therefore, this meta-analysis of randomized controlled trials (RCTs) aimed to evaluate the efficacy of palonosetron for delayed CINV in pediatric patients. METHODS: A literature search of MEDLINE/PubMed, Embase, Cochrane Library, and Web of Science databases was performed. A meta-analysis was performed using forest plots, and risk ratios (RRs) and 95% confidence intervals (CIs) were calculated. A funnel plot was constructed to explore publication bias. RESULTS: The literature search retrieved 842 records, of which 23 full-text articles were assessed, including six RCTs. Meta-analysis of four RCTs that reported on the complete response (CR: defined as no emesis and no rescue medication) rate for delayed CINV revealed that palonosetron was statistically superior to first-generation 5-HT3 RAs (RR = 1.21 [95% CI 1.09-1.35]; p < 0.01). Although the number of studies included was small, no publication bias was observed in the funnel plots. In addition, the CR rate for overall and acute CINV was also significantly higher for palonosetron (RR = 1.25 [95% CI 1.01-1.54]; p = 0.04 and RR = 1.06 [95% CI 1.01-1.12]; p = 0.03, respectively). CONCLUSION: Palonosetron is effective in the prophylaxis of delayed CINV in pediatric patients.
• Evaluation of the additional prophylactic effect of topical steroid ointment to systemic minocycline against anti-epidermal growth factor antibody-induced skin toxicities in metastatic colorectal cancer treatment.
  Yoshitaka Saito; Kazuki Uchiyama; Yoh Takekuma; Yoshito Komatsu; Mitsuru Sugawara
  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 32, 1, 8, 8, 2023年12月06日, ［査読有り］, ［最終著者］, ［国際誌］
  英語, 研究論文（学術雑誌）, BACKGROUND: Anti-epidermal growth factor receptor (EGFR) antibodies often cause skin toxicities. Preemptive skin treatments using systemic antibiotics with or without topical steroid are reportedly effective although the most suitable method remains unclear. This study aimed to determine whether combination prophylaxis using systemic minocycline and topical steroid is superior to minocycline alone in a real-world metastatic colorectal cancer (mCRC) treatment. METHODS: Patients with mCRC (n = 87) who received anti-EGFR monoclonal antibodies were retrospectively assessed. The primary objective was to compare the incidence of grade ≥ 2 overall skin toxicities during all treatment periods between the control group receiving prophylactic minocycline 100 mg/day, and the combination prophylaxis group receiving minocycline 100 mg/day + topical steroid. The incidence of each skin symptom was also evaluated. RESULTS: The incidence of grade ≥ 2 overall skin toxicities was 63.6% in the control and 56.9% in the combination groups, with no significant difference (P = 0.63). Similarly, the incidence of grade ≥ 2 dry skin, fissures, paronychia, and pruritus did not significantly differ. In addition, incidence of all-grade skin toxicities was not different. However, the incidence of grade ≥ 2 papulopustular rashes was significantly lower in the combination group (23.1% vs. 50.0%, P = 0.03). Propensity score-matched analysis supported these results. Multivariate logistic regression analysis showed no significant association between combination prophylaxis and grade ≥ 2 overall skin toxicities, but it did show a reduction in grade ≥ 2 papulopustular rashes. CONCLUSION: Adding topical steroids to systemic minocycline did not mitigate grade ≥ 2 overall skin toxicities induced by anti-EGFR antibodies; however, it significantly improved papulopustular rashes.
• Detection of factors related to treatment reduction in docetaxel and ramucirumab for non-small cell lung cancer treatment.
  Yoshitaka Saito; Shinya Tamaki; Daisuke Hirate; Shinya Takada; Kenta Takahashi; Yoh Takekuma; Jun Sakakibara-Konishi; Yasushi Shimizu; Ichiro Kinoshita; Mitsuru Sugawara
  Scientific reports, 13, 1, 19457, 19457, 2023年11月09日, ［査読有り］, ［最終著者, 責任著者］, ［国際誌］
  英語, 研究論文（学術雑誌）, Treatment using docetaxel (DOC) and ramucirumab (RAM) is an effective regimen in second or later line advanced non-small cell lung carcinoma (NSCLC) treatment. However, it induces severe adverse effects, resulting in treatment reduction such as dose reduction and/or discontinuation. This study aimed to reveal the factor(s) associated with treatment reduction in DOC + RAM. We retrospectively evaluated patients with advanced NSCLC (n = 155). Treatment reduction of the second course due to severe adverse effects was conducted in 25.8% of the participants, and relative dose intensity at the second course was 95.7 ± 8.4% for DOC and 91.9 ± 24.8% for RAM. Multivariate logistic regression analyses identified that baseline anemia and prophylactic granulocyte colony-stimulating factor (G-CSF) administration are preventive factors for the reduction (adjusted odds ratio, 0.29; 95% confidence interval, 0.12-0.66; P = 0.004 for baseline anemia, 0.18; 0.08-0.42; P < 0.0001 for prophylactic G-CSF administration). The primary cause of the reduction was febrile neutropenia, and the same factors were identified. Our study revealed that patients with baseline anemia and prophylactic G-CSF administration have less risk for treatment reduction in DOC + RAM for NSCLC treatment.
• 食道胃接合部癌術後に食道狭窄を繰り返す症例に対して持効性注射薬カボテグラビル+リルピビリン(CAB+RPV)を導入した一例
  田澤 佑基; 遠藤 知之; 武隈 洋; 菅原 満
  日本エイズ学会誌, 25, 4, 483, 483, (一社)日本エイズ学会, 2023年11月
  日本語
• Risk factor analysis for cisplatin-induced nephrotoxicity with the short hydration method in diabetic patients.
  Yoshitaka Saito; Masaki Kobayashi; Shinya Tamaki; Katsuyuki Nakamura; Daisuke Hirate; Kenta Takahashi; Yoh Takekuma; Jun Sakakibara-Konishi; Yasushi Shimizu; Ichiro Kinoshita; Mitsuru Sugawara
  Scientific reports, 13, 1, 17126, 17126, 2023年10月10日, ［査読有り］, ［最終著者, 責任著者］, ［国際誌］
  英語, 研究論文（学術雑誌）, The occurrence of cisplatin (CDDP)-induced nephrotoxicity (CIN) has decreased with advancements in supportive care. In contrast, we reported that baseline diabetes mellitus (DM) complications significantly worsen CIN. This study aimed to determine further risk factors associated with CIN development in DM patients. Patients with thoracic cancer requiring DM pharmacotherapy, who received CDDP (≥ 60 mg/m2)-containing regimens using the short hydration method (n = 140), were enrolled in this retrospective multicenter observational study. The primary endpoint of the present study was the elucidation of risk factors (patient factors, DM medication influence, and treatment-related factors) associated with CIN development in patients with DM. Cisplatin-induced nephrotoxicity occurred in 22.1% of patients with DM. The median worst variation of serum creatinine levels and creatinine clearance (worst level - baseline level) was 0.16 mg/dL (range: - 0.12-1.41 mg/dL) and - 15.9 mL/min (- 85.5-24.3 mL/min), respectively. Multivariate logistic regression analyses identified female sex as the singular risk factor for CIN development in the DM population (adjusted odds ratio; 2.87, 95% confidence interval; 1.08-7.67, P = 0.04). Diabetes mellitus medication and treatment-related factors did not affect CIN development. In conclusion, our study revealed that female sex is significantly associated with CIN development in patients with DM and thoracic cancer.
• Quantitative analysis of communication changes in online medication counseling -Using the Roter Interaction Analysis System.
  Ayako Mori; Izumi Kato; Katsuya Narumi; Yoh Takekuma; Hitoshi Kashiwagi; Yuki Sato; Mitsuru Sugawara; Masaki Kobayashi
  Research in social & administrative pharmacy : RSAP, 20, 1, 36, 42, 2023年10月04日, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, BACKGROUND: Quantitative analysis and objective evaluation of communication play an important role in medical communication education. In the process of developing an online methodology for medication counseling practice, we felt the necessity of conducting a quantitative evaluation to enhance its effectiveness. OBJECTIVES: This study aimed to quantitatively evaluate the communication in each scenario to comprehensively identify the differences between face-to-face and online communication in medication counseling practicum. In addition, we examined how patient satisfaction changes between face-to-face and online interactions. METHODS: Face-to-face and online role-playing were conducted between simulated patients (SPs) and students acting as pharmacists, and their dialogues were videotaped. The utterances in each recorded dialogue were categorized and analyzed by the Roter interaction analysis system (RIAS). The Japanese version of the Medical Interview Satisfaction Scale (MISS-21J) responses of the SPs were analyzed for the patient satisfaction survey. RESULT: The results of the RIAS analysis revealed that the socio-emotional category appeared significantly more frequently in face-to-face communication, with more utterances that were more attuned to the feelings of the other person and more considerate of his or her feelings. The ratio of the number of utterances between students and SPs suggested that the communication was more interactive. CONCLUSION: Based on the respective communication tendencies may have led to higher satisfaction in face-to-face than in online patient satisfaction surveys, less anxiety about illness and medications, and easier trusting relationships. Since it is difficult to grasp the mood of the other party and to open up to them due to the lack of nonverbal information in online dialogue, it is necessary to be more conscious of conversations that capture the feelings of patients in online medication counseling.
• Development of a risk prediction model for surgical site infection after lower third molar surgery.
  Akira Yamagami; Katsuya Narumi; Yoshitaka Saito; Ayako Furugen; Shungo Imai; Yoshimasa Kitagawa; Yoichi Ohiro; Ryo Takagi; Yoh Takekuma; Mitsuru Sugawara; Masaki Kobayashi
  Oral diseases, 2023年09月27日, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, BACKGROUND: There is little evidence regarding risk prediction for surgical site infection (SSI) after lower third molar (L3M) surgery. METHODS: We conducted a nested case-control study to develop a multivariable logistic model for predicting the risk of SSI after L3M surgery. Data were obtained from Hokkaido University Hospital from April 2013 to March 2020. Multiple imputation was applied for the missing values. We conducted decision tree (DT) analysis to evaluate the combinations of factors affecting SSI risk. RESULTS: We identified 648 patients. The final model retained the available distal space (Pell & Gregory II [p = 0.05], Pell & Gregory III [p < 0.01]), depth (Pell & Gregory B [p < 0.01], Pell & Gregory C [p < 0.01]), surgeon's experience (3-10 years [p = 0.25], <3 years [p < 0.01]), and simultaneous extraction of both L3M [p < 0.01]; the concordance-statistic was 0.72. The DT analysis demonstrated that patients with Pell and Gregory B or C and simultaneous extraction of both L3M had the highest risk of SSI. CONCLUSIONS: We developed a model for predicting SSI after L3M surgery with adequate predictive metrics in a single center. This model will make the SSI risk prediction more accessible.
• Factors associated with household transmission of SARS-CoV-2 omicron variant to health care workers: A retrospective cohort study.
  Keisuke Kagami; Reiko Oyamada; Tsubasa Watanabe; Sho Nakakubo; Takahiro Hayashi; Sumio Iwasaki; Tatsuya Fukumoto; Takayuki Usami; Kasumi Hayasaka; Shinichi Fujisawa; Chiaki Watanabe; Mutsumi Nishida; Takanori Teshima; Yusuke Niinuma; Isao Yokota; Yoh Takekuma; Mitsuru Sugawara; Nobuhisa Ishiguro
  International journal of nursing practice, 29, 5, e13195, 2023年08月24日, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, AIM: The aim of this study was to determine the risk factors for household transmission of the omicron variant of SARS-CoV-2. BACKGROUND: The household infection rate has been reported to be higher for the omicron variant than for non-omicron variants of SARS-CoV-2. Determination of the risk factors for household transmission of the omicron variant is therefore important. DESIGN: A Retrospective Cohort Study was conducted. METHODS: When family members of health care workers (HCWs) were found to be infected with SARS-CoV-2, the HCWs had to receive two nucleic acid amplification tests for SARS-CoV-2: immediately after and 5 to 10 days after the onset of COVID-19 in the family members. Risk factors of household transmission were analysed by comparing cases (HCWs infected with SARS-CoV-2) and controls (HCWs not infected with SARS-CoV-2) using multivariable analysis. RESULTS: Unvaccinated status (OR: 3.97), age of index cases (≤6 years) (OR: 1.94) and staying at home with index cases (OR: 10.18) were risk factors for household transmission. CONCLUSION: If there is a strong desire to avoid household infection, family members infected with SARS-CoV-2 should live separately during the period of viral shedding.
• Risk factor analysis for anti-epidermal growth factor receptor monoclonal antibody-induced skin toxicities in real-world metastatic colorectal cancer treatment.
  Yoshitaka Saito; Kazuki Uchiyama; Yoh Takekuma; Yoshito Komatsu; Mitsuru Sugawara
  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 31, 8, 504, 504, 2023年08月02日, ［査読有り］, ［責任著者］, ［国際誌］
  英語, 研究論文（学術雑誌）, PURPOSE: Anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibodies are effective in treating RAS wild-type metastatic colorectal cancer (mCRC). However, their administration induces skin toxicity, markedly reducing patients' quality of life. This study is aimed at identifying the risk factors associated with anti-EGFR monoclonal antibody-induced skin toxicities. METHODS: Patients with mCRC (n = 116) who received anti-EGFR monoclonal antibody treatment were retrospectively evaluated. Primary endpoint was evaluation of the risk factors for grade ≥ 2 overall skin toxicities during all the treatment periods. Furthermore, factors associated with each grade ≥ 2 skin symptoms were assessed. RESULTS: Incidence of total grade ≥ 2 skin toxicity symptoms was 61.2%, and those of grade ≥ 2 rash, dry skin, fissures, and paronychia were 34.5%, 25.9%, 20.7%, and 25.0%, respectively. Multivariate logistic regression analyses revealed that liver metastasis was an independent risk factor for overall grade ≥ 2 skin toxicities (adjusted odds ratio [OR], 2.88; 95% confidence interval [CI], 1.22-6.78; P = 0.02) and prophylactic administration of antibiotics as a preventive factor (OR 0.10; 95%CI 0.01-0.91; P = 0.04). For grade ≥ 2 rash, prophylactic use of systemic antibiotics and topical steroid ointment was a preventive factor (OR 0.37; 95%CI 0.16-0.89; P = 0.03). Moreover, liver metastasis (OR 8.37; 95%CI 1.98-35.47; P = 0.004) and prophylactic administration of antibiotics (OR 0.15; 95%CI 0.03-0.76; P = 0.02) were significantly associated with grade ≥ 2 paronychia. CONCLUSION: Liver metastasis was suggested to be a risk factor for the incidence of overall grade ≥ 2 skin toxicities; moreover, preemptive systemic antibiotic administration drastically decreased this risk during all periods of anti-EGFR treatment for mCRC.
• Correlation between antibiotic use and resistance of gram-negative bacteria at a university hospital in Japan from 2013 to 2021: a study using the Japan Surveillance for Infection Prevention and Healthcare Epidemiology (J-SIPHE) system.
  Keisuke Kagami; Nobuhisa Ishiguro; Sumio Iwasaki; Keisuke Taki; Tatsuya Fukumoto; Kasumi Hayasaka; Reiko Oyamada; Tsubasa Watanabe; Sho Nakakubo; Yusuke Niinuma; Mitsuru Sugawara; Yoh Takekuma
  European journal of hospital pharmacy : science and practice, 2023年07月12日, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, OBJECTIVES: The Japan Surveillance for Infection Prevention and Healthcare Epidemiology (J-SIPHE) system aggregates information related to antimicrobial resistance (AMR) measures. We aimed to investigate the correlation between antibiotic use and AMR at a university hospital from 2013 to 2021 in a time series analysis using the J-SIPHE system. We also studied this correlation in each ward (inter-ward analysis). METHODS: Data on antibiotic use and resistance rates were collected from the J-SIPHE system, except for the resistance rate in each ward, which was calculated from the source data prepared for this system. RESULTS: Piperacillin/tazobactam use was positively correlated with piperacillin/tazobactam resistance in Escherichia coli and Klebsiella pneumoniae in the inter-ward analysis, and in Pseudomonas aeruginosa in both analyses. Carbapenem use was positively correlated with meropenem resistance in Enterobacter cloacae in the time series analysis and in P. aeruginosa in both analyses, and imipenem/cilastatin resistance in P. aeruginosa in inter-ward analysis. Quinolone use was positively correlated with levofloxacin resistance in E. coli in both analyses, and in K. pneumoniae in inter-ward analysis. CONCLUSIONS: This is the first study to investigate the correlation between antibiotic use and AMR at a single hospital in time series and inter-ward analyses using the J-SIPHE system and data prepared for this system, suggesting that this system may be useful for promoting AMR measures.
• Acid suppressants reduce the therapeutic effect of immune checkpoint inhibitors and increase the risk of acute kidney injury: a meta-analysis
  Keisuke Okamoto; Yoshitaka Saito; Atsushi Yamaguchi; Yoh Takekuma; Mitsuru Sugawara
  International Journal of Clinical Oncology, 28, 10, 1343, 1353, Springer Science and Business Media LLC, 2023年07月08日, ［査読有り］, ［最終著者, 責任著者］, ［国内誌］
  英語, 研究論文（学術雑誌）, BACKGROUND: Immune checkpoint inhibitors (ICIs) are used in cancer immunotherapy; however, they can lead to immune-related adverse events (irAEs) through immune function of patients. Therefore, this meta-analysis aimed to assess the concomitant effect of acid suppressants (ASs) on ICIs, including several subgroup analyses. METHODS: We identified related studies and generated the forest plot. The primary endpoint was defined as the change in progression free survival (PFS) and overall survival (OS) with or without ASs administration. We also evaluated the effect of ASs on the incidence of irAEs. RESULTS: The total hazard ratio (HR) of ASs on PFS with ICI treatment was 1.39 and the 95% confidence interval (95% CI) was 1.21-1.59 (Z: p < 0.00001). Moreover, the total HR of ASs on OS was 1.40 and the 95% CI was 1.21-1.61 (Z: p < 0.00001), suggesting that ASs reduced ICI's therapeutic effect. The total odds ratio (OR) for evaluating the effect of ASs on irAEs was 1.23 with a 95% CI of 0.81-1.88 (Z: p = 0.34). However, ASs significantly worsened acute kidney injury (AKI) (total OR 2.10; 95% CI 1.74-2.53 (Z, p < 0.00001)). Furthermore, although proton pump inhibitors (PPIs) reduced ICI's therapeutic effect, histamine H2-receptor antagonists (H2RAs) did not affect OS. CONCLUSIONS: It was shown that ASs, especially PPIs, reduced ICI's therapeutic effect, while H2RAs had no effect, and ASs did not affect irAEs; however, it is a risk factor for ICIs-induced AKI.
• Monitoring Salivary Concentrations of Tedizolid and Linezolid Using Rats
  Yuki Inoue; Yuki Sato; Hitoshi Kashiwagi; Shunsuke Nashimoto; Mitsuru Sugawara; Yoh Takekuma
  European Journal of Drug Metabolism and Pharmacokinetics, 48, 4, 387, 395, Springer Science and Business Media LLC, 2023年06月27日, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, BACKGROUND AND OBJECTIVE: Therapeutic drug monitoring (TDM) is an effective tool for the management of patients who are administered linezolid. The use of saliva for TDM has potential advantages over the use of plasma; however, only a few reports have compared drug concentrations in the saliva and plasma. Moreover, there are no reports on the salivary concentration of tedizolid, an oxazolidinone antibiotic similar to linezolid. In the present study, the concentrations of tedizolid and linezolid in rat submandibular saliva were compared with those measured in the plasma. METHODS: Tedizolid (10 mg/kg, n = 6) and linezolid (12 mg/kg, n = 5) were administered via the rat tail vein. Submandibular saliva and plasma samples were collected for up to 8 h after the initiation of drug administration, and assayed for the concentrations of tedizolid and linezolid. RESULTS: A strong correlation was found between the saliva and plasma concentrations of tedizolid (r = 0.964, p < 0.001) and linezolid (r = 0.936, p < 0.001). The value of tedizolid maximum concentration of drug (Cmax) was 0.99 ± 0.08 µg/mL in the saliva and 14.46 ± 1.71 µg/mL in the plasma. Meanwhile, the Cmax of linezolid was 8.01 ± 1.42 µg/mL in the saliva and 13.00 ± 1.90 µg/mL in the plasma. According to these results, the saliva/plasma concentration ratios of tedizolid and linezolid in rats were 0.0513 ± 0.0080 and 0.6341 ± 0.0339, respectively. CONCLUSIONS: Considering the correlation between saliva and plasma concentrations of tedizolid and linezolid, as well as the characteristics of saliva, the results of this study suggest that saliva is a useful matrix for TDM.
• Impact of systemic dexamethasone dosage on docetaxel-induced oral mucositis in patients with breast cancer.
  Yoshitaka Saito; Yoh Takekuma; Takashi Takeshita; Tomohiro Oshino; Mitsuru Sugawara
  Scientific reports, 13, 1, 10169, 10169, 2023年06月22日, ［査読有り］, ［最終著者, 責任著者］, ［国際誌］
  英語, 研究論文（学術雑誌）, Oral mucositis (OM) is a common adverse effect of docetaxel-containing treatment. This study aimed to assess whether dexamethasone (DEX) dose-dependently attenuates docetaxel-induced OM and dysgeusia. We retrospectively analyzed medical records of patients with breast cancer receiving docetaxel-containing regimens at Hokkaido University Hospital between June 2015 and June 2022. The patients were divided into low-dose and high-dose groups (DEX 4 or 8 mg/day on days 2-4, respectively), and incidence of OM and dysgeusia, and risk factor(s) for OM incidence were evaluated. The incidence of all-grade OM in the first cycle was 57.8% in the low-dose group and 19.2% in the high-dose group (P = 0.0002), which met our primary endpoint. The incidence of OM in all treatment cycles was also significantly lowered by DEX-dose increase (P = 0.01). In contrast, the incidence of dysgeusia was similar between the two groups in the first and all cycles (P = 0.50 and P = 0.28, respectively). These results were also confirmed in a propensity score-matched population. Multivariate logistic regression analysis also suggested that lower DEX dosage was a singular risk factor for all-grade OM incidence. In conclusion, our study suggests that DEX dose-dependently reduces the incidence of OM in docetaxel-containing regimens for breast cancer treatment.
• Severe hypertension development significantly improves progression-free survival in regorafenib treatment for metastatic colorectal cancer.
  Yoshitaka Saito; Yoh Takekuma; Yoshito Komatsu; Mitsuru Sugawara
  International journal of clinical oncology, 28, 9, 1183, 1190, 2023年06月15日, ［査読有り］, ［最終著者, 責任著者］, ［国内誌］
  英語, 研究論文（学術雑誌）, PURPOSE: Regorafenib is the first multikinase inhibitor used for metastatic colorectal cancer (mCRC) treatment. Reports regarding other multikinase inhibitors have suggested that the development of hypertension is associated with improved clinical benefits. We aimed to reveal the relationship between the development of severe hypertension and regorafenib efficacy in an mCRC real-world setting. METHODS: Patients with mCRC (n = 100) who received regorafenib were assessed retrospectively. The primary endpoint was a comparison of progression-free survival (PFS) between patients with and without ≥ grade 3 hypertension. The secondary endpoints were overall survival (OS), disease control rate (DCR), and adverse effects. RESULTS: Patients developing ≥ grade 3 hypertension accounted for 30%, and obtained significantly longer PFS than control patients (median PFS of 53 and 56 days, 95% confidence interval [CI] of 46-144 and 49-63 days, respectively; P = 0.04). In contrast, OS and DCR were not statistically different between the groups (P = 0.13 and P = 0.46, respectively). The incidence and severity of adverse effects were not significantly different, except for hypertension. Treatment interruption was significantly more frequent in patients with hypertension (P = 0.04). Multivariate Cox hazard analysis suggested that the development of ≥ grade 3 severe hypertension was an independent factor for improved PFS (adjusted hazard ratio 0.57, 95% CI 0.35-0.93; P = 0.02). In contrast, baseline hypoalbuminemia was associated with a worse PFS (1.85, 1.14-3.01; P = 0.01). CONCLUSION: We have revealed that patients who develop severe hypertension after regorafenib treatment for mCRC have improved PFS. Management of hypertension is important for effective treatment with less burden; therefore, further evaluation is needed.
• High dose of dexamethasone attenuates docetaxel-induced fluid retention in breast cancer treatment.
  Yoshitaka Saito; Ryota Kanno; Yoh Takekuma; Takashi Takeshita; Tomohiro Oshino; Mitsuru Sugawara
  Scientific reports, 13, 1, 9247, 9247, 2023年06月07日, ［査読有り］, ［最終著者, 責任著者］, ［国際誌］
  英語, 研究論文（学術雑誌）, Docetaxel-induced fluid retention (DIFR) cumulatively occurs and is one of the most troublesome adverse effects. This study aimed to determine whether high dose dexamethasone (DEX) could prevent DIFR during breast cancer treatment. Breast cancer patients receiving docetaxel (75 mg/m2)-containing regimens were divided into 4 and 8 mg/day DEX groups, with each DEX dose administered on days 2-4 and retrospectively assessed. Incidence of greater than or equal to grade 2 DIFR was significantly lower in the 8 mg group (13.0%) compared to the 4 mg group (39.6%, P = 0.001). All-grade DIFR was also less in the 8 mg group (P = 0.01). Furthermore, the maximum variation of body weight was significantly lower in the 8 mg group (P = 0.0003). These results were also confirmed in the propensity score-matched population. Additionally, time-related DIFR incidence was also significantly delayed in the 8 mg group (P = 0.0005). Our study revealed that high dose DEX prevents DIFR. Therefore, further studies on its management are required for less onerous chemotherapy provision with better DIFR control.
• Dexamethasone dose-dependently prevents taxane-associated acute pain syndrome in breast cancer treatment.
  Yoshitaka Saito; Yoh Takekuma; Takashi Takeshita; Tomohiro Oshino; Mitsuru Sugawara
  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 31, 6, 372, 372, 2023年06月03日, ［査読有り］, ［最終著者, 責任著者］, ［国際誌］
  英語, 研究論文（学術雑誌）, PURPOSE: Taxane-associated acute pain syndrome (T-APS) is one of the most bothersome adverse effects caused by taxanes. We have previously reported the attenuating effect of dexamethasone (DEX) on T-APS and its risk factors under DEX prophylaxis. However, the appropriate DEX dosage administration remains unclear. Therefore, this study aimed to investigate whether DEX dose-dependently prevents T-APS in breast cancer patients. METHODS: We retrospectively evaluated patients with breast cancer who received docetaxel (75 mg/m2)-containing chemotherapy without pegfilgrastim and regular non-steroidal anti-inflammatory drugs. The patients were divided into 4 mg/day and 8 mg/day DEX groups, with each DEX dosage on days 2-4 (n = 68 for each group). Primary endpoint was the comparison of all-grade T-APS incidence between the groups. Propensity score-matching was performed to adjust the baseline factors between the groups, and outcomes in the matched-population were also assessed. RESULTS: The incidence of all-grade T-APS was 72.1% in 4 mg/day group and 48.5% in 8 mg/day group, which was significantly lowered by higher DEX dosage (P = 0.008). The severity of T-APS was also significantly reduced in 8 mg/day group (P = 0.02). These results were confirmed in the propensity score matching. Multivariate logistic analysis showed that higher DEX dosage was an independent T-APS preventive factor, whereas age < 55 years was a risk factor. Moreover, DEX-dosage-associated adverse effects similarly appeared in both groups. CONCLUSION: Our study suggested that DEX dose-dependently prevents T-APS in breast cancer treatment. As understanding of the nature of T-APS and its appropriate management can significantly contribute to less onerous chemotherapy provision, further studies are required.
• Cyclosporine A乳剤ならびに自己乳化型製剤の特性と経口吸収性評価
  佐藤 夕紀; 木下 祐介; 上村 聡; 丸山 真吾; 武隈 洋; 菅原 満
  日本薬剤学会年会講演要旨集, 38年会, 171, 171, (公社)日本薬剤学会, 2023年05月
  日本語
• 医薬品の在庫管理における医療機器の導入効果
  山崎 浩二郎; 久保田 康生; 川岸 亨; 武隈 洋; 菅原 満
  北海道病院薬剤師会誌, 104, 17, 19, (一社)北海道病院薬剤師会, 2023年04月, ［最終著者, 責任著者］
  日本語
• Efficacy of antacids for cisplatin-induced gastrointestinal symptoms in the treatment of lung cancer.
  Osamu Taniguchi; Yoshitaka Saito; Yoh Takekuma; Hirotoshi Akita; Ichiro Kinoshita; Yasushi Shimizu; Naofumi Shinagawa; Mitsuru Sugawara
  International journal of clinical pharmacology and therapeutics, 61, 6, 246, 254, 2023年03月27日, ［査読有り］, ［責任著者］, ［国際誌］
  英語, 研究論文（学術雑誌）, OBJECTIVE: Chemotherapy-induced nausea and vomiting (CINV) and chemotherapy-associated dyspepsia syndrome (CADS) are frequently appearing adverse effects of cisplatin (CDDP)-containing chemotherapy. Antiemetic guidelines suggest that the administration of antacids such as proton pump inhibitors (PPIs) or histamine type-2 receptor antagonists be considered for CADS, although their efficacy for treating these symptoms remains unknown. This study aimed to reveal whether antacids attenuate gastrointestinal symptoms in CDDP-containing chemotherapy. MATERIALS AND METHODS: In total, 138 patients with lung cancer who received ≥ 75 mg/m2 CDDP-containing regimens were enrolled in this retrospective study. Patients were divided into an antacid group including patients administered PPIs or vonoprazan during all chemotherapy periods and controls without antacid administration. The primary endpoint was the comparison of anorexia incidence during the first cycle of chemotherapy. Secondary endpoints were CINV evaluation and risk factor analysis for the incidence of anorexia using logistic regression analysis. RESULTS: The incidence of anorexia during the first cycle was 54.4% in the control group and 60.3% in the antacid group, without significant differences (p = 0.60). The incidence of nausea was also similar between the groups (p = 1.00). Multivariate analysis suggested that antacid administration was not associated with anorexia. CONCLUSION: Baseline antacid administration does not affect gastrointestinal symptoms associated with CDDP-containing treatment in lung cancer.
• Onset timing and duration of augmented renal clearance in a mixed intensive care unit.
  Ryusei Mikami; Mineji Hayakawa; Shungo Imai; Mitsuru Sugawara; Yoh Takekuma
  Journal of intensive care, 11, 1, 13, 13, 2023年03月23日, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, BACKGROUND: Augmented renal clearance (ARC) is associated with lower blood plasma concentrations of renally excreted drugs; however, its time course is unknown. The current study aimed to determine the onset timing/duration of ARC, its risk factors, and its association with clinical outcomes by continuous monitoring of urinary creatinine clearance (CrCl) in critically ill patients. METHODS: Data were retrospectively obtained from the medical records of 2592 critically ill patients admitted to the intensive care unit (ICU) from January 2019 to June 2022 at a tertiary emergency hospital. Among these, patients with continuously measured urinary CrCl were selected and observed over time. We evaluated the onset timing and duration of ARC by plotting Kaplan-Meier curves. Furthermore, by multivariate analyses, factors associated with the onset and persistence of ARC were analyzed, and the association between the ARC time course and clinical outcomes was evaluated. RESULTS: The prevalence of ARC was 33.4% (245/734). ARC onset was within 3 days of admission in approximately half of the cases, and within 1 week in most of the other cases. In contrast, the persistence duration of ARC varied widely (median, 5 days), and lasted for more than a month in some cases. Multivariate analysis identified younger age, male sex, lower serum creatinine at admission, admission with central nervous system disease, no medical history, use of mechanically assisted ventilation, and vasopressor use as onset factors for ARC. Furthermore, factors associated with ARC persistence such as younger age and higher urinary CrCl on ARC day 1 were detected. The onset of ARC was significantly associated with reduced mortality, but persistent of ARC was significantly associated with fewer ICU-free days. CONCLUSIONS: Despite the early onset of ARC, its duration varied widely and ARC persisted longer in younger patients with higher urinary CrCl. Since the duration of ARC was associated with fewer ICU-free days, it may be necessary to consider a long-term increased-dose regimen of renally excreted drugs beginning early in patients who are predicted to have a persistent ARC.
• Usefulness of the Albumin–Bilirubin Score in Determining the Initial Dose of Voriconazole for Patients with Liver Cirrhosis
  Shunsuke Nashimoto; Shungo Imai; Mitsuru Sugawara; Yoh Takekuma
  Biological and Pharmaceutical Bulletin, 46, 2, 230, 236, Pharmaceutical Society of Japan, 2023年02月01日, ［査読有り］, ［国内誌］
  英語, 研究論文（学術雑誌）, The Child-Pugh score is widely used to assess liver function and estimate drug clearance in patients with liver cirrhosis. Recently, the albumin-bilirubin (ALBI) score, which objectively assesses liver function based only on albumin and total bilirubin levels, was developed as a new method. The purpose of this study was to analyze the relationship between the liver function assessment method and the plasma concentration of voriconazole (VRCZ), an antifungal drug for patients with liver cirrhosis. This single-center retrospective study enrolled 159 patients who received VRCZ between 2012 and 2020. In patients administered VRCZ orally, the median concentration to dose (C : D) ratio increased with the progression of Child-Pugh and ALBI grades. Positive correlations between the ALBI score and VRCZ C : D ratio were observed in patients with cirrhosis (r = 0.52 (95% confidence interval, 0.069-0.79); p < 0.05). In addition, a highly negative correlation was observed between the ALBI score and VRCZ daily maintenance dose (r=-0.79 (95% confidence interval, -0.92 to -0.50); p < 0.0001). In contrast, for patients administered VRCZ intravenously, no increase in C : D ratio was observed for both Child-Pugh and ALBI scores compared to the non-liver cirrhosis group. This may be because the injection is often used in severely ill patients, and factors other than impaired liver function may affect the plasma concentrations of VRCZ. In conclusion, the ALBI score was shown to be useful in predicting VRCZ clearance as well as the Child-Pugh score, and the initial dose of VRCZ might be determined according to the ALBI score.
• Use of Japanese big data from electronic medical records to investigate risk factors and identify their high-risk combinations for linezolid-induced thrombocytopenia.
  Yuki Inoue; Yoh Takekuma; Takayuki Miyai; Hitoshi Kashiwagi; Yuki Sato; Mitsuru Sugawara; Shungo Imai
  European journal of clinical pharmacology, 79, 3, 415, 425, 2023年01月30日, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, PURPOSE: Thrombocytopenia is a major event associated with linezolid (LZD) therapy. Factors affecting LZD-induced thrombocytopenia (LIT) have been reported in previous studies. However, several issues pertaining to LIT have not yet been clarified. In the present study, we used Japanese big data to investigate associated factors and their high-risk combinations that influence LIT. METHODS: Patients administered LZD between May 2006 and October 2020 were included in this study. LIT was defined as either a 30% or more reduction from the baseline platelets or platelet values of < 100,000/µL. We evaluated factors affecting LIT and combinations of factors that alter LIT risk according to a decision tree (DT) analysis, a typical machine learning method. RESULTS: We successfully enrolled 1399 patients and LIT occurred in 44.7% of the patients (n = 626). We classified the laboratory data on renal function, LZD duration, age, and body weight (BW) into smaller categories. The results of multivariate analysis showed that prolonged LZD therapy, BW < 45 kg, estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m2, and dialysis were risk factors for LIT. The DT analysis revealed that the highest risk was a combination of LZD duration ≥ 14 days and eGFR < 30 mL/min/1.73 m2. CONCLUSIONS: The present study extracted four risk factors and identified high-risk combinations for LIT. Patients with these risk factors should be closely monitored.
• Prediction and Implications of Edoxaban-Associated Bleeding in Patients after Critical Illness
  Ryusei Mikami; Mineji Hayakawa; Shungo Imai; Kunihiko Maekawa; Kojiro Yamazaki; Mitsuru Sugawara; Yoh Takekuma
  Journal of Clinical Medicine, 12, 3, 860, 860, MDPI AG, 2023年01月21日, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, In this retrospective study, we aimed to identify the risk factors for bleeding in patients after critical illness during edoxaban treatment. Data from patients who received edoxaban after critical illness at the Emergency Department at a tertiary care hospital were obtained from the hospital medical records. Multivariate analysis revealed the risk factors for edoxaban-associated bleeding. Additionally, we developed an edoxaban-associated bleeding score (EAB score) based on these results. The derived EAB score was compared with the HAS-BLED score using receiver operating characteristic (ROC) curve analysis. Bleeding was observed in 42 of 114 patients (36.8%). We identified the following bleeding predictors (odds ratios, 95% confidence interval, score points) using multivariate analysis: concomitant use of antiplatelet agents (6.759, 2.047–22.32, 2 points), concomitant use of P-glycoprotein inhibitors (3.825, 1.484–9.856, 1 point), prothrombin time (PT)% following edoxaban administration of <75% and ≥60% (2.507, 0.788–7.970, 1 point), and PT% following edoxaban administration of <60% (11.23, 3.560–35.42, 3 points). The ROC curve analysis revealed an area under the curve of 0.826 for the EAB score and 0.625 for the HAS-BLED score. Under appropriate edoxaban dosing regimens in patients after critical illness, a combination of antiplatelet agents, P-gp inhibitors, and a low PT% following edoxaban administration were identified as strong risk factors for bleeding.
• Effects of Body Composition on Renal Function Estimates in Older Patients.
  Soyoko Kaburaki; Shungo Imai; Hitoshi Kashiwagi; Yuki Sato; Mitsuru Sugawara; Yoh Takekuma
  Biological & pharmaceutical bulletin, 46, 11, 1609, 1618, 2023年, ［国内誌］
  英語, 研究論文（学術雑誌）, The modified Cockcroft-Gault (CG) equation, previously developed for an aged-oriented cohort, was validated in a newly obtained dataset. Estimates of creatinine clearance (CCr) using this equation were found to be more accurate than those determined using the conventional CG equation, particularly for patients exceeding 65 years of age. We identified a subset of patients in this cohort whose estimates were inadequate. Using statistical analysis, we found that the deviation from estimates was attributed to a decreased albumin level. In addition, we determined a reduced albumin cutoff value for the modified CG equation to obtain a good estimate. Univariate linear regression analysis was applied to measure the CCr in this cohort and identify parameters related to body composition, and we found that extracellular water (ECW)/total body water (TBW) and body fat (%) were relevant. Using measured values of ECW/TBW and body fat (%), a multivariate linear regression (MLR) estimating equation was developed based on the modified CG equation. This equation was applied to a cohort over 65 years of age, and it was found that a good estimate was obtained for older patients with low albumin levels. Thus, we propose a flow diagram that illustrates conditions for selecting an appropriate estimating equation from among the CG, modified CG, and MLR equations.
• Temporary Severe Neutropenia during Administration of Atezolizumab: A Novel Case Report.
  Ryota Kanno; Yoshitaka Saito; Yoh Takekuma; Hajime Asahina; Mitsuru Sugawara
  Case reports in oncology, 16, 1, 372, 377, 2023年, ［査読有り］, ［最終著者, 責任著者］, ［国際誌］
  英語, Here, we describe a case of temporary severe neutropenia after atezolizumab monotherapy and its treatment course. Atezolizumab monotherapy was introduced as a 6th-line treatment for a man in his late 60s, who was diagnosed with stage Ⅳ lung adenocarcinoma. The first treatment cycle was administered during hospitalization, and the patient presented with a fever of 37.8°C on the first day. The fever resolved after the administration of acetaminophen and naproxen, and the white blood cell count, neutrophil count, and other white blood cell fractions were normal. However, grade 3 leukopenia and grade 4 neutropenia appeared at the beginning of the third cycle, and treatment was discontinued. After treatment, monocyte count in the leukocyte fraction increased from approximately 10% to 25.6%. Lenograstim 100 μg subcutaneous injection and oral levofloxacin 500 mg once daily were started of onset of neutropenia, and he was hospitalized the next day. Laboratory findings upon admission showed a significant improvement to 5,300/µL for leukocytes and 3,376/µL for neutrophils. Lenograstim was discontinued, with no further decrease in the neutrophil count. Atezolizumab therapy was resumed, and there was no further reduction in leukocyte, neutrophil, or leukocyte fractions over about a 2-year period. Concomitant drugs were maintained during the atezolizumab treatment, suggesting that they did not induce neutropenia. In conclusion, we observed temporary severe neutropenia during atezolizumab monotherapy. Neutrophil recovery with cautious monitoring has enabled longer efficacy. We should consider temporary symptom occurrence in cases of haematological immune-related adverse events.
• Gefitinib-induced Myositis: A Novel Case Report.
  Tatsuhiko Sakamoto; Yoshitaka Saito; Yoh Takekuma; Eiki Kikuchi; Mitsuru Sugawara
  Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 143, 7, 617, 620, 2023年, ［査読有り］, ［最終著者, 責任著者］, ［国内誌］
  英語, 研究論文（学術雑誌）, Chemotherapy-induced myositis is a severe adverse event caused by chemotherapeutic agents such as immune checkpoint inhibitors (ICIs) or cytotoxic agents. We experienced a patient with gefitinib-induced myositis with symptoms of muscle cramps and stiffness in the limbs, and reported the treatment process. A 70-year-old woman received four courses of carboplatin (CBDCA)+pemetrexed (PEM)+gefitinib (intravenous CBDCA area under the curve (AUC) 5 and PEM 500 mg/m2, every 3 weeks, and oral gefitinib 250 mg daily), for epidermal growth factor receptor (EGFR) mutation-positive stage IV lung cancer treatment; followed by seven courses of PEM+gefitinib, and continued gefitinib monotherapy thereafter. Myositis occurred 5 months after the initiation of gefitinib monotherapy. She developed strong limb cramps despite regular oral administration of 400 mg acetaminophen three times a day and complained of pain on a numeric rating scale of 10/10. Her creatine kinase (CK) was elevated from the second course of CBDCA+PEM+gefitinib but was stable at grade 1-2 thereafter. However, the muscle symptoms disappeared with CK normalization within a few days of gefitinib discontinuation due to disease progression. The Naranjo Adverse Drug Reaction Scale score was 6, suggesting a probable association. Osimertinib (an EGFR tyrosine kinase inhibitor)-induced myositis has been reported, but similar events were first observed with gefitinib in this case. Consequently, when treating with gefitinib, myositis, including the CK variation, should be monitored and appropriately managed with multidirectional treatment.
• Risk Factor Analysis of Vancomycin-Induced Nephrotoxicity in Paediatric Patients Aged 0-1 Year Using Japanese Medical Database.
  Takayuki Miyai; Yoh Takekuma; Hitoshi Kashiwagi; Yuki Sato; Shunsuke Nashimoto; Mitsuru Sugawara; Shungo Imai
  Biological & pharmaceutical bulletin, 46, 6, 817, 823, 2023年, ［査読有り］, ［国内誌］
  英語, 研究論文（学術雑誌）, Vancomycin (VCM)-induced nephrotoxicity (VIN) is a major side effect in paediatric patients. However, most studies are limited to patients aged 0-18 years. We evaluated the risk factors of VIN in patients aged 0-1 year using Japanese electronic medical record database. We used RWD database which was contained electronic medical records and claims data of approximately 20 million people from 160 medical institutions. We targeted hospitalized patients who were administered VCM between June 2000 and December 2020. VIN was defined by two criteria: Criterion 1 was an increase in serum creatinine (Scr) ≥ 0.5 mg/dL or 50% during VCM treatment period compared to the Scr baseline; and criterion 2 was an increase in Scr ≥50% within seven days or Scr ≥0.3 mg/dL within two days during VCM treatment. The risk factors of VIN were evaluated using multivariate logistic regression analysis. We analysed 446 patients; patients with VIN in Criteria 1 and 2 were 33 and 58, respectively. In Criterion 1, multivariate logistic regression analysis identified four independent factors with p-value <0.05 (VCM concentration ≥20 mg/L, amphotericin B (AMPH-B), piperacillin-tazobactam (TAZ/PIPC), and vasopressor drugs). In Criterion 2, multivariate logistic regression analysis identified concomitant use of vasopressor drugs with p-value <0.05. Therefore, concomitant use of vasopressor drugs was suggested to affect the risk of VIN in patients aged 0-1 year. The findings may help in developing estimation models to assess the risk of VIN in paediatric patients.
• Therapeutic Drug Monitoring of Oral Voriconazole in an Infant Less than Six Months of Age and Pharmacokinetics Changes Induced by Development of CYP2C19 in the Growth Process: A Novel Case Report.
  Atsushi Yamaguchi; Yuki Tazawa; Masashiro Ueki; Masafumi Yamada; Atsushi Manabe; Mitsuru Sugawara; Yoh Takekuma
  Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 143, 6, 545, 549, 2023年, ［査読有り］, ［国内誌］
  英語, 研究論文（学術雑誌）, Therapeutic drug monitoring (TDM) is recommended for voriconazole (VRCZ) to avoid adverse events and maximize antifungal efficacy. Currently, the appropriate dose for patients under the age of 2 years is unknown. Here, we report the case of a 1.5-month-old infant with inborn errors of immunity who was orally administered VRCZ. This patient's plasma concentration decreased significantly from 3.8 µg/mL (day 6) to 0.09 µg/mL (day 21), leading to repeated dose escalations to achieve the target concentration (1.38 µg/mL, day 58). The signal intensity ratio of VRCZ to its main metabolite, N-oxide VRCZ, in LC/MS/MS also decreased from 5.30 (day 6) to 0.57 (day 64). Consequently, we suspected that VRCZ metabolism may be enhanced during infant growth. To our knowledge, this is the first report of remarkable changes in VRCZ pharmacokinetics with metabolic activity enhanced by the growth process. In conclusion, we propose that frequent TDM helped to maintain adequate VRCZ plasma concentration in a infants less than 6 months of age.
• Diabetes mellitus degenerates cisplatin-induced nephrotoxicity in short hydration method: a propensity score-matching analysis
  Yoshitaka Saito; Tatsuhiko Sakamoto; Yoh Takekuma; Masaki Kobayashi; Keisuke Okamoto; Naofumi Shinagawa; Yasushi Shimizu; Ichiro Kinoshita; Mitsuru Sugawara
  Scientific Reports, 12, 1, 21819, 21819, Springer Science and Business Media LLC, 2022年12月17日, ［査読有り］, ［最終著者, 責任著者］, ［国際誌］
  英語, 研究論文（学術雑誌）, Abstract
  
  Cisplatin (CDDP)-induced nephrotoxicity (CIN) is dose-limiting. We revealed that co-administration of non-steroid anti-inflammatory drugs and baseline comorbidity of diabetes mellitus (DM) are associated with CIN development in the short hydration method; however, the results were accessorily obtained without appropriate power calculation. This study aimed to demonstrate the influence of DM complications on CIN incidence in a real-world setting. Lung cancer patients receiving CDDP (≥ 75 mg/m²)-containing regimens with a short hydration method (n = 227) were retrospectively evaluated. The patients were divided into control and baseline DM complication groups. The primary endpoint was the evaluation of CIN incidence between the groups. Propensity score-matching was performed to confirm the robustness of the primary analysis results. CIN occurred in 6.8% of control and 27.0% of DM patients, respectively, with a significant difference in all-patient populations (P = 0.001). In addition, variation of serum creatinine and creatinine clearance significantly worsened in DM patients. Similar results were obtained in a propensity-matched population. Multivariate logistic regression analysis found that DM complication is a singular risk factor for CIN development (adjusted odds ratio; 4.31, 95% confidence interval; 1.62–11.50, P = 0.003). In conclusion, our study revealed that baseline DM complications significantly worsen CIN.
• Association between skin immune-related adverse events (irAEs) and multisystem irAEs during PD-1/PD-L1 inhibitor monotherapy.
  Atsushi Yamaguchi; Yoshitaka Saito; Katsuya Narumi; Ayako Furugen; Yoh Takekuma; Naofumi Shinagawa; Yasushi Shimizu; Hirotoshi Dosaka-Akita; Mitsuru Sugawara; Masaki Kobayashi
  Journal of cancer research and clinical oncology, 149, 4, 1659, 1666, 2022年11月08日, ［査読有り］, ［国際誌］
  英語, PURPOSE: Patients treated with immune checkpoint inhibitors (ICIs) often develop immune-related adverse events (irAEs) in various organs of the body. However, the patient factors associated with the development of multisystem irAEs are not well known. Skin irAEs most frequently occur and appear early after ICI treatment initiation. They may be a predictive marker for the development of multisystem irAEs, and their occurrence should be evaluated. METHODS: Data of patients receiving ICI monotherapy for lung cancer, melanoma, and head and neck cancer treatment were retrospectively evaluated (n = 207); the single irAE development group (n = 69) was compared with the multisystem irAE development group (n = 37). The primary endpoint was the comparison of the incidence of skin irAEs between the two groups. RESULTS: Skin, thyroid, and hepatic irAEs were associated with the development of multisystem irAEs (odds ratio: 3.30, 95% confidence interval: 1.27-8.52, p = 0.01 for skin; 5.07, 2.09-12.3, p = 0.0003 for thyroid; 10.63, 1.19-94.7, p = 0.03 for hepatic). Skin irAEs were the most common type (65.0% of total participants) and appeared earlier than other irAEs, except for gastrointestinal and ocular irAEs (median time to onset of skin irAEs: 7.5 weeks). Skin irAEs occurred more frequently in the multisystem irAE group (81.0%) than in the single irAE group (56.5%, p = 0.02). CONCLUSION: Skin irAEs can be a useful predictive marker for multisystem irAE development due to ICI treatment. Consequently, patients with skin irAEs should be treated and monitored for other types of irAEs.
• Risk factor analysis for regorafenib-induced severe hypertension in metastatic colorectal cancer treatment.
  Yoshitaka Saito; Yoh Takekuma; Yoshito Komatsu; Mitsuru Sugawara
  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 30, 12, 10203, 10211, 2022年10月11日, ［査読有り］, ［責任著者］, ［国際誌］
  英語, 研究論文（学術雑誌）, Regorafenib, a multikinase inhibitor, is effective in treating metastatic colorectal cancer (mCRC). Hypertension is a frequently occurring adverse effect caused by regorafenib regardless of previous treatment with vascular endothelial growth factor (VEGF) inhibitors in almost all patients. We identified the risk factors associated with regorafenib-induced severe hypertension. Patients with mCRC (n = 100) who received regorafenib were evaluated retrospectively. The primary endpoint was the evaluation of the risk factors for grade ≥ 3 hypertension. The association between pre-existing hypertension at baseline and grade ≥ 3 hypertension symptoms was also assessed. Patients with pre-existing hypertension at baseline accounted for 55% of the total patients. The starting doses of regorafenib were 160 mg (49.0% of patients), 120 mg (29.0%), and 80 mg (22.0%). The incidence of grade ≥ 3 hypertension was 30.0%. The median time to grade ≥ 3 symptom development was 7 days (range: 1-56 days). Additional antihypertensive treatment was administered to 83.6% of patients who developed hypertension. Logistic regression analyses revealed that baseline pre-existing hypertension complications and previous anti-VEGF treatment for ≥ 700 days were independent risk factors for grade ≥ 3 hypertension development. Further analyses revealed that pre-existing hypertension before anti-VEGF treatment (primary hypertension) was significantly related to the symptom development (adjusted odds ratio, 8.74; 95% confidence interval, 2.86-26.72; P = 0.0001). Our study suggests that pre-existing primary hypertension and previous anti-VEGF treatment for ≥ 700 days are independent risk factors for regorafenib-induced severe hypertension. Deeper understanding of the symptom nature and management can significantly contribute to safer interventions, necessitating further studies.
• 妊娠中にラコサミドを使用し、健児を得た一症例
  北村 聖花; 西村 あや子; 武隈 洋; 齋藤 佳敬; 馬詰 武; 菅原 満
  薬学雑誌, 142, 9, 1031, 1035, (公社)日本薬学会, 2022年09月
  日本語, 症例は33歳女性で、24歳時に症候性部分てんかんを発症した。第一子、第二子の妊娠、出産まではレベチラセタムを漸増しながら使用し、第二子出産後にラコサミド100mg/日の内服が開始された。今回、ペランパネルの開始14日後(妊娠7週2日)に第三子の妊娠が判明したためラコサミド単剤で妊娠経過をみる方針となり、ペランパネルは同日に中止された。妊娠中はラコサミド400mg/日の内服を継続し、軽度の発作は繰り返し出現したものの、重篤な症状の出現は認められなかった。妊娠37週2日に選択的帝王切開での分娩となり、児は男児、体重3025g、Apgar score 1分8点、5分9点、臍帯動脈血pH 7.348であった。出生時に児に先天異常は認められず、新生児薬物離脱症状もなかった。1ヵ月検診においても児に異常はなかった。
• 妊娠中にラコサミドを使用し、健児を得た一症例
  北村 聖花; 西村 あや子; 武隈 洋; 齋藤 佳敬; 馬詰 武; 菅原 満
  薬学雑誌, 142, 9, 1031, 1035, (公社)日本薬学会, 2022年09月, ［査読有り］, ［責任著者］
  日本語
• 薬局薬剤師を対象としたメディアによる「くすりの危険性」に関する報道に起因する患者からの相談応需の実態調査
  今井 俊吾; 阿部 真也; 松井 洸; 柏木 仁; 佐藤 夕紀; 武隈 洋; 吉町 昌子; 菅原 満
  医薬品情報学, 24, 2, 75, 87, (一社)日本医薬品情報学会, 2022年08月, ［査読有り］, ［最終著者］
  日本語
• Impact of systemic dexamethasone administration on oral mucositis induced by anthracycline-containing regimens in breast cancer treatment.
  Yoshitaka Saito; Yoh Takekuma; Takashi Takeshita; Tomohiro Oshino; Mitsuru Sugawara
  Scientific reports, 12, 1, 12587, 12587, 2022年07月22日, ［査読有り］, ［最終著者, 責任著者］, ［国際誌］
  英語, 研究論文（学術雑誌）, Oral mucositis (OM) is one of the most common complications associated with chemotherapy. Here, we evaluated whether systemic dexamethasone (DEX) dosage in prophylactic antiemetics affected the incidence of OM in anthracycline-containing regimens. Patients receiving anthracycline-containing regimens for breast cancer were divided into high- and low-DEX dose groups and retrospectively evaluated. The incidence of all-grade OM in the first cycle in the high- and low-dose groups was 27.3% and 53.5%, respectively, and was significantly lowered by increasing the DEX dose (P < 0.01); thus, the study met its primary endpoint. The result in all treatment cycles was also significant (P = 0.02). In contrast, the incidence of dysgeusia was similar between the high- and low-dose groups in the first and all cycles (13.6% and 16.3% in the first cycle [P = 0.79] and 27.3% and 34.9% in all cycles [P = 0.42], respectively). Multivariate analysis revealed that low DEX dosage was an independent risk factor for all-grade OM development. In conclusion, our study suggests that DEX attenuates OM in anthracycline-containing regimens for breast cancer treatment in a dose-dependent manner. Further evaluation of OM prophylaxis, including DEX administration, is required for better control.
• Influence of Dose Reduction of Prophylactic Dexamethasone on Chemotherapy-induced Nausea and Anorexia in Patients Under 55 Years Old Treated With Anthracycline-containing Regimens.
  Yoshitaka Saito; Yoh Takekuma; Takashi Takeshita; Mitsuru Sugawara
  Anticancer research, 42, 7, 3753, 3758, 2022年07月, ［査読有り］, ［責任著者］, ［国際誌］
  英語, 研究論文（学術雑誌）, BACKGROUND/AIM: The incidence of acute nausea in patients treated with anthracycline-containing regimens for breast cancer, was significantly increased by dose reduction of prophylactic antiemetic dexamethasone on day 1, whilst reducing it on days 2-4 did not affect delayed nausea. We also found that patients <55 years old were at higher risk of developing nausea. In this retrospective study, we evaluated the influence of dexamethasone dosage on gastrointestinal symptoms in patients <55 years old. PATIENTS AND METHODS: Patients (20-54 years old) who had received anthracycline-containing regimens for breast cancer were divided into reduced dose (6.6 mg dexamethasone on day 1, and 4 mg on days 2-4) and control (9.9 mg and 8 mg, respectively) groups and retrospectively evaluated. The incidence and severity of nausea, vomiting and anorexia were compared. Risk factors associated with nausea were also assessed. RESULTS: The incidence of acute nausea was significantly higher in the reduced dosage group than in the control group (75.0% and 45.2%, respectively; p=0.02). In contrast, the rate of delayed nausea was not different (p=0.41); the incidence of vomiting and anorexia, and the severity of nausea and anorexia were also not statistically different. Multivariate logistic analysis suggested that patients with no-to-low alcohol consumption and those administered 6.6 mg dexamethasone on day 1 were at a higher risk of acute nausea. CONCLUSION: Our study suggests that dexamethasone dose reduction on day 1 in patients treated with anthracycline-containing regimens is not suitable for acute nausea management, and that the dosage can be reduced to at least 4 mg on days 2-4, even in patients under 55 years of age.
• Risk Factor Analysis for the Occurrence of Severe Adverse Effects in Eribulin Treatment.
  Yoshitaka Saito; Yoh Takekuma; Takashi Takeshita; Takuro Noguchi; Satoshi Takeuchi; Yasushi Shimizu; Ichiro Kinoshita; Hirotoshi Dosaka-Akita; Mitsuru Sugawara
  Anticancer research, 42, 7, 3693, 3700, 2022年07月, ［査読有り］, ［責任著者］, ［国際誌］
  英語, 研究論文（学術雑誌）, BACKGROUND/AIM: Eribulin is an effective chemotherapeutic agent for the treatment of metastatic breast cancer and advanced or metastatic soft-tissue sarcomas. However, severe adverse effects (SAEs) occur in 30-40% of the patients, and significantly reduce the patients' quality of life and disturb the recommended treatment schedules. Neutropenia is the main cause of treatment suspension, delay, and/or dose reductions, also leading to relative dose intensity reduction. This study aimed to examine the risk factors for SAE occurrence after eribulin treatment. PATIENTS AND METHODS: Eighty patients with metastatic breast cancer or advanced or metastatic soft tissue sarcoma who received eribulin were retrospectively evaluated. Risk factors for SAE occurrence in the first cycle were primarily assessed. In addition, factors associated with SAE occurrence during all treatment cycles were evaluated. RESULTS: SAEs in the first cycle occurred in 45% of patients. The primary SAE was neutropenia (91.7%). The incidence of SAEs during all treatment cycles was 61.3%. Multivariate analyses suggested that lower baseline neutrophil and hemoglobin levels were risk factors for SAE occurrence and severe neutropenia incidence in the first cycle. An independent factor associated with SAE occurrence during all cycles was age ≥65 years and a tendency was confirmed for baseline anemia. CONCLUSION: Baseline neutropenia and anemia were risk factors for SAE occurrence during the first eribulin treatment cycle. Age ≥65 years was also associated with SAE occurrence during all treatment cycles. Patients with these risk factors should be carefully monitored for assessment and prophylaxis.
• Combination of Mirogabalin and Duloxetine Attenuates Peripheral Neuropathy by Eribulin: A Novel Case Report
  Yoshitaka Saito; Yoh Takekuma; Tomohiro Oshino; Mitsuru Sugawara
  Case Reports in Oncology, 15, 2, 606, 610, S. Karger AG, 2022年06月10日, ［査読有り］, ［責任著者］, ［国際誌］
  英語, 研究論文（学術雑誌）, Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most severe complications associated with chemotherapy for breast cancer. We encountered a case in which mirogabalin initially ameliorated, and additional duloxetine further attenuated eribulin-induced CIPN. Herein, we report its management. A 53-year-old woman received eribulin treatment as third-line chemotherapy for recurrent breast cancer. She experienced grade 2 CIPN with adjuvant docetaxel and cyclophosphamide treatment (worst numeric rating scale (NRS) 6/10 for numbness and 6/10 for pain) and had baseline grade 1 symptoms only in the hands (NRS 1/10 for each). CIPN in the hands and feet worsened to NRS 3/10 on day 1 of cycle 4. Mirogabalin (5 mg twice daily) was initiated, resulting in stable symptoms for approximately 6 weeks with grade 1 somnolence and heaviness of the head. The dosage was increased with careful attention to adverse effects to 22.5 mg per day, and the NRS was reduced from 5/10 to 3/10 for numbness and from 8/10 to 5/10 for pain. We administered duloxetine 20 mg with domperidone (10 mg three times a day) for further pain attenuation on day 1 of cycle 15, decreasing the NRS to 1/10 for numbness and 3/10 for pain. Duloxetine was increased due to CIPN degradation (NRS 3/10 and 5/10), resulting in a significant pain attenuation to 1/10. As the CIPN-attenuating mechanisms of mirogabalin and duloxetine are different, we consider that the additive and synergetic effects of this combination affected the results. Combination therapy with these drugs may be a promising strategy.
• Correlation between antibiotic use and antibiotic resistance: A multicenter study using the Japan Surveillance for Infection Prevention and Healthcare Epidemiology (J-SIPHE) system in Hokkaido, Japan.
  Keisuke Kagami; Nobuhisa Ishiguro; Sumio Iwasaki; Takayuki Usami; Tatsuya Fukumoto; Kasumi Hayasaka; Reiko Oyamada; Tsubasa Watanabe; Sho Nakakubo; Yusuke Niinuma; Takashi Hagino; Yoshifumi Abe; Ikuya Fujimoto; Hideki Maekawa; Ryo Fujibayashi; Satoshi Fuke; Kuniko Asahi; Shuichi Ota; Tatsuya Nagakura; Toshinari Okubo; Hideomi Asanuma; Toshihiro Ito; Sho Okano; Erika Komatsu; Kota Sasaki; Kei Hashimoto; Kazutoshi Washiya; Yumiko Kato; Katsunori Kusumi; Yasufumi Asai; Yuichi Saito; Yoshiyuki Sakai; Minoru Sakurada; Yuji Sakimoto; Yukari Ichikawa; Takahiro Kinebuchi; Dai Kondo; Syuhei Kanno; Minoru Kobayashi; Kagami Hirabayashi; Shinako Saitou; Katsuhiko Saito; Yuuki Ebina; Yuusuke Koshizaki; Makoto Chiba; Atsushi Yasuda; Toshiya Sato; Atsuo Togashi; Takashi Abe; Takahiro Fujita; Kengo Umehara; Masaru Amishima; Nobuo Murakami; Tetsuya Yagi; Shuhei Fujimoto; Taichi Tajima; Mitsuru Sugawara; Yoh Takekuma
  American journal of infection control, 51, 2, 163, 171, 2022年06月04日, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, BACKGROUND: The Japan Surveillance for Infection Prevention and Healthcare Epidemiology (J-SIPHE) system aggregates information related to antimicrobial resistance (AMR) measures in participating medical institutions nationwide and is intended to be used for promotion of AMR measures in participating facilities and their communities. This multicenter study aimed to determine the usefulness of the J-SIPHE system for evaluating the correlation between antibiotic use and antibiotic resistance in Hokkaido, Japan. METHODS: Data on antibiotic use and detection rate of major resistant Gram-negative bacteria at 19 hospitals in 2020 were collected from the J-SIPHE system, and data correlations were analyzed using JMP Pro. RESULTS: The detection rate of carbapenem-resistant Pseudomonas aeruginosa was significantly positively correlated with carbapenem use (Spearman's ρ = 0.551; P = 0.015). There were significant positive correlations between the detection rate of fluoroquinolone-resistant Escherichia coli and the use of piperacillin/tazobactam, carbapenems, and quinolones [ρ = 0.518 (P = 0.023), ρ = 0.76 (P < 0.001), and ρ = 0.502 (P = 0.029), respectively]. CONCLUSION: This is the first multicenter study to investigate the correlation between antibiotic use and antibiotic resistance using the J-SIPHE system. The results suggest that using this system may be beneficial for promoting AMR measures.
• 週刊誌に掲載された「危ないクスリ」に関する情報の整理とその適切性評価
  今井 俊吾; 柏木 仁; 佐藤 夕紀; 武隈 洋; 菅原 満
  日本医薬品情報学会総会・学術大会講演要旨集, 24回, 91, 91, (一社)日本医薬品情報学会, 2022年06月
  日本語
• Suitability of Oral Rehydration Solution (ORS) for Use in the Cisplatin Short Hydration Method.
  Yoshitaka Saito; Yoh Takekuma; Masaki Kobayashi; Naofumi Shinagawa; Takuro Noguchi; Satoshi Takeuchi; Yasushi Shimizu; Ichiro Kinoshita; Hirotoshi Dosaka-Akita; Mitsuru Sugawara
  Anticancer research, 42, 6, 3185, 3193, 2022年06月, ［査読有り］, ［最終著者, 責任著者］, ［国際誌］
  英語, 研究論文（学術雑誌）, BACKGROUND/AIM: Short hydration is a method to change partial intravenous hydration to oral to administer cisplatin (CDDP); however, the most suitable form of oral hydration is unknown. This study aimed to determine whether oral rehydration solution (ORS) affects CDDP-induced nephrotoxicity (CIN) and electrolyte imbalance. PATIENTS AND METHODS: Lung cancer patients (n=200) who had received CDDP-including regimens (CDDP dosage ≥75 mg/m2) were retrospectively evaluated. We used logistic analysis to evaluate whether ORS intake could be a preventive factor for CIN (≥grade 2 serum creatinine elevation). Moreover, incidence of CIN and electrolyte imbalance and the variation in serum creatinine and electrolyte levels were compared between ORS and non-ORS (control) patients. RESULTS: CIN occurred in 9.8% of ORS patients, and 7.5% of non-ORS patients (p=0.79). The variation in serum creatinine level was also similar in both groups. Multivariate analysis suggested that ORS intake does not affect CIN, although CIN was associated with the coadministration of non-steroidal anti-inflammatory drugs and the presence of diabetes mellitus. The variations in serum electrolyte levels did not differ, and incidence of hyponatremia, hypokalemia, and hypochloremia was also similar between the groups. Moreover, patients in ORS group experienced significantly more anorexia compared to controls, and approximately 40% of the patients were unable to continue ORS intake. CONCLUSION: ORS intake in CDDP short hydration regimens does not affect CIN and CDDP-induced electrolyte imbalance; however, its intake is associated with the incidence of anorexia suggesting that ORS should not be used for oral hydration.
• 週刊誌に掲載された「危ないクスリ」に関する情報の整理とその適切性評価
  今井 俊吾; 柏木 仁; 佐藤 夕紀; 武隈 洋; 菅原 満
  医薬品情報学, 24, 1, 1, 10, (一社)日本医薬品情報学会, 2022年05月
  日本語, 週刊誌に記載された処方箋の「危険性」に関する記事の適切性を、オーストラリアで開発されたマスメディアによる医療・健康記事の質を評価するための指標である「メディアドクター指標」を処方箋等に適用できるよう改変したものを用いて明らかにすることを目的に、2018年1月1日から2021年5月24日までに発行された「週刊朝日」「サンデー毎日」など週刊誌10誌を対象に、「薬剤名や薬効分類を特定可能」かつ「当該薬剤・薬効分類におけるヒトに対する具体的な副作用・有害事象に関して記述」している記事19本(週刊誌6誌)を2名の評価者により評価した。その結果、19本の記事のうち10本はB誌に掲載されたもので、計179種類の薬剤(薬効分類で34種類)の危険性について言及されていた。対象となった19本の記事の内容を9項目について評価者2人が評価した結果、11本で2名とも不満足とした評価項目が半数を超えていた。
• 週刊誌に掲載された「危ないクスリ」に関する情報の整理とその適切性評価
  今井 俊吾; 柏木 仁; 佐藤 夕紀; 武隈 洋; 菅原 満
  医薬品情報学, 24, 1, 1, 10, (一社)日本医薬品情報学会, 2022年05月, ［査読有り］
  日本語, 週刊誌に記載された処方箋の「危険性」に関する記事の適切性を、オーストラリアで開発されたマスメディアによる医療・健康記事の質を評価するための指標である「メディアドクター指標」を処方箋等に適用できるよう改変したものを用いて明らかにすることを目的に、2018年1月1日から2021年5月24日までに発行された「週刊朝日」「サンデー毎日」など週刊誌10誌を対象に、「薬剤名や薬効分類を特定可能」かつ「当該薬剤・薬効分類におけるヒトに対する具体的な副作用・有害事象に関して記述」している記事19本(週刊誌6誌)を2名の評価者により評価した。その結果、19本の記事のうち10本はB誌に掲載されたもので、計179種類の薬剤(薬効分類で34種類)の危険性について言及されていた。対象となった19本の記事の内容を9項目について評価者2人が評価した結果、11本で2名とも不満足とした評価項目が半数を超えていた。
• Hepatic drug metabolism in older people with body composition changes.
  Soyoko Kaburaki; Eri Yoshimura; Yasushi Miyamoto; Shungo Imai; Hitoshi Kashiwagi; Hidefumi Ueno; Mitsuru Sugawara; Yoh Takekuma
  Geriatrics & gerontology international, 22, 5, 449, 454, 2022年05月, ［査読有り］, ［国内誌］
  英語, 研究論文（学術雑誌）, AIM: Dosage adjustment is essential in older individuals because they are prone to experience a decline in liver function and changes in body composition. However, quantitative tests or equations for evaluating the activity of hepatic drug metabolism have not yet been clearly established. We examined hepatic drug metabolism activities in older individuals, focusing on changes in body composition parameters. METHODS: Lansoprazole and nifedipine, substrates of the metabolic enzymes cytochrome P450 (CYP) 2C19 and 3A4, respectively, were selected to study hepatic drug metabolism. Residual samples from blood test for older patients were evaluated to determine drug metabolism. The body composition of relevant patients was determined by analyzing characteristic parameters of skeletal muscle mass index (SMI), handgrip strength (HGS) and hepatic steatosis index (HSI). The differences in hepatic drug metabolism were studied statistically among categories in terms of the cut-off value of these parameters. RESULTS: Older male patients receiving lansoprazole and nifedipine in the low SMI (<7.0 kg/m2 ) category showed an 85-90% reduction in respective CYP2C19 and CYP3A4 metabolic activities compared with the normal SMI category. For the female patients, CYP2C19 and CYP3A4 metabolic activities showed no significant correlation with SMI and HGS. Fatty liver disease (HSI ≥36) was found to reduce CYP2C19 metabolic activity particularly in older female patients. CONCLUSIONS: Low CYP2C19 metabolic activity was statistically correlated with low SMI in male patients and high HSI in female patients, whereas low CYP3A4 metabolic activity was statistically correlated with low HGS in male patients. Geriatr Gerontol Int 2022; 22: 449-454.
• 医療の質向上、臨床の薬剤師による研究推進を目指した医療ビッグデータの活用 大規模レセプトデータベースを用いた臨床研究
  武隈 洋; 今井 俊吾; 菅原 満
  薬学雑誌, 142, 4, 331, 336, (公社)日本薬学会, 2022年04月, ［査読有り］
  日本語
• Evaluation of the strategies to reduce third-generation oral cephalosporins in dentistry at a Japanese academic hospital: An interrupted time series analysis.
  Akira Yamagami; Katsuya Narumi; Yoshitaka Saito; Ayako Furugen; Shungo Imai; Yoshimasa Kitagawa; Yoichi Ohiro; Ryo Takagi; Yoh Takekuma; Mitsuru Sugawara; Masaki Kobayashi
  Journal of clinical pharmacy and therapeutics, 47, 7, 1010, 1019, 2022年03月07日, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, WHAT IS KNOWN AND OBJECTIVE: Third-generation oral cephalosporins, especially cefcapene-pivoxil (CFPN-PI), have been used frequently in the Japanese dental field. In December 2014 and April 2016, the newly published clinical guidelines recommended the use of amoxicillin (AMPC). Thus, it is important to evaluate the impact of these guidelines on the prescription profiles of prophylactic antibiotics, clinical outcomes and cost-effectiveness of antibiotics. METHODS: We conducted a retrospective study to analyse an interrupted time series analysis from April 2013 to March 2020 at the Department of Dentistry of Hokkaido University Hospital. A segmented regression model was used to estimate the changes in the incidence of infectious complications following tooth extraction. Prescribed antibiotic data were evaluated via days of therapy (DOT). Antibiotic costs were calculated in terms of the Japanese yen (JPY). RESULTS AND DISCUSSION: We identified 17,825 eligible patients. The incidence rates of infectious complications (SSI + dry socket) and SSI after tooth extraction were 3.2% and 2.2%, respectively, during the entire period. The extraction of impacted third molars corresponded to 5.0% and 3.4%, respectively. However, their incidence rates were not significantly different during this period. The use of prophylactic antibiotics and antibiotic cost showed consistent trends following the implementation of guidelines. The mean DOT of CFPN-PI decreased (ranging from 4893.6 DOTs/1000 patients [March 2013 to November 2014] to 3856.4 DOTs/1000 patients [December 2014 to March 2016]; p < 0.001, and from 3856.4 DOTs/1000 patients [December 2014 to March 2016] to 2293.9 DOTs/1000 patients [April 2016 to March 2020]; p < 0.001). In contrast, the mean DOT of AMPC was found to be increased (ranging from 1379.7 DOTs/1000 patients [March 2013 to November 2014] to 3236.3 DOTs/1000 patients [December 2014 to March 2016]; p < 0.001, and from 3236.3 DOTs/1000 patients [December 2014 to March 2016] to 4597.8 DOTs/1000 patients [April 2016 to March 2020]; p < 0.001). The mean monthly cost was decreased (ranging from 905.3 JPY [March 2013 to November 2014] to 788.7 JPY [December 2014 to March 2016]; p = 0.003, and from 788.7 JPY [December 2014 to March 2016] to 614.0 JPY [April 2016 to March 2020]; p < 0.001). WHAT IS NEW AND CONCLUSION: After December 2014, prophylactic antibiotics were switched from CFPN-PI to AMPC, and the incidence rate of infectious complications was not significantly different over time. However, changing antibiotics is useful from a cost-effectiveness perspective.
• 大規模レセプトデータベースを用いたボリコナゾールの治療薬物モニタリング実施に関する実態調査
  宮井 貴之; 今井 俊吾; 百 賢二; 柏木 仁; 佐藤 夕紀; 菅原 満; 武隈 洋
  日本薬学会年会要旨集, 142年会, 27G, am09S, (公社)日本薬学会, 2022年03月
  日本語
• がんの多剤耐性を克服する新規エトポシド誘導体の探索
  山田 隼大; 王子谷 健太; 柏木 仁; 佐藤 夕紀; 今井 俊吾; 宮地 弘幸; 武隈 洋; 菅原 満
  日本薬学会年会要旨集, 142年会, 28C, pm04S, (公社)日本薬学会, 2022年03月
  日本語
• ビッグデータとデータマイニング手法を用いたリネゾリド誘発性血小板減少症の要因分析
  井上 優希; 武隈 洋; 宮井 貴之; 柏木 仁; 佐藤 夕紀; 菅原 満; 今井 俊吾
  日本薬学会年会要旨集, 142年会, 28H, pm13S, (公社)日本薬学会, 2022年03月
  日本語
• Using Japanese big data to investigate novel factors and their high-risk combinations that affect vancomycin-induced nephrotoxicity.
  Shungo Imai; Shota Kadomura; Takayuki Miyai; Hitoshi Kashiwagi; Yuki Sato; Mitsuru Sugawara; Yoh Takekuma
  British journal of clinical pharmacology, 88, 7, 3241, 3255, 2022年02月01日, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, AIMS: Several factors related to vancomycin-induced nephrotoxicity (VIN) have not yet been clarified. In the present study, we used Japanese big data to investigate novel factors and their high-risk combinations that influence VIN. METHODS: We employed a large Japanese electronic medical record database and included patients who had been administered intravenous vancomycin between June 2000 and December 2020. VIN was defined as an increase in serum creatinine ≥0.5 mg/dL or 1.5-fold higher than the baseline. The outcomes were: (1) factors affecting VIN that were identified using multiple logistic regression analysis, and (2) combinations of factors that affect the risk of VIN according to a decision tree analysis, which is a typical machine learning method. RESULTS: Of the 7,306 patients that were enrolled, VIN occurred in 14.2% of them (1,035). A multivariate analysis extracted 22 variables as independent factors. Concomitant ramelteon use (odds ratio; 0.701, 95% confidence interval; 0.512-0.959), ward pharmacy service (0.741, 0.638-0.861), duration of VCM <7 days (0.748, 0.623-0.899) and trough concentrations 10-15 mg/L (0.668, 0.556-0.802) reduce the risk of VIN. Meanwhile, concomitant piperacillin-tazobactam use (2.056, 1.754-2.409) and piperacillin use (2.868, 1.298-6.338) increase the risk. The decision tree analysis showed that a combination of vancomycin trough concentrations ≥20 mg/L and concomitant piperacillin-tazobactam use was associated with the highest risk. CONCLUSIONS: We revealed that the concomitant ramelteon use and ward pharmacy service may decrease the risk of VIN, while the concomitant use of not only piperacillin-tazobactam but also piperacillin may increase the risk.
• Evaluation of risk factors associated with carboplatin and nab-paclitaxel treatment suspension in patients with non-small cell lung cancer.
  Yoshitaka Saito; Yoh Takekuma; Naofumi Shinagawa; Mitsuru Sugawara
  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 30, 5, 4081, 4088, 2022年01月23日, ［査読有り］, ［責任著者］, ［国際誌］
  英語, 研究論文（学術雑誌）, PURPOSE: Carboplatin (CBDCA) + nanoparticle albumin-bound paclitaxel (nab-PTX) is one of the most effective chemotherapeutic regimens for advanced non-small cell lung cancer (NSCLC) treatment. However, neutropenia and neuropathy are well-known dose-limiting toxicities associated with this regimen, frequently resulting in treatment suspension and dose reduction. In the present study, we aimed to identify risk factors associated with CBDCA + nab-PTX treatment suspension. METHODS: Patients with NSCLC who received CBDCA + nab-PTX ± atezolizumab or pembrolizumab regimens were retrospectively evaluated. The risk factor(s) for treatment suspension and primary causes underlying suspension during the first course were assessed; the relative dose intensity (RDI) was compared between patients with and without identified factors. RESULTS: The frequency of treatment suspension was determined as 55%. The causes for suspension were neutropenia (65.2%), infection (24.2%), thrombocytopenia (6.1%), and other conditions. The calculated RDI was 98.5% for CBDCA and 79.3% for nab-PTX. Based on univariate and multivariate analyses, grade 1 or higher liver dysfunction was identified as a risk factor for treatment suspension. We determined primary causes for treatment suspension as neutropenia and/or infection, as they are closely related. Next, we evaluated associated factors and determined age ≥65 years and performance status (PS) 2 as potential factors, in addition to liver dysfunction. CONCLUSION: We observed that liver dysfunction at baseline is a risk factor for treatment suspension. In addition, age ≥65 years and PS 2 can result in treatment suspension owing to neutropenia and/or infection during CBDCA + nab-PTX treatment.
• がん治療医・緩和ケアスタッフを対象としたターミナルケア態度尺度を用いた意識調査
  熊井 正貴; 加藤 信太郎; 小柳 遼; 敦賀 健吉; 伊藤 陽一; 山田 武宏; 武隈 洋; 菅原 満; 川本 泰之; 小松 嘉人
  Palliative Care Research, 17, 2, 51, 58, (NPO)日本緩和医療学会, 2022年
  日本語
• Chronic Maxillary Atelectasis without Obstruction of the Maxillary Ostium - A Case Report.
  Yuki Numano; Kazuhiro Nomura; Tomotaka Hemmi; Jun Suzuki; Risako Kakuta; Mitsuru Sugawara
  Annals of maxillofacial surgery, 12, 2, 224, 226, 2022年, ［国際誌］
  英語, RATIONALE: Chronic maxillary atelectasis (CMA) is assumed to be caused by negative pressure in the maxillary sinus secondary to the obstruction of the ostiomeatal complex. PATIENT CONCERNS: A 49-year-old female patient first presented to our hospital complaining of right nasal congestion, rhinorrhoea and cheek pain. DIAGNOSIS: Computed tomography (CT) accidentally revealed the inward bowing of the left maxillary sinus, which is a typical sign of CMA or silent sinus syndrome despite the maxillary ostium being potent. TREATMENT: We did not consider any intervention for CMA because she had no symptoms related to it. OUTCOMES AND TAKE-AWAY LESSONS: No progression was noted clinically or on CT at the 6-month follow-up. The pathogenesis of CMA in our patient was not explainable by the commonly accepted theory. Apparent hypertrophy of the left maxillary bone was confirmed on CT, thus osteitis with chronic rhinosinusitis might be the potential cause of CMA in the open maxillary sinus.
• がん治療医・緩和ケアスタッフを対象としたターミナルケア態度尺度を用いた意識調査
  熊井 正貴; 加藤 信太郎; 小柳 遼; 敦賀 健吉; 伊藤 陽一; 山田 武宏; 武隈 洋; 菅原 満; 川本 泰之; 小松 嘉人
  Palliative Care Research, 17, 2, 51, 58, (NPO)日本緩和医療学会, 2022年, ［査読有り］
  日本語
• Machine Learning-Based Model for Estimating Vancomycin Maintenance Dose to Target the Area under the Concentration Curve of 400-600 mg·h/L in Japanese Patients.
  Takayuki Miyai; Shungo Imai; Eri Yoshimura; Hitoshi Kashiwagi; Yuki Sato; Hidefumi Ueno; Yoh Takekuma; Mitsuru Sugawara
  Biological & pharmaceutical bulletin, 45, 9, 1332, 1339, 2022年, ［査読有り］, ［最終著者, 責任著者］, ［国内誌］
  英語, 研究論文（学術雑誌）, In therapeutic drug monitoring of vancomycin (VCM), the area under the concentration-time curve (AUC) is related to clinical efficacy and toxicity. Determining the maintenance for patient is necessary since VCM concentrations are affected by factors such as renal function. We constructed a machine learning-based model to estimate the maintenance dose to target an AUC of 400-600 mg⋅h/L in each combination of patient's factors. This retrospective observational study was conducted at two hospitals. Patients who received VCM intravenously with measured trough and another point (e.g., peak) concentrations within the November 2011 to March 2019 period were enrolled. We extracted the factors that affect VCM concentration and constructed a decision tree model using a classification and regression tree algorithm. Of the 1380 patients, 822 were included. Training data were split up to four times and included 24 subgroups. The average corrected VCM daily doses ranged 17.6-59.4 mg/kg. Estimated glomerular filtration rate, age, and body mass index were selected as predictive variables that affected the recommended daily dose. In the validation data, our model had slightly higher proportions of AUC of 400-600 mg⋅h/L than other nomograms. However, our model was based only on limited patients. Thus, further clinical studies are needed to develop a general-purpose model in the future. We successfully constructed a model that recommends VCM maintenance daily doses with AUC of 400-600 mg⋅h/L for each combination of independent variables. Our model has the potential for application as a simple decision-making tool for medical staff.
• [Case Report on a Woman with Epilepsy Who Took Lacosamide during Pregnancy and Gave Birth to a Healthy Infant].
  Seika Kitamura; Ayako Nishimura; Yoh Takekuma; Yoshitaka Saito; Takeshi Umazume; Mitsuru Sugawara
  Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 142, 9, 1031, 1035, 2022年, ［査読有り］, ［責任著者］, ［国内誌］
  日本語, 研究論文（学術雑誌）, Lacosamide is a novel antiepileptic drug. Although many antiepileptic drugs reportedly pose a risk to fetuses, patients with epilepsy are advised to continue their medications during pregnancy. There have been few reports on lacosamide use during pregnancy, and its effects on the fetus remain unclear. Here, we report a case of lacosamide use during pregnancy. The 33-year-old patient was treated with oral lacosamide (400 mg/d) for symptomatic partial epilepsy. She was concomitantly treated with folic acid (5 mg/d) beginning 4 days before her last menstrual cycle. She was also concomitantly treated with oral perampanel (2 mg/d) at 5-7 weeks' gestation for seizure control but discontinued perampanel after the pregnancy was discovered. She progressed through her pregnancy with only mild seizures. Fetal growth was normal and ultrasonography revealed no external malformations. The patient had an elective cesarean section at 37 weeks and 2 days owing to a previous post-cesarean pregnancy. Her baby boy weighed 3025 g; his Apgar score was 8 and 9, 1 and 5 min, respectively, and his umbilical artery blood pH was 7.348. He had no congenital anomalies and no neonatal drug withdrawal symptoms. This suggests that lacosamide may have a low risk of teratogenicity and fetal toxicity. Thus, this case is valuable for clinicians who are considering the administration of antiepileptic drugs during pregnancy. In the future, more reports on the use of lacosamide during pregnancy should be collected.
• Performance Status不良群におけるナルデメジンの有効性の検証
  加藤 信太郎; 齋藤 佳敬; 小野田 紘子; 熊井 正貴; 今井 俊吾; 敦賀 健吉; 武隈 洋; 菅原 満
  薬学雑誌, 142, 7, 755, 760, (公社)日本薬学会, 2022年, ［査読有り］, ［責任著者］, ［国内誌］
  日本語, 研究論文（学術雑誌）, performance status(PS)不良患者におけるナルデメジン(Nal)の有効性を検証した。対象期間にNalが投与された383例のうち解析対象患者は141例であり、そのうちPS良好群は113例、PS不良群は28例であった。投与1日目から7日目までにおけるNalの有効率はPS良好群が71.7%、PS不良群が71.4%であり、有意な差は認められなかった。Nal投与前後の1週間当たりの自発排便回数の変化はPS良好群が2.8回/週の増加、PS不良群が3.6回/週の増加であり、ともに有意に増加していた。治療早期におけるNalの有効率はPS良好群が61.1%、PS不良群が57.1%、治療効果判定期間における有効率は各々60.2%、71.4%であり、ともに有意な差は認められなかった。Nalの効果はPS不良群においてもPS良好群と差が認められないことが明らかとなった。
• Prescription and Therapeutic Drug Monitoring Status of Valproic Acid among Patients Receiving Carbapenem Antibiotics: A Preliminary Survey Using a Japanese Claims Database
  Shungo Imai; Kenji Momo; Hitoshi Kashiwagi; Yuki Sato; Takayuki Miyai; Mitsuru Sugawara; Yoh Takekuma
  Annals of Clinical Epidemiology, 4, 1, 6, 10, Society for Clinical Epidemiology, 2022年, ［査読有り］
  研究論文（学術雑誌）
• [Clinical Research Using the Large Health Insurance Claims Database].
  Yoh Takekuma; Shungo Imai; Mitsuru Sugawara
  Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 142, 4, 331, 336, 2022年, ［査読有り］, ［国内誌］
  日本語, 研究論文（学術雑誌）, The JMDC Claims Database® contains completely anonymized receipt information on the insured members of health insurance associations. The number of registered users is approximately 9.6 million (6% of the population) as of May 2020. In this database, it is possible to track even outpatient treatment, even if the patient changes the medical facility, as long as the insurer of the subscriber's health insurance does not change, so that long-term medical treatment could be targeted as a research theme. However, as the data do not contain medical record information, it is not possible to obtain laboratory values, although it is possible to know whether clinical tests have been performed. For pharmaceutics-related research, the most suitable use of the receipt database like JMDC Claims Database® seems to be the investigation of actual prescriptions. However, the research topics that pharmacists are interested in are probably comparisons of drug effects, drug-drug interactions, or causal analysis of drugs and side effects. However, laboratory data for evaluating drug efficacy is not available in the receipt database, and the accuracy of the disease name in the database becomes problematic when using the disease name as information indicating the occurrence of side effects. In this review, we introduce our studies performed by using JMDC Claims Database® and how to manage the above-described problems. We hope that this study will be helpful to those who are going to engage in research using medical big data.
• Development of a Method of Liquid Chromatography Coupled with Tandem Mass Spectrometry for Simultaneous Determination of Linezolid and Tedizolid in Human Plasma.
  Yuki Sato; Yoh Takekuma; Takayuki Daisho; Hitoshi Kashiwagi; Shungo Imai; Mitsuru Sugawara
  Biological & pharmaceutical bulletin, 45, 4, 421, 428, 2022年, ［査読有り］, ［国内誌］
  英語, 研究論文（学術雑誌）, It is important to select appropriate antibiotics for infection control. Linezolid and tedizolid are newly developed and synthesized oxazolidinone antibacterial agents. It has been pointed out that there is a relationship between a high plasma concentration of the target drug and incidence of adverse effects, although it has been reported that neither linezolid nor tedizolid requires dose adjustment according to renal function. Due to the high incidence of adverse effects, both are often switched. Precise plasma concentration control by therapeutic drug monitoring (TDM) is desirable for reducing the adverse effects of both drugs and obtaining a better therapeutic effect. In this study, we aimed to establish a method for simultaneous quantification of linezolid and tedizolid in human plasma using LC coupled with tandem mass spectrometry. Sample preparation was performed by a simple operation with acetonitrile. Linezolid and tedizolid were separated by an octadecylsilyl column using a gradient elution of acetonitrile in aqueous 0.1% formic acid solution and were detected in the positive ion electrospray mode with multiple reaction monitoring. Quantification of linezolid and tedizolid ranged from 0.5 to 50 and 0.5 to 20 µg/mL, respectively. The intra-day and inter-day precision and accuracy of data were assessed and found to be acceptable. The developed method was successfully applied to measurement of the concentrations of linezolid and tedizolid. This simple method, which can simultaneously quantify both drug concentrations for daily TDM, could contribute to safer treatment of patients.
• A 5% Glucose Solution for the Liquid Formulation Gemcitabine Solvent Decreases Gemcitabine-induced Vascular Pain.
  Kazuki Uchiyama; Yoshitaka Saito; Tatsuhiko Sakamoto; Yoh Takekuma; Yoshito Komatsu; Mitsuru Sugawara
  Anticancer research, 42, 1, 343, 348, 2022年01月, ［査読有り］, ［責任著者］, ［国際誌］
  英語, 研究論文（学術雑誌）, BACKGROUND/AIM: Gemcitabine (GEM)-induced vascular pain often occurs in patients. A 5% glucose solution for the lyophilized formulation of GEM solvent is known to decrease the frequency of GEM-induced vascular pain compared with saline. In this study, we aimed to examine the availability of glucose for a liquid formulation GEM solvent for the prevention of GEM-induced vascular pain. PATIENTS AND METHODS: In total, 214 patients with bile tract or pancreatic cancer, who received GEM-containing regimens, were enrolled in this retrospective study. The patients were divided into a glucose group, which was administered the liquid formation GEM diluted with glucose, and a saline group. The frequency of GEM-induced vascular pain was compared between them. RESULTS: Glucose significantly decreased the frequency of GEM-induced vascular pain during the first GEM administration (36% vs. 55%, p=0.005). CONCLUSION: Switching the solution for liquid formulation GEM from saline to glucose significantly decreased the frequency of vascular pain.
• Therapeutic drug monitoring-enabled long-term use of linezolid for the successful treatment of refractory pyogenic spondylodiscitis without development of thrombocytopenia: A case report.
  Takayuki Daisho; Keisuke Kagami; Koujiro Yamazaki; Nobuhisa Ishiguro; Tsutomu Endo; Masahiko Takahata; Hisataka Suzuki; Mitsuru Sugawara; Yoh Takekuma
  Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association, 2021年12月15日, ［査読有り］, ［国内誌］
  英語
• Impact of reducing day 1 dexamethasone dose in anthracycline-containing regimens on acute gastrointestinal symptoms associated with breast cancer treatment.
  Yoshitaka Saito; Yoh Takekuma; Takashi Takeshita; Mitsuru Sugawara
  Scientific reports, 11, 1, 23298, 23298, 2021年12月02日, ［査読有り］, ［責任著者］, ［国際誌］
  英語, 研究論文（学術雑誌）, The potential of steroid sparing from day 2 onward is reported in anthracycline-containing regimens for breast cancer treatment. We evaluated whether the reduction of dexamethasone (DEX) dose from 9.9 to 6.6 mg on day 1 is possible in anthracycline-containing treatments. Patients receiving anthracycline-containing regimens were divided into control (9.9 mg DEX on day 1) and reduced (6.6 mg DEX on day 1) groups, and retrospectively evaluated. The complete response (CR) rate and the incidence and severity of nausea, vomiting, anorexia, and fatigue were evaluated. The CR rate in the acute phase (day 1) was 63.1% and 38.1% in the control and reduced groups, respectively, with significant difference (P = 0.01) between the groups. However, no difference was found in the delayed phase (days 2-7). The incidence of anorexia and vomiting during treatment was not statistically different. Severity of nausea tended to, but not statistically, worsen while anorexia significantly worsened in the reduced group. Multivariate analysis suggested that patients < 55 years, with non- or less-alcohol drinking habit (< 5 days/week), and administered reduced-DEX dosage on day 1, have a higher risk of acute nausea development. Thus, reducing day 1 DEX dose in anthracycline-containing regimens is not suitable for acute nausea management.
• Clinical applicability of urinary creatinine clearance for determining the initial dose of vancomycin in critically ill patients.
  Ryusei Mikami; Shungo Imai; Mineji Hayakawa; Mitsuru Sugawara; Yoh Takekuma
  Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 28, 2, 199, 205, 2021年10月19日, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, INTRODUCTION: The purpose of this study was to evaluate the clinical applicability of urinary creatinine clearance (CrCl) for determining the initial dose of vancomycin (VCM) in critically ill patients and to assess VCM trough plasma concentration/maintenance daily dose (C/D) ratio in patients with augmented renal clearance (ARC). METHODS: As the primary outcome measure, correlations between estimated renal function and the VCM C/D ratio were compared using the following formulas: CrCl, Cockcroft-Gault equation (eCrClC-G) and KineticGFR equation (KeGFR). Patients were divided into those with or without changes in renal function. The patients were further classified based on the presence or absence of ARC. The secondary outcome was the comparison of VCM C/D ratio between ARC and Non-ARC patients. RESULTS: A total of 65 patients were enrolled for analysis. In all groups, CrCl tended to correlate better with the VCM C/D ratio than eCrClC-G and KeGFR. A significantly lower VCM C/D ratio was observed in patients with persistent ARC than in the Non-ARC group (0.24 versus 0.52 kg/L). CONCLUSIONS: The clinical applicability of CrCl for the initial dosing design of VCM in critically ill patients was shown. Furthermore, the results indicated that patients with persistent ARC required a higher VCM dose than Non-ARC patients. Although our findings are limited, they have a value for further verification.
• Effects of piperacillin/tazobactam or cefepime on folinate dose in patients receiving high-dose methotrexate: A retrospective cohort study using Japanese administrative claims data.
  Shota Kadomura; Shungo Imai; Kenji Momo; Yuki Sato; Hitoshi Kashiwagi; Tatsuya Itoh; Mitsuru Sugawara; Yoh Takekuma
  Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 28, 7, 10781552211034703, 10781552211034703, 2021年10月18日, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, INTRODUCTION: Delayed methotrexate (MTX) clearance with the co-administration of piperacillin/tazobactam (PIPC/TAZ) has been reported. Penicillins have been associated with reduced MTX clearance but the evidence is limited. There are no cases described with cefepime but penicillins are listed as interacting with MTX. We aimed to reveal whether the co-administration of PIPC/TAZ or CFPM affects MTX clearance using data from an administrative database. METHODS: We used data from the JMDC database, a large insurance claims database constructed in Japan. We included patients who were prescribed PIPC/TAZ or CFPM between days 1 and 3 in high-dose MTX (HD-MTX). We compared one co-administration episode (with PIPC/TAZ or CFPM) to one control episode (without), as a match-control study of two different episodes in the same patient. The primary outcomes were the duration and cumulative dose of leucovorin (LV) as a surrogate indicator of delayed MTX clearance. RESULTS: Three patients who were co-administered PIPC/TAZ and 16 patients who were co-administered CFPM with HD-MTX were included. In the PIPC/TAZ group, the duration and the cumulative doses of LV were similar in co-administration and control episode (median 3.0 vs. 3.0 days and 288.0 vs. 219.0 mg). In the CFPM group, the duration and the cumulative doses of LV were not significantly different in co-administration and control episode (3.0 vs. 4.0 days and 169.5 vs. 258.0 mg). CONCLUSIONS: Our findings revealed that PIPC/TAZ did not necessarily cause a delay in MTX clearance during HD-MTX therapy. Moreover, the co-administration of CFPM with HD-MTX did not affect MTX clearance.
• Pregabalin Attenuates Carboplatin-Induced Akathisia-Like Neuropathy: A Novel Case Report
  Yoshitaka Saito; Yoh Takekuma; Megumi Furuta; Mitsuru Sugawara
  Case Reports in Oncology, 14, 3, 1418, 1421, S. Karger AG, 2021年10月04日, ［査読有り］, ［責任著者］
  研究論文（学術雑誌）
• Investigation of the risk factors of vomiting during linezolid therapy: a retrospective observational study.
  Takezo Tsutsumi; Shungo Imai; Hitoshi Kashiwagi; Yuki Sato; Mitsuru Sugawara; Yoh Takekuma
  European journal of clinical pharmacology, 78, 2, 279, 286, 2021年09月28日, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, PURPOSE: Some clinical studies have reported the occurrence of nausea and vomiting with linezolid (LZD) administration. However, no studies have evaluated nausea and vomiting as primary endpoints. In a previous study, we noted a possible relationship between LZD and vomiting, but risk factors were not identified. Therefore, the aim of the present study was to identify them. METHODS: Patients who received LZD 600 mg twice daily at Hokkaido University Hospital from September 2008 to April 2019 were enrolled in this retrospective observational study. Patient characteristics, concomitant medications, laboratory data, and the occurrence of vomiting were obtained from electronic medical records. Logistic regression analysis was performed to identify risk factors for vomiting, including age, sex, body weight, concomitant medications, and surgeries. RESULTS: A total of 496 patients were included in this study, of which 90 experienced vomiting. By multivariate logistic regression analysis, female sex (adjusted odds ratio [aOR], 2.69; 95% confidence interval [CI], 1.62-4.47), ≥ 10 days of LZD administration (aOR, 2.57; CI, 1.46-4.50), and hyponatraemia (aOR, 2.96; CI, 1.72-5.10) were identified as independent risk factors for vomiting; administration of serotonergic agents (aOR, 0.23; CI, 0.07-0.82) was negatively associated. CONCLUSIONS: This study is the first to successfully identify risk factors for LZD-induced vomiting. Careful monitoring of patients with these risk factors may lead to safer and sustainable LZD administration.
• Severe hypertriglyceridemia induced by S-1: Subsequent case series of four patients and further review of the literature.
  Yoshitaka Saito; Yoh Takekuma; Satoshi Takeuchi; Yoshito Komatsu; Mitsuru Sugawara
  International journal of clinical pharmacology and therapeutics, 59, 12, 787, 793, 2021年09月10日, ［査読有り］, ［責任著者］, ［国際誌］
  英語, 研究論文（学術雑誌）, OBJECTIVE: We previously reported a case where S-1, containing tegafur, gimeracil, and oteracil potassium, induced severe hypertriglyceridemia. After the case, we regularly monitored serum lipid levels and surprisingly observed an additional 4 cases within 1.5 years. We here report the treatment process. CASE REPORT: At least 3 patients exhibited hyperlipidemia at baseline; in 2 of them, this was caused by previous fluoropyrimidine treatment. One patient experienced grade 4 hypertriglyceridemia, and the other 3 grade 3 hypertriglyceridemia. One patient developed temporary serum triglyceride elevation during the S-1 administration period, and the 3 experienced persistent elevation. The severity of serum triglyceride level worsened with increasing administration and peaked in cycles 2 - 6. Fenofibrate 80 - 160 mg/day and S-1 dose reduction were effective, with some significantly and others gradually decreasing to grade 0 - 1. DISCUSSION: The summarized clinical features are as follows: (1) Severe hypertriglyceridemia tends to appear after several treatment cycles and worsens with increasing administration. (2) It tends to occur in patients with hyperlipidemia at baseline. (3) Patients previously affected with fluoropyrimidines-induced hypertriglyceridemia can experience S-1 symptoms. (4) In some cases, it might decrease after the S-1 suspension period. (5) Fibrates and S-1 dose reductions were effective. As the final fluoropyrimidine product is fluorouracil, its presence or that of its metabolizing enzymes and the genetic background of the patients might have affected the results. We should be aware of the risk of temporal and asymptomatic occurrence of S-1-induced hypertriglyceridemia for early detection with appropriate treatment.
• Severe Hypertriglyceridemia Induced by Docetaxel: A Novel Case Report
  Yoshitaka Saito; Yoh Takekuma; Takashi Takeshita; Mitsuru Sugawara
  Case Reports in Oncology, 14, 3, 1277, 1282, S. Karger AG, 2021年09月09日, ［査読有り］, ［最終著者, 責任著者］
  研究論文（学術雑誌）
• 大規模レセプトデータベースを用いたボリコナゾールの治療薬物モニタリング実施に関する実態調査
  宮井 貴之; 今井 俊吾; 百 賢二; 柏木 仁; 佐藤 夕紀; 菅原 満; 武隈 洋
  TDM研究, 38, 3, 39, 48, (一社)日本TDM学会, 2021年09月, ［査読有り］
  日本語
• Factors affecting creatine phosphokinase elevation during daptomycin therapy using combination of machine learning and conventional methods.
  Shungo Imai; Hitoshi Kashiwagi; Yuki Sato; Takayuki Miyai; Mitsuru Sugawara; Yoh Takekuma
  British journal of clinical pharmacology, 88, 3, 1211, 1222, 2021年08月26日, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, AIMS: Musculoskeletal toxicity is a typical side effect of daptomycin (DAP). However, the risk factors have not been well established. Here, we aimed to identify independent factors affecting DAP-induced musculoskeletal toxicity using a combination of machine learning and conventional statistical methods. METHODS: A population-based, retrospective, observational cohort study was conducted using the Japanese electronic medical record database. Patients who received DAP between October 2011 and December 2020 were enrolled. Two definitions of musculoskeletal toxicity were employed: (1) elevation of creatine phosphokinase (CPK) value more than twice from baseline and > 200 IU/L, and (2) > 1,000 IU/L. First, multiple logistic regression analyses (a conventional statistical method) were performed to identify independent factors affecting CPK elevation. Then, decision tree (DT) analyses, a machine learning method, were performed to detect combinations of factors that change CPK elevation risk. RESULTS: Of the 2,970 patients who received DAP, 706 were included. Elevation of CPK values > 200 IU/L and > 1,000 IU/L occurred in 83 (11.8%) and 17 (2.41%) patients, respectively. In multiple logistic regression analysis, baseline CPK value and concomitant use of hydrophobic statins were commonly extracted as independent factors affecting each CPK elevation, but concomitant use of hydrophilic statins was not. In DT analysis, patients who received hydrophobic statins and had high baseline CPK values were classified into the high-risk group. CONCLUSIONS: Our novel approach revealed new risk factors for CPK elevation. Our findings suggest that high-risk patients require frequent CPK monitoring.
• Clinical outcomes of intervention for carbapenems and anti-methicillin-resistant Staphylococcus aureus antibiotics by an antimicrobial stewardship team.
  Keisuke Kagami; Nobuhisa Ishiguro; Takehiro Yamada; Yusuke Niinuma; Sumio Iwasaki; Keisuke Taki; Tatsuya Fukumoto; Kasumi Hayasaka; Mutsumi Nishida; Junichi Sugita; Takanori Teshima; Mitsuru Sugawara; Yoh Takekuma
  American journal of infection control, 49, 12, 1493, 1498, 2021年08月17日, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, BACKGROUND: There are no reports on the effects of interventions, such as discontinuation and change/de-escalation of carbapenems and anti-methicillin-resistant Staphylococcus aureus (MRSA) antibiotics by an antimicrobial stewardship team focusing on detailed patient outcomes. This study aimed to evaluate these effects. METHODS: This retrospective cohort study was conducted at a tertiary care hospital from December 2018 to November 2019. RESULTS: Favorable clinical responses were obtained in 165/184 cases (89.7%) in the intervention-accepted group, higher than those in the not accepted group (14/19 cases, 73.7%; P=0.056). All-cause 30-day mortality was lower in the accepted group than in the not accepted group (1.1% and 10.5%, respectively; P=0.045). The microbiological outcomes were similar between the two groups. Duration of carbapenem and anti-MRSA antibiotic use in the accepted group was significantly lower than that in the not accepted group (median [interquartile range]: 8 days [5-13] versus 14 days [8-15], respectively, P=0.026 for carbapenem; 10 days [5.3-15] versus 15.5 days [13.8-45.3], respectively, P=0.014 for anti-MRSA antibiotic). CONCLUSION: This is the first study to investigate the effects of interventions such as discontinuation and change/de-escalation of antibiotics on detailed outcomes. Our intervention could reduce the duration of carbapenem and anti-MRSA antibiotic use without worsening clinical and microbiological outcomes.
• A cross-sectional survey of hospitalization and blood tests implementation status in patients who received tolvaptan under 75 years of age using a Japanese claims database.
  Shungo Imai; Kenji Momo; Hitoshi Kashiwagi; Yuki Sato; Takayuki Miyai; Mitsuru Sugawara; Yoh Takekuma
  Expert opinion on drug safety, 20, 10, 1, 10, 2021年07月19日, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）
• Risk factor analysis for taxane-associated acute pain syndrome under the dexamethasone prophylaxis.
  Yoshitaka Saito; Yoh Takekuma; Masaki Kobayashi; Tatsuhiko Sakamoto; Hiroko Yamashita; Mitsuru Sugawara
  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 29, 12, 8059, 8067, 2021年07月06日, ［査読有り］, ［責任著者］, ［国際誌］
  英語, 研究論文（学術雑誌）
• Preexisting autoimmune disease is a risk factor for immune-related adverse events: a meta-analysis.
  Atsushi Yamaguchi; Yoshitaka Saito; Keisuke Okamoto; Katsuya Narumi; Ayako Furugen; Yoh Takekuma; Mitsuru Sugawara; Masaki Kobayashi
  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2021年06月23日, ［査読有り］, ［責任著者］, ［国際誌］
  英語, 研究論文（学術雑誌）
• Alleviation of Abdominal Pain due to Irinotecan-Induced Cholinergic Syndrome Using Loperamide: A Case Report
  Kazuki Uchiyama; Yoshitaka Saito; Yoh Takekuma; Satoshi Yuki; Mitsuru Sugawara
  Case Reports in Oncology, 14, 2, 806, 811, 2021年06月10日, ［査読有り］, ［責任著者］
  研究論文（学術雑誌）
• Adding aprepitant to palonosetron does not decrease carboplatin-induced nausea and vomiting in patients with gynecologic cancer.
  Yuko Watanabe; Yoshitaka Saito; Takashi Mitamura; Yoh Takekuma; Mitsuru Sugawara
  Journal of pharmaceutical health care and sciences, 7, 1, 21, 21, 2021年06月01日, ［査読有り］, ［最終著者, 責任著者］, ［国際誌］
  英語, 研究論文（学術雑誌）
• Detection of risk factors related to administration suspension and severe neutropenia in gemcitabine and nab-paclitaxel treatment.
  Yoshitaka Saito; Yoh Takekuma; Masaki Kobayashi; Yoshito Komatsu; Mitsuru Sugawara
  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 29, 6, 3277, 3285, 2021年06月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）
• Hypertriglyceridemia induced by S-1: A novel case report and review of the literature.
  Yoshitaka Saito; Yoh Takekuma; Yoshito Komatsu; Mitsuru Sugawara
  Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 27, 4, 1020, 1025, 2021年06月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）
• Benzodiazepine Concentrations in the Breast Milk and Plasma of Nursing Mothers: Estimation of Relative Infant Dose.
  Ayako Nishimura; Ayako Furugen; Takeshi Umazume; Seika Kitamura; Mayuko Soma; Kiwamu Noshiro; Yoh Takekuma; Mitsuru Sugawara; Ken Iseki; Masaki Kobayashi
  Breastfeeding medicine : the official journal of the Academy of Breastfeeding Medicine, 16, 5, 424, 431, Mary Ann Liebert Inc, 2021年05月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）
• Sarcopenia in a patient with most serious complications after highly invasive surgeries treated with nutrition, rehabilitation, and pharmacotherapy: a case report.
  Michiyo Tatsumi; Satomi Kumagai; Takahiro Abe; Soichi Murakami; Hiroshi Takeda; Toshiaki Shichinohe; Yuko Watanabe; Shinsuke Katayama; Shiaki Hirai; Aiko Honda; Yoh Takekuma; Mitsuru Sugawara
  Journal of pharmaceutical health care and sciences, 7, 1, 16, 16, 2021年04月06日, ［査読有り］, ［責任著者］, ［国際誌］
  英語, 研究論文（学術雑誌）
• 北海道大学病院における新型コロナウイルス感染症の流行に伴う職務上の影響にかかわる調査結果
  阿部 結希; 清水 薫子; 中司 展人; 船木 典子; 長堀 紀子; 菅原 満; 澁谷 斉; 高橋 久美子; 北川 善政; 今野 哲; 渥美 達也
  日本医師会雑誌, 150, 1, 95, 100, (公社)日本医師会, 2021年04月, ［査読有り］
  日本語
• レセプトデータに基づくクローン病新規ブデソニド徐放性製剤の実態調査
  窪田 篤人; 今井 俊吾; 百 賢二; 菅原 満; 武隈 洋
  薬局薬学, 13, 1, 54, 61, (一社)日本薬局学会, 2021年04月, ［査読有り］
  日本語
• 薬局薬剤師による「患者への聞き取り」に基づいて実施された疑義照会の実態解明と医療安全への貢献度評価
  今井 俊吾; 難波 正志; 柏木 仁; 佐藤 夕紀; 武隈 洋; 菅原 満
  薬局薬学, 13, 1, 68, 78, (一社)日本薬局学会, 2021年04月, ［査読有り］, ［責任著者］
  日本語
• Efficacy and safety of colistin for the treatment of infections caused by multidrug-resistant gram-negative bacilli.
  Keisuke Kagami; Nobuhisa Ishiguro; Takehiro Yamada; Yusuke Niinuma; Sumio Iwasaki; Keisuke Taki; Tatsuya Fukumoto; Kasumi Hayasaka; Reiko Oyamada; Tsubasa Watanabe; Mutsumi Nishida; Junichi Sugita; Takanori Teshima; Mitsuru Sugawara; Yoh Takekuma
  Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 27, 3, 473, 479, 2021年03月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）
• Impact of histamine type-2 receptor antagonists on the anticancer efficacy of gefitinib in patients with non-small cell lung cancer.
  Yoshitaka Saito; Yoh Takekuma; Masaki Kobayashi; Naofumi Shinagawa; Yasushi Shimizu; Ichiro Kinoshita; Hirotoshi Dosaka-Akita; Ken Iseki; Mitsuru Sugawara
  European journal of clinical pharmacology, 77, 3, 381, 388, 2021年03月, ［査読有り］, ［責任著者］, ［国際誌］
  英語, 研究論文（学術雑誌）
• A new system to evaluate characteristics of Niemann-Pick C1 Like 1-mediated cholesterol transport using Xenopus laevis oocytes.
  Shunsuke Nashimoto; Saori Yagi; Naoki Takeda; Miku Nonaka; Yoh Takekuma; Mitsuru Sugawara; Yuki Sato
  Biochimica et biophysica acta. Biomembranes, 1863, 2, 183508, 183508, 2021年02月01日, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）
• Risk Analysis of Denosumab-Induced Hypocalcemia in Bone Metastasis Treatment: Renal Dysfunction Is Not a Risk Factor for Its Incidence in a Strict Denosumab Administration Management System with Calcium/Vitamin D Supplementation.
  Yoshitaka Saito; Yoh Takekuma; Yoshito Komatsu; Mitsuru Sugawara
  Biological & pharmaceutical bulletin, 44, 12, 1819, 1823, 2021年, ［査読有り］, ［責任著者］, ［国内誌］
  英語, 研究論文（学術雑誌）, We have reported that a strict denosumab administration management system with oral calcium/vitamin D supplementation attenuates denosumab-induced hypocalcemia in 158 cancer patients with bone metastasis. In this report, 27.8% of the patients experienced hypocalcemia, including 0.6% with grade 2. So far, the risk factors for ≥grade 2 hypocalcemia incidence have been identified in denosumab-treated cancer patients, including patients without calcium/vitamin D supplementation. Therefore, the present study aimed to reveal the factors that affect all-grade hypocalcemia incidence with calcium/vitamin D supplementation and team medical care according to the management system. A receiver operating characteristic curve analysis suggested that the cutoff of baseline serum calcium level for all-grade hypocalcemia incidence was 9.3 mg/dL. Multivariate analysis revealed that age ≥65 years (odds ratio, 95% confidence interval: 2.57, 1.11-5.95, p = 0.03), grade 1 or higher serum alkaline phosphatase elevation (3.70, 1.71-8.00, p < 0.01), an adjusted serum calcium level of less than 9.3 mg/dL (3.21. 1.25-8.24, p = 0.02) at baseline, and co-administration of cytotoxic agents (2.33, 1.06-7.11, p = 0.03) are risk factors for the incidence of all-grade hypocalcemia. However, renal dysfunction, which has been suggested to be a risk factor in previous reports, was not a factor. In conclusion, we revealed the risk factors for all-grade hypocalcemia in calcium/vitamin D supplementation and awareness, as demonstrated by the management system. Moreover, renal dysfunction was not a risk factor in our strict denosumab administration management system. Our results support the value of early detection of hypocalcemia incidence to guide the selection of an appropriate management strategy.
• Hypertriglyceridemia Induced by Fluorouracil: A Novel Case Report
  Yoshitaka Saito; Yoh Takekuma; Satoshi Yuki; Yoshito Komatsu; Mitsuru Sugawara
  Case Reports in Oncology, 14, 1, 207, 211, 2021年01月, ［査読有り］, ［責任著者］
  研究論文（学術雑誌）
• Implementation Status of Liver Function Tests for Monitoring Benzbromarone-Induced Hepatotoxicity: An Epidemiological Survey Using the Japanese Claims Database.
  Shungo Imai; Yasuyuki Nasuhara; Kenji Momo; Hiromitsu Oki; Hitoshi Kashiwagi; Yuki Sato; Takayuki Miyai; Mitsuru Sugawara; Yoh Takekuma
  Biological & pharmaceutical bulletin, 44, 10, 1499, 1505, 2021年, ［査読有り］, ［国内誌］
  英語, 研究論文（学術雑誌）, A major adverse effect of benzbromarone is hepatotoxicity. Therefore, periodic liver function tests are required at least for the first 6 months of benzbromarone administration. However, it is not clear whether the relevant blood tests are implemented appropriately. Here, we performed a cross-sectional survey of the implementation status of liver function tests in patients who were newly prescribed benzbromarone, using the Japanese large claims database. Male patients who were newly prescribed benzbromarone from January 2010 to December 2016 were included. We targeted patients who continued benzbromarone during the observation period (up to 180 d from the start of administration). The primary endpoint was the proportion of patients in whom periodic liver function tests were implemented. A periodic liver function test was defined as one or more liver function tests performed during both 1-90 and 91-180 d of initial benzbromarone administration. We labeled the tests as a "periodic test" or "non-periodic test" based on whether periodic liver function tests were performed or not, respectively. Furthermore, factors influencing non-periodic test were analyzed. Periodic testing was implemented only in 28.7% of patients. Additionally, factors such as number of hospital beds ≤19 (compared to 100-199 beds) and duration of the first prescription of benzbromarone were associated with non-periodic testing. Our study revealed that periodic liver function tests are not performed sufficiently in Japan. Thus, clinicians prescribing benzbromarone should be educated about the test. Our blood-test-based approach should be applied to other drugs and countries in future research.
• cAMP Signaling Pathway Prevents Dasatinib-Induced Vascular Hyperpermeability.
  Tsuyoshi Aoyama; Hiroki Kuriyama; Yuki Sato; Shungo Imai; Hitoshi Kashiwagi; Mitsuru Sugawara; Yoh Takekuma
  Biological & pharmaceutical bulletin, 44, 8, 1101, 1110, 2021年, ［査読有り］, ［国内誌］
  英語, 研究論文（学術雑誌）, Dasatinib is a first-line pharmacotherapeutic treatment for chronic myeloid leukemia (CML). It is more effective than traditional treatments but causes adverse effects such as pleural effusion that limits its effective treatment cycle. Since pleural effusion is caused by vascular hyperpermeability and causes discontinuation of treatment with dasatinib, it is important to explore the mechanism of pleural effusion caused by dasatinib and how to prevent it. In this study, we investigated how dasatinib increase vascular permeability, and how it can be prevented. Cytotoxicity was observed in vascular endothelial cells or epithelial cells were exposed to high concentrations of dasatinib. Thus, it was observed in vascular endothelial cells such as human umbilical vascular endothelial cell (HUVEC). Vascular endothelial (VE)-cadherin is one of the important factors that control vascular permeability. When VE-cadherin expression decreases, vascular permeability increases, but it did not change with tyrosine kinase inhibitor exposure. Monolayer permeability significantly increased only with high concentration of dasatinib, but this increase was prevented by cAMP activation. Furthermore, dasatinib affects the cell morphology of HUVEC, with increased inter celluar space compared to control and bosutinib, which were also attenuated by cAMP activation. Dasatinib significantly affected permeability control of vascular endothelial cells compared to bosutinib and imatinib. These results indicated that the cAMP signaling pathway may be involved in the pleural effusion caused by dasatinib in CML patients.
• Investigation of the Real-World Situation and Risk Factors Associated with Olanzapine Prescribed to Diabetes Patients by Using a Japanese Claims Database.
  Shinsuke Yamashita; Shungo Imai; Kenji Momo; Hitoshi Kashiwagi; Yuki Sato; Mitsuru Sugawara; Yoh Takekuma
  Biological & pharmaceutical bulletin, 44, 8, 1151, 1155, 2021年, ［査読有り］, ［国内誌］
  英語, 研究論文（学術雑誌）, Olanzapine is effective for schizophrenia management; however, it is contraindicated in diabetes patients. In addition, olanzapine is useful for treating nausea and vomiting, such as in the case of chemotherapy-induced nausea and vomiting (CINV). Therefore, we hypothesized that the contraindicated prescription of olanzapine likely occurs among cancer patients with diabetes, especially by non-psychiatric physicians. Hence, we conducted a nationwide survey to elucidate the situation of such contraindicated prescriptions and the associated risk factors. We extracted the data of patients who were newly prescribed olanzapine between April 2015 and March 2017 from the health insurance claims database developed by JMDC, Inc., Tokyo. The patients who were prescribed contraindicated olanzapine were defined as those who were prescribed olanzapine after a diagnosis of diabetes and diabetes drug prescription. In all, the data of 7181 patients were analyzed. We evaluated the proportion of diabetes patients who were prescribed contraindicated olanzapine from among those who were prescribed olanzapine. Furthermore, we investigated the background of patients who were prescribed olanzapine for information such as olanzapine prescribers and history of cancer chemotherapy. In all, 100 diabetes patients (1.39%) were prescribed olanzapine. In these patients, the frequency of olanzapine prescription was higher by non-psychiatry/neurology physicians than by psychiatry/neurology physicians (3.25 and 0.85%, respectively). Additionally, all olanzapine prescriptions in cancer chemotherapy-treated diabetes patients were issued by non-psychiatry/neurology physicians. Thus, our study revealed there were diabetes patients who were prescribed olanzapine. Additionally, olanzapine for CINV management was more likely to be a contraindicated prescription.
• [Pharmaceutical Intervention According to Strict Management System Can Normalize Decreased Serum Calcium Level by Denosumab and Prevent Its Aggravation].
  Yoshitaka Saito; Kazuki Uchiyama; Tatsuhiko Sakamoto; Kojiro Yamazaki; Kosei Kubota; Yoh Takekuma; Yoshito Komatsu; Mitsuru Sugawara
  Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 141, 8, 1023, 1030, 2021年, ［査読有り］, ［責任著者］, ［国内誌］
  日本語, 研究論文（学術雑誌）, Denosumab is a fully monoclonal antibody against the receptor activator of nuclear factor kappa-B ligand (RANKL), and prevents skeletal-related events by bone metastasis. Hypocalcemia is the most typical adverse effect of denosumab use. We have developed a management system for the more efficient and safer management of denosumab administration, and evaluated pharmaceutical interventions for the better control of hypocalcemia. All pharmaceutical interventions in the system from April 2016 to March 2020 were retrospectively evaluated. We have also assessed the incidence of hypocalcemia in 158 patients who were administered denosumab for six months or more in the period. A total of 282 pharmaceutical interventions (7.0% of the total administration) were conducted. The most conducted intervention was regarding hypocalcemia, which involved the suspension of the injection and/or the increase of calcium and vitamin D supplement with 65% adoption and 17% temporary treatment suspensions. Other interventions were about hypercalcemia, request of laboratory examination and ordering supplements, dental consultation, and poor renal function. A total of 199 interventions (70.6%) were adopted, with 33 administrations suspended. The frequency of hypocalcemia was 27.8% with just one patient having grade 2 hypocalcemia, suggesting that there were no severe cases. Moreover, hypocalcemia was significantly normalized following pharmaceutical intervention and/or handling by physicians (p=0.02) according to the system. Conversely, the normalization rate in hypercalcemia did not differ according to the countermeasures. In conclusion, pharmaceutical interventions according to our management system benefit safe denosumab treatment, especially in severe hypocalcemia prevention.
• An imaging approach for determining the mechanism of enhancement of intestinal absorption of an L-theanine supplement.
  Yuki Sato; Kazuki Yamaguchi; Mikako Ogawa; Yoh Takekuma; Mitsuru Sugawara
  PloS one, 16, 6, e0253066, 2021年, ［査読有り］, ［責任著者］, ［国際誌］
  英語, 研究論文（学術雑誌）
• Safety Evaluation of Initial CT-P6 Administration for 30 min during the Switch from Reference Trastuzumab in Maintenance Infusion: A Multicenter Observational Study.
  Yoshitaka Saito; Shinya Tamaki; Haruka Hasegawa; Kenta Takahashi; Akira Tokutome; Yoh Takekuma; Hiroko Yamashita; Yoshito Komatsu; Mitsuru Sugawara
  Biological & pharmaceutical bulletin, 44, 4, 474, 477, 2021年, ［査読有り］, ［責任著者］, ［国内誌］
  英語, 研究論文（学術雑誌）
• Construction of a Risk Prediction Model of Extended Release Oxycodone Tablet-Induced Nausea and Clarification of Predictive Factors.
  Masayoshi Kumai; Shungo Imai; Shintaro Kato; Ryo Koyanagi; Kenkichi Tsuruga; Takehiro Yamada; Yoh Takekuma; Mitsuru Sugawara
  Biological & pharmaceutical bulletin, 44, 4, 593, 598, 2021年, ［査読有り］, ［責任著者］, ［国内誌］
  英語, 研究論文（学術雑誌）
• Evaluation of Chemotherapy Regimen Management Practice by Oncology-Specialized and Non-specialized Pharmacists Collaboration.
  Yoshitaka Saito; Kazuki Uchiyama; Tatsuhiko Sakamoto; Kosei Kubota; Hiromitsu Oki; Miwako Iwai; Yoh Takekuma; Yoshito Komatsu; Mitsuru Sugawara
  Biological & pharmaceutical bulletin, 44, 3, 293, 297, 2021年, ［査読有り］, ［責任著者］, ［国内誌］
  英語, 研究論文（学術雑誌）
• Probiotic Prescription Status of Pediatric Patients with Otitis Media Receiving Oral Amoxicillin or Amoxicillin/Clavulanate from April 2016 to March 2017 Using a Japanese Health Insurance Claims Database.
  Shungo Imai; Kenji Momo; Hitoshi Kashiwagi; Takayuki Miyai; Mitsuru Sugawara; Yoh Takekuma
  Biological & pharmaceutical bulletin, 44, 3, 448, 452, 2021年, ［査読有り］, ［国内誌］
  英語, 研究論文（学術雑誌）
• Pharmacokinetics of mycophenolic acid after haplo-hematopoietic stem cell transplantation in Japanese recipients.
  Kazuki Uchiyama; Yoshitaka Saito; Yoh Takekuma; Junichi Sugita; Takanori Teshima; Mitsuru Sugawara
  Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 28, 1, 1078155220980815, 1078155220980815, SAGE Publications, 2020年12月22日, ［査読有り］, ［責任著者］, ［国際誌］
  英語, 研究論文（学術雑誌）
• A Risk Prediction Flowchart of Vancomycin-Induced Acute Kidney Injury to Use When Starting Vancomycin Administration: A Multicenter Retrospective Study.
  Takayuki Miyai; Shungo Imai; Hitoshi Kashiwagi; Yuki Sato; Shota Kadomura; Kenji Yoshida; Eri Yoshimura; Toshiaki Teraya; Takashi Tsujimoto; Yukari Kawamoto; Tatsuya Itoh; Hidefumi Ueno; Yoshikazu Goto; Yoh Takekuma; Mitsuru Sugawara
  Antibiotics (Basel, Switzerland), 9, 12, 1, 12, 2020年12月18日, ［査読有り］, ［責任著者］, ［国際誌］
  英語, 研究論文（学術雑誌）
• 救急/集中治療領域における薬剤師介入の実態と有害事象回避による潜在的な医療経済評価
  小林 洋平; 山岡 怜央; 三上 龍生; 山崎 浩二郎; 熊井 正貴; 山田 武宏; 武隈 洋; 菅原 満; 井関 健
  日本臨床救急医学会雑誌, 23, 6, 771, 779, (一社)日本臨床救急医学会, 2020年12月, ［査読有り］
  日本語
• オピオイド使用患者の眠気に対する安息香酸ナトリウムカフェイン散の効果
  熊井 正貴; 山田 武宏; 敦賀 健吉; 武隈 洋; 菅原 満
  日本緩和医療薬学雑誌, 13, 4, 119, 125, (一社)日本緩和医療薬学会, 2020年12月, ［査読有り］, ［責任著者］
  日本語
• Transport via Niemann-Pick C1 Like 1 contributes to the intestinal absorption of ubiquinone.
  Shunsuke Nashimoto; Yuto Takekawa; Yoh Takekuma; Mitsuru Sugawara; Yuki Sato
  Drug metabolism and pharmacokinetics, 35, 6, 527, 533, 2020年12月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）
• Comparison of interactions between warfarin and cephalosporins with and without the N-methyl-thio-tetrazole side chain.
  Shungo Imai; Shota Kadomura; Kenji Momo; Hitoshi Kashiwagi; Yuki Sato; Takayuki Miyai; Mitsuru Sugawara; Yoh Takekuma
  Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 26, 11, 1224, 1228, Elsevier BV, 2020年11月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）
• A cross-sectional exploratory survey on occurrence of triple-whammy prescription pattern in Japan.
  Shungo Imai; Kenji Momo; Hitoshi Kashiwagi; Takayuki Miyai; Mitsuru Sugawara; Yoh Takekuma
  International journal of clinical pharmacy, 42, 5, 1369, 1373, Springer Science and Business Media LLC, 2020年10月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）
• Transfer of orally administered hyaluronan to the lymph.
  Yuki Sato; Tatsuru Joumura; Yoh Takekuma; Mitsuru Sugawara
  European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 154, 210, 213, 2020年09月, ［査読有り］, ［責任著者］, ［国際誌］
  英語, 研究論文（学術雑誌）
• Nonsteroidal anti-inflammatory drugs use in patients with chronic kidney disease are often prescribed from different clinicians than those who diagnosed them.
  Shungo Imai; Kenji Momo; Hitoshi Kashiwagi; Takayuki Miyai; Mitsuru Sugawara; Yoh Takekuma
  Pharmacoepidemiology and drug safety, 29, 8, 873, 880, 2020年08月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）
• Effect of palonosetron and dexamethasone administration on the prevention of gastrointestinal symptoms in hepatic arterial chemoembolization with epirubicin.
  Tatsuhiko Sakamoto; Yoshitaka Saito; Masaki Kobayashi; Takehiro Yamada; Yoh Takekuma; Masato Nakai; Koji Ogawa; Ken Iseki; Mitsuru Sugawara
  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 28, 7, 3251, 3257, 2020年07月, ［査読有り］, ［責任著者］, ［国際誌］
  英語, 研究論文（学術雑誌）
• Possibility for Dose Optimization of Pazopanib from Its Plasma Concentration in Japanese Patients with Cancer.
  Hiroyuki Tanaka; Hiroaki Hiraga; Yoh Takekuma; Toru Harabayashi; Satoshi Nagamori; Masayuki Endo; Mitsuru Sugawara
  Biological & pharmaceutical bulletin, 43, 5, 762, 766, 2020年05月01日, ［査読有り］, ［責任著者］, ［国内誌］
  英語, 研究論文（学術雑誌）
• Serotonin Syndrome Developing Immediately after the Initiation of Low-Dose Methadone Therapy: A Case Report
  Masayoshi Kumai; Yosuke Maeda; Mototsugu Miura; Kenkichi Tsuruga; Takehiro Yamada; Yoh Takekuma; Mitsuru Sugawara
  Case Reports in Oncology, 13, 1, 281, 284, S. Karger AG, 2020年03月24日, ［査読有り］, ［責任著者］
  研究論文（学術雑誌）
• Interaction Between Piperacillin/Tazobactam and Warfarin: a Single-Center Retrospective Single-Arm Cohort Study
  Shota Kadomura; Yoh Takekuma; Shungo Imai; Hitoshi Kashiwagi; Kotaro Kawamoto; Tatsuya Itoh; Mitsuru Sugawara
  BPB Reports, 3, 2, 65, 69, 2020年03月, ［査読有り］, ［責任著者］
• Influence of gastrointestinal activity on the absorption of nilotinib.
  Maaya Sasaki; Tsuyoshi Aoyama; Mitsuru Sugawara; Yoh Takekuma
  Drug metabolism and pharmacokinetics, 35, 1, 102, 110, 2020年02月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）
• Enhancement of intestinal absorption of coenzyme Q10 using emulsions containing oleyl polyethylene acetic acids.
  Yuki Sato; Sayaka Yokoyama; Yoshiaki Yamaki; Yuta Nishimura; Mami Miyashita; Shingo Maruyama; Yoh Takekuma; Mitsuru Sugawara
  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 142, 105144, 105144, 2020年01月15日, ［査読有り］, ［責任著者］, ［国際誌］
  英語, 研究論文（学術雑誌）
• Pharmaceutical Care Contributes to the Advanced Management of Patients Receiving Immune Checkpoint Inhibitors.
  Yoshitaka Saito; Kazuki Uchiyama; Tatsuhiko Sakamoto; Kojiro Yamazaki; Kosei Kubota; Yoh Takekuma; Yoshito Komatsu; Mitsuru Sugawara
  Biological & pharmaceutical bulletin, 43, 12, 1969, 1974, Pharmaceutical Society of Japan, 2020年, ［査読有り］, ［責任著者］, ［国内誌］
  英語, 研究論文（学術雑誌）
• Prescription of Colchicine with Other Dangerous Concomitant Medications: A Nation-Wide Survey Using the Japanese Claims Database.
  Shungo Imai; Kenji Momo; Hitoshi Kashiwagi; Takayuki Miyai; Mitsuru Sugawara; Yoh Takekuma
  Biological & pharmaceutical bulletin, 43, 10, 1519, 1525, 2020年, ［査読有り］, ［国内誌］
  英語, 研究論文（学術雑誌）
• Association of the ward pharmacy service with active implementation of therapeutic drug monitoring for vancomycin and teicoplanin-an epidemiological surveillance study using Japanese large health insurance claims database.
  Shungo Imai; Kenji Momo; Hitoshi Kashiwagi; Takayuki Miyai; Mitsuru Sugawara; Yoh Takekuma
  Journal of pharmaceutical health care and sciences, 6, 1, 18, 18, 2020年, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）
• Validation of the usefulness of artificial neural networks for risk prediction of adverse drug reactions used for individual patients in clinical practice.
  Shungo Imai; Yoh Takekuma; Hitoshi Kashiwagi; Takayuki Miyai; Masaki Kobayashi; Ken Iseki; Mitsuru Sugawara
  PloS one, 15, 7, e0236789, 2020年, ［査読有り］, ［責任著者］, ［国際誌］
  英語, 研究論文（学術雑誌）
• A New Algorithm Optimized for Initial Dose Settings of Vancomycin Using Machine Learning.
  Shungo Imai; Yoh Takekuma; Takayuki Miyai; Mitsuru Sugawara
  Biological & pharmaceutical bulletin, 43, 1, 188, 193, 2020年, ［査読有り］, ［責任著者］, ［国内誌］
  英語, 研究論文（学術雑誌）
• Continuous Cytostatic Effects of BCR-ABL Tyrosine Kinase Inhibitors (TKIs) after Washout in Human Leukemic K562 Cells.
  Tsuyoshi Aoyama; Yoshihiko Shibayama; Tatsuhiko Furukawa; Mitsuru Sugawara; Yoh Takekuma
  Biological & pharmaceutical bulletin, 42, 11, 1805, 1813, 2019年11月01日, ［査読有り］, ［国内誌］
  英語, 研究論文（学術雑誌）
• Comparison of predictive performance of drug dose settings using renal function estimation equations based on the Japanese population: a preliminary retrospective study using vancomycin dosing data.
  Shungo Imai; Soyoko Kaburaki; Takayuki Miyai; Hitoshi Kashiwagi; Mitsuru Sugawara; Yoh Takekuma
  BPB Reports, 2, 5, 80, 85, 2019年10月, ［査読有り］
  英語, 研究論文（学術雑誌）
• レビー小体型認知症に対してリバスチグミンからの切り替えで低用量長期間ガランタミン投与が有効だった1症例
  濱野 宏美; 土井 正剛; 武隈 洋; 菅原 満; 一木 崇宏
  日本老年薬学会雑誌, 2, 2, 27, 34, (一社)日本老年薬学会, 2019年09月, ［査読有り］
  日本語, 症例は70歳代女性で、かかりつけ医が当該患者を引き継ぐ前、アルツハイマー型認知症(AD)の診断にてドネペジル5mg/日を服用していた。その後、ドネペジル5mg/日からガランタサミン(GAL)8mg/日へ変更された。数ヵ月後に無症候性脳梗塞を発症し、近隣脳外科の退院後、ニセルゴリン錠5mg、レボドパ・カルビドパ配合錠、リバスチグミンパッチ4.5mg/日が開始された。貼付開始後から皮膚炎を発症し、ステロイド外用薬を使用したが改善しなかった。皮膚炎のためやむを得ずGAL服用へ処方が変更され、会話にはならないが発語が増加し、右手でコップを掴めるようになった。しかし、強い嘔気をきたして近隣病院へ入院しGAL服用は中止されたが、クロピドグレルとレボドパ・カルビドパ配合錠服用は継続されていた。高齢者施設に再入居後にGAL 4mg/日服用を開始したところ、悪化していた覚醒レベルは徐々に回復し、寝床上のみでの生活から車椅子に座り、リビングで過ごせるようになった。
• Higher incidence of acute kidney injury in patients treated with piperacillin/tazobactam than in patients treated with cefepime: a single-center retrospective cohort study.
  Shota Kadomura; Yoh Takekuma; Yuki Sato; Masato Sumi; Kotaro Kawamoto; Tatsuya Itoh; Mitsuru Sugawara
  Journal of pharmaceutical health care and sciences, 5, 13, 13, 2019年, ［査読有り］, ［責任著者］, ［国際誌］
  英語, 研究論文（学術雑誌）, Background: Piperacillin/tazobactam (PIPC/TAZ) and cefepime (CFPM) are commonly used for the treatment of nosocomial and healthcare-associated infections. Recent reports have suggested that the incidence of acute kidney injury (AKI) in patients treated with a combination of vancomycin (VCM) and PIPC/TAZ is higher than that in patients treated with CFPM. However, there have been few reports on a comparison of the incidences of AKI in patients treated with PIPC/TAZ monotherapy and patients treated with CFPM. In this study, we investigated whether the incidence of AKI in patients treated with PIPC/TAZ is higher than that in patients treated with CFPM. Methods: This study was a single-center retrospective observational study. Patients who died during the therapeutic period, patients younger than 18 years of age, and patients undergoing hemodialysis were excluded. Primary outcomes were the incidence of AKI and the AKIN stages defined by the Acute Kidney Injury Network. Secondary outcomes were discontinuation and/or change of antibiotics and initiation of dialysis due to AKI. We also investigated the time to onset and the risk factors of AKI in this population. Results: There were 163 patients in the PIPC/TAZ group and 103 patients in the CFPM group. The incidence of AKI in patients treated with PIPC/TAZ (8.6%) was significantly higher than that in patients treated with CFPM (0.9%) (odds ratio (OR), 9.53; 95% confidence interval (CI), 1.41-408; p= 0.011). AKI severity was mostly stage 1 in both groups. There was no discontinuation and/or changes of antibiotics and there was no initiation of dialysis in either group. The onset of AKI in the PIPC/TAZ group (median period of 4 days) was earlier than that in the CFPM group. PIPC/TAZ was determined to be an independent risk factor of AKI in multivariate analysis (adjusted OR, 9.56; 95% CI, 1.21-75.3; p = 0.032). Conclusions: This study showed that the incidence of AKI in patients who received PIPC/TAZ was higher than that in patients who received CFPM. Furthermore, the onset of AKI was earlier in patients who received PIPC/TAZ than in patients who received CFPM. PIPC/TAZ was an independent risk factor of AKI in this study population.
• Improvement of renal function estimation equations for elderly Japanese people.
  Soyoko Kaburaki; Eri Yoshimura; Nozomi Kojima; Hidefumi Ueno; Mitsuru Sugawara; Yoh Takekuma
  Health science reports, 1, 10, e85, 2018年10月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）
• Enhancement of lymphatic transport of lutein by oral administration of a solid dispersion and a self-microemulsifying drug delivery system.
  Yuki Sato; Tatsuru Joumura; Shunsuke Nashimoto; Sayaka Yokoyama; Yoh Takekuma; Hideto Yoshida; Mitsuru Sugawara
  European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 127, 171, 176, 2018年06月, ［査読有り］, ［責任著者］, ［国際誌］
  英語, 研究論文（学術雑誌）
• Plasma and intracellular concentrations in an elderly patient with chronic myeloid leukemia receiving low-dose dasatinib therapy.
  Masahiro Imamura; Yusuke Nakamura; Mitsuru Sugawara
  Geriatrics & gerontology international, 18, 3, 505, 507, 2018年03月, ［査読有り］, ［国内誌］
  英語
• 薬学実務実習前後における薬学生のコミュニケーション分析 Roter method of interaction process analysis(RIAS)を用いて
  武隈 洋; 森 綾子; 小林 正紀; 山田 勇磨; 佐藤 夕紀; 鳴海 克哉; 古堅 彩子; 菅原 満
  薬学雑誌, 138, 12, 1579, 1586, (公社)日本薬学会, 2018年, ［査読有り］, ［責任著者］, ［国内誌］
  日本語, 研究論文（学術雑誌）, 病院・薬局実務実習を履修する前の薬学部内での事前実習において模擬患者を相手に行ったロールプレイと、実務実習後に同じシナリオで行ったロールプレイとをRIASによって比較し、コミュニケーション能力がどのように変化しているか検討した。対象は、本学薬学部薬学科の学生で、4年次の事前実習時と6年次の実務実習後に同じ服薬指導のシナリオでロールプレイを行った19名とした。検討の結果、学生は実務実習を経てコミュニケーションへの慣れや知識の増加により発話が流暢になったことが示唆された。また、4年次に比べて6年次には、「単純な相槌」(Back-channel responses)が減少し、「同意・理解」(Shows agreement or understanding)が増加していたことから、相手に対する理解の姿勢を表現できるようになったものと思われた。発話内容をみると、4年次に比べて6年次には「聞き取り」の割合が減少し、「相手への気持ちの寄り添い」や「助言」の割合が増加していた。
• パゾパニブの血中濃度に影響する因子の探索
  田中 寛之; 平賀 博明; 武隈 洋; 橋下 浩紀; 三浪 圭太; 原林 透; 永森 聡; 遠藤 雅之; 菅原 満
  TDM研究, 34, 3, 140, 140, (一社)日本TDM学会, 2017年09月, ［査読有り］, ［責任著者］
  日本語
• 小学校の授業を通して見えてきたことと今後の課題
  佐藤夕紀; 宮下元樹; 菅原満
  道学薬, 13, 37, 40, 2017年05月, ［招待有り］
  日本語, 研究論文（研究会，シンポジウム資料等）
• Inhibitory effect of ezetimibe can be prevented by an administration interval of 4 h between α-tocopherol and ezetimibe.
  Nashimoto S; Sato Y; Takekuma Y; Sugawara M
  Biopharmaceutics & drug disposition, 38, 4, 280, 289, 2017年05月, ［査読有り］, ［責任著者］, ［国際誌］
  英語, 研究論文（学術雑誌）
• 耳鼻咽喉科領域におけるアレルギー性咳嗽症状を有する患者に対する抗アレルギー薬併用の実態調査
  武隈 洋; 石坂 悠; 高地 里佳; 吉村 恵理; 小嶋 希望; 上野 英文; 平野 卓哉; 野田 敏宏; 熊井 惠美; 菅原 満
  薬局薬学, 9, 1, 159, 168, (一社)日本薬局学会, 2017年04月, ［査読有り］
  日本語
• Guidelines for Therapeutic Drug Monitoring of Cardiovascular Drugs Clinical Use of Blood Drug Concentration Monitoring (JCS 2015) - Digest Version.
  Kazutaka Aonuma; Tsuyoshi Shiga; Hirotsugu Atarashi; Kosuke Doki; Hirotoshi Echizen; Nobuhisa Hagiwara; Junichi Hasegawa; Hideharu Hayashi; Kenzo Hirao; Fukiko Ichida; Takanori Ikeda; Yorinobu Maeda; Naoki Matsumoto; Toshiyuki Sakaeda; Wataru Shimizu; Mitsuru Sugawara; Kyoichi Totsuka; Yoshimasa Tsuchishita; Kazuyuki Ueno; Eiichi Watanabe; Masayuki Hashiguchi; Sumio Hirata; Hidefumi Kasai; Yoshiaki Matsumoto; Akihiko Nogami; Yukio Sekiguchi; Tokuko Shinohara; Atsushi Sugiyama; Naokata Sumitomo; Atsushi Suzuki; Naohiko Takahashi; Eiji Yukawa; Masato Homma; Minoru Horie; Hiroshi Inoue; Hiroshi Ito; Takanori Miura; Tohru Ohe; Kimikazu Shinozaki; Kazuhiko Tanaka
  Circulation journal : official journal of the Japanese Circulation Society, 81, 4, 581, 612, 2017年03月24日, ［査読有り］, ［国内誌］
  英語, 研究論文（学術雑誌）
• Simple blood sample pre-treatment to remove DAMPA in ARCHITECT® for methotrexate
  Tanaka H; Sako M; Morioka Y; Motoshige H; Takekuma Y; Kawamoto H; Sugawara M; Hiraga H
  TDM研究, 34, 1, 1, 7, 2017年03月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Difference in the Dissolution Behaviors of Tablets Containing Polyvinylpolypyrrolidone (PVPP) Depending on Pharmaceutical Formulation After Storage Under High Temperature and Humid Conditions
  Yoh Takekuma; Haruka Ishizaka; Masato Sumi; Yuki Sato; Mitsuru Sugawara
  JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, 19, 4, 511, 519, 2016年, ［査読有り］
  英語, 研究論文（学術雑誌）
• Pharmacokinetics and dose adjustment of etoposide administered in a medium-dose etoposide, cyclophosphamide and total body irradiation regimen before allogeneic hematopoietic stem cell transplantation.
  Yuki Tazawa; Akio Shigematsu; Kumiko Kasashi; Junichi Sugita; Tomoyuki Endo; Takeshi Kondo; Takanori Teshima; Ken Iseki; Mitsuru Sugawara; Yoh Takekuma
  Journal of pharmaceutical health care and sciences, 2, 18, 18, 2016年, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, BACKGROUND: We investigated the pharmacokinetics of etoposide (ETP) to reduce the inter-individual variations of ETP concentrations in patients with acute leukemia who underwent allogeneic hematopoietic stem cell transplantation. We also carried out an in vivo study using rats to verify the dose adjustment. METHODS: This study included 20 adult patients. ETP was administered intravenously at a dose of 15 mg/kg once daily for 2 days (total dose: 30 mg/kg) combined with standard conditioning of cyclophosphamide and total body irradiation. In an in vivo study using rats, ETP was administered intravenously at a dose of 15 mg/kg or an adjusted dose. The ETP plasma concentration was determined by using HPLC. The pharmacokinetic parameters were estimated by using a 1-compartment model. RESULTS: The peak concentration (Cmax) of ETP and the area under the plasma concentration-time curve (AUC) of ETP differed greatly among patients (range of Cmax, 51.8 - 116.5 μg/mL; range of AUC, 870 - 2015 μg · h/mL). A significant relationship was found between Cmax and AUC (R = 0.85, P < 0.05). Distribution volume (Vd) was suggested to be one of the factors of inter-individual variation in plasma concentration of ETP in patients (range of Vd, 0.13 - 0.27 L/kg), and correlated with Alb and body weight (R = 0.56, P < 0.05; R = 0.40, P < 0.05 respectively). We predicted Vd of rats by body weight of rats (with normal albumin levels and renal function), and the dose of ETP was adjusted using predicted Vd. In the dose adjustment group, the target plasma ETP concentration was achieved and the variation of plasma ETP concentration was decreased. CONCLUSION: The results suggested that inter-individual variation of plasma concentration of ETP could be reduced by predicting Vd. Prediction of Vd is effective for reducing individual variation of ETP concentration and might enable a good therapeutic effect to be achieved.
• An Approach to Improve Intestinal Absorption of Poorly Absorbed Water-Insoluble Components via Niemann-Pick C1-Like 1.
  Yuto Takekawa; Yuki Sato; Yoshiaki Yamaki; Mei Imai; Kazuma Noto; Masato Sumi; Yoh Takekuma; Ken Iseki; Mitsuru Sugawara
  Biological & pharmaceutical bulletin, 39, 3, 301, 7, 2016年, ［査読有り］, ［国内誌］
  英語, 研究論文（学術雑誌）
• 開封後のスタチン製剤の安定性に及ぼす光・温度・湿度の影響
  武隈 洋; 高地 里佳; 石坂 悠; 佐藤 夕紀; 鷲見 正人; 菅原 満
  医療薬学, 40, 3, 135, 146, (一社)日本医療薬学会, 2014年03月, ［査読有り］
  日本語, 開封後のスタチン製剤の安定性に及ぼす光・温度・湿度の影響について検討した。安定性評価の対象とした薬剤は、ロスバスタチン製剤1銘柄2規格、シンバスタチン製剤4銘柄、プラバスタチン製剤4銘柄である。安定性評価の対象薬剤を、一包化した状態を想定してPTPシートから出し、薬包紙を用いて1錠ずつ包んだ。また、散光条件下のみセロポリ分包紙を用いて1錠ずつ分包した。ロスバスタチン製剤はPTPから開封しても室温散光条件下で1年間安定で、一包化調剤後でも患者が通常家庭内で保存する分には大きな問題は生じないことが示唆されたが、粉砕調剤時には遮光保存が必須条件であることが示された。シンバスタチン製剤は、6ヵ月間保存した場合、すべての条件下で安定であったのは1製剤のみであった。プラバスタチン製剤は、すべての製剤において室温遮光条件下で6ヵ月間安定であることが示されたが、散光条件下では一部の製剤に変色が確認された。
• Schedule-dependent cytotoxicity of Etoposide and cyclophosphamide in P-glycoprotein-expressing human leukemic K-562 cells.
  Yuki Tazawa; Ippei Usukubo; Kazuki Takada; Yoh Takekuma; Yoshihiro Shibayama; Mitsuru Sugawara
  Biological & pharmaceutical bulletin, 37, 8, 1323, 9, 2014年, ［査読有り］, ［国内誌］
  英語, 研究論文（学術雑誌）
• Emulsification using highly hydrophilic surfactants improves the absorption of orally administered coenzyme Q10.
  Yuki Sato; Hanami Mutoh; Mika Suzuki; Yoh Takekuma; Ken Iseki; Mitsuru Sugawara
  Biological & pharmaceutical bulletin, 36, 12, 2012, 7, 2013年, ［査読有り］, ［国内誌］
  英語, 研究論文（学術雑誌）
• Intracellular uptake mechanism of lutein in retinal pigment epithelial cells.
  Yuki Sato; Yu Kondo; Masato Sumi; Yoh Takekuma; Mitsuru Sugawara
  Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques, 16, 3, 494, 501, 2013年, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）
• Estimation of the duration after methamphetamine injection using a pharmacokinetic model in suspects who caused fatal traffic accidents.
  Kazuo Matsubara; Masaru Asari; Manabu Suno; Toshio Awaya; Mitsuru Sugawara; Tomohiro Omura; Joe Yamamoto; Chikatoshi Maseda; Yoshikazu Tasaki; Hiroshi Shiono; Keiko Shimizu
  Legal medicine (Tokyo, Japan), 14, 4, 191, 6, 2012年07月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）
• Successful transplantation of rat hearts subjected to extended cold preservation with a novel preservation solution.
  Kenji Wakayama; Moto Fukai; Kenichiro Yamashita; Taichi Kimura; Gentaro Hirokata; Susumu Shibasaki; Daisuke Fukumori; Sanae Haga; Mitsuru Sugawara; Tomomi Suzuki; Masahiko Taniguchi; Tsuyoshi Shimamura; Hiroyuki Furukawa; Michitaka Ozaki; Toshiya Kamiyama; Satoru Todo
  Transplant international : official journal of the European Society for Organ Transplantation, 25, 6, 696, 706, 2012年06月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）
• 効果発現パターンにより抗がん薬を分類するための基礎的検討
  高橋 夏子; 小林 正紀; 板垣 史郎; 平野 剛; 武隈 洋; 菅原 満; 井関 健
  薬学雑誌, 132, 6, 777, 783, 2012年06月, ［査読有り］, ［国内誌］
  日本語
• 国立大学における「実践的医療薬学教育プログラム」の現状
  小澤 光一郎; 菅原 満; 関根 祐子; 中嶋 幹郎
  薬学雑誌, 132, 3, 345, 350, 2012年03月, ［査読有り］, ［国内誌］
  日本語
• オピオイドによる難治性の嘔気とめまいに対してヒスタミンH1受容体拮抗薬とペロスピロンの併用が有効であった2症例
  長田 貴之; 柴山 良彦; 熊井 正貴; 山田 武宏; 笠師 久美子; 倉本 倫之介; 洲崎 真吾; 赤澤 茂; 真栄田 浩行; 坂下 智博; 折舘 伸彦; 本間 明宏; 福田 諭; 菅原 満; 井関 健
  医療薬学, 38, 1, 51, 55, (一社)日本医療薬学会, 2012年01月, ［査読有り］
  日本語, 研究論文（学術雑誌）, オピオイドによる難治性の嘔気とめまいに対してヒスタミンH1受容体拮抗薬とペロスピロンの併用が有効であった2例を経験した。症例1は50歳代女で、舌癌の診断で、舌半側切除+両頸部郭清後、術後放射線治療の方針となった。放射線照射部位である舌根周辺に疼痛の増悪を認め、硫酸モルヒネを開始した。しかし、めまいと嘔気が発現し摂食困難となったため、オピオイドローテーションの方針となった。塩酸ペロスピロン錠を処方を開始すると、嘔吐、嘔気は消失し、摂食も可能となった。めまいもほぼ消失した。症例2は30歳代女で、中咽頭癌の診断で、シスプラチン超選択的動注併用放射線治療の方針となった。舌根部に疼痛を訴え、塩酸オキシコドン水和物徐放錠で疼痛をコントロールした。舌根の疼痛が増悪し、塩酸モルヒネ液を開始したが、嘔吐したためオピオイドローテーションの方針となった。塩酸ペロスピロン錠に変更し、嘔吐、嘔気とめまいは消失した。
• Mutual inhibition between carvedilol enantiomers during racemate glucuronidation mediated by human liver and intestinal microsomes.
  Yoh Takekuma; Keiji Yagisawa; Mitsuru Sugawara
  Biological & pharmaceutical bulletin, 35, 2, 151, 63, 2012年, ［査読有り］, ［国内誌］
  英語, 研究論文（学術雑誌）
• Involvement of cholesterol membrane transporter Niemann-Pick C1-like 1 in the intestinal absorption of lutein.
  Yuki Sato; Risa Suzuki; Masaki Kobayashi; Shirou Itagaki; Takeshi Hirano; Toshihiro Noda; Satoshi Mizuno; Mitsuru Sugawara; Ken Iseki
  Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques, 15, 2, 256, 64, 2012年, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）
• Schedule-dependent cytotoxicity of etoposide (VP-16) and cyclophosphamide in leukemia cell line K-562.
  Yuki Tazawa; Kazunori Matsumura; Yoh Takekuma; Mitsuru Sugawara
  Biological & pharmaceutical bulletin, 35, 7, 1132, 6, 2012年, ［査読有り］, ［国内誌］
  英語, 研究論文（学術雑誌）
• Protective effect of lutein after ischemia-reperfusion in the small intestine.
  Yuki Sato; Masaki Kobayashi; Shirou Itagaki; Takeshi Hirano; Toshihiro Noda; Satoshi Mizuno; Mitsuru Sugawara; Ken Iseki
  Food chemistry, 127, 3, 893, 8, 2011年08月01日, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）
• Pharmacokinetic properties of lutein emulsion after oral administration to rats and effect of food intake on plasma concentration of lutein.
  Yuki Sato; Masaki Kobayashi; Shirou Itagaki; Takeshi Hirano; Toshihiro Noda; Satoshi Mizuno; Mitsuru Sugawara; Ken Iseki
  Biopharmaceutics & drug disposition, 32, 3, 151, 8, 2011年04月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）
• In vitro and in vivo antioxidant properties of chlorogenic acid and caffeic acid.
  Yuki Sato; Shirou Itagaki; Toshimitsu Kurokawa; Jiro Ogura; Masaki Kobayashi; Takeshi Hirano; Mitsuru Sugawara; Ken Iseki
  International journal of pharmaceutics, 403, 1-2, 136, 8, 2011年01月17日, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）
• Multidrug resistance protein 2 implicates anticancer drug-resistance to sorafenib.
  Yoshihiko Shibayama; Kou Nakano; Hiroshi Maeda; Miyuki Taguchi; Ryuji Ikeda; Mitsuru Sugawara; Ken Iseki; Yasuo Takeda; Katsushi Yamada
  Biological & pharmaceutical bulletin, 34, 3, 433, 5, 2011年, ［査読有り］, ［国内誌］
  英語, 研究論文（学術雑誌）
• Effect of 5-fluorouracil treatment on SN-38 absorption from intestine in rats.
  Yoshihiko Shibayama; Yoshitaka Iwashita; Yoshimi Yoshikawa; Tomoko Kondo; Ryuji Ikeda; Yasuo Takeda; Takayuki Osada; Mitsuru Sugawara; Katsushi Yamada; Ken Iseki
  Biological & pharmaceutical bulletin, 34, 9, 1418, 25, 2011年, ［査読有り］, ［国内誌］
  英語, 研究論文（学術雑誌）
• Protective effect of soy isoflavone genistein on ischemia-reperfusion in the rat small intestine.
  Yuki Sato; Shirou Itagaki; Setsu Oikawa; Jiro Ogura; Masaki Kobayashi; Takeshi Hirano; Mitsuru Sugawara; Ken Iseki
  Biological & pharmaceutical bulletin, 34, 9, 1448, 54, 2011年, ［査読有り］, ［国内誌］
  英語, 研究論文（学術雑誌）
• Penetration of linezolid into rabbit intervertebral discs and surrounding tissues.
  Miki Komatsu; Masahiko Takahata; Mitsuru Sugawara; Yoh Takekuma; Takashi Kato; Manabu Ito; Yuichiro Abe; Tohru Irie; Norimasa Iwasaki; Akio Minami
  European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society, 19, 12, 2149, 55, 2010年12月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）
• 放射線治療に伴う口腔粘膜障害に対する予防・軽減効果が期待される物質の探索
  板垣 史郎; 中田 千絵; 平野 剛; 鷹野 瑠美; 笠師 久美子; 菅原 満; 高橋 夏子; 小林 正紀; 井関 健
  医療薬学, 36, 9, 696, 702, (一社)日本医療薬学会, 2010年09月, ［査読有り］
  日本語, 放射線台療に伴う口腔粘膜障害に対する予防・軽減効果が期待される物質を探索した。16Gyの放射線照射を行った後、5日間培養したHO-1-N-1細胞を用いて、種々の化合物の障害抑制効果について検討した。抗酸化作用を有するN-アセチルシステイン(NAC)およびカテキン類に着目し、その障害抑制効果について検討した。高濃度のNACの添加により、放射線照射による細胞生存率の低下が有意に抑制された。カテキン類の添加により、放射線照射による細胞生存率の低下は有意に抑制された。NACおよびカテキン類の添加により、放射線照射による蛍光強度の増大は抑制された。HO-1-N-1細胞に放射線を照射したところ、アポトーシスに特徴的なDNAの断片化が観察され、アポトーシスが誘導されていることが示された。一方、NACおよびカテキン類の添加により、DNAの断片化は顕著に抑制された。
• Grapefruit juice enhance the uptake of coenzyme Q10 in the human intestinal cell-line Caco-2
  Shirou Itagaki; Akiko Ochiai; Masaki Kobayashi; Mitsuru Sugawara; Takeshi Hirano; Ken Iseki
  FOOD CHEMISTRY, 120, 2, 552, 555, 2010年05月, ［査読有り］
  英語, 研究論文（学術雑誌）
• In vitro実験系による肺がん化学療法レジメンの抗腫瘍効果の評価
  斎藤 由起子; 平野 剛; 沖 洋充; 笠師 久美子; 菅原 満; 小林 正紀; 高橋 夏子; 板垣 史郎; 井関 健
  医療薬学, 36, 4, 220, 226, (一社)日本医療薬学会, 2010年04月, ［査読有り］
  日本語, In vitro実験系による肺がん化学療法レジメンの抗腫瘍効果について検討した。肺がんのモデルとしてヒト肺扁平上皮がん由来A549細胞を使用した。CDDP+CPT-11(IP)療法において、CDDPは長期間にわたって抗腫瘍効果を示すことが示唆された。SN-38はday2からday5にかけて細胞生存率の回復を認め、CPT-11の1回日の投与により死滅したがん細胞が回復してきたところを再投与によりさらに攻撃するというレジメンの投与スケジュールに相関した。CDDP+VP-16(EP)療法において、各々の単剤のときと比較して抗腫瘍効果が増大することが示された。
• Heavy Water Containing Solution Ameliorates Cold Preservation Injury of the Rat Heart
  Kenji Wakayama; Moto Fukai; Kenichiro Yamashita; Daisuke Fukumori; Mitsuru Sugawara; Susumu Shibasaki; Gentaro Hirokata; Masaaki Zaitsu; Yusuke Tsunetoshhi; Michitaka Ozaki; Satoru Todo
  AMERICAN JOURNAL OF TRANSPLANTATION, 10, 494, 494, 2010年04月, ［査読有り］
  英語
• 気分障害圏患者における副作用に対する認知とコンプライアンスへの影響、および心理検査との相関性の検討
  久保田 康生; 木村 俊也; 渡邉 紀子; 大崎 明美; 鈴木 克治; 菅原 満; 小山 司; 井関 健
  日本病院薬剤師会雑誌, 46, 3, 359, 362, (一社)日本病院薬剤師会, 2010年03月, ［査読有り］
  日本語, 研究論文（学術雑誌）
• Kinetic study of anti-viral ribavirin uptake mediated by hCNT3 and hENT1 in Xenopus laevis oocytes.
  Takashi Yamamoto; Mitsuru Sugawara; Takashi Kikukawa; Seiji Miyauchi; Masahiro Yamaguchi; Atsushi Tero; Seiji Takagi; Toshiyuki Nakagaki
  Biophysical chemistry, 147, 1-2, 59, 65, 2010年03月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）
• 高度腎機能障害患者におけるリネゾリドの体内動態
  山崎 浩二郎; 武隈 洋; 西村 あや子; 宮本 剛典; 菅原 満; 井関 健
  TDM研究, 26, 4, 137, 141, (一社)日本TDM学会, 2009年10月, ［査読有り］
  日本語
• がん化学療法に伴う口内炎の予防・改善に有効な抗酸化物質の探索
  鷹野 瑠美; 平野 剛; 中田 千絵; 笠師 久美子; 菅原 満; 小林 正紀; 板垣 史郎; 井関 健
  医療薬学, 35, 4, 247, 253, (一社)日本医療薬学会, 2009年04月, ［査読有り］
  日本語, 癌化学療法に伴う口内炎の予防・改善に有効な抗酸化物質を探索するため、種々の化合物についてスーパーオキシドアニオン消去作用を評価した。対象物は含嗽として汎用されている3薬剤、抗酸化作用が記載されている8薬剤、カテキンのEGCgを用いた。その結果、含嗽剤ではアロプリノールの消去作用がレバミピドと比較して非常に強く、カモスタットはほとんど消去作用を示さなかった。他剤ではトラニラスト、メサラジン、ピロキシカムは作用が強く、ガベキサート、L-カルボシステインは弱かった。また、EGCgはアロプリノールと同等の強い消去作用を示した。次いで、組織障害に関与するラジカル連鎖反応停止作用を調べた結果、含嗽3薬剤には同作用は認めず、メサラジン、EGCgには強力な作用を認めた。更に、酸化障害性口内炎モデルに対する細胞障害抑制作用を調べたところ、EGCgは強力な効果を、アロプリノール、メサラジンは弱い効果を示し、レバミピド、カモスタットには効果を認めなかった。
• 多発性骨髄腫における同種造血幹細胞移植後の慢性消化管GVHDに対しベクロメタゾン腸溶性製剤を投与した症例
  久保田 康生; 小林 正紀; 笠師 久美子; 高畑 むつみ; 菅原 満; 橋野 聡; 井関 健
  医療薬学, 35, 3, 213, 218, (一社)日本医療薬学会, 2009年03月, ［査読有り］
  日本語, 研究論文（学術雑誌）, 57歳女。多発性骨髄腫を発症した。MP(メルファラン+プレドニゾロン)療法を開始し、ビスホスホネート製剤を併用したが、病勢のコントロールが不良であった。サリドマイド+デキサメタゾン療法を開始したが奏効しなかった。自己末梢血幹細胞移植は、十分なCD34陽性細胞数を得ることができず施行できなかった。サリドマイド併用によるCP(シクロホスファミド+プレドニゾロン)療法、サリドマイド併用による少量のシクロホスファミドの内服治療を順次施行したが、出血性膀胱炎などの副作用により継続できなかった。非血縁者間同種造血幹細胞移植を施行し、GVHD予防としてFK506の持続点滴を開始した。内視鏡検査と病理検査により回盲部と結腸における急性消化管GVHDの発症を確認した。プロピオン酸ベクロメタゾン(BDP)腸溶性カプセル剤を投与し、改善傾向を認めた。
• Regulatory mechanisms of SNAT2, an amino acid transporter, in L6 rat skeletal muscle cells by insulin, osmotic shock and amino acid deprivation.
  Hitoshi Kashiwagi; Kojiro Yamazaki; Yoh Takekuma; Vadivel Ganapathy; Mitsuru Sugawara
  Amino acids, 36, 2, 219, 30, 2009年02月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）
• Improvement of renal function estimation equations for elderly Japanese people
  Kaburaki, S; Yoshimura, E; Kojima, N; Ueno, H; Sugawara, M; Takekuma, Y
  Health Science Reports, 2008年09月, ［査読有り］
• Interaction of coenzyme Q10 with the intestinal drug transporter P-glycoprotein.
  Shirou Itagaki; Akiko Ochiai; Masaki Kobayashi; Mitsuru Sugawara; Takeshi Hirano; Ken Iseki
  Journal of agricultural and food chemistry, 56, 16, 6923, 7, 2008年08月27日, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）
• MRSA感染症治療におけるteicoplaninの投与設計の検討
  菅原 満; 山澤 裕司; 齋藤 嘉津彦; 小林 道也; 田中 寛之; 唯野 貢司
  TDM研究, 25, 1, 28, 36, (一社)日本TDM学会, 2008年01月, ［査読有り］
  日本語, 研究論文（学術雑誌）
• 心臓血管造影剤による急性腎機能低下に対するアセチルシステインの予防効果および製剤の評価
  清川 真美; 澤口 利香; 須田 範行; 武隈 洋; 菅原 満; 相馬 孝光; 川嶋 望; 筒井 裕之; 井関 健
  医療薬学, 34, 1, 20, 25, (一社)日本医療薬学会, 2008年01月, ［査読有り］
  日本語, 研究論文（学術雑誌）, 造影剤投与を受けた患者に発現する造影剤腎症に対するN-アセチルシステイン(NAC)の予防効果を検討した。また、従来のNAC液の不快な臭いと味覚を改善したNACゼリー製剤の服用性を評価した。腎症予防効果の対象はNACを服用した造影剤投与患者(NAC群)67名と、それ以前に検査を受けたNAC非服用造影剤投与患者(対照群)81名で、腎障害の有無を血清クレアチニン値で評価した。NACゼリー製剤の服用感はNAC群の35名を対象としてアンケート調査を行った。その結果、NAC群の腎障害は対照群に比べて有意に低く、NACは腎機能低下を予防することが示唆された。また、種々の合併症を持つ患者の造影剤腎症に起因する腎機能悪化を予防する可能性が示された。一方、NACゼリー製剤はNAC液の不快な臭いや味覚を改善するが、その味付けには改善の余地があると思われた。
• Functional analysis of phenolsulfonphthalein transport system in Long-Evans Cinnamon rats.
  Shirou Itagaki; Makoto Chiba; Masaki Kobayashi; Mitsuru Sugawara; Michiya Kobayashi; Takeshi Hirano; Ken Iseki
  Biochimica et biophysica acta, 1778, 1, 270, 5, 1, 2008年01月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, It has been reported that the transport function for organic anions on the kidney is maintained in multidrug resistance-associated protein 2 (Mrp2)-deficient rats. Different from Mrp2-deficient rats, Long-Evans Cinnamon (LEC) rats have impaired urinary excretion of Mrp2-substrate, phenolsulfonphthalein (PSP). PSP is transported by the potential-sensitive urate transport system in rat brush-border membranes. We analyzed the function of PSP transport system in LEC rats. Unlike Long-Evans Agouti (LEA) rats, the initial uptake of PSP and urate into the renal brush-border membrane vesicles of LEC rats were not significantly enhanced in the presence of positive intravesicular potential, suggesting that the potential-sensitive urate transport system is impaired in LEC rats. LEC rats should be useful for elucidating the potential-sensitive urate transport system in rats at the molecular level.
• Functional analysis of phenolsulfonphthalein transport system in Long-Evans Cinnamon rats
  Shirou Itagaki; Makoto Chiba; Masaki Kobayashi; Mitsuru Sugawara; Michlya Kobayashi; Takeshi Hirano; Ken Iseki
  BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 1778, 1, 270, 275, 2008年01月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Stereoselective metabolism of racemic carvedilol by UGT1A1 and UGT2B7, and effects of mutation of these enzymes on glucuronidation activity.
  Yoh Takekuma; Toru Takenaka; Koujiro Yamazaki; Kazuyuki Ueno; Mitsuru Sugawara
  Biological & pharmaceutical bulletin, 30, 11, 2146, 53, 2007年11月, ［査読有り］, ［国内誌］
  英語, 研究論文（学術雑誌）
• Evaluation of effects of polymorphism for metabolic enzymes on pharmacokinetics of carvedilol by population pharmacokinetic analysis.
  Yoh Takekuma; Toru Takenaka; Masami Kiyokawa; Koujiro Yamazaki; Hiroshi Okamoto; Akira Kitabatake; Hiroyuki Tsutsui; Mitsuru Sugawara
  Biological & pharmaceutical bulletin, 30, 3, 537, 42, 2007年03月, ［査読有り］, ［国内誌］
  英語, 研究論文（学術雑誌）
• Ribavirin uptake by cultured human choriocarcinoma (BeWo) cells and Xenopus laevis oocytes expressing recombinant plasma membrane human nucleoside transporters.
  Takashi Yamamoto; Kenichi Kuniki; Yoh Takekuma; Takeshi Hirano; Ken Iseki; Mitsuru Sugawara
  European journal of pharmacology, 557, 1, 1, 8, 2007年02月14日, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）
• 外来化学療法における服薬指導の充実のための病棟-外来間連携ツールの構築
  久保田 康生; 中里 恭子; 須田 範行; 沖 洋充; 菅原 満; 小林 道也; 齊藤 浩司; 井関 健
  医療薬学, 33, 2, 152, 158, (一社)日本医療薬学会, 2007年02月, ［査読有り］
  日本語, 研究論文（学術雑誌）, 患者の入院中の各種状況を把握し、それに応じたテーラーメイド的な服薬指導を行うため、病棟担当薬剤師からセンター担当薬剤師向けへの患者情報伝達手段の方法・内容の検討とその評価を行った。外来治療センターで抗がん剤調製業務および服薬指導を担当しているセンター担当薬剤師5例を対象とし、選択・記述併用形式のアンケート調査を行った。センター担当薬剤師が必要としている情報のアンケート調査結果を基に、病棟担当薬剤師から提供可能な情報を抽出し、外来治療センターへの連絡表を作成した。外来治療センターでの治療患者のおよそ30%の患者に対し、連絡表を使用しており、その有用性が見出されてきている。
• Difference between pharmacokinetics of mycophenolic acid (MPA) in rats and that in humans is caused by different affinities of MRP2 to a glucuronized form.
  Yoh Takekuma; Haruka Kakiuchi; Koujiro Yamazaki; Seiji Miyauchi; Takashi Kikukawa; Naoki Kamo; Vadivel Ganapathy; Mitsuru Sugawara
  Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques, 10, 1, 71, 85, 2007年, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）
• 神経因性疼痛に対する酢酸フレカイニドの鎮痛効果と血中濃度の関係
  山崎 浩二郎; 武隈 洋; 志賀 弘康; 菅原 満; 小澤 剛久; 柴田 万里子; 橋本 聡一; 森本 裕二
  TDM研究, 23, 4, 253, 256, (一社)日本TDM学会, 2006年10月, ［査読有り］
  日本語, 研究論文（学術雑誌）
• 患者の健康食品摂取状況および意識調査と健康食品データベース構築
  久保田 康生; 沖 洋充; 山崎 浩一; 菅原 満; 西村 正治; 井関 健
  日本病院薬剤師会雑誌, 42, 7, 927, 929, (一社)日本病院薬剤師会, 2006年07月, ［査読有り］
  日本語, 研究論文（学術雑誌）, 入院患者を73例を対象として,健康食品に関する認識や摂取状況を調査し,特に,化学療法施行患者への服薬指導における健康食品摂取に対する薬剤師としての対応を検証した.また,これらの調査から得られた情報を基に,健康食品に関するデータベースの構築を行った.57.5%が健康食品を摂取し,特にがん患者の摂取率が高かった.摂取群,非摂取群ともに健康被害や相互作用の可能性を疑う頻度に差は見られなかった.既知の健康被害や相互作用だけでも回避できるよう,摂取状況は医療従事者へ報告してもらうよう促すため「患者用注意書き」を作成した.医療従事者へ可能な限りの正確な情報をいち早く提供できるようデータベースを構築した
• Contribution of polymorphisms in UDP-glucuronosyltransferase and CYP2D6 to the individual variation in disposition of carvedilol.
  Yoh Takekuma; Toru Takenaka; Masami Kiyokawa; Koujiro Yamazaki; Hiroshi Okamoto; Akira Kitabatake; Hiroyuki Tsutsui; Mitsuru Sugawara
  Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques, 9, 1, 101, 12, 2006年, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）
• 30P3-019 ポリアクリル酸ナトリウム(PANA)人工唾液の使用動向とその評価(院内製剤(薬局製剤),医療薬学の扉は開かれた)
  笠師 久美子; 須田 範行; 鄭 漢忠; 菅原 満; 井関 健
  日本医療薬学会年会講演要旨集, 16, 0, 435, 435, 一般社団法人 日本医療薬学会, 2006年, ［査読有り］
  日本語
• 麻薬管理の一元化を可能とした麻薬オーダリングシステムの構築と運用
  志賀 弘康; 川合 真次; 荻野 修; 菅原 満; 遠藤 晃; 櫻井 恒太郎; 宮崎 勝巳
  医療薬学, 31, 12, 1027, 1035, (一社)日本医療薬学会, 2005年12月, ［査読有り］
  日本語, 研究論文（学術雑誌）, より正確に,かつ効率的に麻薬を管理することを目的として,麻薬オーダリングシステム(麻薬オーダ)を構築した.各種オーダ(処方,注射,物流)と連動させることにより,麻薬帳票類の自動作成を可能とした麻薬オーダの詳細と,その運用方法,さらにはその有用性を検討した.オーダの麻薬データを利用し,各種麻薬の入出庫データ,廃棄データ等をあらためて手入力することなく,麻薬帳票・届け出類の自動作成が可能となった.これにより麻薬使用量等の集計業務は簡便になり,各種帳票類の作成に要する時間も大幅に短縮し,麻薬受払簿の正確性の向上で,システム導入前と比較して在庫確認作業も簡便になった
• 外来治療センターにおける薬剤師業務
  瀬戸 恵介; 須田 範行; 荻野 修; 菅原 満
  日本病院薬剤師会雑誌, 41, 11, 1407, 1409, (一社)日本病院薬剤師会, 2005年11月, ［査読有り］
  日本語, 研究論文（学術雑誌）, 外来治療センターを利用している患者49名を対象に,がん化学療法の現状と問題点についてアンケート調査を行った.その結果,約70%の患者が薬についての注意事項や副作用についてのパンフレットを希望していた.また,多くの患者が薬の名前や副作用を知っているのに対し,その対処法や治療後に注意すべき点を知っているのは約1/3と少なかった.現在,このアンケート結果を基に患者向け情報提供用紙を作成し,外来治療センターを初めて利用した患者にこの情報提供用紙を用い,患者個別に注射剤や副作用の説明を行っている
• The use of an in vitro dissolution and absorption system to evaluate oral absorption of two weak bases in pH-independent controlled-release formulations.
  Mitsuru Sugawara; Shota Kadomura; Xin He; Yoh Takekuma; Naonori Kohri; Katsumi Miyazaki
  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 26, 1, 1, 8, 2005年09月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）
• Phenolsulfonphthalein transport by potential-sensitive urate transport system.
  Shirou Itagaki; Soji Shimamoto; Mitsuru Sugawara; Michiya Kobayashi; Katsumi Miyazaki; Takeshi Hirano; Ken Iseki
  European journal of pharmacology, 518, 2-3, 83, 9, 2005年08月22日, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）
• Structure-affinity relationship in the interactions of human organic anion transporter 1 with caffeine, theophylline, theobromine and their metabolites.
  Mitsuru Sugawara; Takahiro Mochizuki; Yoh Takekuma; Katsumi Miyazaki
  Biochimica et biophysica acta, 1714, 2, 85, 92, 2, 2005年08月15日, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, It is well known that human organic anion transporter 1 (hOAT1) transports many kinds of drugs, endogenous compounds, and toxins. However, little is known about the structure-affinity relationship. The aim of this study was to elucidate the structure-affinity relationship using a series of structurally related compounds that interact with hOAT1. Inhibitory effects of xanthine- and uric acid-related compounds on the transport of p-aminohippuric acid were examined using CHO-K1 cells stably expressing hOAT1. The order of potency for the inhibitory effects of xanthine-related compounds on PAH uptake was 1-methyl derivative>7-methyl derivative>3-methyl derivative falling dotsxanthine>1,3,7-trimethyl derivative (caffeine). The order of potency of the inhibition was 1,3,7-trimethyluric acid>1,3-dimethyluric acid>1,7-dimethyluric acid>1-methyluric acid>uric acid. A significant correlation between inhibitory potency and lipophilicity of the tested uric acid-related compounds was observed. The main determinant of the affinity of xanthine-related compounds is the position of the methyl group. On the other hand, lipophilicity is the main determinant of the affinity of uric acid-related compounds.
• Structure-affinity relationship in the interactions of human organic anion transporter 1 with caffeine, theophylline, theobromine and their metabolites
  M Sugawara; T Mochizuki; Y Takekuma; K Miyazaki
  BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 1714, 2, 85, 92, 2005年08月, ［査読有り］
  英語, 研究論文（学術雑誌）
• がん化学療法の調剤業務支援のためのプロトコールデータベースの構築と運用
  武隈 洋; 岩井 美和子; 藤原 俊恵; 川岸 亨; 熊井 正貴; 松浦 麻耶; 馬渕 朋美; 須田 範行; 宮本 剛典; 荻野 修; 菅原 満; 宮崎 勝巳
  医療薬学, 31, 7, 575, 584, (一社)日本医療薬学会, 2005年07月, ［査読有り］
  日本語, 研究論文（学術雑誌）, がん化学療法における調剤および処方鑑査を知識や経験年数の差によらず,正確かつ円滑に行うために,全診療科のがん化学療法プロトコールを収集し,そのデータベースを構築・運用した.構築したデータベースの使用マニュアルを作成した.疾患を12に分類し,必要な情報をプロトコール名,対象診療科,対象疾患,薬品名,投与量,単位,投与日,投与経路の項目に沿って,表形式に整理・電子データ化した.データベースシステムは独自の特化したものではなく,他の施設でも内容のメンテナンスを行えば利用可能な汎用データベースシステムとしたため,多くの施設へ提供が可能となり,情報発信基地としての大学病院の役割を果たし得たと考えた
• 造影剤による腎機能低下の予防を目的としたアセチルシステインゼリーの調製と評価
  須田 範行; 新里 利香; 清川 真美; 金内 美妃; 菅原 満; 郡 修徳; 宮崎 勝巳
  医療薬学, 31, 5, 355, 359, (一社)日本医療薬学会, 2005年05月, ［査読有り］
  日本語, 研究論文（学術雑誌）, 患者のコンプライアンスの向上を目的として内用液に代わる剤形としてゲル化剤を用いたゼリー製剤の調製を試みた.アセチルシステイン(AC)は市販の内用液剤,ゲル化剤はゼラチンあるいは寒天を用いた.矯味剤にはアミノレバンEN専用フレーバーミックスを用いた.ゲル化剤にはゼラチンが適切であった.3種の矯味剤のうち被験者50%がリンゴ味を選択した.ミルクコーヒー味,抹茶味を選択した者はおのおの25%であった.AC水と比較し,ACジュース,ACゼリーは評価が高かった.すべての項目でゼラチンゼリーの評価は最も高く,特に,においの項目では被験者の90%が最もよいと答えた.ACゼリーの服用感はAC内用液と比較し著しく優れていることが示唆された.ゼラチンゼリーは第1液,第2液ともに試験開始後約10分で100%の溶出率を示した.少なくとも7日間は品質を保証できた
• Characterization of secretory intestinal transport of phenolsulfonphthalein.
  Shirou Itagaki; Makoto Chiba; Soji Shimamoto; Mitsuru Sugawara; Michiya Kobayashi; Katsumi Miyazaki; Takeshi Hirano; Ken Iseki
  Drug metabolism and pharmacokinetics, 20, 1, 72, 8, Japanese Society for the Study of Xenobiotics, 2005年02月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）
• Expression of slc5a8 in kidney and its role in Na(+)-coupled transport of lactate.
  Elangovan Gopal; You-Jun Fei; Mitsuru Sugawara; Seiji Miyauchi; Lina Zhuang; Pamela Martin; Sylvia B Smith; Puttur D Prasad; Vadivel Ganapathy
  The Journal of biological chemistry, 279, 43, 44522, 32, 2004年10月22日, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）
• Comparison of urinary excretion of phenolsulfonphthalein in an animal model for Wilson's disease (Long-Evans Cinnamon rats) with that in normal Wistar rats: involvement of primary active organic anion transporter.
  Shirou Itagaki; Soji Shimamoto; Takeshi Hirano; Ken Iseki; Mitsuru Sugawara; Sachiho Nishimura; Michio Fujimoto; Michiya Kobayashi; Katsumi Miyazaki
  Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques, 7, 2, 227, 34, 2, 2004年07月13日, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）
• Absorption of ester prodrugs in Caco-2 and rat intestine models.
  Xin He; Mitsuru Sugawara; Yoh Takekuma; Katsumi Miyazaki
  Antimicrobial agents and chemotherapy, 48, 7, 2604, 9, 2004年07月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）
• The variability of liver graft function and urinary 6beta-hydroxycortisol to cortisol ratio during liver regeneration in liver transplant recipients.
  Satoshi Kishino; Maki Ogawa; Yoh Takekuma; Mitsuru Sugawara; Tsuyoshi Shimamura; Hiroyuki Furukawa; Satoru Todo; Katsumi Miyazaki
  Clinical transplantation, 18, 2, 124, 9, 2004年04月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）
• Comparison of the disposition behavior of organic anions in an animal model for Wilson's disease (Long-Evans Cinnamon rats) with that in normal Long-Evans Agouti rats.
  Shirou Itagaki; Mitsuru Sugawara; Michiya Kobayashi; Katsumi Miyazaki; Takeshi Hirano; Ken Iseki
  Drug metabolism and pharmacokinetics, 19, 2, 150, 4, Japanese Society for the Study of Xenobiotics, 2004年04月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）
• Erratum: Differential binding of disopyramide and warfarin enantiomers to human x1-acid glycoprotein variants (British Journal of Clinical Pharmacology (2003) 56:6 (664-669))
  T. Nakagawa; S. Kishino; S. Itoh; M. Sugawara; K. Miyazaki
  British Journal of Clinical Pharmacology, 57, 2, 226, 2004年02月, ［査読有り］
  研究論文（学術雑誌）
• 生体部分肝移植患者におけるLinezolid(Zyvox)の体内動態
  岸野 吏志; 馬渕 朋美; 武隈 洋; 菅原 満; 嶋村 剛; 古川 裕之; 藤堂 省; 宮崎 勝巳
  TDM研究, 21, 1, 21, 25, (一社)日本TDM学会, 2004年01月, ［査読有り］
  日本語, 研究論文（学術雑誌）, 38歳男性生体部分肝移植患者におけるリネゾリド(LZD)連続投与中の血中動態を検討した.LZDは,1回600mg(点滴時間2時間),1日2回連続投与とした.総(結合型+非結合型)薬物の最高血中濃度は31.70μg/ml,トラフ濃度は10.75±3.76μg/mlであり,非結合型薬物の最高血中濃度は25.29μg/ml,トラフ濃度は8.97±2.84μg/mlであった.また,消失半減期は7.46hr,分布容積は5.54L,Vssは30.63Lであり,健常人と異なる傾向が認められた.一方,総薬物,および非結合型薬物の血中濃度曲線面積は,それぞれ228.21μg/ml・hr,210.72μg/ml・hrと,健常人と比較して増加する傾向が認められた.また,肝移植患者の血漿蛋白結合率は13.18±4.67%であり,健常人の平均結合率に比べて顕著に低下していることが明らかになった.この症例では副作用が認められなかったことから,LZDは臓器移植患者においても比較的安全に使用可能であることが示唆された
• A new system for the prediction of drug absorption using a pH-controlled Caco-2 model: evaluation of pH-dependent soluble drug absorption and pH-related changes in absorption.
  Xin He; Shota Kadomura; Yoh Takekuma; Mitsuru Sugawara; Katsumi Miyazaki
  Journal of pharmaceutical sciences, 93, 1, 71, 7, 2004年01月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）
• Differential binding of disopyramide and warfarin enantiomers to human alpha(1)-acid glycoprotein variants
  T Nakagawa; S Kishino; S Itoh; M Sugawara; K Miyazaki
  BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 56, 6, 664, 669, 2003年12月, ［査読有り］
  英語, 研究論文（学術雑誌）
• 癌化学療法時にみられる口内炎発症予防を目的としたメシル酸カモスタット口腔内崩壊錠の調製と評価
  須田 範行; 今野 安大; 森田 豊; 中田 宏; 菅原 満; 宮崎 正三; 宮崎 勝巳
  医療薬学, 29, 6, 705, 710, (一社)日本医療薬学会, 2003年12月, ［査読有り］
  日本語, 研究論文（学術雑誌）, メシル酸カモスタット口腔内停留性を調整し,その物理的性質及び口腔内停留性について検討した.20名の健康成人被験者に対するアンケートから矯味としてミククコーヒー味を選択し,D-マンニトールを賦形剤としPVPを結合剤として錠剤を調整し,十分な硬度と口腔内崩壊性を持つことを確かめた.口腔内停留性実験の結果,この口腔内崩壊錠はメシル酸カモスタットの粘膜付着性及び口腔内停留性が含嗽剤よりも優れていることが明らかとなり,口に含むだけで唾液で速やかに崩壊し,水を用いなくても容易に服用でき,服薬コンプライアンスの向上が期待できる
• Influence of continuous venovenous haemodiafiltration on the pharmacokinetics of tacrolimus in liver transplant recipients with small-for-size grafts
  S Kishino; Y Takekuma; M Sugawara; T Shimamura; H Furukawa; S Todo; K Miyazaki
  CLINICAL TRANSPLANTATION, 17, 5, 412, 416, 2003年10月, ［査読有り］
  英語, 研究論文（学術雑誌）
• An in vitro system for prediction of oral absorption of relatively water-soluble drugs and ester prodrugs.
  Xin He; Mitsuru Sugawara; Michiya Kobayashi; Yoh Takekuma; Katsumi Miyazaki
  International journal of pharmaceutics, 263, 1-2, 35, 44, 2003年09月16日, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）
• Major role of organic anion transporters in the uptake of phenolsulfonphthalein in the kidney.
  Shirou Itagaki; Mitsuru Sugawara; Michiya Kobayashi; Sachiho Nishimura; Michio Fujimoto; Katsumi Miyazaki; Ken Iseki
  European journal of pharmacology, 475, 1-3, 85, 92, 2003年08月15日, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）
• 循環器系薬剤に関する総合的な医薬品情報データベースの構築
  笠原 勇太; 高田 陽美; 小林 道也; 川合 真次; 荻野 修; 菅原 満; 関川 彬; 宮崎 勝巳
  医療薬学, 29, 2, 165, 172, (一社)日本医療薬学会, 2003年04月, ［査読有り］
  日本語, 研究論文（学術雑誌）
• Uptake of dipeptide and beta-lactam antibiotics by the basolateral membrane vesicles prepared from rat kidney.
  Mitsuru Sugawara; Toru Ogawa; Michiya Kobayashi; Katsumi Miyazaki
  Biochimica et biophysica acta, 1609, 1, 39, 44, 1, 2003年01月10日, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, The transport of dipeptides and beta-lactam antibiotics across the rat renal basolateral membrane was examined. The initial uptake of glycylsarcosine and cefadroxil by rat renal basolateral membrane vesicles was inhibited by the presence of all the di- and tripeptides and beta-lactam antibiotics that were tested in this study. However, the uptake of both substrates was not inhibited by glycine, an amino acid. The initial uptake of zwitterionic beta-lactam antibiotics, cefadroxil, cephradine, and cephalexin, was stimulated by preloaded glycylsarcosine (countertransport effect). On the other hand, the uptake of dianionic beta-lactam antibiotics, ceftibuten and cefixime, was not affected. A concentration-dependent initial uptake of glycylsarcosine and cefadroxil suggested the existence of a carrier-mediated mechanism, whereas the transport of ceftibuten did not show any saturated uptake. The transporter that participates in the permeation of dipeptides and beta-lactam antibiotics across basolateral membranes showed lower affinity than did PEPT1 and PEPT2. This is the first study that showed an evidence for a peptide transporter, expressed in the rat renal basolateral membrane, that recognizes zwitterionic beta-lactam antibiotics using basolateral membrane vesicles isolated from normal rat kidney.
• 生体肝移植患者における持続血液濾過透析(CHDF)施行時のタクロリムスの血中動態
  岸野 吏志; 越浪 由加; 菅原 満; 丸藤 哲; 古川 博之; 藤堂 省; 宮崎 勝巳
  TDM研究, 20, 1, 24, 29, (一社)日本TDM学会, 2003年01月, ［査読有り］
  日本語, 研究論文（学術雑誌）, 生体部分肝移植後患者3例を対象に標題の血中動態を検討した.CHDF施行時と非施行時の全血中タクロリムス濃度に有意な違いは認めなかった.ダイアライザーの流入側,流出側のタクロリムス濃度にも違いは認められなかった.又,CHDF非施行例との間に体内動態パラメーターの有意な違いは認めなかった.これらより,CHDFの血中タクロリムス濃度への影響は極めて小さいと考えられた
• Inhibitory Effects of Basic Drugs on the Sodium-Dependent Transport of L-Alanine via System B^0 in the Small Intestine
  SUGAWARA Mitsuru; KATO Masaya; KITAKUBO Mayumi; TAKEKUMA Yoh; GANAPATHY Vadivel; MIYAZAKI Katsumi
  Drug metabolism and pharmacokinetics, 18, 3, 186, 93, 日本薬物動態学会, 2003年, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）
• Mechanism of active secretion of phenolsulfonphthalein in the liver via Mrp2 (abcc2), an organic anion transporter.
  Shirou Itagaki; Mitsuru Sugawara; Michiya Kobayashi; Katsumi Miyazaki; Ken Iseki
  Drug metabolism and pharmacokinetics, 18, 4, 238, 44, 4, 2003年, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）
• Uptake of dipeptide and beta-lactam antibiotics by the basolateral membrane vesicles prepared from rat kidney
  M Sugawara; T Ogawa; M Kobayashi; K Miyazaki
  BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 1609, 1, 39, 44, 2003年01月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Age- and gender-related differences in carbohydrate concentrations of alpha1-acid glycoprotein variants and the effects of glycoforms on their drug-binding capacities.
  Satoshi Kishino; Akikazu Nomura; Shin Itoh; Tsutomu Nakagawa; Yoh Takekuma; Mitsuru Sugawara; Hiroyuki Furukawa; Satoru Todo; Katsumi Miyazaki
  European journal of clinical pharmacology, 58, 9, 621, 8, 2002年12月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）
• Liquid chromatographic method for the determination of ganciclovir and/or acyclovir in human plasma using pulsed amperometric detection.
  Satoshi Kishino; Yoh Takekuma; Mitsuru Sugawara; Tsuyoshi Shimamura; Hiroyuki Furukawa; Satoru Todo; Katsumi Miyazaki
  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 780, 2, 289, 94, 2002年11月25日, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）
• Ionic strength has a greater effect than does transmembrane electric potential difference on permeation of tryptamine and indoleacetic acid across Caco-2 cells.
  Mitsuru Sugawara; Megumi Kurosawa; Kasumi Sakai; Michiya Kobayashi; Ken Iseki; Katsumi Miyazaki
  Biochimica et biophysica acta, 1564, 1, 149, 55, 1, 2002年08月19日, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, The effects of transmembrane electric potential difference and ionic strength on the permeation of tryptamine and indoleacetic acid across a Caco-2 cell monolayer were examined. A decrease in the transmembrane electric potential difference caused by the addition of potassium ion to the transport buffer had no effect on the permeation rate of either compound. On the other hand, an increase in ionic strength resulted in a decrease in the permeation rate of tryptamine and an increase in the permeation rate of indoleacetic acid. The changes in the permeation rate with changes in the ionic strength were correlated with the membrane surface potential monitored by 1-anilino-8-naphthalenesulfonic acid (ANS), a fluorescent probe. We tested these effects using several other cationic and anionic compounds. These effects of ionic strength were found to be common to all drugs tested. The compound that showed a relatively lower permeation rate was given relatively stronger effect. The possibility of overestimation or underestimation caused by these effects should be considered when the permeation of an ionic compound is evaluated using a cell monolayer system.
• Ionic strength has a greater effect than does transmembrane electric potential difference on permeation of tryptamine and indoleacetic acid across Caco-2 cells
  M Sugawara; M Kurosawa; K Sakai; M Kobayashi; K Iseki; K Miyazaki
  BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 1564, 1, 149, 155, 2002年08月, ［査読有り］
  英語, 研究論文（学術雑誌）
• ザイボックス錠を粉砕して製した懸濁液の安定性に関する検討
  菅原 満; 萩野 修; 宮崎 勝巳
  医療薬学, 28, 3, 256, 258, (一社)日本医療薬学会, 2002年06月, ［査読有り］
  日本語, 研究論文（学術雑誌）
• 胃癌患者における胃切除術後の薬物吸収動態
  井藤達也; 福田由布子; 竹本 功; 斉藤正信; 松岡伸一; 秦 温信; 平野 剛; 井関 健; 菅原 満; 宮崎勝巳
  臨床薬理, 33, 3, 67, 72, Japanese Society of Clinical Pharmacology and Therapeutics, 2002年, ［査読有り］
  日本語, 研究論文（学術雑誌）
• 肺癌患者における塩酸イリノテカン(CPT-11)の胸水中および心嚢液中への移行性
  井藤達也; 高岡和夫; 竹本 功; 秦 温信; 井上勝一; 佐々木健太郎; 平野 剛; 井関 健; 菅原 満; 宮崎勝巳
  臨床薬理, 33, 2, 47, 52, Japanese Society of Clinical Pharmacology and Therapeutics, 2002年, ［査読有り］
  日本語, 研究論文（学術雑誌）
• Cloning and functional characterization of a new subtype of the amino acid transport system N
  T Nakanishi; R Kekuda; YJ Fei; T Hatanaka; M Sugawara; RG Martindale; FH Leibach; PD Prasad; Ganapathy, V
  AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY, 281, 6, C1757, C1768, 2001年12月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Development of a new system for prediction of drug absorption that takes into account drug dissolution and pH change in the gastro-intestinal tract
  M Kobayashi; N Sada; M Sugawara; K Iseki; K Miyazaki
  INTERNATIONAL JOURNAL OF PHARMACEUTICS, 221, 1-2, 87, 94, 2001年06月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Involvement of transporter recruitment as well as gene expression in the substrate-induced adaptive regulation of amino acid transport system A
  R Ling; CC Bridges; M Sugawara; T Fujita; FH Leibach; PD Prasad; Ganapathy, V
  BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 1512, 1, 15, 21, 2001年05月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Structure, function, and tissue expression pattern of human SN2, a subtype of the amino acid transport system N
  T Nakanishi; M Sugawara; W Huang; RG Martindale; FH Leibach; ME Ganapathy; PD Prasad; Ganapathy, V
  BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 281, 5, 1343, 1348, 2001年03月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Evidence for the transport of neutral as well as cationic amino acids by ATA3, a novel and liver-specific subtype of amino acid transport system A
  T Hatanaka; W Huang; R Ling; PD Prasad; M Sugawara; FH Leibach; Ganapathy, V
  BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 1510, 1-2, 10, 17, 2001年02月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Structure and function of ATA3, a new subtype of amino acid transport system A, primarily expressed in the liver and skeletal muscle
  M Sugawara; T Nakanishi; YJ Fei; RG Martindale; ME Ganapathy; FH Leibach; Ganapathy, V
  BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 1509, 1-2, 7, 13, 2000年12月, ［査読有り］
  英語, 研究論文（学術雑誌）
• イリノテカンと活性代謝物のラクトン体・カルボキシル体およびその抱合体のHPLC同時定量法の確立
  井藤達也; 竹本 功; 秦 温信; 高岡和夫; 菅原 満; 井関 健; 宮崎勝巳
  TDM研究, 17, 4, 383, 389, 2000年10月, ［査読有り］
  日本語, 研究論文（学術雑誌）
• Primary structure, genomic organization, and functional and electrogenic characteristics of human system N 1, a Na+- and H+-coupled glutamine transporter
  YJ Fei; M Sugawara; T Nakanishi; W Huang; HP Wang; PD Prasad; FH Leibach; Ganapathy, V
  JOURNAL OF BIOLOGICAL CHEMISTRY, 275, 31, 23707, 23717, 2000年08月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Cloning of an Amino Acid Transporter with Functional Characteristics and Tissue Expression Pattern Identical to That of System A
  Sugawara M; Nakanishi T; Fei Y.-J; Huang W; Ganapathy M. E; Leibach F. H; Ganapathy V
  J. Biol. Chem., 275, 22, 16473, 16477, 2000年08月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Primary Structure, Functional Characteristics and Tissue Expression Pattern of Human ATA2, a Subtype of Amino Acid Transport System
  Hatanaka T; Huang W; Wang H; Sugawara M; Prasad P. D; Leibach F. H; Ganapathy V
  Biochim. Biophys. Acta, 1467, 1, 1, 6, 2000年07月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Cloning and functional expression of ATA1, a subtype of amino acid transporter A, from human placenta
  HP Wang; W Huang; M Sugawara; LD Devoe; FH Leibach; PD Prasad; Ganapathy, V
  BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 273, 3, 1175, 1179, 2000年07月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Primary structure, functional characteristics and tissue expression pattern of human ATA2, a subtype of aminoacid transport system A
  T Hatanaka; W Huang; HP Wang; M Sugawara; PD Prasad; FH Leibach; Ganapathy, V
  BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 1467, 1, 1, 6, 2000年07月, ［査読有り］
  英語, 研究論文（学術雑誌）
• cDNA structure, genomic organization, and promoter analysis of the mouse intestinal peptide transporter PEPT1
  YJ Fei; M Sugawara; JC Liu; HW Li; Ganapathy, V; ME Ganapathy; FH Leibach
  BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION, 1492, 1, 145, 154, 2000年06月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2
  M Sugawara; W Huang; YL Fei; FH Leibach; Ganapathy, V; ME Ganapathy
  JOURNAL OF PHARMACEUTICAL SCIENCES, 89, 6, 781, 789, 2000年06月, ［査読有り］
  英語, 研究論文（学術雑誌）
• β-Lactam Antibiotics as Substrates for OCTN2, an Organic Cation/Carnitine Transporter
  Ganapathy M. E; Huang W; Rajan D. P; Carter A. L; Sugawara M; Iseki K; Leibach F. H; Ganapathy V
  J. Biol. Chem., 275, 3, 1699, 1707, 2000年01月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Effects of interactions between drugs on the renal excretion of trientine in rats - Acetazolamide and furosemide increase trientine excretion
  M Kobayashi; H Fujisaki; M Sugawara; K Iseki; K Miyazaki
  PHARMACEUTICAL RESEARCH, 16, 12, 1888, 1892, 1999年12月, ［査読有り］
  英語, 研究論文（学術雑誌）
• 高速液体クロマトグラフィーによる血清中ピルニカイジド定量法の確立と有効濃度の検討
  井藤達也; 福島紘司; 尾形仁子; 中川英久; 渡辺 晃; 菅原 満; 井関 健; 宮崎勝巳
  TDM研究, 16, 3, 273, 278, 1999年07月, ［査読有り］
  日本語, 研究論文（学術雑誌）
• Multiplicity of the H+-Dependent Transport Mechanism of Dipeptide and Anionic β-Lactam Antibiotic Ceftibuten in Rat Intestinal Brush-Border Membrane
  Iseki K; Sugawara M; Sato K; Naasani I; Hayakawa T; Kobayashi M; Miyazaki K
  J. Pharmacol. Exp. Ther., 289, 1, 66, 71, 1999年04月, ［査読有り］
  英語, 研究論文（学術雑誌）
• The presence of an Na+/spermine antiporter in the rat renal brush-border membrane
  M Kobayashi; H Fujisaki; M Sugawara; K Iseki; K Miyazaki
  JOURNAL OF PHARMACY AND PHARMACOLOGY, 51, 3, 279, 284, 1999年03月, ［査読有り］
  英語, 研究論文（学術雑誌）
• A general approach for the prediction of the intestinal absorption of drugs: Regression analysis using the physicochemical properties and drug-membrane electrostatic interaction
  M Sugawara; Y Takekuma; H Yamada; M Kobayashi; K Iseki; K Miyazaki
  JOURNAL OF PHARMACEUTICAL SCIENCES, 87, 8, 960, 966, 1998年08月, ［査読有り］
  英語, 研究論文（学術雑誌）
• 血液透析患者におけるランソプラゾールの薬物動態
  井藤達也; 稲垣真実子; 福島紘司; 岡本延彦; 安田卓二; 布施川尚; 菅原 満; 井関 健; 宮崎勝巳
  ＴＤＭ研究, 15, 3, 259, 265, 1998年07月, ［査読有り］
  日本語, 研究論文（学術雑誌）
• Ionic-diffusion potential-dependent transport of a new quinolone, sparfloxacin, across rat intestinal brush-border membrane
  K Iseki; T Hirano; K Tsuji; S Miyazaki; M Takada; M Kobayashi; M Sugawara; K Miyazaki
  JOURNAL OF PHARMACY AND PHARMACOLOGY, 50, 6, 627, 634, 1998年06月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Mechanism of the inhibitory effect of imipramine on the Na+-dependent transport of L-glutamic acid in rat intestinal brush-border membrane
  M Sugawara; M Kato; M Kobayashi; K Iseki; K Miyazaki
  BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 1370, 2, 252, 258, 1998年03月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Purification by ceftibuten-affinity chromatography and the functional reconstitution of oligopeptide transporter(s) in rat intestinal brush-border membrane
  K Iseki; K Yonemura; T Kikuchi; Naasani, I; M Sugawara; M Kobayashi; N Kohri; K Miyazaki
  BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 1370, 1, 161, 168, 1998年03月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Purification and liposomal reconstitution of the oligopeptide transport activity in rat renal cortex using ceftibuten-affinity chromatography
  K Iseki; Naasani, I; T Kikuchi; M Sugawara; M Kobayashi; N Kohri; K Miyazaki
  BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 1368, 2, 329, 337, 1998年01月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Single-step isolation method for six glycoforms of human α1-acid glycoprotein by hydroxylapatite chromatography and study of their binding capacities for disopyramide
  Satoshi Kishino; Akikazu Nomura; Michiyo Saitoh; Mitsuru Sugawara; Ken Iseki; Akira Kitabatake; Katsumi Miyazaki
  Journal of Chromatography B: Biomedical Applications, 703, 1-2, 1, 6, 1997年12月05日, ［査読有り］
  英語, 研究論文（学術雑誌）
• Single-Step Isolation Method for Six Glycoforms of Human α1-Acid Glycoprotein by Hydroxylapatite Chromatography and Study of Their Binding Capacities for Disopyramide
  Kishino S; Nomura A; Saitoh M; Sugawara M; Iseki K; Kitabatake A; Miyazaki K
  J. Chromatogr. B, 703, 1-2, 1, 6, 1997年12月, ［査読有り］
  英語, 研究論文（学術雑誌）
• The effect of membrane surface potential on the permeability of anionic compounds across the apical membrane in human intestinal epithelial (Caco-2) cells
  K Iseki; K Kaido; M Kobayashi; M Sugawara; K Miyazaki
  BIOLOGICAL & PHARMACEUTICAL BULLETIN, 20, 7, 794, 799, 1997年07月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Structure-relationship study of the uptake of aliphatic polyamine compounds by rat intestinal brush-border membrane vesicles
  M Kobayashi; S Suruga; H Takeuchi; M Sugawara; K Iseki; K Miyazaki
  JOURNAL OF PHARMACY AND PHARMACOLOGY, 49, 5, 511, 515, 1997年05月, ［査読有り］
  英語, 研究論文（学術雑誌）
• The mechanism of excretion of trientine from the rat kidney: Trientine is not recognized by the H+ organic cation transporter
  M Kobayashi; R Tanabe; M Sugawara; K Iseki; K Miyazaki
  JOURNAL OF PHARMACY AND PHARMACOLOGY, 49, 4, 426, 429, 1997年04月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Solubilization and reconstitution characteristics of the carrier protein(s) responsible for the transport of ceftibuten, a substrate for the oligopeptide transporters, in rat renal brush-border membrane
  Naasani, I; T Kikuchi; M Sugawara; M Kobayashi; K Iseki; K Miyazaki
  BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 1283, 2, 185, 191, 1996年09月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Uptake mechanism of trientine by rat intestinal brush-border membrane vesicles
  R Tanabe; M Kobayashi; M Sugawara; K Iseki; K Miyazaki
  JOURNAL OF PHARMACY AND PHARMACOLOGY, 48, 5, 517, 521, 1996年05月, ［査読有り］
  英語, 研究論文（学術雑誌）
• 理論式による多剤配合時のpH予測方法
  井関 健; 中垣 悌; 小林道也; 菅原 満; 荻野 修; 宮崎勝巳
  病院薬学, 22, 2, 183, 188, 日本病院薬剤師会, 1996年03月, ［査読有り］
  日本語, 研究論文（学術雑誌）, A method for predicting pH changes in multiple admixtures was designed on the basis of the acid-base equilibrium theory. The pH's of transfusions mixed with the various injections were estimated by solving a general theoretical equation for proton concentrations in the multicomponents-blended aquaous solution obtained using a dichotomy as the algorithm. Eighty-two transfusions and parenteral solution mixture combinations were examined for the efficacy of the predicted equation. As a result, the estimated pH was in good agreement with the measured pH in all examinations, and a good corelation existed between the measured and calculated values of pH. Furthermore, the incompatibility of the parenteral admixture can be easily predicted using the present estimation-program for pH changes without any preliminary pH titration tests. These results suggest that this prediction method will be a useful tool for constructing and handling database incompatipility.
• Transport Mechanisms of Nucleosides and the Derivative, 6-Mercaptopurine Riboside across Rat Intestinal Brush-border Membranes
  Iseki K; Sugawara M; Fujiwara T; Naasani I; Kobayashi M; Miyazaki K
  Biochim. Biophys. Acta, 1278, 1, 105, 110, 1996年01月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Transport mechanisms of nucleosides and the derivative, 6-mercaptopurine riboside across rat intestinal brush-border membranes
  K Iseki; M Sugawara; T Fujiwara; Naasani, I; M Kobayashi; K Miyazaki
  BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 1278, 1, 105, 110, 1996年01月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Purification Method for α-1-Acid Glycoprotein with Subsequent High-Performance Liquid Chromatographic Determination of Monosaccharides in Plasma of Healthy Subjects and Patients with Renal Insufficiency
  Kishino S; Nomura A; Sugawara M; Iseki K; Kakinoki S; Kitabatake A; Miyazaki K
  J. Chromatogr. B, 672, 2, 199, 205, 1995年10月, ［査読有り］
  英語, 研究論文（学術雑誌）
• CHANGES IN THE BINDING-CAPACITY OF ALPHA-1-ACID GLYCOPROTEIN IN PATIENTS WITH RENAL-INSUFFICIENCY
  S KISHINO; A NOMURA; ZS DI; M SUGAWARA; K ISEKI; S KAKINOKI; A KITABATAKE; K MIYAZAKI
  THERAPEUTIC DRUG MONITORING, 17, 5, 449, 453, 1995年10月, ［査読有り］
  英語, 研究論文（学術雑誌）
• THE INTESTINAL TRANSPORT MECHANISM OF FLUOROQUINOLONES - INHIBITORY EFFECT OF CIPROFLOXACIN, AN ENOXACIN DERIVATIVE, ON THE MEMBRANE POTENTIAL-DEPENDENT UPTAKE OF ENOXACIN
  T HIRANO; K ISEKI; SATO, I; S MIYAZAKI; M TAKADA; M KOBAYASHI; M SUGAWARA; K MIYAZAKI
  PHARMACEUTICAL RESEARCH, 12, 9, 1299, 1303, 1995年09月, ［査読有り］
  英語, 研究論文（学術雑誌）
• COMPARISON OF THE TRANSPORT CHARACTERISTICS OF CEFTIBUTEN IN RAT RENAL AND INTESTINAL BRUSH-BORDER MEMBRANES
  NAASANI, I; K SATO; K ISEKI; M SUGAWARA; M KOBAYASHI; K MIYAZAKI
  BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS, 1231, 2, 163, 168, 1995年09月, ［査読有り］
  英語, 研究論文（学術雑誌）
• ALPHA-1-ACID GLYCOPROTEIN CONCENTRATION AND THE PROTEIN-BINDING OF DISOPYRAMIDE IN HEALTHY-SUBJECTS
  S KISHINO; A NOMURA; ZS DI; M SUGAWARA; K ISEKI; S KAKINOKI; A KITABATAKE; K MIYAZAKI
  JOURNAL OF CLINICAL PHARMACOLOGY, 35, 5, 510, 514, 1995年05月, ［査読有り］
  英語, 研究論文（学術雑誌）
• TRANSPORT MECHANISM OF CEFTIBUTEN, A DIANIONIC CEPHEM, IN RAT RENAL BRUSH-BORDER MEMBRANE
  NAASANI, I; M SUGAWARA; M KOBAYASHI; K ISEKI; K MIYAZAKI
  PHARMACEUTICAL RESEARCH, 12, 4, 605, 608, 1995年04月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Effect of Membrane Surface Potential on the Uptake and Inhibition of Cationic Compounds in Rat Intestinal Brush-Border Membrane Vesicles and Liposomes
  Sugawara M; Oikawa H; Kobayashi M; Iseki K; Miyazaki K
  Biochim. Biophys. Acta, 1234, 1, 22, 28, 1995年03月, ［査読有り］
  英語, 研究論文（学術雑誌）
• EFFECT OF MEMBRANE-SURFACE POTENTIAL ON THE UPTAKE AND THE INHIBITION OF CATIONIC COMPOUNDS IN RAT INTESTINAL BRUSH-BORDER MEMBRANE-VESICLES AND LIPOSOMES
  M SUGAWARA; H OIKAWA; M KOBAYASHI; K ISEKI; K MIYAZAKI
  BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 1234, 1, 22, 28, 1995年03月, ［査読有り］
  英語, 研究論文（学術雑誌）
• TRANSPORT MECHANISMS OF ENOXACIN IN RAT BRUSH-BORDER MEMBRANE OF RENAL-CORTEX - INTERACTION WITH ORGANIC CATION-TRANSPORT SYSTEM AND IONIC-DIFFUSION POTENTIAL-DEPENDENT UPTAKE
  T HIRANO; K ISEKI; M SUGAWARA; S MIYAZAKI; M TAKADA; K MIYAZAKI
  BIOLOGICAL & PHARMACEUTICAL BULLETIN, 18, 2, 342, 346, 1995年02月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Predicting the Intestinal Absorption of Anionic Drugs from Their Physicochemical Properties
  Mitsuru Sugawara; Yoh Takekuma; Michiya Kobayashi; Ken Iseki; Katsumi Miyazaki
  Pharmacy and Pharmacology Communications, 1, 10, 491, 493, 1995年, ［査読有り］
  英語, 研究論文（学術雑誌）
• Sodium‐dependent Putrescine Transport in Rat Intestinal Basolateral Membrane
  MICHIYA KOBAYASHI; RYOU TANABE; MITSURU SUGAWARA; KEN ISEKI; KATSUMI MIYAZAKI
  Pharmacy and Pharmacology Communications, 1, 7, 337, 339, 1995年, ［査読有り］
  英語, 研究論文（学術雑誌）
• Uptake of 6‐Mercaptopurine Riboside via the Nucleoside Transporter in the Human Intestinal Brush‐border Membrane
  KEN ISEKI; IMAD NAASANI; MITSURU SUGAWARA; TOSHIE FUJIWARA; MICHIYA KOBAYASHI; KATSUMI MIYAZAKI
  Pharmacy and Pharmacology Communications, 1, 3, 127, 129, 1995年, ［査読有り］
  英語, 研究論文（学術雑誌）
• THE STIMULATIVE EFFECT OF DIFFUSION POTENTIAL ON ENOXACIN UPTAKE ACROSS RAT INTESTINAL BRUSH-BORDER MEMBRANES
  T HIRANO; K ISEKI; S MIYAZAKI; M TAKADA; M KOBAYASHI; M SUGAWARA; K MIYAZAKI
  JOURNAL OF PHARMACY AND PHARMACOLOGY, 46, 8, 676, 679, 1994年08月, ［査読有り］
  英語, 研究論文（学術雑誌）
• THE INHIBITORY EFFECTS OF CEPHALOSPORIN AND DIPEPTIDE ON CEFTIBUTEN UPTAKE BY HUMAN AND RAT INTESTINAL BRUSH-BORDER MEMBRANE-VESICLES
  M SUGAWARA; T TODA; M KOBAYASHI; K ISEKI; K MIYAZAKI; H SHIROTO; JI UCHINO; Y KONDO
  JOURNAL OF PHARMACY AND PHARMACOLOGY, 46, 8, 680, 684, 1994年08月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Effect of Membrane Surface Potential on the Uptake of Anionic Compounds by Liposomes
  Sugawara M; Hashimoto A; Kobayashi M; Iseki K; Miyazaki K
  Biochim. Biophys. Acta, 1192, 2, 241, 246, 1994年06月, ［査読有り］
  英語, 研究論文（学術雑誌）
• EFFECT OF MEMBRANE-SURFACE POTENTIAL ON THE UPTAKE OF ANIONIC COMPOUNDS BY LIPOSOMES
  M SUGAWARA; A HASHIMOTO; M KOBAYASHI; K ISEKI; K MIYAZAKI
  BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 1192, 2, 241, 246, 1994年06月, ［査読有り］
  英語, 研究論文（学術雑誌）
• 経口セフェム系抗生物質の消化管吸収に及ぼすペプチド結腸栄養剤エンテルード(R)併用の影響
  井関 健; 佐藤 佳子; 菅原 満
  薬学雑誌, 114, 4, 233, 240, (公社)日本薬学会, 1994年04月, ［査読有り］
  日本語, 研究論文（学術雑誌）, 1)ペプチド製剤エンテルード(R)は,CETBの吸収を顕著に遅らせた。しかし,CEXの吸収には何ら変化が認められなかったことより,両薬物の消化管吸収に違いのあることが明らかになった。2)エンテルード(R)の吸収抑制効果は,主成分であるペプチドによる輸送担体の阻害ではなく,その他の構成成分によって生じることが認められた
• EFFECT OF ENTERUED(R) ADMINISTRATION ON THE INTESTINAL-ABSORPTION OF ORALLY-ACTIVE CEFEM ANTIBIOTICS
  K ISEKI; Y SATOH; M SUGAWARA; K MIYAZAKI
  YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 114, 4, 233, 240, 1994年04月, ［査読有り］
  日本語, 研究論文（学術雑誌）
• Changes in the Permeation Rate of Organic Anions through the Intestinal Brush-Border Membrane with Membrane Surface Potential
  Sugawara M; Hashimoto A; Toda T; Takahashi M; Kobayashi M; Iseki K; Miyazaki K
  Biochim. Biophys. Acta, 1190, 1, 85, 90, 1994年02月, ［査読有り］
  英語, 研究論文（学術雑誌）
• CHANGES IN THE PERMEATION RATE OF ORGANIC-ANIONS THROUGH THE INTESTINAL BRUSH-BORDER MEMBRANE WITH MEMBRANE-SURFACE POTENTIAL
  M SUGAWARA; A HASHIMOTO; T TODA; M TAKAHASHI; M KOBAYASHI; K ISEKI; K MIYAZAKI
  BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 1190, 1, 85, 90, 1994年02月, ［査読有り］
  英語, 研究論文（学術雑誌）
• The transport mechanisms of organic cations and their zwitterionic derivatives across rat intestinal brush-border membrane. II. Comparison of the membrane potential effect on the uptake by membrane vesicles
  Ken Iseki; Mitsuru Sugawara; Nobutaka Saitoh; Katsumi Miyazaki
  BBA - Biomembranes, 1152, 1, 9, 14, 1993年10月10日, ［査読有り］
  英語, 研究論文（学術雑誌）
• The Transport Mechanisms of Organic Cations and Their Zwitterionic Derivatives across Rat Intestinal Brush-Border Membrane. 2. Comparison of the Membrane Potential Effect on the Uptake by Membrane Vesicles
  Iseki K; Sugawara M; Saitoh N; Miyazaki K
  Biochim. Biophys. Acta, 1152, 1, 9, 14, 1993年10月, ［査読有り］
  英語, 研究論文（学術雑誌）
• THE TRANSPORT MECHANISMS OF ORGANIC CATIONS AND THEIR ZWITTERIONIC DERIVATIVES ACROSS RAT INTESTINAL BRUSH-BORDER MEMBRANE .2. COMPARISON OF THE MEMBRANE-POTENTIAL EFFECT ON THE UPTAKE BY MEMBRANE-VESICLES
  K ISEKI; M SUGAWARA; N SAITOH; K MIYAZAKI
  BIOCHIMICA ET BIOPHYSICA ACTA, 1152, 1, 9, 14, 1993年10月, ［査読有り］
  英語, 研究論文（学術雑誌）
• The diversity of Na+-independent uptake systems for polyamines in rat intestinal brush-border membrane vesicles
  Michiya Kobayashi; Ken Iseki; Mitsuru Sugawara; Katsumi Miyazaki
  BBA - Biomembranes, 1151, 2, 161, 167, 1993年09月19日, ［査読有り］
  英語, 研究論文（学術雑誌）
• The Diversity of Na+-Independent Uptake Systems for Polyamines in Rat Intestinal Brush-border Membrane Vesicles
  Kobayashi M; Iseki K; Sugawara M; Miyazaki K
  Biochim. Biophys. Acta, 1151, 2, 161, 167, 1993年09月, ［査読有り］
  英語, 研究論文（学術雑誌）
• THE DIVERSITY OF NA+-INDEPENDENT UPTAKE SYSTEMS FOR POLYAMINES IN RAT INTESTINAL BRUSH-BORDER MEMBRANE-VESICLES
  M KOBAYASHI; K ISEKI; M SUGAWARA; K MIYAZAKI
  BIOCHIMICA ET BIOPHYSICA ACTA, 1151, 2, 161, 167, 1993年09月, ［査読有り］
  英語, 研究論文（学術雑誌）
• THE TRANSPORT MECHANISM OF AN ORGANIC CATION, DISOPYRAMIDE, BY BRUSH-BORDER MEMBRANES - COMPARISON BETWEEN RENAL-CORTEX AND SMALL-INTESTINE OF THE RAT
  Y TAKAHASHI; T ITOH; M KOBAYASHI; M SUGAWARA; H SAITOH; K ISEKI; K MIYAZAKI; S MIYAZAKI; M TAKADA; Y KAWASHIMA
  JOURNAL OF PHARMACY AND PHARMACOLOGY, 45, 5, 419, 424, 1993年05月, ［査読有り］
  英語, 研究論文（学術雑誌）
• ウィルソン病治療薬トリエンチンの患者における血清中濃度推移と尿中排泄挙動
  小林 道也; 長原 しのぶ; 菅原 満
  TDM研究, 10, 2, 166, 171, (一社)日本TDM学会, 1993年04月, ［査読有り］
  日本語, 研究論文（学術雑誌）
• The transport mechanisms of organic cations and their zwitterionic derivatives across rat intestinal brush-border membrane. 1. Binding characteristics to the bio- and lipid-membranes
  Ken Iseki; Mitsuru Sugawara; Nobutaka Saitoh; Katsumi Miyazaki
  BBA - Biomembranes, 1146, 1, 121, 126, 1993年02月23日, ［査読有り］
  英語, 研究論文（学術雑誌）
• THE TRANSPORT MECHANISMS OF ORGANIC CATIONS AND THEIR ZWITTERIONIC DERIVATIVES ACROSS RAT INTESTINAL BRUSH-BORDER MEMBRANE .1. BINDING CHARACTERISTICS TO THE BIO-MEMBRANES AND LIPID-MEMBRANES
  K ISEKI; M SUGAWARA; N SAITOH; K MIYAZAKI
  BIOCHIMICA ET BIOPHYSICA ACTA, 1146, 1, 121, 126, 1993年02月, ［査読有り］
  英語, 研究論文（学術雑誌）
• TRANSPORT CHARACTERISTICS OF CEPHALOSPORIN ANTIBIOTICS ACROSS INTESTINAL BRUSH-BORDER MEMBRANE IN MAN, RAT AND RABBIT
  M SUGAWARA; T TODA; K ISEKI; K MIYAZAKI; H SHIROTO; Y KONDO; JI UCHINO
  JOURNAL OF PHARMACY AND PHARMACOLOGY, 44, 12, 968, 972, 1992年12月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Carrier-mediated transport system for choline and its related quaternary ammonium compounds on rat intestinal brush-border membrane
  Hiroshi Saitoh; Michiya Kobayashi; Mitsuru Sugawara; Ken Iseki; Katsumi Miyazaki
  BBA - Biomembranes, 1112, 1, 153, 160, 1992年11月23日, ［査読有り］
  英語, 研究論文（学術雑誌）
• Membrane-potential-dependent uptake of tryptamine by rat intestinal brush-border membrane vesicles
  Mitsuru Sugawara; Makoto Sasaki; Ken Iseki; Katsumi Miyazaki
  BBA - Biomembranes, 1111, 2, 145, 150, 1992年11月09日, ［査読有り］
  英語, 研究論文（学術雑誌）
• CARRIER-MEDIATED TRANSPORT-SYSTEM FOR CHOLINE AND ITS RELATED QUATERNARY AMMONIUM-COMPOUNDS ON RAT INTESTINAL BRUSH-BORDER MEMBRANE
  H SAITOH; M KOBAYASHI; M SUGAWARA; K ISEKI; K MIYAZAKI
  BIOCHIMICA ET BIOPHYSICA ACTA, 1112, 1, 153, 160, 1992年11月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Membrane-Potential-Dependent Uptake of Tryptamine by Rat Intestinal Brush-Border Membrane Vesicles
  Sugawara M; Sasaki M; Iseki K; Miyazaki K
  Biochim. Biophys. Acta, 1111, 2, 145, 150, 1992年11月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Rapid and Simple Method for the Determination of α1-Acid Glycoprotein in Serum By Liquid Chromatography
  Kishino S; Zai D.S; Sugawara M; Iseki K; Miyazaki K
  J. Chromatogr., 582, 1-2, 246, 248, 1992年11月, ［査読有り］
  英語, 研究論文（学術雑誌）
• MEMBRANE-POTENTIAL-DEPENDENT UPTAKE OF TRYPTAMINE BY RAT INTESTINAL BRUSH-BORDER MEMBRANE-VESICLES
  M SUGAWARA; M SASAKI; K ISEKI; K MIYAZAKI
  BIOCHIMICA ET BIOPHYSICA ACTA, 1111, 2, 145, 150, 1992年11月, ［査読有り］
  英語, 研究論文（学術雑誌）
• ニコランジルの血中微量定量法と血中動態
  岸野 吏志; 菅原 満; 井関 健
  TDM研究, 9, 2, 94, 100, (一社)日本TDM学会, 1992年09月, ［査読有り］
  日本語, 研究論文（学術雑誌）
• THE PH DEPENDENT UPTAKE OF ENOXACIN BY RAT INTESTINAL BRUSH-BORDER MEMBRANE-VESICLES
  K ISEKI; T HIRANO; Y FUKUSHI; Y KITAMURA; S MIYAZAKI; M TAKADA; M SUGAWARA; H SAITOH; K MIYAZAKI
  JOURNAL OF PHARMACY AND PHARMACOLOGY, 44, 9, 722, 726, 1992年09月, ［査読有り］
  英語, 研究論文（学術雑誌）
• UPTAKE CHARACTERISTICS OF POLYAMINES INTO RAT INTESTINAL BRUSH-BORDER MEMBRANE-VESICLES
  M KOBAYASHI; M SUGAWARA; K ISEKI; K MIYAZAKI
  JOURNAL OF PHARMACOBIO-DYNAMICS, 15, 6, S67, S67, 1992年06月, ［査読有り］
  英語, 研究論文（学術雑誌）
• TRANSPORT CHARACTERISTICS OF CEFTIBUTEN, CEFIXIME AND CEPHALEXIN ACROSS HUMAN JEJUNAL BRUSH-BORDER MEMBRANE
  M SUGAWARA; K ISEKI; K MIYAZAKI; H SHIROTO; Y KONDO; JI UCHINO
  JOURNAL OF PHARMACY AND PHARMACOLOGY, 43, 12, 882, 884, 1991年12月, ［査読有り］
  英語, 研究論文（学術雑誌）
• H+ Coupled Transport of Orally Active Cephalosporins Lacking an α-Amino Group across Brush-Border Membrane Vesicles from Rat Small Intestine
  Sugawara M; Iseki K; Miyazaki K
  J. Pharm. Pharmacol., 43, 6, 433, 435, 1991年06月, ［査読有り］
  英語, 研究論文（学術雑誌）
• ウィルソン病治療薬トリエチレンテトラミンのラットにおける消化管吸収と尿中排泄
  小林 道也; 菅原 満; 斎藤 浩司
  薬学雑誌, 110, 10, 759, 763, (公社)日本薬学会, 1990年10月, ［査読有り］
  日本語, 研究論文（学術雑誌）, トリエンチンのより有効な投与方法を確立するための基礎的知見を得ることを目的として,ラットにおける消化管吸収および尿中排泄について検討を行った.小腸からの吸収では,トリエンチンの1時間における平均吸収率は空腸上部で42.0%,回腸部で22.5%であった.tight junction blockerであるTAPの共存下では空腸上部でのみ吸収が阻害され,回腸部では全く影響なかった.が,空腸上部でも阻害率は全吸収量の27%であり,消化管でのトリエンチンの吸収過程は小腸の上皮細胞膜の透過が主であることが示唆された.小腸刷子縁膜(BBM)に対する結合を調べると,トリエンチンは無機イオン(Na+, K+, Ca2+, Mg2+, Cu2+)非存在下ではアミノ糖抗生物質アミカシンと同程度に強く結合した.が,無機イオン存在下では結合は強く阻害され,トリエンチンのBBMに対する結合が静電気的なものであることを示唆する.食餌による吸収挙動の変化では,非絶食時の血中濃度推移は絶食時と比較して有意に低かった.トリエンチン経口投与後24時間に排泄された尿中未変化体は投与量の3%であったが,加水分解尿中のトリエンチンの総量は約35%と多く,トリエンチンの経口投与後の低い血漿中濃度は吸収性が低いことによるだけでなく,代謝を受けることにもよると考えられた.以上からトリエンチンの経口投与後の吸収は食餌内容により大きく変動すると考えられた
• INTESTINAL-ABSORPTION AND URINARY-EXCRETION OF TRIETHYLENETETRAMINE FOR WILSONS-DISEASE IN RAT
  M KOBAYASHI; M SUGAWARA; H SAITOH; K ISEKI; K MIYAZAKI
  YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 110, 10, 759, 763, 1990年10月, ［査読有り］
  日本語, 研究論文（学術雑誌）
• Contribution of Passive Transport Mechanisms to the Intestinal Absorption of β-Lactam Antibiotics
  Sugawara M; Saitoh H; Iseki K; Miyazaki K; Arita T
  J. Pharm. Pharmacol., 42, 5, 314, 318, 1990年05月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Mechanism of gastrointestinal absorption of β-lactam antibiotics - contribution of passive diffusion to the BBM permeation process -
  M. Sugawara; K. Iseki; H. Saitoh; K. Miyazaki; T. Arita
  Journal of Pharmacobio-Dynamics, 13, 4, 1990年, ［査読有り］, ［筆頭著者］
  研究論文（国際会議プロシーディングス）
• Comparison of Transport Characteristics of Amino β-Lactam Antibiotics and Dipeptides across Rat Intestinal Brush Border Membrane
  Iseki K; Sugawara M; Saitoh H; Miyazaki K; Arita T
  J. Pharm. Pharmacol., 41, 9, 628, 632, 1989年09月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Effect of Chlorpromazine on the Permeability of β-Lactam Antibiotics across Rat Intestinal Brush Border Membrane Vesicles
  Iseki K; Sugawara M; Saitoh H; Miyazaki K; Arita T
  J. Pharm. Pharmacol., 40, 10, 701, 705, 1988年10月, ［査読有り］
  英語, 研究論文（学術雑誌）

• トランスポーターの輸送活性評価が可能な空腸上皮細胞単層培養系の確立
  笹川義樹; 神嶋莉穂; 柏木仁; 佐藤夕紀; 梨本俊亮; 武隈洋; 菅原満; 菅原満, 日本薬学会年会要旨集(Web), 145th, 2025年
• P-gp基質性評価のためのP-gp高発現細胞樹立とその中分子化合物への応用
  柏木仁; 山田隼大; 王子谷健太; 佐藤夕紀; 梨本俊亮; 渡邉瑞貴; 廣瀬友靖; 廣瀬友靖; 岩月正人; 岩月正人; 砂塚敏明; 砂塚敏明; 金光佳世子; 石井真由美; 渡邊恵里; 宮地弘幸; 武隈洋; 菅原満; 菅原満, 日本薬学会年会要旨集(Web), 145th, 2025年
• 血小板によるアミノ酸トランスポーターSNAT4の輸送活性変動
  柏木仁; 佐藤夕紀; 梨本俊亮; 今井俊吾; 武隈洋; 菅原満; 菅原満, 日本薬学会年会要旨集(Web), 145th, 2025年
• 日本の集中治療室における過大腎クリアランス予測スコアの開発と検証
  三上龍生; 三上龍生; 今井俊吾; 早川峰司; 佐藤夕紀; 柏木仁; 梨本俊亮; 菅原満; 武隈洋, 日本薬学会年会要旨集(Web), 145th, 2025年
• 簡易懸濁法でドラビリンとドルテグラビルを投与後に血漿中薬物濃度を測定した一例
  田澤 佑基; 松川 敏大; 新井 崇之; 遠藤 知之; 武隈 洋; 菅原 満, 日本エイズ学会誌, 26, 4, 402, 402, 2024年11月
  (一社)日本エイズ学会, 日本語
• 持続性注射薬カボテグラビル+リルピビリン(CAB+RPV)使用患者の臨床的特徴
  新井 崇之; 田澤 佑基; 遠藤 知之; 武隈 洋; 菅原 満, 日本エイズ学会誌, 26, 4, 417, 417, 2024年11月
  (一社)日本エイズ学会, 日本語
• トラブルシューティングに効果的な電子マニュアルの作成・運用
  小柳 遼; 川岸 亨; 水口 貴史; 山崎 浩二郎; 武隈 洋; 菅原 満, 北海道病院薬剤師会誌, 107, 7, 9, 2024年11月
  (一社)北海道病院薬剤師会, 日本語
• オレキシン受容体拮抗薬のUPLC/MS/MS定量法構築とヒト乳汁移行性評価への応用
  石川 陽菜; 古堅 彩子; 西村 あや子; 馬詰 武; 青柳 亮一; 石川 修平; 鳴海 克哉; 岡本 敬介; 武隈 洋; 菅原 満; 小林 正紀, TDM研究, 41, 2, 149, 149, 2024年07月
  (一社)日本TDM学会, 日本語
• 小児造血幹細胞移植におけるブスルファンの1日4回投与法と1日1回投与法による薬物動態パラメータの比較
  山口 敦史; 平林 真介; 仁木 加寿子; 鏡 圭介; 寺下 友佳代; 長 祐子; 真部 淳; 菅原 満; 武隈 洋, TDM研究, 41, 2, 155, 155, 2024年07月
  (一社)日本TDM学会, 日本語
• メチシリン耐性コアグラーゼ陰性ブドウ球菌におけるバンコマイシンMICと治療効果の関連性
  新沼 悠介; 鏡 圭介; 武隈 洋; 菅原 満, TDM研究, 41, 2, 172, 172, 2024年07月
  (一社)日本TDM学会, 日本語
• オレキシン受容体拮抗薬のUPLC/MS/MS定量法構築とヒト乳汁移行性評価への応用
  石川 陽菜; 古堅 彩子; 西村 あや子; 馬詰 武; 青柳 亮一; 石川 修平; 鳴海 克哉; 岡本 敬介; 武隈 洋; 菅原 満; 小林 正紀, TDM研究, 41, 2, 149, 149, 2024年07月
  (一社)日本TDM学会, 日本語
• ナノリポソーマルイリノテカンとレボホリナートの並列投与における有効性、安全性の評価
  坂本 達彦; 齋藤 佳敬; 渡辺 拓也; 内山 数貴; 武隈 洋; 小松 嘉人; 菅原 満, 日本臨床腫瘍薬学会雑誌, 36, 191, 191, 2024年05月
  (一社)日本臨床腫瘍薬学会, 日本語
• ヒアルロン酸4,6,8糖の同時定量法の確立
  佐藤 夕紀; 高林 直央; 青柳 空馬; 梨本 俊亮; 柏木 仁; 武隈 洋; 菅原 満, 日本薬剤学会年会講演要旨集, 39年会, 201, 201, 2024年05月
  (公社)日本薬剤学会, 日本語
• ヒアルロン酸4,6,8糖の同時定量法の確立
  佐藤 夕紀; 高林 直央; 青柳 空馬; 梨本 俊亮; 柏木 仁; 武隈 洋; 菅原 満, 日本薬剤学会年会講演要旨集, 39年会, 201, 201, 2024年05月
  (公社)日本薬剤学会, 日本語
• 新たなTDM対象抗菌薬の最前線 オキサゾリジノン系抗菌薬のTDM
  武隈 洋; 井上 優希; 菅原 満, 感染症学雑誌, 98, 1, 53, 53, 2024年01月
  (一社)日本感染症学会, 日本語
• 新たなTDM対象抗菌薬の最前線 オキサゾリジノン系抗菌薬のTDM
  武隈 洋; 井上 優希; 菅原 満, 日本化学療法学会雑誌, 72, 1, 61, 61, 2024年01月
  (公社)日本化学療法学会, 日本語
• 食道胃接合部癌術後に食道狭窄を繰り返す症例に対して持効性注射薬カボテグラビル+リルピビリン(CAB+RPV)を導入した一例
  田澤 佑基; 遠藤 知之; 武隈 洋; 菅原 満, 日本エイズ学会誌, 25, 4, 483, 483, 2023年11月
  (一社)日本エイズ学会, 日本語
• 医療事故の再発防止への提言(第3号)に対する取り組み(第2報) アドレナリン注射液0.3mg製剤の院内配置
  植田 孝介; 沖 洋充; 宮前 祐士; 久保田 康生; 岡本 千秋; 三上 薫子; 藤原 晶; 根岸 淳; 菅原 満; 南須原 康行, 医療の質・安全学会誌, 18, Suppl., 348, 348, 2023年11月
  (一社)医療の質・安全学会, 日本語
• 採血に依らないTDM～Alternative samplingによるTDMに関する最新知見～ 唾液サンプリングに基づくTDMの実際
  武隈 洋; 井上 優希; 菅原 満, TDM研究, 40, 2, 80, 80, 2023年06月
  (一社)日本TDM学会, 日本語
• 肝機能障害患者に対するボリコナゾールの初期投与設計におけるAlbumin-Bilirubinスコアの有用性検証
  梨本 俊亮; 今井 俊吾; 菅原 満; 武隈 洋, TDM研究, 40, 2, 175, 175, 2023年06月
  (一社)日本TDM学会, 日本語
• ブスルファンの著しい薬物動態変動が認められた小児の1例
  山口 敦史; 武隈 洋; 仁木 加寿子; 平林 真介; 寺下 友佳代; 長谷河 昌孝; 長 祐子; 真部 淳; 菅原 満, TDM研究, 40, 2, 212, 212, 2023年06月
  (一社)日本TDM学会, 日本語
• マスメディアによる「くすりの危険性」に関する報道に起因した患者相談の実態調査
  今井 俊吾; 阿部 真也; 松井 洸; 柏木 仁; 佐藤 夕紀; 武隈 洋; 吉町 昌子; 菅原 満, 日本医薬品情報学会総会・学術大会講演要旨集, 25回, 132, 132, 2023年06月
  (一社)日本医薬品情報学会, 日本語
• 肝機能障害患者に対するボリコナゾールの初期投与設計におけるAlbumin-Bilirubinスコアの有用性検証
  梨本 俊亮; 今井 俊吾; 菅原 満; 武隈 洋, TDM研究, 40, 2, 175, 175, 2023年06月
  (一社)日本TDM学会, 日本語
• ブスルファンの著しい薬物動態変動が認められた小児の1例
  山口 敦史; 武隈 洋; 仁木 加寿子; 平林 真介; 寺下 友佳代; 長谷河 昌孝; 長 祐子; 真部 淳; 菅原 満, TDM研究, 40, 2, 212, 212, 2023年06月
  (一社)日本TDM学会, 日本語
• 医薬品の在庫管理における医療機器の導入効果
  山崎 浩二郎; 久保田 康生; 川岸 亨; 武隈 洋; 菅原 満, 北海道病院薬剤師会誌, 104, 17, 19, 2023年04月
  近年バイオ医薬品の開発が進み、高額な医薬品が次々に上市されている。当院のような急性期病院においては、治療の変更や中止により、その高額な医薬品を使用しなくなることがあり、使用しなかった医薬品は不動在庫となり期限切れを起こすことがあり、これは病院経営的に大きな損失となる。そこで当院では、特に高額な冷所保管医薬品をリフレッシュできる医薬品専用保冷庫「Cubixx」(スズケングループ)を2019年2月に導入した。また、治療の変更や中止により投与中止となった一包化の内服薬を分別し再利用する目的で「TABSORT」(YUYAMA社)を2021年3月に導入した。Cubixx導入後3年間の各年度に7～9種類の医薬品をリフレッシュし、その効果として、薬価にして合計100万円以上の損失を未然に防ぐことができた。TABSORT導入後1年間に再利用することができた錠剤は延べ66701剤(薬価にして252万円)であった。, (一社)北海道病院薬剤師会, 日本語
• Enterobacter cloacae感染症に対する第3世代セファロスポリンの有効性調査
  新沼 悠介; 鏡 圭介; 武隈 洋; 菅原 満, 日本化学療法学会雑誌, 71, 2, 181, 182, 2023年03月
  (公社)日本化学療法学会, 日本語
• 【STOP!AMR 抗菌薬の適正使用を考える】歯科における最適な抗菌薬に関する考察
  山神 彰; 菅原 満, DENTAL DIAMOND, 48, 3, 46, 50, 2023年02月
  (株)デンタルダイヤモンド社, 日本語
• 下顎埋伏智歯抜歯手術における手術部位感染予測モデルの開発:リサンプリング手法を用いた予後予測モデル
  山神彰; 鳴海克也; 鳴海克也; 齋藤佳敬; 古堅彩子; 今井俊吾; 北川善政; 大廣洋一; 高木諒; 武隈洋; 菅原満; 菅原満; 小林正紀; 小林正紀, 日本医療薬学会年会講演要旨集(Web), 33rd, 2023年
• 中分子創薬の課題克服を指向した構造-物性相関解析:光学活性シクロプロパン含有環状ペプチド類の構造と溶解性,受動拡散性,細胞膜透過性,P-gp基質性相関
  宮地弘幸; 金光佳世子; 石井真由美; 渡邊恵里; 佐藤優希菜; 長田貴行; 山崎祐季; 柏木仁; 菅原満; 周東智; 重田育照; 渡邉瑞貴; 前仲勝実, 日本薬学会年会要旨集(Web), 143rd, 2023年
• Cyclosporine A乳剤ならびに自己乳化型製剤の特性と経口吸収性評価
  佐藤夕紀; 木下祐介; 上村聡; 丸山真吾; 武隈洋; 菅原満; 菅原満, 日本薬剤学会年会講演要旨集(CD-ROM), 38th, 2023年
• 大規模レセプトデータベースを活用した炎症性腸疾患患者におけるHBVスクリーニング検査と核酸アナログ製剤の医療経済学的検討
  青柳亮一; 窪田篤人; 窪田篤人; 今井俊吾; 今井俊吾; 八木澤啓司; 沖洋充; 山崎浩二郎; 小島弘幸; 菅原満; 菅原満; 武隈洋, 日本薬学会年会要旨集(Web), 143rd, 2023年
• 成分栄養療法の制御性T細胞誘導に及ぼす抗菌薬併用の影響
  窪田篤人; 村瀬渉; 今井俊吾; 菅原満; 武隈洋; 小島弘幸, 日本免疫毒性学会学術年会講演要旨集, 30th, 2023年
• 長時間作用型ベンゾジアゼピン(BZD)系薬のMilk/Plasma ratio(M/P比)およびRelative Infant Dose(RID)の算出
  西村あや子; 古堅彩子; 馬詰武; 北村聖花; 武隈洋; 菅原満; 菅原満; 小林正紀, 医療薬学フォーラム講演要旨集, 31st, 2023年
• 経口投与されたヒアルロン酸オリゴ糖の同時定量法開発
  高林直央; 佐藤夕紀; 柏木仁; 梨本俊亮; 武隈洋; 菅原満; 菅原満, バイオメディカル分析科学シンポジウム講演要旨集, 35th, 2023年
• ドルテグラビル/アバカビル/ラミブジン(DTG/ABC/3TC)からDTG/3TCへの薬剤変更における薬剤師介入効果の検証
  田澤 佑基; 遠藤 知之; 武隈 洋; 菅原 満, 日本エイズ学会誌, 24, 4, 383, 383, 2022年11月
  (一社)日本エイズ学会, 日本語
• 週刊誌に掲載された「危ないクスリ」に関する情報の整理とその適切性評価
  今井 俊吾; 柏木 仁; 佐藤 夕紀; 武隈 洋; 菅原 満, 日本医薬品情報学会総会・学術大会講演要旨集, 24回, 91, 91, 2022年06月
  (一社)日本医薬品情報学会, 日本語
• サーベイランスシステムJ-SIPHE(感染対策連携共通プラットフォーム)を用いた多施設解析-抗菌薬使用量と耐性菌の関連
  鏡 圭介; 石黒 信久; 新沼 悠介; 武隈 洋; 菅原 満, 日本化学療法学会雑誌, 70, Suppl.A, 311, 311, 2022年05月
  (公社)日本化学療法学会, 日本語
• 重症病態後の患者におけるエドキサバン関連出血の予測モデルの構築
  三上 龍生; 早川 峰司; 今井 俊吾; 前川 邦彦; 山崎 浩二郎; 菅原 満; 武隈 洋, 日本血栓止血学会誌, 33, 2, 269, 269, 2022年05月
  (一社)日本血栓止血学会, 日本語
• 機械学習を活用した定常状態のAUC400-600mg・h/Lを目標とするバンコマイシン投与量推定モデルの構築
  宮井 貴之; 今井 俊吾; 吉村 理恵; 柏木 仁; 佐藤 夕紀; 上野 英文; 武隈 洋; 菅原 満, TDM研究, 39, 2, 128, 128, 2022年05月
  (一社)日本TDM学会, 日本語
• 乳児へのボリコナゾール投与中に、代謝機能の発達によると考えられる著しい血中濃度低下が認められた1例
  山口 敦史; 田澤 佑基; 武隈 洋; 植木 将弘; 山田 雅文; 真鍋 淳; 菅原 満, TDM研究, 39, 2, 136, 136, 2022年05月
  (一社)日本TDM学会, 日本語
• 重症患者におけるバンコマイシンの初期投与量決定のための実測クレアチニンクリアランスの臨床適用性
  三上 龍生; 今井 俊吾; 早川 峰司; 菅原 満; 武隈 洋, 日本薬学会年会要旨集, 142年会, 27G, am10, 2022年03月
  (公社)日本薬学会, 日本語
• 大規模レセプトデータベースを用いたボリコナゾールの治療薬物モニタリング実施に関する実態調査
  宮井 貴之; 今井 俊吾; 百 賢二; 柏木 仁; 佐藤 夕紀; 菅原 満; 武隈 洋, 日本薬学会年会要旨集, 142年会, 27G, am09S, 2022年03月
  (公社)日本薬学会, 日本語
• がんの多剤耐性を克服する新規エトポシド誘導体の探索
  山田 隼大; 王子谷 健太; 柏木 仁; 佐藤 夕紀; 今井 俊吾; 宮地 弘幸; 武隈 洋; 菅原 満, 日本薬学会年会要旨集, 142年会, 28C, pm04S, 2022年03月
  (公社)日本薬学会, 日本語
• ビッグデータとデータマイニング手法を用いたリネゾリド誘発性血小板減少症の要因分析
  井上 優希; 武隈 洋; 宮井 貴之; 柏木 仁; 佐藤 夕紀; 菅原 満; 今井 俊吾, 日本薬学会年会要旨集, 142年会, 28H, pm13S, 2022年03月
  (公社)日本薬学会, 日本語
• レセプトデータベースを用いた糖尿病患者へのオランザピンの処方実態調査
  山下慎介; 山下慎介; 今井俊吾; 今井俊吾; 百賢二; 百賢二; 柏木仁; 佐藤夕紀; 菅原満; 菅原満; 武隈洋, 日本医療薬学会年会講演要旨集(Web), 32, 2022年
• LC/MS/MSを用いたリネゾリドならびにテジゾリドのヒト血漿中濃度同時定量法の確立
  佐藤夕紀; 大聖貴之; 柏木仁; 今井俊吾; 武隈洋; 菅原満; 菅原満, 日本医療薬学会年会講演要旨集(Web), 32, 2022年
• リネゾリド投与患者における嘔吐発現要因の探索
  堤竹蔵; 堤竹蔵; 今井俊吾; 今井俊吾; 柏木仁; 佐藤夕紀; 菅原満; 菅原満; 菅原満; 武隈洋, 日本医療薬学会年会講演要旨集(Web), 32, 2022年
• 歯科領域における経口第3世代セフェム系抗菌薬減少戦略の評価:中断時系列分析
  山神彰; 鳴海克哉; 齋藤佳敬; 古堅彩子; 今井俊吾; 北川善政; 大廣洋一; 高木諒; 武隈洋; 菅原満; 菅原満; 小林正紀; 小林正紀, 医療薬学フォーラム講演要旨集, 30th, 2022年
• 炎症性腸疾患の病態制御に対する免疫学的アプローチ
  窪田 篤人; 寺崎 将; 小林 正紀; 室本 竜太; 青栁 亮一; 武隈 洋; 菅原 満; 小島 弘幸, 日本毒性学会学術年会, 49.1, Suppl., S39-5, S70, 2022年
  はじめに
  
  炎症性腸疾患（IBD）は、腸管の慢性炎症を呈する自己免疫疾患である。本邦における患者数は、近年増加の一途を辿り患者数は30万人を超えると推測されている。これまでの報告からIBDの病態形成には、遺伝的要因を基盤とした免疫機能、環境因子、腸内細菌叢など様々な因子が関与している。治療は内科的療法が主軸となり、抗炎症作用を有する 5-アミノサリチル酸（5-ASA）や免疫抑制剤などが用いられる。我々は、本邦における最大の疫学レセプトデータベースである JMDC Claims Database （累積母集団数1400万人）の2016年4月から2021年3月までの5年間に IBD と診断された全患者 44,328 名のデータを用い、治療傾向を調査した。その結果、頻度の高い治療として5-ASAや経口成分栄養（ED）療法が抽出された。
  
  
  
  IBDと制御性T細胞
  
  近年5-ASAは、既存の抗炎症機序の他に芳香族炭化水素受容体（AhR）を介して制御性T細胞（Treg）を誘導することが示唆された。更に、演者らは5-ASAがAhRの直接的なリガンドとなり、その結合部位について報告している（Kubota et al., Pharmacol. 2022）。そこで処方頻度の高いED療法についてもAhRに着目し、種々検討を行った。その結果、IBDモデルマウスに対するED療法は、腸管の炎症を抑制し、脾臓Tregの比率を有意に上昇させた。また、ED療法に含まれるトリプトファン（Trp）は、腸内細菌叢で代謝されAhRリガンドとなる事が知られていることから、Trpを強化したED療法をIBDモデルマウスに投与した。その結果、腸管の炎症抑制効果に加え、血中IL-10の上昇、TNF-αの抑制、脾臓Tregの上昇が認められた。本演題ではAhRに着目した免疫学的アプローチがIBDの病態制御の一助となることを紹介したい。, 日本毒性学会, 日本語
• がん治療医・緩和ケアスタッフを対象としたターミナルケア態度尺度を用いた意識調査
  熊井 正貴; 加藤 信太郎; 小柳 遼; 敦賀 健吉; 伊藤 陽一; 山田 武宏; 川本 泰之; 武隈 洋; 菅原 満; 小松 嘉人, Palliative Care Research, 16, Suppl._Hokkaido, S492, S492, 2021年10月
  (NPO)日本緩和医療学会, 日本語
• がん治療医・緩和ケアスタッフを対象としたターミナルケア態度尺度を用いた意識調査
  熊井 正貴; 加藤 信太郎; 小柳 遼; 敦賀 健吉; 伊藤 陽一; 山田 武宏; 川本 泰之; 武隈 洋; 菅原 満; 小松 嘉人, Palliative Care Research, 16, Suppl._Hokkaido, S492, S492, 2021年10月
  (NPO)日本緩和医療学会, 日本語
• 北海道版・令和元年度次世代薬剤師指導者研修会における研修6ヵ月後のアンケート調査による行動変容からの研修効果評価
  片山 真二; 伊藤 優; 岩尾 一生; 前田 直大; 宇野 雅樹; 野田 敏宏; 山田 武志; 五十君 篤哉; 菅原 満; 竹内 伸仁; 令和元年度次世代薬剤師指導者研修会WG, 日本薬剤師会学術大会講演要旨集, 54回, 214, 214, 2021年09月
  (公社)日本薬剤師会, 日本語
• 北海道版・令和元年度次世代薬剤師指導者研修会における研修6ヵ月後のアンケート調査による行動変容からの研修効果評価
  片山 真二; 伊藤 優; 岩尾 一生; 前田 直大; 宇野 雅樹; 野田 敏宏; 山田 武志; 五十君 篤哉; 菅原 満; 竹内 伸仁; 令和元年度次世代薬剤師指導者研修会WG, 日本薬剤師会学術大会講演要旨集, 54回, 214, 214, 2021年09月
  (公社)日本薬剤師会, 日本語
• 大規模レセプトデータベースを用いた日本におけるTriple Whammy処方の実態解明
  今井 俊吾; 百 賢二; 柏木 仁; 宮井 貴之; 菅原 満; 武隈 洋, 日本医薬品情報学会総会・学術大会講演要旨集, 23回, 78, 78, 2021年06月
  (一社)日本医薬品情報学会, 日本語
• オキシコドン徐放錠による悪心危険因子の解明と機械学習を用いたリスク推定モデルの構築
  熊井 正貴; 今井 俊吾; 加藤 信太郎; 小柳 遼; 敦賀 健吉; 山田 武宏; 武隈 洋; 菅原 満, 日本臨床腫瘍薬学会雑誌, 20, 3, 3, 2021年05月
  (一社)日本臨床腫瘍薬学会, 日本語
• 医療の質向上、臨床の薬剤師による研究推進を目指した医療ビッグデータの活用 JMDCレセプトデータベースを用いた臨床研究
  武隈 洋; 今井 俊吾; 菅原 満, 日本薬学会年会要旨集, 141年会, S13, 3, 2021年03月
  (公社)日本薬学会, 日本語
• 若手薬学研究者で加速させる感染症トランスレーショナルリサーチ バンコマイシンによる腎機能障害リスクを投与開始前に推定するためのフローチャートの構築 感染症診療におけるデータマイニング手法の活用
  宮井 貴之; 今井 俊吾; 菅原 満, 日本薬学会年会要旨集, 141年会, GS01, 6, 2021年03月
  (公社)日本薬学会, 日本語
• 卵黄レシチンを用いた乳剤化に適した化合物の物理化学的特性
  鳥山 竜也; 佐藤 夕紀; 柏木 仁; 今井 俊吾; 武隈 洋; 菅原 満, 日本薬学会年会要旨集, 141年会, 28V11, pm06S, 2021年03月
  (公社)日本薬学会, 日本語
• 吸収トランスポーターの機能解析へのエンテロイドの応用
  島田 美紀子; 佐藤 夕紀; 柏木 仁; 今井 俊吾; 武隈 洋; 菅原 満, 日本薬学会年会要旨集, 141年会, 29V07, am05S, 2021年03月
  (公社)日本薬学会, 日本語
• 医療の質向上、臨床の薬剤師による研究推進を目指した医療ビッグデータの活用 JMDCレセプトデータベースを用いた臨床研究
  武隈 洋; 今井 俊吾; 菅原 満, 日本薬学会年会要旨集, 141年会, S13, 3, 2021年03月
  (公社)日本薬学会, 日本語
• 若手薬学研究者で加速させる感染症トランスレーショナルリサーチ バンコマイシンによる腎機能障害リスクを投与開始前に推定するためのフローチャートの構築 感染症診療におけるデータマイニング手法の活用
  宮井 貴之; 今井 俊吾; 菅原 満, 日本薬学会年会要旨集, 141年会, GS01, 6, 2021年03月
  (公社)日本薬学会, 日本語
• 卵黄レシチンを用いた乳剤化に適した化合物の物理化学的特性
  鳥山 竜也; 佐藤 夕紀; 柏木 仁; 今井 俊吾; 武隈 洋; 菅原 満, 日本薬学会年会要旨集, 141年会, 28V11, pm06S, 2021年03月
  (公社)日本薬学会, 日本語
• 吸収トランスポーターの機能解析へのエンテロイドの応用
  島田 美紀子; 佐藤 夕紀; 柏木 仁; 今井 俊吾; 武隈 洋; 菅原 満, 日本薬学会年会要旨集, 141年会, 29V07, am05S, 2021年03月
  (公社)日本薬学会, 日本語
• 日本におけるコルヒチンと強力なCYP3A4阻害薬/P糖蛋白質阻害薬の併用実態の解明
  今井 俊吾; 百 賢二; 柏木 仁; 宮井 貴之; 菅原 満; 武隈 洋, 日本腎臓病薬物療法学会誌, 9, 特別号, S140, S140, 2020年11月
  日本腎臓病薬物療法学会, 日本語
• ASTによるカルバペネム系抗菌薬および抗MRSA薬のdaily reviewが抗菌薬使用量および患者アウトカムに与える影響
  鏡 圭介; 石黒 信久; 山田 武宏; 新沼 悠介; 武隈 洋; 菅原 満; 小山田 玲子; 渡邊 翼; 早坂 かすみ; 福元 達也; 岩崎 澄央; 瀧 圭介, 日本化学療法学会雑誌, 68, Suppl.A, 333, 333, 2020年09月
  (公社)日本化学療法学会, 日本語
• 院内製造18F-FDGのエンドトキシン試験における反応干渉因子に関する検討
  小林 准; 西嶋 剣一; 大曲 茂生; 山崎 純一; 菊池 康子; 久下 裕司; 武隈 洋; 菅原 満, 日本薬学会年会要旨集, 140年会, 26I, pm21, 2020年03月
  (公社)日本薬学会, 日本語
• BCR-ABLチロシンキナーゼ阻害剤(TKI)の一時的曝露による持続的細胞増殖抑制効果の検討
  青山 剛; 武隈 洋; 今井 俊吾; 柏木 仁; 菅原 満, 日本薬学会年会要旨集, 140年会, 27Y, am01, 2020年03月
  (公社)日本薬学会, 日本語
• 高齢者における肝薬物代謝能低下時の体組成変化
  蕪木 素代子; 吉村 恵理; 宮本 康史; 今井 俊吾; 柏木 仁; 上野 英文; 菅原 満; 武隈 洋, 日本薬学会年会要旨集, 140年会, 27Z, am11S, 2020年03月
  (公社)日本薬学会, 日本語
• シクロプロパン鎖導入環状ペプチド化合物の膜透過性および吸収性の評価
  加藤 七海; 植村 真衣; 松井 耕平; 渡邉 瑞貴; 武隈 洋; 周東 智; 菅原 満, 日本薬学会年会要旨集, 140年会, 27Z, pm13, 2020年03月
  (公社)日本薬学会, 日本語
• 下顎埋伏智歯抜歯術におけるセフカペンピボキシルとアモキシシリンの手術部位感染予防効果の比較
  山神 彰; 小林 正紀; 山田 武宏; 北川 善政; 大廣 洋一; 佐藤 淳; 石黒 信久; 今井 俊吾; 武隈 洋; 菅原 満; 井関 健, 日本薬学会年会要旨集, 140年会, 28Z, am10S, 2020年03月
  (公社)日本薬学会, 日本語
• 院内製造18F-FDGのエンドトキシン試験における反応干渉因子に関する検討
  小林 准; 西嶋 剣一; 大曲 茂生; 山崎 純一; 菊池 康子; 久下 裕司; 武隈 洋; 菅原 満, 日本薬学会年会要旨集, 140年会, 26I, pm21, 2020年03月
  (公社)日本薬学会, 日本語
• BCR-ABLチロシンキナーゼ阻害剤(TKI)の一時的曝露による持続的細胞増殖抑制効果の検討
  青山 剛; 武隈 洋; 今井 俊吾; 柏木 仁; 菅原 満, 日本薬学会年会要旨集, 140年会, 27Y, am01, 2020年03月
  (公社)日本薬学会, 日本語
• 高齢者における肝薬物代謝能低下時の体組成変化
  蕪木 素代子; 吉村 恵理; 宮本 康史; 今井 俊吾; 柏木 仁; 上野 英文; 菅原 満; 武隈 洋, 日本薬学会年会要旨集, 140年会, 27Z, am11S, 2020年03月
  (公社)日本薬学会, 日本語
• シクロプロパン鎖導入環状ペプチド化合物の膜透過性および吸収性の評価
  加藤 七海; 植村 真衣; 松井 耕平; 渡邉 瑞貴; 武隈 洋; 周東 智; 菅原 満, 日本薬学会年会要旨集, 140年会, 27Z, pm13, 2020年03月
  (公社)日本薬学会, 日本語
• 下顎埋伏智歯抜歯術におけるセフカペンピボキシルとアモキシシリンの手術部位感染予防効果の比較
  山神 彰; 小林 正紀; 山田 武宏; 北川 善政; 大廣 洋一; 佐藤 淳; 石黒 信久; 今井 俊吾; 武隈 洋; 菅原 満; 井関 健, 日本薬学会年会要旨集, 140年会, 28Z, am10S, 2020年03月
  (公社)日本薬学会, 日本語
• Performance Status不良患者群におけるナルデメジンの有効性の検証
  加藤信太郎; 小野田紘子; 齋藤佳敬; 今井俊吾; 熊井正貴; 敦賀健吉; 渡辺祐子; 武隈洋; 菅原満; 菅原満, 日本医療薬学会年会講演要旨集(Web), 30, 2020年
• Xenopus laevis oocyteを用いたコレステロールトランスポーターNiemann-Pick C1-Like1(NPC1L1)発現系の構築
  梨本俊亮; 八木沙織; 武田直樹; 野中美玖; 武隈洋; 菅原満; 菅原満; 佐藤夕紀, トランスポーター研究会年会抄録集, 15th, 2020年
• 医療事故の再発防止への提言(第3号)に対する取り組み アドレナリン注射液0.3mg製剤の院内配置
  沖 洋充; 山崎 浩二郎; 熊井 正貴; 古藤 幸子; 本田 秀子; 根岸 淳; 菅原 満; 南須原 康行, 医療の質・安全学会誌, 14, Suppl., 498, 498, 2019年11月
  (一社)医療の質・安全学会, 日本語
• 外来化学療法における検査オーダ項目の事前確認及び提案の有益性
  大聖貴之; 西村紗綾; 山﨑浩二郎; 志賀弘康; 齋藤佳敬; 内山数貴; 坂本達彦; 武隈洋; 菅原満, 第24回 札幌病院薬剤師会会員発表会講演要旨集, 2019年11月
• 牛車腎気丸によるドセタキセル誘発性末梢神経障害の予防効果
  菅野 亮太; 齋藤 佳敬; 山下 啓子; 武隈 洋; 菅原 満, 第24回 札幌病院薬剤師会会員発表会講演要旨集, 2019年11月
• monthlyTC施行時のアプレピタントによる消化器症状予防・軽減効果の評価
  渡辺祐子; 齋藤佳敬; 武隈洋; 菅原満, 第24回 札幌病院薬剤師会会員発表会講演要旨集, 2019年11月
• Performance Status 不良群におけるナルデメジンの有効性の検証．
  加藤信太郎; 小野田紘子; 今井俊吾; 熊井正貴; 武隈洋; 菅原満, 日本緩和医療学会 第2回関西支部学術大会, 142, 7, 755, 760, 2019年10月
  performance status(PS)不良患者におけるナルデメジン(Nal)の有効性を検証した。対象期間にNalが投与された383例のうち解析対象患者は141例であり、そのうちPS良好群は113例、PS不良群は28例であった。投与1日目から7日目までにおけるNalの有効率はPS良好群が71.7%、PS不良群が71.4%であり、有意な差は認められなかった。Nal投与前後の1週間当たりの自発排便回数の変化はPS良好群が2.8回/週の増加、PS不良群が3.6回/週の増加であり、ともに有意に増加していた。治療早期におけるNalの有効率はPS良好群が61.1%、PS不良群が57.1%、治療効果判定期間における有効率は各々60.2%、71.4%であり、ともに有意な差は認められなかった。Nalの効果はPS不良群においてもPS良好群と差が認められないことが明らかとなった。, (公社)日本薬学会, 日本語
• バンコマイシンの初回投与設計ノモグラム(抗菌薬TDMガイドライン2016)の臨床的検証
  田中 寛之; 森岡 悠紀; 武隈 洋; 藤田 崇宏; 遠藤 雅之; 菅原 満, TDM研究, 36, 2, 179, 179, 2019年05月
  (一社)日本TDM学会, 日本語
• 臨床製剤と薬学教育をめぐる現状と課題 薬剤学から臨床製剤を考える
  菅原 満, 日本薬学会年会要旨集, 139年会, 1, 258, 258, 2019年03月
  (公社)日本薬学会, 日本語
• 門脈およびリンパ管への薬物移行を考慮した消化管吸収の評価
  定村 樹; 佐藤 夕紀; 武隈 洋; 菅原 満, 日本薬学会年会要旨集, 139年会, 4, 61, 61, 2019年03月
  (公社)日本薬学会, 日本語
• エンテロイドを用いた薬物排出トランスポーターの機能解析
  小関 千尋; 石川 岳彦; 佐藤 夕紀; 武隈 洋; 菅原 満, 日本薬学会年会要旨集, 139年会, 4, 68, 68, 2019年03月
  (公社)日本薬学会, 日本語
• Xenopus laevis oocytesを用いたNiemann-Pick C1-Like 1(NPC1L1)発現系の最適化
  八木 沙織; 梨本 俊亮; 佐藤 夕紀; 鷲見 正人; 武隈 洋; 菅原 満, 日本薬学会年会要旨集, 139年会, 4, 68, 68, 2019年03月
  (公社)日本薬学会, 日本語
• 薬学実務実習前後における薬学生のコミュニケーション分析 RIAS(Roter method of interaction process analysis)を用いて
  武隈 洋; 森 綾子; 小林 正紀; 山田 勇磨; 佐藤 夕紀; 鳴海 克哉; 古堅 彩子; 菅原 満, 日本薬学会年会要旨集, 139年会, 4, 212, 212, 2019年03月
  (公社)日本薬学会, 日本語
• エンテロイドは薬物排出トランスポーターの機能解析ツールになり得るか
  小関千尋; 石川岳彦; 佐藤夕紀; 武隈 洋; 菅原 満, 第32回北海道薬物作用談話会, 2018年07月
  日本語, 研究発表ペーパー・要旨（全国大会，その他学術会議）
• 消化管活動性がニロチニブの吸収性に及ぼす影響
  佐々木真彩; 青山剛; 佐藤夕紀; 武隈洋; 菅原満, 医療薬学フォーラム講演要旨集, 26th, 249, 2018年06月
  日本語
• テアニンの製剤に含有される成分によるテアニンの消化管吸収増大機構の解明
  佐藤 夕紀; 山口 和奎; 小川 美香子; 武隈 洋; 足立 知基; 櫻田 剛史; 中川 公太; 本城 政稔; 菅原 満, 日本薬剤学会年会講演要旨集, 33年会, 184, 184, 2018年05月
  (公社)日本薬剤学会, 日本語
• オキサ酸を用いた乳剤化によるクルクミンの吸収改善と消化管への影響の評価
  西村悠汰; 八巻義朗; 佐藤夕紀; 武隈 洋; 丸山真吾; 菅原 満, 日本薬学会北海道支部第145 回例会, 2018年05月
  日本語, 研究発表ペーパー・要旨（全国大会，その他学術会議）
• 肝遊離細胞サンドイッチ培養法を用いたカルベジロールの輸送および代謝における光学異性体間相互作用の解析
  伊藤 圭祐; 佐々木 萌子; 佐藤 夕紀; 鷲見 正人; 武隈 洋; 菅原 満, 日本薬学会年会要旨集, 138年会, 4, 51, 51, 2018年03月
  (公社)日本薬学会, 日本語
• オキサ酸を乳化剤として用いたCoenzyme Q10乳剤の性質とその消化管吸収性
  八巻 義朗; 西村 悠汰; 横山 さや香; 佐藤 夕紀; 武隈 洋; 丸山 真吾; 菅原 満, 日本薬学会年会要旨集, 138年会, 4, 86, 86, 2018年03月
  (公社)日本薬学会, 日本語
• 後期高齢者における腎機能推定式の乖離とその補正法の確立
  蕪木 素代子; 吉村 恵理; 小嶋 希望; 上野 英文; 菅原 満; 武隈 洋, 日本薬学会年会要旨集, 138年会, 4, 174, 174, 2018年03月
  (公社)日本薬学会, 日本語
• シクロプロパンの構造特性に基づく膜透過性環状ペプチドの設計と合成
  植村 真衣; 加藤 七海; 松井 耕平; 桑原 智希; 渡邉 瑞貴; 福田 隼; 武隈 洋; 菅原 満; 周東 智, 日本薬学会年会要旨集, 138年会, 2, 116, 116, 2018年03月
  (公社)日本薬学会, 日本語
• 肝遊離細胞サンドイッチ培養法を用いたカルベジロールの輸送および代謝における光学異性体間相互作用の解析
  伊藤圭祐; 佐々木萌子; 佐藤夕紀; 鷲見正人; 武隈洋; 菅原満, 日本薬学会年会要旨集(CD-ROM), 138th, 4, ROMBUNNO.27C‐am03, 51, 2018年03月
  (公社)日本薬学会, 日本語
• 小腸オルガノイドを利用した排出系トランスポータの基質関与探索ツールの構築
  佐藤夕紀; 中村公則; 小関千尋; 石川岳彦; 島田美紀子; 横井友樹; 本間直幸; 森山隆則; 菅原満, トランスポーター研究会年会抄録集, 13th, 2018年
• 新しい錠剤包装ESOP(easy seal open pack)の使用感とその改良に向けた調査研究
  佐藤夕紀; 梨本俊亮; 武隈洋; 平野卓哉; 野田敏宏; 須田範行; 井関健; 盛本修司; 菅原満, 日本医療薬学会年会講演要旨集(Web), 28, 2018年
• 高齢者における腎機能推定式の補正法の確立
  蕪木素代子; 武隈 洋; 吉村恵理; 小嶋希望; 上野博文; 菅原 満, 第31回北海道TDM研究会研究発表会, 2017年11月
  日本語, 研究発表ペーパー・要旨（全国大会，その他学術会議）
• ヒトK562細胞に対するBCR-ABLチロシンキナーゼインヒビター(TKIs)Washout後持続的細胞増殖抑制効果の検証
  青山 剛; 武隈 洋; 佐藤夕紀; 鷲見正人; 菅原 満, 第31回北海道TDM研究会研究発表会, 2017年11月
  日本語, 研究発表ペーパー・要旨（全国大会，その他学術会議）
• 脳梗塞を合併したレビー小体型認知症に対してリバスチグミンからの切り替えで低用量長期間投与ガランタミンが有効だった1症例
  濱野 宏美; 土井 正剛; 武隈 洋; 菅原 満; 一木 崇宏, 日本薬剤師会学術大会講演要旨集, 50回, [P, 418], 2017年10月
  (公社)日本薬剤師会, 日本語
• 【臓器摘出・切除の晩期合併症 手術歴のある患者で考慮すべきポイント総まとめ】臓器摘出・切除後の薬物動態!どこに注意すべきか?! 胃腸摘出・切除術後の薬物動態学的注意点
  菅原 満, 薬局, 68, 9, 3026, 3031, 2017年08月
  (株)南山堂, 日本語
• ルテインの製剤化による消化管吸収改善
  定村樹; 佐藤夕紀; 梨本俊亮; 鷲見正人; 武隈洋; 菅原満, 日本薬学会北海道支部第144 回例会, 2017年05月
  日本語, 研究発表ペーパー・要旨（全国大会，その他学術会議）
• 実務実習前後における薬学生のRIASによるコミュニケーション分析
  森 綾子; 武隈 洋; 小林正紀; 山田勇磨; 佐藤夕紀; 鳴海克哉; 古堅彩子; 菅原 満, 総合技術研究会2017東京大学, 2017年03月08日
  日本語, 研究発表ペーパー・要旨（全国大会，その他学術会議）
• オキサ酸を乳化剤として用いたCoenzyme Q10の乳剤化と消化管吸収改善
  横山 さや香; 宮下 真美; 佐藤 夕紀; 武隈 洋; 丸山 真吾; 菅原 満, 日本薬学会年会要旨集, 137年会, 4, 67, 67, 2017年03月
  (公社)日本薬学会, 日本語
• テアニン錠剤(速放錠・徐放錠)の溶出性および吸収性の変動要因
  山口 和奎; 佐藤 夕紀; 武隈 洋; 櫻田 剛史; 中川 公太; 本城 政稔; 菅原 満, 日本薬学会年会要旨集, 137年会, 4, 67, 67, 2017年03月
  (公社)日本薬学会, 日本語, 研究発表ペーパー・要旨（全国大会，その他学術会議）
• シクロプロパンの構造特性に基づく環状ペプチド膜透過性の飛躍的向上
  植村 真衣; 松井 耕平; 桑原 智希; 渡邉 瑞貴; 福田 隼; 加藤 七海; 武隈 洋; 菅原 満; 周東 智, 日本薬学会年会要旨集, 137年会, 2, 120, 120, 2017年03月
  (公社)日本薬学会, 日本語
• 卵黄レシチンを用いた自己乳化製剤によるクルクミンの消化管吸収改善
  宮下 真美; 横山 さや香; 佐藤 夕紀; 武隈 洋; 吉田 英人; 菅原 満, 日本薬学会年会要旨集, 137年会, 4, 67, 67, 2017年03月
  (公社)日本薬学会, 日本語
• 肝遊離細胞サンドイッチ培養法を用いたカルベジロールのグルクロン酸抱合反応に及ぼす光学異性体相互作用の評価
  佐々木 萌子; 武隈 洋; 佐藤 夕紀; 鷲見 正人; 菅原 満, 日本薬学会年会要旨集, 137年会, 4, 63, 63, 2017年03月
  (公社)日本薬学会, 日本語
• 慢性骨髄性白血病治療薬ダサチニブの消化管吸収に及ぼす消化管内pHおよびトランスポーターの影響
  助畑 歩; 武隈 洋; 鷲見 正人; 佐藤 夕紀; 菅原 満, 日本薬学会年会要旨集, 137年会, 4, 66, 66, 2017年03月
  (公社)日本薬学会, 日本語
• ダサチニブの週2回投与で分子遺伝学寛解に達成した一症例
  中村雄亮; 齊藤嘉津彦; 青山剛; 武隈 洋; 菅原 満, 第30回北海道TDM研究会研究発表会, 2016年11月26日
  日本語, 研究発表ペーパー・要旨（全国大会，その他学術会議）
• piperacillin/tazobactamとcefepimeの急性腎障害発症に関する後ろ向き観察 比較研究
  門村将太; 佐藤夕紀; 鷲見正人; 武隈 洋; 菅原 満; 福田由布子; 井藤達也, 第30回北海道TDM研究会研究発表会, 2016年11月26日
  日本語, 研究発表ペーパー・要旨（全国大会，その他学術会議）
• 日本循環器学会/日本TDM学会合同ガイドライン(2013-2014年度合同研究班報告)【ダイジェスト版】 2015年版 循環器薬の薬物血中濃度モニタリングに関するガイドライン
  青沼 和隆; 志賀 剛; 新 博次; 池田 隆徳; 市田 蕗子; 上野 和行; 越前 宏俊; 栄田 敏之; 清水 渉; 菅原 満; 土下 喜正; 土岐 浩介; 戸塚 恭一; 萩原 誠久; 長谷川 純一; 林 秀晴; 平尾 見三; 前田 頼伸; 松本 直樹; 渡邉 英一; 笠井 英史; 篠原 徳子; 杉山 篤; 鈴木 敦; 住友 直方; 関口 幸夫; 高橋 尚彦; 野上 昭彦; 橋口 正行; 平田 純生; 松本 宜明; 湯川 栄二; 伊藤 宏; 井上 博; 大江 透; 篠崎 公一; 田中 一彦; 本間 真人; 堀江 稔; 三浦 崇則; 日本循環器学会; 日本TDM学会, TDM研究, 33, 3, 123, 157, 2016年09月
  (一社)日本TDM学会, 日本語
• 日本循環器学会/日本TDM学会合同ガイドライン(2013-2014年度合同研究班報告)【ダイジェスト版】 2015年版 循環器薬の薬物血中濃度モニタリングに関するガイドライン
  青沼 和隆; 志賀 剛; 新 博次; 池田 隆徳; 市田 蕗子; 上野 和行; 越前 宏俊; 栄田 敏之; 清水 渉; 菅原 満; 土下 喜正; 土岐 浩介; 戸塚 恭一; 萩原 誠久; 長谷川 純一; 林 秀晴; 平尾 見三; 前田 頼伸; 松本 直樹; 渡邉 英一; 笠井 英史; 篠原 徳子; 杉山 篤; 鈴木 敦; 住友 直方; 関口 幸夫; 高橋 尚彦; 野上 昭彦; 橋口 正行; 平田 純生; 松本 宜明; 湯川 栄二; 伊藤 宏; 井上 博; 大江 透; 篠崎 公一; 田中 一彦; 本間 真人; 堀江 稔; 三浦 崇則; 日本循環器学会; 日本TDM学会, TDM研究, 33, 3, 123, 157, 2016年09月
  (一社)日本TDM学会, 日本語
• パゾパニブの投与量と推定血中トラフ濃度の関連性の評価
  田中 寛之; 平賀 博明; 武隈 洋; 三浪 圭太; 原林 透; 永森 聡; 遠藤 雅之; 菅原 満, 日本整形外科学会雑誌, 90, 6, S1214, S1214, 2016年06月
  (公社)日本整形外科学会, 日本語
• コレステロールを含有する乳剤によるコエンザイムQ10の吸収改善
  佐藤 夕紀; 八巻 義朗; 竹川 悠人; 武隈 洋; 菅原 満, 日本薬剤学会年会講演要旨集, 31年会, 186, 186, 2016年05月
  (公社)日本薬剤学会, 日本語
• イマチニブのTDMにより副作用軽減と治療継続が可能となった二重癌の一症例
  元茂 拓法; 田中 寛之; 森岡 悠紀; 武隈 洋; 遠藤 雅之; 菅原 満; 黒澤 光俊, TDM研究, 33, 2, 194, 194, 2016年05月
  (一社)日本TDM学会, 日本語, 研究発表ペーパー・要旨（全国大会，その他学術会議）
• 先導的薬剤師養成に向けた実践的アドバンスト教育プログラムの共同開発 国立大学における実践的医療薬学教育プログラム及びチーム医療・地域医療プログラムの開発
  小澤 光一郎; 中嶋 幹郎; 菅原 満; 関根 祐子, 日本薬学会年会要旨集, 136年会, 1, 213, 213, 2016年03月
  (公社)日本薬学会, 日本語
• 脂質異常症治療薬エゼチミブによるα-トコフェロールの消化管吸収抑制とその回避策
  梨本 俊亮; 佐藤 夕紀; 鷲見 正人; 武隈 洋; 菅原 満, 日本薬学会年会要旨集, 136年会, 4, 55, 55, 2016年03月
  (公社)日本薬学会, 日本語, 研究発表ペーパー・要旨（全国大会，その他学術会議）
• 小腸コレステロールトランスポーターNPC1L1 (Niemann-Pick C1-Like 1)を介したCoenzyme Q10の消化管吸収改善
  佐藤夕紀; 八巻義朗; 横山さや香; 竹川悠人; 鷲見正人; 武隈洋; 菅原満, 第13回日本コエンザイムQ協会研究会, 2016年02月02日
  日本語, 研究発表ペーパー・要旨（全国大会，その他学術会議）
• 日本循環器学会/日本TDM学会合同ガイドライン(2013-2014年度合同研究班報告) 2015年版 循環器薬の薬物血中濃度モニタリングに関するガイドライン
  青沼 和隆; 志賀 剛; 新 博次; 池田 隆徳; 市田 蕗子; 上野 和行; 越前 宏俊; 栄田 敏之; 清水 渉; 菅原 満; 土下 喜正; 土岐 浩介; 戸塚 恭一; 萩原 誠久; 長谷川 純一; 林 秀晴; 平尾 見三; 前田 頼伸; 松本 直樹; 渡邉 英一; 笠井 英史; 篠原 徳子; 杉山 篤; 鈴木 敦; 住友 直方; 関口 幸夫; 高橋 尚彦; 野上 昭彦; 橋口 正行; 平田 純生; 松本 宜明; 湯川 栄二; 伊藤 宏; 井上 博; 大江 透; 篠崎 公一; 田中 一彦; 本間 真人; 堀江 稔; 三浦 崇則; 日本循環器学会, 日本TDM学会, 循環器病ガイドシリーズ, 2015, 循環器薬の薬物血中濃度モニタリングに関するガイドライン, 3, 54, 2016年02月
  (一社)日本循環器学会, 日本語
• 日本循環器学会/日本TDM学会合同ガイドライン(2013-2014年度合同研究班報告)【ダイジェスト版】2015年版 循環器薬の薬物血中濃度モニタリングに関するガイドライン
  青沼 和隆; 志賀 剛; 新 博次; 池田 隆徳; 市田 蕗子; 上野 和行; 越前 宏俊; 栄田 敏之; 清水 渉; 菅原 満; 土下 喜正; 土岐 浩介; 戸塚 恭一; 萩原 誠久; 長谷川 純一; 林 秀晴; 平尾 見三; 前田 頼伸; 松本 直樹; 渡邉 英一; 笠井 英史; 篠原 徳子; 杉山 篤; 鈴木 敦; 住友 直方; 関口 幸夫; 高橋 尚彦; 野上 昭彦; 橋口 正行; 平田 純生; 松本 宜明; 湯川 栄二; 伊藤 宏; 井上 博; 大江 透; 篠崎 公一; 田中 一彦; 本間 真人; 堀江 稔; 三浦 崇則; 日本循環器学会, 日本TDM学会, 循環器病ガイドシリーズ, 2015, 循環器薬の薬物血中濃度モニタリングに関するガイドライン, 55, 89, 2016年02月
  (一社)日本循環器学会, 日本語
• α-トコフェロールの吸収動態に及ぼすエゼチミブの影響
  佐藤夕紀; 梨本俊亮; 武隈洋; 菅原満, 第27回ビタミンE研究会, 2016年01月08日
  日本語, 研究発表ペーパー・要旨（全国大会，その他学術会議）
• クロスポビドンを含む錠剤の製剤処方による溶出性の違い
  武隈洋; 石坂悠; 佐藤夕紀; 鷲見正人; 菅原満, 日本医療薬学会年会講演要旨集(Web), 26, 2016年
• 薬剤師会と大学の連携が保険調剤薬局での無菌調剤業務の推進に及ぼす効果
  柴山 良彦; 竹内 伸仁; 菅原 満; 井関 健, 日本薬剤師会学術大会講演要旨集, 48回, 421, 421, 2015年11月
  (公社)日本薬剤師会, 日本語
• 可溶性ローヤルゼリー蛋白質MRJP1の腸管透過性評価と吸収成分の生理機能の解析
  本間 直幸; 山日 千明; 面 すみれ; 佐藤 夕紀; 菅原 満; 森山 隆則, 日本未病システム学会学術総会抄録集, 22回, 119, 119, 2015年09月
  (一社)日本未病学会, 日本語
• テアニン製剤(速放錠・徐放錠)を用いた溶出性および吸収性の検討
  山口和奎; 佐藤夕紀; 武隈 洋; 中川公太; 大野智弘; 本城政稔; 菅原 満, 第29回北海道薬物作用談話会, 2015年08月09日
  日本語, 研究発表ペーパー・要旨（全国大会，その他学術会議）
• アレルギー性咳嗽患者に対する抗アレルギー薬の適用と治療効果に関する疫学研究
  石坂 悠; 武隈 洋; 平野 卓哉; 野田 敏宏; 熊井 恵美; 菅原 満, 日本医薬品情報学会総会・学術大会講演要旨集, 18回, 73, 73, 2015年06月
  (一社)日本医薬品情報学会, 日本語
• 造血幹細胞移植時の抗がん剤併用療法における投与量および薬物曝露順序の最適化
  武隈 洋; 田澤 佑基; 臼窪 一平; 高田 一輝; 柴山 良彦; 重松 明男; 笠師 久美子; 豊嶋 崇徳; 井関 健; 菅原 満, 臨床薬理の進歩, 36, 142, 152, 2015年06月
  造血幹細胞移植時の抗がん剤併用療法における投与量および薬物曝露順序の最適化について検討した。成人急性リンパ性白血病(ALL)およびその類縁疾患に対し、中等量エトポシド(VP-16)/シクロホスファミド(CY)/全身放射線照射(TBI)前処置を用いた同種造血幹細胞移植を施行した21例を対象とした。VP-16の薬物動態は個体差が大きく、最高血中濃度(Cmax)とサイトメガロウイルス(CMV)感染との関建性が示唆された。ROC曲線解析から、Cmaxのカットオフ値は80.8μg/mLと算出した。また、K-562/P-gp細胞への低濃度4-ヒドロペルオキシシクロホスファミドの事前曝露によりVP-16の感受性が高いS期の細胞が増大し、VP-16の殺細胞効果が増強することが示唆された。, (公財)臨床薬理研究振興財団, 日本語
• TDMへの応用を目指した3種のチロシンキナーゼ阻害剤の血中濃度測定法の検証
  助畑 歩; 武隈 洋; 佐藤夕紀; 鷲見正人; 田中寛之; 遠藤 雅之; 菅原 満, 日本薬学会北海道支部第142回例会（札幌）, 2015年05月16日
  日本語, 研究発表ペーパー・要旨（全国大会，その他学術会議）
• 実務実習をより良くするために(12)実務実習を効果的に実施するための事前学習と実習後のアドバンストプログラムの開発
  菅原 満; 武隈 洋; 柴山 良彦, 医薬ジャーナル, 51, 5, 145, 149, 2015年05月
  医薬ジャーナル社, 日本語
• 実務実習をより良くするために 実務実習を効果的に実施するための事前学習と実習後のアドバンストプログラムの開発
  菅原 満; 武隈 洋; 柴山 良彦; 井関 健, 医薬ジャーナル, 51, 5, 1381, 1385, 2015年05月
  (株)医薬ジャーナル社, 日本語
• 骨肉腫MAP療法における2-compartment modelによる非タンパク結合Platinum推定CmaxとCDDP腎毒性の予測
  田中 寛之; 森岡 悠紀; 深井 雄太; 武隈 洋; 川口 啓之; 平賀 博明; 菅原 満; 遠藤 雅之, TDM研究, 32, 2, 151, 151, 2015年05月
  (一社)日本TDM学会, 日本語
• エゼチミブ(ゼチーア)が機能性食品成分α-トコフェロールの吸収に与える影響
  梨本 俊亮; 佐藤 夕紀; 鷲見 正人; 武隈 洋; 菅原 満, 日本薬剤学会年会講演要旨集, 30年会, 131, 131, 2015年05月
  (公社)日本薬剤学会, 日本語
• 乳剤化によるコエンザイムQ10の消化管吸収改善
  佐藤 夕紀; 竹川 悠人; 能登 数馬; 武隈 洋; 菅原 満, 日本薬剤学会年会講演要旨集, 30年会, 136, 136, 2015年05月
  (公社)日本薬剤学会, 日本語
• 耳鼻咽喉科領域におけるアレルギー性咳嗽患者に対する抗アレルギー薬の適用と治療効果
  武隈 洋; 石坂 悠; 平野 卓哉; 野田 敏宏; 熊井 惠美; 菅原 満, アレルギー, 64, 3-4, 576, 576, 2015年04月
  (一社)日本アレルギー学会, 日本語
• 先導的薬剤師養成に向けた実践的アドバンスト教育プログラムの共同開発 国立大学における「実践的医療薬学教育プログラム」および「チーム医療・地域医療プログラム」の開発
  小澤 光一郎; 中嶋 幹郎; 菅原 満; 関根 祐子, 日本薬学会年会要旨集, 135年会, 1, 231, 231, 2015年03月
  (公社)日本薬学会, 日本語
• Niemann-Pick C1 Like-1(NPC1L1)を標的とした乳剤化による難吸収性物質の吸収改善
  竹川 悠人; 佐藤 夕紀; 鷲見 正人; 武隈 洋; 菅原 満, 日本薬学会年会要旨集, 135年会, 4, 76, 76, 2015年03月
  (公社)日本薬学会, 日本語
• 2種の血中テイコプラニン濃度測定キット間の測定値の相関性
  田中 寛之; 山田 武宏; 戸田 貴大; 小林 道也; 菅原 満; 猪爪 信夫, 日本化学療法学会雑誌, 63, 2, 254, 254, 2015年03月
  (公社)日本化学療法学会, 日本語
• 【妊婦の薬物治療管理 リスクと不安を最小にするための基礎と実践】妊娠による生理変化と薬物動態 吸収過程
  菅原 満, 薬局, 66, 1, 34, 35, 2015年01月
  (株)南山堂, 日本語
• ローヤルゼリー機能性成分の腸管透過性評価と吸収成分の生理機能の解析
  本間 直幸; 山日 千明; 面 すみれ; 佐藤 夕紀; 菅原 満; 村田 清志; 山口 喜久二; 森山 隆則, 機能性食品と薬理栄養, 8, 5, 436, 436, 2014年12月
  (株)インフォノーツパブリッシング, 日本語, 研究発表ペーパー・要旨（全国大会，その他学術会議）
• UDP-グルクロン酸転移酵素の生細胞と細胞破砕液での代謝活性の比較
  池上由麻; 佐藤夕紀; 鷲見正人; 武隈洋; 菅原満, 第28回北海道TDM研究会研究発表会（札幌）, 2014年11月29日
  研究発表ペーパー・要旨（全国大会，その他学術会議）
• 28-O4PM-10 アレルギー性咳嗽治療に用いられる抗アレルギー薬の使用実態 : 内科と耳鼻咽喉科の比較(薬物療法(その他)3,一般演題(口頭),新時代を拓く医療薬学フロンティア)
  石坂 悠; 武隈 洋; 吉村 恵理; 吉田 憲史; 小嶋 希望; 上野 英文; 菅原 満, 日本医療薬学会年会講演要旨集, 24, 244, 244, 2014年08月25日
  日本医療薬学会, 日本語
• UGT1A1 p.P364L変異体および UGT2B7 p.P366L変異体の光学異性体認識性
  依田めぐみ; 佐藤夕紀; 鷲見正人; 武隈洋; 菅原満, 第28回北海道薬物作用談話会（札幌）, 2014年07月19日
• 抗ウイルス薬 リバビリンのトランスポーターを介した消化管吸収の解析
  早風郁美; 佐藤夕紀; 鷲見正人; 武隈洋; 菅原満, 第28回北海道薬物作用談話会（札幌）, 2014年07月19日
• 中等量エトポシド(VP‐16)/シクロホスファミド(CY)/全身放射線(TBI)前処置レジメンにおけるVP‐16のPK/PD解析による投与量の最適化に関する検討
  田澤佑基; 武隈洋; 佐藤夕紀; 鷲見正人; 笠師久美子; 井関健; 菅原満, 医療薬学フォーラム講演要旨集, 22nd, 242, 2014年06月
  日本語
• 細胞周期変化がエトポシド(VP-16)の殺細胞効果に与える影響
  田澤佑基; 吉岡美咲; 武隈 洋; 佐藤夕紀; 鷲見 正人; 菅原 満, 日本薬学会北海道支部第141回例会（札幌）, 2014年05月24日
• 臨床応用を目指したHPLC-UV法による血中imatinib定量法の確立
  田中 寛之; 木村 雄太; 川口 啓之; 武隈 洋; 高崎 雅彦; 菅原 満, TDM研究, 31, 3, 169, 169, 2014年05月
  (一社)日本TDM学会, 日本語
• 先導的薬剤師養成に向けた実践的アドバンスト教育プログラムの共同開発 実践的医療薬学教育プログラム及びチーム医療・地域医療プログラム
  菅原 満, 日本薬学会年会要旨集, 134年会, 1, 150, 150, 2014年03月
  (公社)日本薬学会, 日本語
• Coenzyme Q10の消化管吸収改善
  佐藤夕紀; 能登数馬; 竹川悠人; 鷲見正人; 武隈 洋; 菅原 満, 特定非営利活動法人 日本コエンザイムQ 協会 第11回研究会プログラム（東京）, 2014年01月28日
• Caco-2細胞におけるNPC1L1を介したコレステロール輸送の特徴
  阿部沙也華; 佐藤夕紀; 鷲見 正人; 武隈 洋; 菅原 満, 第27回北海道TDM研究会研究発表会（札幌）, 2013年11月30日
• 薬物曝露による細胞周期変化が細胞周期依存性の抗癌剤の作用に与える影響
  吉岡美咲; 田澤佑基; 佐藤夕紀; 鷲見 正人; 武隈 洋; 菅原 満, 第27回北海道TDM研究会研究発表会（札幌）, 2013年11月30日
• テアニンの体内動態および吸収機構の解明
  亀田佑生; 佐藤夕紀; 鷲見 正人; 武隈 洋; 菅原 満, 第27回北海道TDM研究会研究発表会（札幌）, 2013年11月30日
• 土-10-O14-09 乳剤化による難吸収性物質の吸収改善 : コレステロール輸送担体NPC1L1の利用(薬物動態,一般演題(口頭)14,再興、再考、創ろう最高の医療の未来)
  竹川 悠人; 佐藤 夕紀; 鷲見 正人; 武隈 洋; 菅原 満, 日本医療薬学会年会講演要旨集, 23, 219, 219, 2013年08月28日
  日本医療薬学会, 日本語
• 抗アレルギー薬の使用実態調査およびそのアレルギー性咳嗽への適用に関する疫学的研究
  武隈 洋; 高地 里佳; 野田 敏宏; 平野 卓哉; 菅原 満, 日本医薬品情報学会総会・学術大会講演要旨集, 16回, 132, 132, 2013年08月
  (一社)日本医薬品情報学会, 日本語
• 難吸収性ポリフェノールの乳剤化によるバイオアベイラビリティ改善
  星山博俊; 佐藤夕紀; 鷲見正人; 武隈洋; 菅原満, 第27回北海道薬物作用談話会（江別）, 2013年07月20日
• Niemann-pick C1 Like-1 (NPC1L1) を介した難吸収性物質の吸収改善へのアプローチ
  竹川悠人; 佐藤夕紀; 鷲見 正人; 武隈 洋; 菅原 満, 日本薬学会北海道支部第140回例会（札幌）, 2013年05月18日
• 熱力学的手法を用いた多剤排出輸送担体の基質探索の検討
  森岡悠紀; 鷲見正人; 佐藤夕紀; 武隈洋; 菅原満, 日本薬学会北海道支部第140回例会（札幌）, 2013年05月18日
• hOATPs/rOatps を介するミコフェノール酸グルクロナイドの輸送特性の種差
  坂本達彦; 鷲見正人; 佐藤夕紀; 武隈洋; 菅原満, 日本薬学会北海道支部第140回例会（札幌）, 2013年05月
• 黄斑色素成分ルテインのヒト網膜上皮細胞内への取り込み機構の解明
  佐藤 夕紀; 近藤 有; 武隈 洋; 菅原 満, 日本薬剤学会年会講演要旨集, 28年会, 272, 272, 2013年04月
  (公社)日本薬剤学会, 日本語
• 国立大学博士課程における「チーム医療・地域医療モデル教育プログラム」の開発
  関根 祐子; 菅原 満; 小澤 光一郎; 中嶋 幹郎, 日本薬学会年会要旨集, 133年会, 1, 270, 270, 2013年03月
  (公社)日本薬学会, 日本語
• ヌクレオシドトランスポーターの基質輸送に及ぼすエトポシドの影響
  高田 一輝; 田澤 佑基; 佐藤 夕紀; 鷲見 正人; 武隈 洋; 菅原 満, 日本薬学会年会要旨集, 133年会, 4, 78, 78, 2013年03月
  (公社)日本薬学会, 日本語
• 一包化調剤時におけるスタチン製剤の保存安定性
  高地 里佳; 石坂 悠; 佐藤 夕紀; 鷲見 正人; 武隈 洋; 菅原 満, 日本薬学会年会要旨集, 133年会, 4, 153, 153, 2013年03月
  (公社)日本薬学会, 日本語
• シタラビンの白血病細胞内移行に対するエトポシドの影響
  高田一輝; 田澤佑基; 佐藤夕紀; 鷲見正人; 武隈洋; 菅原満, 第26回北海道TDM研究会研究発表会（札幌）, 2012年12月
• テアニンの脳移行に関与するトランスポーター
  川守田渉; 亀田佑生; 佐藤夕紀; 鷲見正人; 武隈 洋; 菅原 満, 第26回北海道薬物作用談話会（札幌）, 2012年07月
• 粒子径に着目した CoQ10 の乳剤化による吸収改善
  能登数馬; 佐藤夕紀; 武隈 洋; 菅原 満, 日本薬学会北海道支部第138回例会（札幌）, 2012年06月
• 先導的薬剤師養成に向けた実践的アドバンスト教育プログラムの共同開発 国立大学における「実践的医療薬学教育プログラム」の開発
  中嶋 幹郎; 菅原 満; 関根 祐子; 小澤 光一郎, 日本薬学会年会要旨集, 132年会, 1, 190, 190, 2012年03月
  (公社)日本薬学会, 日本語
• P糖蛋白質(P-gp)発現白血病由来細胞を用いたエトポシド(VP-16)/シクロホスファミド(CY)曝露順序の殺細胞効果に及ぼす影響
  臼窪 一平; 田澤 佑基; 佐藤 夕紀; 鷲見 正人; 柴山 良彦; 武隈 洋; 菅原 満, 日本薬学会年会要旨集, 132年会, 4, 200, 200, 2012年03月
  (公社)日本薬学会, 日本語
• 中等量VP‐16/シクロホスファミド(CY)/全身放射線(TBI)前処置レジメンにおけるVP‐16のPK/PD解析
  田澤佑基; 松村一仙; 佐藤夕紀; 鷲見正人; 武隈洋; 重松明男; 笠師久美子; 山田武宏; 田中淳司; 橋野聡; 井関健; 今村雅寛; 菅原満, 日本造血細胞移植学会総会プログラム・抄録集, 34th, 224, 2012年02月01日
  日本語
• エトポシド/シクロホスファミド併用の殺細胞効果に及ぼす曝露順序の影響 ～白血病由来 K-562 細胞及び P-糖タンパク質発現株を用いた検討～
  田澤佑基; 臼窪一平; 佐藤夕紀; 鷲見正人; 武隈 洋; 菅原 満, 日本薬学会北海道支部第137回例会（札幌）, 2011年12月
• 抗酸化作用を有する食品成分ルテインの乳化による消化管吸収改善
  佐藤 夕紀; 武隈 洋; 井関 健; 菅原 満, 機能性食品と薬理栄養, 7, 1, 89, 89, 2011年12月
  (株)インフォノーツパブリッシング, 日本語
• オピオイドによる難治性の嘔気とめまいに対しH₁受容体拮抗薬とペロスピロンの併用が有効であった症例
  長田貴之; 柴山良彦; 熊井正貴; 山田武宏; 笠師久美子; 菅原満; 井関健, 医療薬学フォーラム講演要旨集, 19th, 186, 2011年07月
  日本語
• 【授乳期の服薬相談 基礎と臨床からのアプローチ】乳児と成人との薬物動態の違い 吸収過程
  菅原 満, 薬局, 62, 7, 2777, 2780, 2011年06月
  (株)南山堂, 日本語
• 同種造血幹細胞移植時における中等量エトポシド(VP-16)/シクロホスファミド(CY)/全身放射線(TBI)前処置レジメンの検討 VP-16のPK/PD解析および培養細胞系を用いたVP-16/CY曝露順序の検討
  田澤 佑基; 松村 一仙; 佐藤 夕紀; 鷲見 正人; 武隈 洋; 重松 明男; 笠師 久美子; 山田 武宏; 井関 健; 今村 雅寛; 菅原 満, TDM研究, 28, 3, s203, s203, 2011年06月
  (一社)日本TDM学会, 日本語
• 薬物治療の最適化 アレルギー疾患治療薬の使用適正化を目指したTDM
  菅原 満, アレルギー, 60, 3-4, 402, 402, 2011年04月
  (一社)日本アレルギー学会, 日本語
• 先導的薬剤師養成に向けた実践的アドバンスト教育プログラムの共同開発 国立大学における「実践的医療薬学教育プログラム」の現状
  小澤 光一郎; 菅原 満; 関根 祐子; 中嶋 幹郎, 日本薬学会年会要旨集, 131年会, 1, 156, 156, 2011年03月
  (公社)日本薬学会, 日本語
• ルテインの乳化による消化管吸収改善
  佐藤 夕紀; 鈴木 里彩; 武隈 洋; 井関 健; 菅原 満, 日本薬学会年会要旨集, 131年会, 4, 165, 165, 2011年03月
  (公社)日本薬学会, 日本語
• ソラフェニブおよびスニチニブのMRP2(ABCC2)に対する基質特異性
  柴山 良彦; 中野 公; 前田 弘志; 田口 美雪; 池田 龍二; 菅原 満; 井関 健; 武田 泰夫; 山田 勝士, 日本薬学会年会要旨集, 131年会, 4, 288, 288, 2011年03月
  (公社)日本薬学会, 日本語
• 乗り物酔い様の浮遊感を伴うオピオイドの難治性嘔気にペロスピロンが有効であった症例
  長田 貴之; 熊井 正貴; 柴山 良彦; 山田 武宏; 笠師 久美子; 菅原 満; 井関 健, 日本薬学会年会要旨集, 131年会, 4, 293, 293, 2011年03月
  (公社)日本薬学会, 日本語
• テアニンの消化管吸収に関与するトランスポーター
  川守田 渉; 堀田 雄也; 佐藤 夕紀; 鷲見 正人; 武隈 洋; 菅原 満, 日本薬学会年会要旨集, 131年会, 4, 165, 165, 2011年03月
  (公社)日本薬学会, 日本語
• 白血病由来細胞を用いたエトポシド(VP-16)/シクロホスファミド(CY)曝露順序の殺細胞効果への影響
  田澤 佑基; 松村 一仙; 笠師 久美子; 佐藤 夕紀; 鷲見 正人; 武隈 洋; 井関 健; 菅原 満, 日本薬学会年会要旨集, 131年会, 4, 178, 178, 2011年03月
  (公社)日本薬学会, 日本語
• 乳児と成人との薬物動態の違い-① 吸収過程
  菅原 満, 薬局別冊, 62, 7, 55, 58, 2011年
• 医療薬学ブラッシュアップ講座 薬物の体内動態に関する最近の話題-4 腎機能と薬物動態
  菅原 満, 道薬誌, 28, 2, 7, 11, 2011年
• 医療薬学ブラッシュアップ講座 薬物の体内動態に関する最近の話題-3 経口バイオアベイラビリティ
  菅原 満, 道薬誌, 28, 1, 32, 37, 2011年
• マイクロRNA126、210が抗がん薬感受性に及ぼす影響
  柴山 良彦; 田口 深雪; 池田 龍二; 古川 龍彦; 菅原 満; 井関 健; 武田 泰生; 山田 勝士, 臨床薬理, 41, Suppl., S254, S254, 2010年11月
  (一社)日本臨床薬理学会, 日本語
• 薬剤師業務・研究支援ツールとしてのTDM
  菅原 満, TDM研究, 27, 3, s56, s56, 2010年06月
  (一社)日本TDM学会, 日本語
• TDM実践シリーズ プレアボイド報告
  小林 道也; 唯野 貢司; 菅原 満; 野村 憲和; 北海道TDM研究会, 薬事新報, 2628, 2628, 9, 12, 2010年05月
  (株)薬事新報社, 日本語
• A Novel Solution for Rat Liver Preservation Composed of Heavy Water and Swan Buffer; a Pilot Study
  Daisuke Fukumori; Moto Fukai; Kenji Wakayama; Kenichiro Yamashita; Shinya Ueki; Mitsuru Sugawara; Sanae Haga; Hiroyuki Furukawa; Michitaka Ozaki; Satoru Todo, AMERICAN JOURNAL OF TRANSPLANTATION, 10, 496, 497, 2010年04月
  英語, 研究発表ペーパー・要旨（国際会議）
• Heavy Water (D2O) Universally Ameliorates Cold Preservation Injury: Precise Analyses of Cytoprotective Mechanisms In Vitro
  Moto Fukai; Kenji Wakayama; Daisuke Fukumori; Kenichiro Yamashita; Mitsuru Sugawara; Sanae Haga; Ueki Gentaro Hirokata; Hiroyuki Furukawa; Michitaka Ozaki; Satoru Todo, AMERICAN JOURNAL OF TRANSPLANTATION, 10, 492, 493, 2010年04月
  英語, 研究発表ペーパー・要旨（国際会議）
• TDM実践シリーズ 免疫抑制剤ミコフェノール酸モフェチル
  武隈 洋; 菅原 満; 小林 道也; 唯野 貢司; 野村 憲和; 北海道TDM研究会, 薬事新報, 2623, 345, 350, 2010年04月
  (株)薬事新報社, 日本語
• テアニンの消化管吸収に関与するトランスポーター
  堀田 雄也; 武隈 洋; 菅原 満, 薬剤学: 生命とくすり, 70, Suppl., 117, 117, 2010年04月
  (公社)日本薬剤学会, 日本語
• TDM実践シリーズ 免疫抑制剤 シクロスポリン・タクロリムス
  菅原 満; 武隈 洋; 小林 道也; 唯野 貢司; 野村 憲和, 薬事新報, 2626, 2626, 31, 36, 2010年04月
  (株)薬事新報社, 日本語
• カルベジロールのグルクロン酸抱合に及ぼすエナンチオマー間の相互作用
  八木澤 啓司; 武隈 洋; 菅原 満, 日本薬学会年会要旨集, 130年会, 4, 200, 200, 2010年03月
  (公社)日本薬学会, 日本語
• PK/PD概念に基づいた抗がん剤の分類
  高橋 夏子; 武隈 洋; 小林 正紀; 板垣 史郎; 菅原 満; 井関 健, 日本薬学会年会要旨集, 130年会, 4, 298, 298, 2010年03月
  (公社)日本薬学会, 日本語
• 北海道大学薬学部における実務実習事前実習の取り組みとその評価
  武隈 洋; 小林 正紀; 山田 勇磨; 板垣 史郎; 吉田 和幸; 井関 健; 菅原 満, 日本薬学会年会要旨集, 130年会, 4, 346, 346, 2010年03月
  (公社)日本薬学会, 日本語
• TDM実践シリーズ(その他4) ワルファリン
  山崎 将英; 小林 道也; 唯野 貢司; 菅原 満; 野村 憲和, 薬事新報, 2621, 2621, 9, 15, 2010年03月
  (株)薬事新報社, 日本語
• TDM実践シリーズ その他 精神疾患治療薬
  岩尾 一生; 小林 道也; 唯野 貢司; 菅原 満; 野村 憲和; 北海道TDM研究会, 薬事新報, 2619, 2619, 9, 13, 2010年03月
  (株)薬事新報社, 日本語
• TDM実践シリーズ(その他2) 塩酸イリノテカンとTDM
  田中 寛之; 小林 道也; 菅原 満; 野村 憲和; 北海道TDM研究会, 薬事新報, 2617, 2617, 9, 12, 2010年02月
  (株)薬事新報社, 日本語
• TDM実践シリーズ その他 抗がん剤
  井藤 達也; 小林 道也; 唯野 貢司; 菅原 満; 野村 憲和, 薬事新報, 2615, 2615, 9, 14, 2010年02月
  (株)薬事新報社, 日本語
• 医療薬学ブラッシュアップ講座 薬物の体内動態に関する最近の話題-2 薬物の消化管吸収とトランスポーター
  菅原 満, 道薬誌, 27, 12, 4, 9, 2010年
• 医療薬学ブラッシュアップ講座 薬物の体内動態に関する最近の話題-1 薬物の消化管吸収性予測と経口製剤の評価
  菅原 満, 道薬誌, 27, 11, 4, 9, 2010年
• TDM実践シリーズ（17）免疫抑制剤①ミコフェノール酸モフェチル
  武隈 洋; 菅原 満; 小林道也; 唯野貢司; 野村憲和, 薬事新報, 2623, 9, 14, 2010年
• TDM実践シリーズ 抗真菌薬
  野田 久美子; 小林 道也; 唯野 貢司; 菅原 満; 野村 憲和, 薬事新報, 2613, 2613, 27, 31, 2010年01月
  (株)薬事新報社, 日本語
• TDM実践シリーズ 抗生物質製剤(2)
  横山 敏紀; 小林 道也; 唯野 貢司; 菅原 満; 野村 憲和; 北海道TDM研究会, 薬事新報, 2611, 2611, 9, 14, 2010年01月
  (株)薬事新報社, 日本語
• TDM実践シリーズ 抗生物質製剤(1)
  國本 雄介; 小林 道也; 唯野 貢司; 菅原 満; 野村 憲和; 北海道TDM研究会, 薬事新報, 2608, 2608, 9, 13, 2009年12月
  (株)薬事新報社, 日本語
• TDM実践シリーズ 抗不整脈薬(2)
  後藤 仁和; 小林 道也; 唯野 貢司; 菅原 満; 野村 憲和; 北海道TDM研究会, 薬事新報, 2606, 2606, 9, 13, 2009年12月
  (株)薬事新報社, 日本語
• ボリコナゾールの血漿中濃度および髄液移行性をモニタリングした脳クリプトコックス症例
  田島宏恵; 武隈 洋; 沖 洋充; 八島萌美; 秋本幸子; 菅原 満; 井関 健, 第23回北海道TDM研究会研究発表会（札幌）, 2009年11月
• 腎移植患者において腎機能の変動がミコフェノール酸体内動態に与える影響
  大谷 薫; 武隈 洋; 原田幸子; 福澤信之; 下田直彦; 三浦正義; 菅原 満; 野々村克也; 井関 健, 第23回北海道TDM研究会研究発表会（札幌）, 2009年11月
• TDM実践シリーズ 抗不整脈薬(1)
  中村 寛; 小林 道也; 唯野 貢司; 菅原 満; 野村 憲和; 北海道TDM研究会, 薬事新報, 2604, 2604, 9, 13, 2009年11月
  (株)薬事新報社, 日本語
• TDM実践シリーズ ジギタリス製剤
  今田 愛也; 野村 憲和; 小林 道也; 唯野 貢司; 菅原 満, 薬事新報, 2602, 2602, 9, 13, 2009年11月
  (株)薬事新報社, 日本語
• TDM実践シリーズ テオフィリン
  相馬 まゆ子; 小林 道也; 唯野 貢司; 菅原 満; 野村 憲和; 北海道TDM研究会, 薬事新報, 2600, 2600, 9, 14, 2009年10月
  (株)薬事新報社, 日本語
• TDM実践シリーズ 抗てんかん薬
  山田 和範; 河内 邦仁; 山澤 裕司; 小林 道也; 唯野 貢司; 菅原 満; 野村 憲和; 北海道TDM研究会, 薬事新報, 2597, 2597, 31, 37, 2009年10月
  (株)薬事新報社, 日本語
• O13-003 北海道大学病院における内服薬疑義照会率の傾向と分析(一般演題 口頭発表,調剤・処方鑑査・リスクマネジメント/医薬品情報・データベース/有害事象・副作用,医療薬学の創る未来 科学と臨床の融合)
  齋藤 佳敬; 志賀 弘康; 小林 正紀; 須田 範行; 菅原 満; 井関 健, 日本医療薬学会年会講演要旨集, 19, 0, 281, 281, 2009年09月15日
  日本医療薬学会, 日本語
• TDM実践シリーズ TDMの基礎 血中濃度解析とシミュレーションの概要とそのソフトウェア
  齊藤 嘉津彦; 野村 憲和; 小林 道也; 唯野 貢司; 菅原 満, 薬事新報, 2595, 2595, 9, 12, 2009年09月
  (株)薬事新報社, 日本語
• TDM実践シリーズ TDMの基礎(3)
  板垣 史郎; 菅原 満; 唯野 貢司; 小林 道也; 野村 憲和; 北海道TDM研究会, 薬事新報, 2593, 2593, 9, 14, 2009年09月
  (株)薬事新報社, 日本語
• TDM実践シリーズ TDMの基礎 PK-PD
  戸田 貴大; 野村 憲和; 小林 道也; 唯野 貢司; 菅原 満; 北海道TDM研究会, 薬事新報, 2591, 896, 901, 2009年08月
  (株)薬事新報社, 日本語
• 抗MRSA薬リネゾリドとバンコマイシンの脊椎組織への移行性の違い
  武隈 洋; 加藤 貴志; 漆畑 英樹; 小松 幹; 高畑 雅彦; 菅原 満; 三浪 明男; 井関 健, TDM研究, 26, 3, s149, s149, 2009年06月
  (一社)日本TDM学会, 日本語
• テイコプラニン初期投与設計への薬剤師介入の効果
  李 暁光; 武隈 洋; 山崎 浩二郎; 西村 あや子; 菅原 満; 井関 健, TDM研究, 26, 3, s170, s170, 2009年06月
  (一社)日本TDM学会, 日本語
• テイコプラニンのローディングドーズがもたらす血中トラフ濃度と有効性の検討 第2次研究中間報告
  野田 久美子; 田中 寛之; 山澤 裕司; 齊藤 嘉津彦; 小林 道也; 菅原 満; 唯野 貢司, TDM研究, 26, 3, s173, s173, 2009年06月
  (一社)日本TDM学会, 日本語
• ミコフェノール酸モフェチルの大量投与によっても目標AUCに到達しなかった小児生体腎移植患者の1症例
  大谷 薫; 武隈 洋; 原田 幸子; 下田 直彦; 三浦 正義; 菅原 満; 野々村 克也; 井関 健, TDM研究, 26, 3, s208, s208, 2009年06月
  (一社)日本TDM学会, 日本語
• 難水溶性薬物の乳剤化とその消化管吸収性に及ぼす胆汁の影響
  武藤花見; 今井智子; 中山淳司; 鈴木美香; 武隈 洋; 井関 健; 菅原 満, 日本薬学会北海道支部第132回例会（札幌）, 2009年05月
• Na+/モノカルボン酸共輸送担体(SMCT1)の基質認識機構における構造活性相関
  宮内 正二; 駄馬崎 泰洋; 菅原 満; Gopal Elangovan; Ganapathy Vadivel, 日本薬学会年会要旨集, 129年会, 4, 260, 260, 2009年03月
  (公社)日本薬学会, 日本語
• 新規開発臓器保存液を用いた心冷保存限界延長の試み
  若山 顕治; 深井 原; 山下 健一郎; 後藤 了一; 植木 伸也; 福森 大介; 柴崎 晋; 大浦 哲; 廣方 玄太郎; 芳賀 早苗; 谷口 雅彦; 鈴木 友己; 嶋村 剛; 松下 道明; 古川 博之; 尾崎 倫孝; 藤堂 省; 小野 太祐; 絹川 真太郎; 筒井 裕之; 菅原 満, 日本外科学会雑誌, 110, 臨増2, 709, 709, 2009年02月
  (一社)日本外科学会, 日本語
• 頭頸部放射線治療において使用される鎮痛薬と腫瘍部位の関連性に関する後ろ向き観察研究
  長田貴之; 熊井正貴; 山田武宏; 笠師久美子; 鈴木章之; 本間明宏; 福田諭; 菅原満; 井関健; 井関健, 日本緩和医療薬学会年会プログラム・要旨集, 3rd, 2009年
• 返品麻薬再利用のためのオーダリングシステム構築と運用後の現状
  熊井正貴; 志賀弘康; 笠師久美子; 菅原満; 井関健; 井関健, 日本緩和医療学会学術大会プログラム・抄録集, 14th, 2009年
• O11-006 気分障害圏患者の副作用への認知とコンプライアンスへの影響 : 心理検査との相関性(一般演題 口頭発表,精神科領域,医療薬学の創る未来 科学と臨床の融合)
  久保田 康生; 木村 俊也; 渡邉 紀子; 大崎 明美; 笠師 久美子; 菅原 満; 小山 司; 井関 健, 日本医療薬学会年会講演要旨集, 19, 277, 277, 2009年
  一般社団法人 日本医療薬学会, 日本語
• Extended Preservation of Rat Hearts with Novel Organ Preservation Solution: Role of Actin Cytoskeleton and ATP Maintenance.
  Kenji Wakayama; Moto Fukai; Kenichiro Yamashita; Daisuke Fukumori; Susumu Shibasaki; Gentaro Hirokata; Tomohiro Shibata; Tetsu Oura; Ryoichi Goto; Masahiko Taniguchi; Tomomi Suzuki; Tsuyoshi Shimamura; Michiaki Matsushita; Hiroyuki Furukawa; Michitaka Ozaki; Taisuke Ono; Mitsuru Sugawara; Satoru Todo, AMERICAN JOURNAL OF TRANSPLANTATION, 9, 491, 491, 2009年
  英語, 研究発表ペーパー・要旨（国際会議）
• Re-Evaluation of Heavy Water for Organ Preservation Solution; In Vitro Study.
  Moto Fukai; Kenichiro Yamashita; Kenji Wakayama; Daisuke Fukumori; Ryoichi Goto; Sanae Haga; Gentaro Hirokata; Shigeru Nakakimura; Mitsuru Sugawara; Hirofumi Kamachi; Tomomi Suzuki; Tsuyoshi Shimamura; Hiroyuki Furukawa; Michiaki Matsushita; Michitaka Ozaki; Satoru Todo, AMERICAN JOURNAL OF TRANSPLANTATION, 9, 581, 581, 2009年
  英語, 研究発表ペーパー・要旨（国際会議）
• 造血幹細胞移植における栄養指標と口内症状の評価(第二報)
  笠師 久美子; 柏崎 晴彦; 阿部 貴恵; 重松 明男; 池田 陽子; 上野 あさひ; 菅原 満; 井関 健, 静脈経腸栄養, 24, 1, 345, 345, 2009年01月
  (株)ジェフコーポレーション, 日本語
• TDM実践シリーズ（２）TDMの基礎②PK-PD
  戸田貴大; 野村憲和; 小林道也; 唯野貢司; 菅原 満, 薬事新報, 2591, 25, 30, 2009年
• 処方せん発行時の抗MRSA薬初期投与設計による医師への情報提供の有用性
  木村俊也; 山崎浩二郎; 西村あや子; 横田亜季; 小笠原貴子; 大崎由美子; 執行聡美; 清川真美; 宮本剛典; 菅原 満; 井関 健, 北海道病院薬剤師会誌, 76, 27, 30, 2009年
• カルベジロールの体内動態に及ぼす UGT遺伝子多型およびエナンチオマー間の 相互阻害作用の影響
  武隈 洋; 武中 徹; 八木澤啓司; 井幡圭佑; 菅原 満, UGT研究会（福岡）, 2008年10月
• 21C-12 消化管吸収予測システムを用いた後発医薬品の薬剤学的同等性評価(1)(後発医薬品,来るべき時代への道を拓く)
  下山 哲哉; 渡辺 祐子; 山本 千秋; 小林 正紀; 板垣 史郎; 菅原 満; 平野 剛; 井関 健, 日本医療薬学会年会講演要旨集, 18, 0, 267, 267, 2008年09月01日
  日本医療薬学会, 日本語
• 20-P1-168 吸収予測システムを用いた後発医薬品の薬剤学的同等性評価(2) : BCS分類class IおよびIIIの製剤における比較(後発医薬品,来るべき時代への道を拓く)
  渡辺 祐子; 山本 千秋; 下山 哲哉; 小林 正紀; 板垣 史郎; 菅原 満; 平野 剛; 井関 健, 日本医療薬学会年会講演要旨集, 18, 0, 310, 310, 2008年09月01日
  日本医療薬学会, 日本語
• 感染性脊椎炎をターゲットとした新規抗MRSA薬リネゾリドの脊椎周辺組織への移行性に関する実験的研究
  小松 幹; 高畑 雅彦; 武隈 洋; 菅原 満; 加藤 貴志; 入江 徹; 安倍 雄一郎; 伊東 学; 三浪 明男, 日本整形外科学会雑誌, 82, 8, S1248, S1248, 2008年08月
  (公社)日本整形外科学会, 日本語
• 抗MRSA薬テイコプラニンの初期投与設計による適正使用への関わり
  木村 俊也; 山崎 浩二郎; 西村 あや子; 坪内 孝敏; 横田 亜季; 小笠原 貴子; 大崎 由美子; 執行 聡美; 清川 真美; 宮本 剛典; 武隈 洋; 菅原 満; 井関 健, TDM研究, 25, 3, s213, s213, 2008年06月
  (一社)日本TDM学会, 日本語
• BCSクラス4に属する薬物の乳剤化とその消化管吸収性に及ぼす胆汁の影響
  武藤 花見; 鈴木 美香; 武隈 洋; 井関 健; 菅原 満, 薬剤学: 生命とくすり, 68, Suppl., 249, 249, 2008年04月
  (公社)日本薬剤学会, 日本語
• 汎用データベースソフトを用いた持参薬識別システムの構築と運用
  川岸 亨; 熊井 正貴; 齋藤 京之; 笠師 久美子; 菅原 満; 井関 健, 日本薬学会年会要旨集, 128年会, 4, 207, 207, 2008年03月
  (公社)日本薬学会, 日本語
• 化膿性脊椎炎に対するリネゾリドの臨床効果と脊椎への移行性
  加藤 貴志; 菅原 満; 井関 健; 武隈 洋; 高畑 雅彦; 小松 幹; 伊東 学; 三浪 明男, 日本薬学会年会要旨集, 128年会, 4, 85, 85, 2008年03月
  (公社)日本薬学会, 日本語
• 北大病院における内服薬疑義照会率の傾向と分析
  齋藤 佳敬; 榊原 則寛; 志賀 弘康; 沖 洋充; 小林 正紀; 川合 真次; 深井 敏隆; 菅原 満; 井関 健, 日本薬学会年会要旨集, 128年会, 4, 163, 163, 2008年03月
  (公社)日本薬学会, 日本語
• FDG-PET検査における薬剤の影響~院内ガイドライン作成の試み~
  新里利香; 笠師久美子; 鐘ケ江香久子; 菅原満; 井関健, 医療薬学フォーラム講演要旨集, 16th, 2008年
• 当院における緩和ケアチームの活動報告
  熊井正貴; 熊井正貴; 田巻知宏; 笠師久美子; 菅原満; 井関健; 井関健, 日本緩和医療薬学会年会プログラム・要旨集, 2nd, 2008年
• 20C-18 リネゾリドの使用状況調査および有効性、副作用に関する調査(感染対策・ICT,来るべき時代への道を拓く)
  山崎 浩二郎; 西村 あや子; 宮本 剛典; 武隈 洋; 菅原 満; 井関 健, 日本医療薬学会年会講演要旨集, 18, 245, 245, 2008年
  一般社団法人 日本医療薬学会, 日本語
• 20E-03 マイクロエマルジョン型シクロスポリン製剤の先発医薬品と後発医薬品の製剤学的な比較(後発医薬品,来るべき時代への道を拓く)
  植田 孝介; 武隈 洋; 沖 洋充; 須田 範行; 菅原 満; 井関 健, 日本医療薬学会年会講演要旨集, 18, 253, 253, 2008年
  一般社団法人 日本医療薬学会, 日本語
• 20I-04 高齢透析患者の栄養管理におけるNST薬剤師のあり方(栄養管理・NST,来るべき時代への道を拓く)
  清川 真美; 上野 あさひ; 池田 陽子; 須田 範行; 渡邊 昌也; 石川 康暢; 菅原 満; 武田 宏司; 井関 健, 日本医療薬学会年会講演要旨集, 18, 262, 262, 2008年
  一般社団法人 日本医療薬学会, 日本語
• 21C-03 頭頸部癌に対するシスプラチン超選択的動注における副作用調査(がん薬物療法(副作用対策),来るべき時代への道を拓く)
  熊井 正貴; 浅野 順次; 笠師 久美子; 菅原 満; 井関 健, 日本医療薬学会年会講演要旨集, 18, 266, 266, 2008年
  一般社団法人 日本医療薬学会, 日本語
• EVALUATION OF KETOPROFEN ABSORPTION IN TWO PREPARATIONS WITH AN IN VITRO SYSTEM
  Xin He; Mitsuru Sugawara; Xingbin Zhu; Shota Kadomura; Yang Wang; Yoh Takekuma; Changxiao Liu, DRUG METABOLISM REVIEWS, 40, 31, 32, 2008年
  英語, 研究発表ペーパー・要旨（国際会議）
• 造血幹細胞移植における栄養指標と口内症状の評価
  笠師 久美子; 柏崎 晴彦; 阿部 貴恵; 須田 範行; 菅原 満; 井関 健, 静脈経腸栄養, 23, 増刊, 213, 213, 2008年01月
  (株)ジェフコーポレーション, 日本語
• 小腸瘻周囲に皮膚びらんを呈した短腸症候群患者への栄養管理の一例
  植田 孝介; 久保 ちづる; 林 みゆき; 須田 範行; 菅原 満; 井関 健; 七戸 俊明; 武田 宏司, 静脈経腸栄養, 23, 増刊, 319, 319, 2008年01月
  (株)ジェフコーポレーション, 日本語
• 20D-30 がん化学療法における口内炎の予防に対する抗酸化物質の応用(がん薬物療法(副作用対策),来るべき時代への道を拓く)
  鷹野 瑠美; 平野 剛; 中田 千絵; 笠師 久美子; 菅原 満; 小林 正紀; 板垣 史郎; 井関 健; 大江 利治, 日本医療薬学会年会講演要旨集, 18, 0, 253, 253, 2008年
  一般社団法人 日本医療薬学会, 日本語
• ビスホスホネート製剤ゾメタの使用状況調査
  上野英文; 寺林久幸; 澤口利香; 久保田康生; 須田範行; 沖 洋充; 笠師久美子; 菅原 満; 井関 健, 北海道病院薬剤師会誌, 74, 43, 46, 2008年
• 北海道大学病院における持参薬確認業務への取り組み
  齋藤京之; 熊井正貴; 小田島澄子; 海藤文恵; 鳥飼真之介; 執行聡美; 川岸諭佳; 沖 洋充; 深井敏隆; 荻野 修; 菅原 満; 井関 健, 北海道病院薬剤師会誌, 74, 19, 21, 2008年
• Pharmacokineticsの鑑定事例への応用 危険運転行為と覚せい剤摂取
  清水 惠子; 松原 和夫; 菅原 満; 浅利 優; 丹 祐夏; 渡邊 智; 塩野 寛, 中毒研究, 20, 4, 438, 438, 2007年10月
  (株)へるす出版, 日本語
• オピオイド製剤の適正使用に関する調査
  斎藤由起子; 沖洋充; 平野剛; 菅原満; 井関健, 日本医療薬学会年会講演要旨集, 17th, 315, 315, 2007年09月01日
  一般社団法人 日本医療薬学会, 日本語
• 29-C1-10-2 Coenzyme Q10の消化管吸収挙動:排出系トランスポーターの関与(薬物相互作用・薬物動態,社会の期待に応える医療薬学を)
  落合 彰子; 小林 正紀; 板垣 史郎; 平野 剛; 菅原 満; 井関 健, 日本医療薬学会年会講演要旨集, 17, 0, 196, 196, 2007年09月01日
  日本医療薬学会, 日本語
• チーム医療に貢献するTDMの実際 地域の中でのチーム医療 北海道TDM研究会の活動を通じて
  菅原 満; 唯野 貢司, TDM研究, 24, 3, s56, s57, 2007年07月
  (一社)日本TDM学会, 日本語
• テイコプラニンのローディングドーズがもたらす血中トラフ濃度と有効性の検討 中間報告
  田中 寛之; 山澤 裕司; 齋藤 嘉津彦; 小林 道也; 菅原 満; 唯野 貢司, TDM研究, 24, 3, s135, s135, 2007年07月
  (一社)日本TDM学会, 日本語
• タクロリムス(TAC)併用腎移植患者におけるミコフェノール酸(MPA)の血中濃度変動要因解析
  武隈 洋; 寺岡 栄美; 澤口 利香; 山崎 浩二郎; 森田 研; 下田 直彦; 堀田 記世彦; 岩見 大基; 渡井 至彦; 菅原 満; 野々村 克也; 井関 健, 移植, 42, 2, 194, 195, 2007年04月
  (一社)日本移植学会, 日本語
• Pharmacokineticsの鑑定事例への応用 危険運転行為と覚せい剤摂取
  清水 惠子; 浅利 優; 安積 順一; 松原 和夫; 菅原 満; 塩野 寛, 日本法医学雑誌, 61, 1, 52, 52, 2007年03月
  (NPO)日本法医学会, 日本語
• ラット及びヒト間のMPA(ミコフェノール酸)体内動態の違いにおけるMRP2(multidrug resistance-associated protein 2)及びOAT(organic anion transporter)の関与
  垣内 悠; 武隈 洋; 山崎 浩二郎; 井関 健; 菅原 満, 日本薬学会年会要旨集, 127年会, 3, 84, 84, 2007年03月
  (公社)日本薬学会, 日本語
• 30-B2-14-1 処方オーダによる後発医薬品への変更許可システムとその稼働状況(医薬分業・薬薬連携・治験,社会の期待に応える医療薬学を)
  川合 真次; 深井 敏隆; 荻野 修; 菅原 満; 櫻井 恒太郎; 井関 健, 日本医療薬学会年会講演要旨集, 17, 206, 206, 2007年
  一般社団法人 日本医療薬学会, 日本語
• 29-P1-134 テイコプラニン(TEIC)TDM実施患者における血中濃度と疾患別臨床評価(TDM/薬物動態,社会の期待に応える医療薬学を)
  西村 あや子; 坪内 孝敏; 山崎 浩二郎; 宮本 剛典; 武隈 洋; 菅原 満; 井関 健, 日本医療薬学会年会講演要旨集, 17, 239, 239, 2007年
  一般社団法人 日本医療薬学会, 日本語
• 29-P1-143 全身性エリテマトーデス(SLE)患者に対するミコフェノール酸モフェチル(MMF)の適用とTDMの有用性(TDM/薬物動態,社会の期待に応える医療薬学を)
  武隈 洋; 奥 健志; 小笠原 貴子; 山崎 浩二郎; 菅原 満; 井関 健, 日本医療薬学会年会講演要旨集, 17, 240, 240, 2007年
  一般社団法人 日本医療薬学会, 日本語
• リネゾリドの椎間板への移行性
  加藤貴志; 菅原 満; 井関 健; 武隈 洋; 高畑雅彦; 小松幹; 伊東 学; 三浪明男, 第21回北海道TDM研究会（札幌）, 2007年
• 29-P1-39 栄養療法における脂肪乳剤の使用に関する意識調査および適正使用の推進(NST,社会の期待に応える医療薬学を)
  鷹野 瑠美; 須田 範行; 平野 剛; 笠師 久美子; 菅原 満; 井関 健, 日本医療薬学会年会講演要旨集, 17, 0, 223, 223, 2007年
  一般社団法人 日本医療薬学会, 日本語
• 副作用症状を来した肝移植患者における免疫抑制剤の選択
  小笠原貴子; 新沼朋美; 沖 洋充; 深井敏隆; 荻野 修; 武隈 洋; 菅原 満; 井関 健, 北海道病院薬剤師会誌, 72, 35, 37, 2007年
• 30P1-011 外来化学療法における服薬指導充実のための病棟 : 外来間連携ツールの構築(癌薬物療法(外来化学療法、緩和ケア等),医療薬学の扉は開かれた)
  久保田 康生; 中里 恭子; 須田 範行; 沖 洋充; 菅原 満; 小林 道也; 齊藤 浩司; 井関 健, 日本医療薬学会年会講演要旨集, 16, 357, 357, 2006年09月01日
  日本医療薬学会, 日本語
• 01P2-154 テイコプラニン投与時における至適ローディングドーズの検討 : 新旧TDM解析支援ソフトウェア間の有用性の比較(薬物動態(TDM・投与設計等),医療薬学の扉は開かれた)
  小笠原 貴子; 武隈 洋; 山崎 浩二郎; 沖 洋充; 菅原 満; 井関 健, 日本医療薬学会年会講演要旨集, 16, 553, 553, 2006年09月01日
  日本医療薬学会, 日本語
• 01P3-001 スルバクタム/セフォペラゾン製剤の後発医薬品導入に際する有効性の比較検討(薬剤疫学,医療薬学の扉は開かれた)
  大西 潤; 井藤 達也; 志賀 隆博; 高木 智史; 鈴木 岳; 武隈 洋; 菅原 満; 竹本 功; 井関 健, 日本医療薬学会年会講演要旨集, 16, 555, 555, 2006年09月01日
  日本医療薬学会, 日本語
• 30-F-05 心臓血管造影剤による急性腎機能低下に対するアセチルシステインの予防効果および製剤の評価(服薬指導(入院・外来),医療薬学の扉は開かれた)
  清川 真美; 澤口 利香; 須田 範行; 菅原 満; 井関 健, 日本医療薬学会年会講演要旨集, 16, 320, 320, 2006年09月01日
  日本医療薬学会, 日本語
• コエンザイムQ10の消化管吸収挙動:製剤的工夫による違い
  井関健; 落合彰子; 黒川俊光; 板垣史郎; 平野剛; 菅原満, 日本医療薬学会年会講演要旨集, 16th, 433, 433, 2006年09月01日
  日本医療薬学会, 日本語
• 薬物のα1-酸性糖タンパク質への結合と臨床
  菅原 満, TDM研究, 23, 2, 55, 56, 2006年04月
  (一社)日本TDM学会, 日本語
• カルベジロールの体内動態変動に及ぼすグルクロン酸転移酵素およびCYP2D6遺伝子多型の影響
  武隈 洋; 武中 徹; 清川 真美; 山崎 浩二郎; 岡本 洋; 菅原 満; 北畠 顕; 筒井 裕之; 宮崎 勝巳, TDM研究, 23, 2, 77, 78, 2006年04月
  (一社)日本TDM学会, 日本語
• 腎移植患者におけるタクロリムス併用時の少数採血点によるミコフェノール酸AUC0-12推定
  寺岡 栄美; 武隈 洋; 山崎 浩二郎; 高田 晴美; 菅原 満; 渡井 至彦; 森田 研; 福澤 信之; 野々村 克也; 宮崎 勝巳, TDM研究, 23, 2, 145, 146, 2006年04月
  (一社)日本TDM学会, 日本語
• 注射オーダを利用した特定生物由来製剤の使用管理システム
  川合 真次; 山崎 浩二郎; 宮本 剛典; 荻野 修; 菅原 満; 井関 健; 櫻井 恒太郎, 日本薬学会年会要旨集, 126年会, 2, 220, 220, 2006年03月
  (公社)日本薬学会, 日本語
• ヌクレオシドトランスポーターを介した抗ウイルス薬リバビリンの消化管吸収
  國木 賢一; 山本 崇; 武隈 洋; 菅原 満; 井関 健, 薬剤学: 生命とくすり, 66, Suppl., 229, 229, 2006年02月
  (公社)日本薬剤学会, 日本語
• 薬物療法時の血液浄化療法の影響 ～リネゾリド・ガンシクロビルについて～
  武隈 洋; 山﨑浩二郎; 宮本剛典; 菅原 満; 井関 健, 第20回北海道TDM研究会（札幌）, 2006年
• 中性アミノ酸トランスポーターSNAT2の発現変動
  柏木 仁; 山﨑 浩二郎; 武隈 洋; 井関 健; 菅原 満, 第20回北海道薬物作用談話会（札幌）, 2006年
• 血清アルブミンを中心としたMPA血中濃度の変動要因解析
  寺岡 栄美; 山﨑浩二郎; 菅原 満; 井関 健; 武隈 洋; 森田 研; 下田直彦; 堀田記世彦; 岩見大基; 渡井 至彦; 野々村克也, 第24回北海道腎移植談話会（札幌）, 2006年
• 副作用症状を来した肝移植患者に対する免疫抑制剤の選択
  小笠原貴子; 新沼朋美; 武隈 洋; 沖 洋充; 深井敏隆; 荻野 修; 菅原 満; 井関 健, 第53回北海道薬学大会（札幌）, 2006年
• 外来化学療法の取り組み 当院における外来治療センターの現状
  須田 範行; 荻野 修; 菅原 満; 井関 健, 薬事新報, 2398, 9, 15, 2005年12月
  (株)薬事新報社, 日本語
• P-800 健康食品に対する意識と摂取状況およびそのデータベース(DB)化(22.健康食品,医療薬学の未来へ翔(はばた)く-薬剤師の薬剤業務・教育・研究への能動的関わり-)
  久保田 康生; 沖 洋充; 菅原 満; 山崎 浩一; 西村 正治, 日本医療薬学会年会講演要旨集, 15, 428, 428, 2005年09月01日
  日本医療薬学会, 日本語
• P-541 院内LANを用いた情報提供、添付文書閲覧システムの構築(5.医薬品情報・データベース4,医療薬学の未来へ翔(はばた)く-薬剤師の薬剤業務・教育・研究への能動的関わり-)
  橋本 純一; 住吉 一宏; 川合 真次; 深井 敏隆; 荻野 修; 菅原 満; 櫻井 恒太郎; 宮崎 勝巳, 日本医療薬学会年会講演要旨集, 15, 364, 364, 2005年09月01日
  日本医療薬学会, 日本語
• 【泌尿器科の化学療法】泌尿器科化学療法で使用される代表薬剤
  松浦 麻耶; 菅原 満; 篠原 信雄, 泌尿器ケア, 10, 9, 839, 843, 2005年09月
  (株)メディカ出版, 日本語
• 総合ビタミン剤配合型高カロリー輸液キット製剤「フルカリック」1日用量製剤の有用性の検討
  須田 範行; 菅原 満, 新薬と臨牀, 54, 8, 956, 963, 2005年08月
  フルカリックは,初めて総合ビタミン剤を配合した高カロリー輸液キット製剤である.今回,1日容量製剤が開発され,有用性について,高カロリー輸液に適用されている処方を用いて検討した.A群(半日容量製剤2袋に薬剤を混注し,遮光タイプのIVHバッグ1袋に注入し1日分にまとめた群),B群(半日容量製剤2袋それぞれに薬剤を混注した群),C群(1日容量製剤1袋に薬剤を混注した群)とした.調剤順序は無作為に割付けを行った.調製時間はA群が640秒,B群が276秒,C群が224秒であった.C群はA群,B群と比較し有意に調製時間が短縮した.アンケート調査では,調製操作時間,調製操作の簡便性,利便性の総合評価の項目で有意差を認めた.半日容量製剤2袋を1日容量製剤1袋に変更可能な処方は97件あり,半日容量製剤194袋を1日容量製剤97袋に変更可能であった.フルカリック1日容量製剤は,臨床現場にとって有用性の高い製剤であることが示唆された, (株)医薬情報研究所, 日本語
• 神経因性疼痛に対する酢酸フレカイニドの鎮痛効果とTDMの有用性
  山崎 浩二郎; 武隈 洋; 志賀 弘康; 菅原 満; 宮崎 勝巳; 小澤 剛久; 柴田 万里子; 橋本 聡一; 森本 裕二, TDM研究, 22, 3, 238, 238, 2005年07月
  (一社)日本TDM学会, 日本語
• 【癌治療の臨床薬理】イリノテカンの至適投与設計と下痢発症メカニズムに関する研究
  井関 健; 板垣 史郎; 菅原 満; 宮崎 勝巳; 平野 剛, 臨床薬理の進歩, 26, 20, 29, 2005年07月
  (公財)臨床薬理研究振興財団, 日本語
• カルベジロール血漿中濃度に及ぼすグルクロン酸抱合能の影響
  武隈 洋; 清川 真美; 山崎 浩二郎; 米澤 一也; 岡本 洋; 菅原 満; 北畠 顕; 宮崎 勝巳, TDM研究, 22, 2, 151, 152, 2005年04月
  (一社)日本TDM学会, 日本語
• ヌクレオシドトランスポーターを介した薬物輸送 CNTとENTの比較
  山本 崇; 國木 賢一; 武隈 洋; 菅原 満; 宮崎 勝巳, 日本薬学会年会要旨集, 125年会, 2, 112, 112, 2005年03月
  (公社)日本薬学会, 日本語
• 当院における外来治療センターの現状と問題点
  須田 範行; 瀬戸 恵介; 熊井 正貴; 岩井 美和子; 志賀 弘康; 宮本 剛典; 荻野 修; 菅原 満; 宮崎 勝巳, 日本薬学会年会要旨集, 125年会, 2, 165, 165, 2005年03月
  (公社)日本薬学会, 日本語
• 心疾患患者におけるカルベジロール薬物動態の母集団パラメータ解析
  武隈 洋; 清川 真美; 武中 徹; 山崎 浩二郎; 岡本 洋; 菅原 満; 北畠 顕; 筒井 裕之; 宮崎 勝巳, 日本薬学会年会要旨集, 125年会, 2, 181, 181, 2005年03月
  (公社)日本薬学会, 日本語
• 救急・集中治療室12例におけるフレカイニド静注薬の効果解析
  松田直之; 大城あき子; 下嶋秀和; 久保田信彦; 星野弘勝; 早川峰司; 澤村 淳; 石川岳彦; 丸藤 哲; 武隈 洋; 菅原 満, 第6回抗不整脈薬TDM研究会（東京）, 2005年
• 神経因性疼痛に対する酢酸フレカイニドの鎮痛効果の検討
  武隈 洋; 山﨑浩二郎; 志賀弘康; 菅原 満; 宮崎勝巳; 小澤剛久; 柴田万里子; 橋本聡一; 森本裕二, 第6回抗不整脈薬TDM研究会（東京）, 2005年
• 総合ビタミン剤配合型高カロリー輸液キット製剤「フルカリック®」1日容量製剤の有用性の検討
  須田範行; 菅原 満, 新薬と臨床, 54, 8, 18, 25, 2005年
• 【日常診療に用いられる薬剤の上手な使い方と服薬指導】薬物の吸収とその変動要因
  菅原 満; 宮崎 勝巳, 成人病と生活習慣病, 35, 1, 9, 16, 2005年01月
  (株)東京医学社, 日本語
• 肝のう胞治療時のジソピラミド血中濃度モニタリング エタノール注入療法患者の症例
  坪井 瞳; 板垣 まゆこ; 今田 愛也; 阿部 康子; 金重 啓子; 樟本 賢首; 岸野 吏志; 菅原 満; 宮崎 勝巳, TDM研究, 21, 4, 336, 336, 2004年10月
  (一社)日本TDM学会, 日本語
• 【Q&Aで学ぶTDM活用ガイド】TDMを始める準備をする TDMを始める前に知っておきたいこと 特定薬剤治療管理料の算定は薬剤によって異なるそうですね.ややこしいので教えてください
  菅原 満; 宮崎 勝巳, 薬局, 55, 10月臨増, 6, 7, 2004年10月
  (株)南山堂, 日本語
• 【Q&Aで学ぶTDM活用ガイド】TDMを始める準備をする TDMを始める前に知っておきたいこと TDMを実施すると経済的なメリットはあるのでしょうか?
  菅原 満; 宮崎 勝巳, 薬局, 55, 10月臨増, 8, 10, 2004年10月
  (株)南山堂, 日本語
• 【Q&Aで学ぶTDM活用ガイド】TDMを始める準備をする TDMを始める前に知っておきたいこと 血中濃度は常に有効治療域に入れなければならないのでしょうか?
  菅原 満; 宮崎 勝巳, 薬局, 55, 10月臨増, 11, 13, 2004年10月
  (株)南山堂, 日本語
• P-205 造影剤による腎機能低下の予防を目的としたアセチルシステインゼリーの調製と評価(13.院内製剤(薬局製剤),"薬剤師がつくる薬物治療"-薬・薬・学の連携-)
  須田 範行; 新里 利香; 清川 真美; 金内 美妃; 菅原 満; 郡 修徳; 宮崎 勝巳, 日本医療薬学会年会講演要旨集, 14, 268, 268, 2004年09月01日
  日本医療薬学会, 日本語
• P-231 麻薬オーダリンクシステムの構築とその運用(14.調剤・処方管理・オーダリング(注射剤含む),"薬剤師がつくる薬物治療"-薬・薬・学の連携-)
  志賀 弘康; 川合 真次; 荻野 修; 菅原 満; 宮崎 勝巳, 日本医療薬学会年会講演要旨集, 14, 274, 274, 2004年09月01日
  日本医療薬学会, 日本語
• 北海道大学病院における治験実施体制の整備と新たな取り組み
  後藤 瑞子; 橋本 あきら; 荻野 修; 菅原 満; 宮崎 勝巳; 亀田 悦子; 奥原 芳子; 河野 敏春; 佐藤 典宏; 遠藤 晃; 櫻井 恒太郎; 小池 隆夫, 臨床薬理, 35, Suppl., S201, S201, 2004年08月
  (一社)日本臨床薬理学会, 日本語
• 生体部分肝移植患者におけるMicafungin(Funguard)の体内動態
  岸野 吏志; 馬渕 朋美; 菅原 満; 嶋村 剛; 古川 裕之; 藤堂 省; 宮崎 勝巳, TDM研究, 21, 2, 145, 146, 2004年04月
  (一社)日本TDM学会, 日本語
• 拡張型心筋症患者における遺伝子多型性によるβ遮断薬レスポンダー解析
  井上 直樹; 岡本 洋; 福島 新; 本間 恒章; 小松 博史; 長嶋 健一郎; 秋野 正敏; 松井 裕; 小野塚 久夫; 米澤 一也; 北畠 顕; 菅原 満; 東 純一, Circulation Journal, 68, Suppl.II, 758, 758, 2004年04月
  (一社)日本循環器学会, 日本語
• 薬剤師による処方支援(3)薬剤師にできる処方支援法--病棟活動とデータベースの活用
  菅原 満; 宮崎 勝巳, 医薬ジャ-ナル, 40, 3, 130, 136, 2004年03月
  医薬ジャ-ナル社, 日本語
• 肝のう胞治療時のジソピラミド血中濃度モニタリング エタノール注入療法患者の症例
  坪井 瞳; 板垣 まゆ子; 今田 愛也; 金重 啓子; 樟本 賢首; 岸野 吏志; 菅原 満; 宮崎 勝巳, 日本薬学会年会要旨集, 124年会, 4, 184, 184, 2004年03月
  (公社)日本薬学会, 日本語
• AAG variantに対するクロルプロマジンの結合に及ぼすシアル酸の影響
  中川 勉; 佐々木 花; 武隈 洋; 菅原 満; 宮崎 勝巳, 日本薬学会年会要旨集, 124年会, 4, 87, 87, 2004年03月
  (公社)日本薬学会, 日本語
• タキソール注投与時の結晶析出に関する報告
  岩井 美和子; 須田 範行; 菅原 満; 宮崎 勝巳, 日本薬学会年会要旨集, 124年会, 4, 125, 125, 2004年03月
  (公社)日本薬学会, 日本語
• 癌化学療法の調剤業務支援のためのプロトコールデータベースの構築と運用
  武隈 洋; 岩井 美和子; 藤原 俊恵; 川岸 亨; 熊井 正貴; 松浦 麻耶; 前佛 美也子; 高橋 悠子; 相楽 賢一; 馬渕 朋美; 須田 範行; 宮本 剛典; 荻野 修; 菅原 満; 宮崎 勝巳, 日本薬学会年会要旨集, 124年会, 4, 150, 150, 2004年03月
  (公社)日本薬学会, 日本語
• hOAT1を介した有機アニオン輸送に対するキサンチン系薬物の阻害効果
  菅原 満; 望月 敬浩; 武隈 洋; 宮崎 勝巳, 日本薬学会年会要旨集, 124年会, 4, 76, 76, 2004年03月
  (公社)日本薬学会, 日本語
• PSP取り込み過程における有機アニオントランスポーターの寄与
  板垣 史郎; 菅原 満; 小林 道也; 平野 剛; 宮崎 勝巳; 井関 健, 日本薬学会年会要旨集, 124年会, 4, 75, 75, 2004年03月
  (公社)日本薬学会, 日本語
• 【抗がん剤の適正使用へのポイント】がん患者における薬物の吸収と排泄
  菅原 満; 宮崎 勝巳, 薬局, 55, 3, 1481, 1490, 2004年03月
  (株)南山堂, 日本語
• 薬剤師による処方支援 薬剤師にできる処方支援法 病棟活動とデータベースの活用
  菅原 満; 宮崎 勝巳, 医薬ジャーナル, 40, 3, 1012, 1018, 2004年03月
  薬剤師による処方支援の例として,病棟活動を通じて薬剤師が処方計画に参画できたケースについて,北海道大学病院において経験した例を紹介する.一方,病棟活動を行っていない診療科においても,何らかの形で処方を支援する方策が必要である.そこで,薬剤部において作成したデータベースを,処方オーダリングシステムにリンクすることにより,処方作成を支援する取り組みについても述べた, (株)医薬ジャーナル社, 日本語
• Differential binding of disopyramide and warfarin enantiomers to human alpha(1)-acid glycoprotein variants (vol 56, pg 664, 2003)
  T Nakagawa; S Kishino; S Itoh; M Sugawara; K Miyazaki, BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 57, 2, 226, 226, 2004年02月
  英語, その他
• 拡張型心筋症患者におけるβ遮断薬薬剤反応性と遺伝子多型性解析
  岡本 洋; 小野塚 久夫; 米澤 一也; 北畠 顕; 菅原 満; 東 純一, 日本内科学会雑誌, 93, Suppl., 170, 170, 2004年02月
  (一社)日本内科学会, 日本語
• 急性腎不全患者におけるフレカイニドの血中濃度と頻脈抑制作用の一例
  松田直之; 平安山直美; 早川峰司; 澤村 淳; 亀山 隆; 丸藤 哲; 武隈 洋; 菅原 満; 宮崎勝巳, 第5回抗不整脈薬TDM研究会（福岡）, 2004年
• hOAT1の基質認識における構造相関～核酸類似構造化合物を用いた検討～
  小田真也; 望月敬浩; 武隈 洋; 菅原 満; 宮崎勝巳, 日本薬学会北海道支部第122回例会（札幌）, 2004年
• 奥村勝彦監修、Q＆Aで学ぶTDM活用ガイド
  菅原 満; 宮崎勝巳, 薬局, 55, 10月臨時増刊号, 6, 13, 2004年
• 27-02-06 循環器科病棟において TDM を有効利用した症例
  清川 真美; 武隈 洋; 岸野 吏志; 深井 敏隆; 高木 眞弓; 米澤 一也; 菅原 満; 宮崎 勝巳; 北畠 顯, 日本医療薬学会年会講演要旨集, 13, 132, 132, 2003年09月01日
  日本医療薬学会, 日本語
• 抗がん剤適正使用を支える医薬品プロフィール
  政田 幹夫; 菅原 満; 有吉 範高; 森田 邦彦; 川上 純一; 後藤 伸之; 中村 敏明; 栄田 敏之; 直良 浩司; 井関 健; 黒崎 勇二; 谷川原 祐介; 向山 雄人, 日本癌治療学会誌, 38, 2, 202, 202, 2003年09月
  (一社)日本癌治療学会, 日本語
• 慢性心不全患者における遺伝子多型性解析
  岡本 洋; 秋野 正敏; 松井 裕; 米澤 一也; 小野塚 久夫; 北畠 顕; 菅原 満; 東 純一, 日本内分泌学会雑誌, 79, 2, 539, 539, 2003年09月
  (一社)日本内分泌学会, 日本語
• 生体部分肝移植患者におけるLinezolid(Zyvox)の体内動態
  岸野 吏志; 馬渕 朋美; 菅原 満; 嶋村 剛; 古川 裕之; 藤堂 省; 宮崎 勝巳, TDM研究, 20, 2, 183, 184, 2003年04月
  (一社)日本TDM学会, 日本語
• 生体肝移植患者におけるタクロリムスの体内動態の変動とその要因
  岸野 吏志; 菅原 満; 古川 博之; 藤堂 省; 宮崎 勝巳, 日本外科学会雑誌, 104, 臨増, 434, 434, 2003年04月
  (一社)日本外科学会, 日本語
• システムB0を介した中性アミノ酸の輸送におよぼす塩基性薬物の影響
  北窪 真弓; 武隈 洋; 菅原 満; Ganapathy V.; 宮崎 勝巳, 日本薬学会年会要旨集, 123年会, 4, 61, 61, 2003年03月
  (公社)日本薬学会, 日本語
• α1-酸性糖蛋白質への立体選択的な薬物結合におけるシアル酸の影響
  中川 勉; 伊藤 慎; 岸野 吏志; 菅原 満; 宮崎 勝巳, 日本薬学会年会要旨集, 123年会, 4, 69, 69, 2003年03月
  (公社)日本薬学会, 日本語
• 消化管内の生理的条件を考慮した薬物消化管吸収評価系の構築 プロドラッグの吸収評価
  何 新; 武隈 洋; 菅原 満; 宮崎 勝巳, 日本薬学会年会要旨集, 123年会, 4, 101, 101, 2003年03月
  (公社)日本薬学会, 日本語
• 癌化学療法時の口内炎予防を目的としたメシル酸カモスタット口腔内速崩錠の調製とその評価
  須田 範行; 今野 安大; 岩井 美和子; 森田 豊; 中田 宏; 菅原 満; 宮崎 正三; 宮崎 勝巳, 日本薬学会年会要旨集, 123年会, 4, 122, 122, 2003年03月
  (公社)日本薬学会, 日本語
• カルニチントランスポーター（OCTN2）発現細胞を用いた基質認識特性の解明
  高野太樹; 武隈 洋; 菅原 満; 宮崎勝巳, 日本薬学会北海道支部第120回例会（札幌）, 2003年
• システムＡアミノ酸トランスポーターの活性・発現におよぼすインスリンの影響
  柏木 仁; 武隈 洋; 菅原 満; 宮崎勝巳, 日本薬学会北海道支部第120回例会（札幌）, 2003年
• 抗ウイルス薬リバビリンの胎盤透過機構
  森田 崇; 武隈 洋; 菅原 満; 宮崎勝巳, 日本薬学会北海道支部第120回例会（札幌）, 2003年
• フェンタニルパッチ連日投与により傾眠が改善された一症例
  志賀弘康; 荻野 修; 菅原 満; 宮崎勝巳, 北海道病院薬剤師会誌, 65, 37, 40, 2003年
• リスク軽減を目的とした調剤業務のシステム化−薬袋作製機の導入−
  橋本純一; 深井敏隆; 荻野 修; 菅原 満; 宮崎勝巳, 北海道病院薬剤師会誌, 64, 53, 56, 2003年
• グルタミンの動態と臨床的有用性
  菅原 満, 日本医療薬学会会報, 6, 4, 16, 25, 2002年12月
  (一社)日本医療薬学会, 日本語
• P-47 より充実した情報提供に向けて : 新データシステムの構築
  橋本 純一; 山下 恭範; 榊原 則寛; 川合 真次; 深井 敏隆; 荻野 修; 菅原 満; 宮崎 勝巳, 日本医療薬学会年会講演要旨集, 12, 156, 156, 2002年09月24日
  日本医療薬学会, 日本語
• P-433 肝移植患者における内因性 cortisol の尿中代謝物を用いた薬物代謝能(CYP 3 A 4 活性)評価法の検討
  岸野 吏志; 小川 真紀; 菅原 満; 古川 博之; 藤堂 省; 宮崎 勝巳, 日本医療薬学会年会講演要旨集, 12, 253, 253, 2002年09月24日
  日本医療薬学会, 日本語
• 病院における製剤 くる病患者のリン酸補給に対するリン酸バッファー錠の調整と臨在学的評価
  岸野 吏志; 菅原 満; 宮崎 勝巳; 郡 修徳, PHARM TECH JAPAN, 18, 8, 1227, 1233, 2002年07月
  (株)じほう, 日本語
• 膜と薬物の相互作用 生物物理化学的アプローチ 薬物-生体膜間の静電的相互作用をファクターとした薬物吸収性予測
  菅原 満, 日本薬学会年会要旨集, 122年会, 1, 195, 195, 2002年03月
  (公社)日本薬学会, 日本語
• 消化管内pH変動および腸管代謝を考慮した薬物吸収予測システムの構築
  何 新; 菅原 満; 宮崎 勝巳, 日本薬学会年会要旨集, 122年会, 4, 51, 51, 2002年03月
  (公社)日本薬学会, 日本語
• 小腸上皮細胞におけるポリアミン取り込み機構
  瀬戸 恵介; 菅原 満; 宮崎 勝巳, 日本薬学会年会要旨集, 122年会, 4, 63, 63, 2002年03月
  (公社)日本薬学会, 日本語
• α1-酸性糖蛋白質の不均一性体とPropranolol光学異性体の立体選択的結合性
  伊藤 慎; 中川 勉; 岸野 吏志; 菅原 満; 宮崎 勝巳, 日本薬学会年会要旨集, 122年会, 4, 71, 71, 2002年03月
  (公社)日本薬学会, 日本語
• α1-酸性糖蛋白質とその不均一性体の糖鎖構造解析
  中川 勉; 越浪 由加; 佐々木 花; 岸野 吏志; 菅原 満; 宮崎 勝巳, 日本薬学会年会要旨集, 122年会, 4, 71, 71, 2002年03月
  (公社)日本薬学会, 日本語
• 肝移植患者におけるCHDF(持続血液濾過透析)施行時のGanciclovirの血中動態
  岸野 吏志; 菅原 満; 宮崎 勝巳; 古川 博之; 藤堂 省, 日本薬学会年会要旨集, 122年会, 4, 124, 124, 2002年03月
  (公社)日本薬学会, 日本語
• VRE感染症治療剤ザイボックス錠の粉砕可否に関する検討
  菅原 満; 荻野 修; 宮崎 勝巳, 日本薬学会年会要旨集, 122年会, 4, 149, 149, 2002年03月
  (公社)日本薬学会, 日本語
• 薬学部4年生の医薬品情報(DI)実習における修得度のアンケート調査
  川合 真次; 平野 剛; 菅原 満; 井関 健; 岸野 吏志; 荻野 修; 野村 靖幸; 宮崎 勝巳, 日本薬学会年会要旨集, 122年会, 3, 203, 203, 2002年03月
  (公社)日本薬学会, 日本語
• 北大病院におけるＣＲＣ業務について
  高田陽美; 橋本あきら; 荻野 修; 菅原 満; 宮崎勝巳; 竹内ひとみ; 奥原芳子; 小柳知彦, 北海道病院薬剤師会誌, 62, 63, 68, 2002年
• 当院薬剤部におけるリスク回避のための対策
  久保田康生; 深井敏隆; 荻野 修; 菅原 満; 宮崎勝巳, 北海道病院薬剤師会誌, 62, 35, 38, 2002年
• 【新薬展望2002】最近のDDSの進歩
  菅原 満; 宮崎 勝巳, 医薬ジャーナル, 38, 増刊, 342, 346, 2002年01月
  (株)医薬ジャーナル社, 日本語
• O-63 薬剤師主導による心不全患者に対するカルベジロール投与プロトコールの構築 (2) : カルベジロール血中濃度測定が処方構築に有用だった例
  清川 真美; 岸野 吏志; 深井 敏隆; 高木 眞弓; 米澤 一也; 小林 道也; 菅原 満; 宮崎 勝巳; 北畠 顯, 日本医療薬学会年会講演要旨集, 11, 94, 94, 2001年09月01日
  日本医療薬学会, 日本語
• P-94 院内製剤 1.0M 安息香酸ナトリウム注射液, 0.25M フェニル酢酸ナトリウム注射液に関する検討 : 製剤の安定性および生体肝移植直前の高アンモニア血症に対する使用例
  岩井 美和子; 武隈 洋; 須田 範行; 岸野 吏志; 菅原 満; 古川 博之; 藤堂 省; 宮崎 勝巳, 日本医療薬学会年会講演要旨集, 11, 134, 134, 2001年09月01日
  日本医療薬学会, 日本語
• β-ラクタム系抗生物質の消化管吸収における重炭酸イオンの影響
  山崎 浩二郎; 北窪 真弓; 小林 道也; 菅原 満; 宮崎 勝巳, 薬物動態, 16, Suppl., S309, S309, 2001年09月
  (一社)日本薬物動態学会, 日本語
• Caco-2細胞における多剤排出蛋白を介したPSP輸送
  板垣 史郎; 小林 道也; 井関 健; 菅原 満; 宮崎 勝巳, 薬物動態, 16, Suppl., S243, S243, 2001年09月
  (一社)日本薬物動態学会, 日本語
• 【薬剤の相互作用と副作用 より安全な薬物療法を目指して】内科医がとくに注意すべき相互作用・副作用 症状の捉え方と回避法 抗生物質,抗菌薬
  菅原 満; 宮崎 勝巳, 内科, 88, 2, 298, 306, 2001年08月
  (株)南江堂, 日本語
• 肝再生時に活性増大 中性アミノ酸輸送システムA
  菅原 満, ファルマシア, 37, 7, 657, 658, 2001年07月
  (公社)日本薬学会, 日本語
• C6 glioma細胞におけるsystem Aアミノ酸トランスポーターの機能特性
  田中 一成; 杉浦 香織; 藤川 世梨; 岡田 直貴; 藤田 卓也; 山本 昌; 菅原 満; Leibach Frederick H.; Ganapathy Vadivel, 日本薬学会年会要旨集, 121年会, 3, 83, 83, 2001年03月
  (公社)日本薬学会, 日本語
• アミノ酸輸送担体システムAのクローニング及び機能解析
  菅原 満; Leibach Frederick H.; Ganapathy Vadivel; 宮崎 勝巳, 日本薬学会年会要旨集, 121年会, 3, 83, 83, 2001年03月
  (公社)日本薬学会, 日本語
• α1-酸性糖蛋白質とその不均一性体に対する光学異性体薬物の立体選択的結合性
  中川 勉; 伊藤 慎; 岸野 吏志; 小林 道也; 菅原 満; 井関 健; 宮崎 勝巳, 日本薬学会年会要旨集, 121年会, 3, 95, 95, 2001年03月
  (公社)日本薬学会, 日本語
• 院内製剤の安定性と使用期限に関する検討
  岩井 美和子; 志賀 弘康; 山下 恭範; 須田 範行; 武隈 洋; 岸野 吏志; 菅原 満; 宮崎 勝巳, 日本薬学会年会要旨集, 121年会, 3, 139, 139, 2001年03月
  (公社)日本薬学会, 日本語
• 生体肝移植患者におけるタクロリムスの体内動態(2)
  岸野 吏志; 志賀 弘康; 山下 恭範; 岩井 美和子; 菅原 満; 古川 博之; 藤堂 省; 宮崎 勝巳, 日本薬学会年会要旨集, 121年会, 3, 141, 141, 2001年03月
  (公社)日本薬学会, 日本語
• 高アンモニア血症に対する院内製剤供給後の治療成績評価
  山下 恭範; 岩井 美和子; 志賀 弘康; 岸野 吏志; 菅原 満; 宮崎 勝巳; 窪田 満; 小林 邦彦, 日本薬学会年会要旨集, 121年会, 3, 139, 139, 2001年03月
  (公社)日本薬学会, 日本語
• 薬剤師主導による心不全患者に対するカルベジロール投与プロトコールの構築
  清川 真美; 岸野 吏志; 深井 敏隆; 高木 眞弓; 米澤 一也; 小林 道也; 菅原 満; 宮崎 勝巳; 北畠 顯, 日本薬学会年会要旨集, 121年会, 3, 177, 177, 2001年03月
  (公社)日本薬学会, 日本語
• 北大病院における治験コーディネーター業務への取り組み
  橋本 あきら; 高田 陽美; 川合 真次; 荻野 修; 菅原 満; 浅野 弘恵; 木下 克恵; 竹内 ひとみ; 奥原 芳子; 宮崎 勝巳, 日本薬学会年会要旨集, 121年会, 3, 157, 157, 2001年03月
  (公社)日本薬学会, 日本語
• 消化管内pH変動を考慮した薬物吸収評価系の改良と消化管内薬物相互作用の評価
  小林 道也; 佐田 憲昭; 立浪 綾子; 坪井 瞳; 菅原 満; 井関 健; 宮崎 勝巳, 日本薬学会年会要旨集, 121年会, 3, 110, 110, 2001年03月
  (公社)日本薬学会, 日本語
• 病棟業務における薬剤師の職能 循環器科病棟におけるプレアボイド症例
  沖 洋充; 清川 真美; 深井 敏隆; 小林 道也; 荻野 修; 菅原 満; 宮崎 勝巳, 日本薬学会年会要旨集, 121年会, 3, 163, 163, 2001年03月
  (公社)日本薬学会, 日本語
• グルタミントランスポーターの機能解析
  菅原 満, 日本薬剤学会会報”生命とくすり”, 17, 4, 6, 7, 2001年
• 各種イオン型薬物の小腸基底膜透過に及ぼす膜電位の影響
  小林 道也; 吉田 英人; 菅原 満; 井関 健; 宮崎 勝巳, 薬物動態, 15, Suppl., S278, S278, 2000年09月
  (一社)日本薬物動態学会, 日本語
• 消化管内pH変動を考慮した吸収評価系によるヒト薬物動態予測
  佐田 憲昭; 菅原 満; 小林 道也; 中 正道; 井関 健; 宮崎 勝巳, 薬物動態, 15, Suppl., S278, S278, 2000年09月
  (一社)日本薬物動態学会, 日本語
• 塩酸イリノテカン(CPT-11),SN-38及びSN-38グルクロナイド定量法の確立 高速液体クロマトグラフィーによるラクトン閉環体及び総濃度の分離定量
  井藤 達也; 秦 温信; 高岡 和夫; 藤崎 博子; 菅原 満; 井関 健; 宮崎 勝巳, TDM研究, 17, 2, 121, 122, 2000年04月
  (一社)日本TDM学会, 日本語
• 薬物の生体内動態における構造相関(第49報) 消化管内pHの変動を考慮した難溶性薬物の消化管吸収評価法
  佐田 憲昭; 菅原 満; 小林 道也; 中 正道; 井関 健; 宮崎 勝巳, 日本薬学会年会要旨集, 120年会, 4, 51, 51, 2000年03月
  (公社)日本薬学会, 日本語
• ヒト小腸及びCaco-2細胞を用いた薬物吸収性評価 P-glycoproteinによる排出系の異同性
  早川 智久; 菅原 満; 井関 健; 宮崎 勝巳, 薬物動態, 14, Suppl., S170, S170, 1999年09月
  (一社)日本薬物動態学会, 日本語
• 消化管内pHの変動を考慮した薬物の消化管吸収評価法の確立
  佐田 憲昭; 菅原 満; 小林 道也; 中 正道; 井関 健; 宮崎 勝巳, 薬物動態, 14, Suppl., S217, S217, 1999年09月
  (一社)日本薬物動態学会, 日本語
• 高速液体クロマトグラフィーによる血清中ピルジカイニド定量法の確立
  井藤 達也; 新庄 一; 尾形 仁子; 中川 英久; 浜辺 晃; 菅原 満; 井関 健; 宮崎 勝巳, Journal of Cardiology, 34, Suppl.I, 308, 308, 1999年08月
  (一社)日本心臓病学会, 日本語
• 高速液体クロマトグラフィーによる血清中ピルジカイニド定量法の確立と有効濃度の検討
  井藤 達也; 福島 紘司; 尾形 仁子; 中川 英久; 浜辺 晃; 菅原 満; 井関 健; 宮崎 勝巳, TDM研究, 16, 2, 149, 150, 1999年04月
  (一社)日本TDM学会, 日本語
• 胃癌患者における胃切除術後の薬物吸収動態
  井藤 達也; 福田 由布子; 福島 紘司; 真鍋 邦彦; 秦 温信; 佐野 文男; 斎藤 正信; 菅原 満; 井関 健; 宮崎 勝巳, 日本薬学会年会要旨集, 119年会, 4, 146, 146, 1999年03月
  (公社)日本薬学会, 日本語
• 薬物の生体内動態における構造相関(第48報) 多剤排出蛋白を介したPSP(Phenolsulfonphthalein)の腎排泄
  小林 道也; 藤本 道夫; 西村 幸穂; 井上 悟; 菅原 満; 井関 健; 宮崎 勝巳, 日本薬学会年会要旨集, 119年会, 4, 9, 9, 1999年03月
  (公社)日本薬学会, 日本語
• イオン型薬物の消化管吸収に及ぼす膜表面電位の影響
  黒澤 恵; 菅原 満; 井関 健; 宮崎 勝巳, 薬物動態, 13, Suppl., S219, S219, 1998年10月
  (一社)日本薬物動態学会, 日本語
• ラット小腸H+依存性輸送タンパクの精製とその機能評価
  神谷 あや子; 小林 道也; 菅原 満; 井関 健; 宮崎 勝巳, 薬物動態, 13, Suppl., S268, S268, 1998年10月
  (一社)日本薬物動態学会, 日本語
• 12-4-A4 薬学部 4 年次学生に対する 1 ヶ月間病院実習の実施とその評価
  小林 道也; 深井 敏隆; 岸野 吏志; 川合 真次; 菅原 満; 宮本 剛典; 荻野 修; 井関 健; 宮崎 勝巳, 日本病院薬学会年会講演要旨集, 8, 90, 90, 1998年08月17日
  日本医療薬学会, 日本語
• 経腸栄養剤投与時における薬物吸収の変動
  井関 健; 浅子 恵; 金内 美妃; 菅原 満; 宮崎 勝巳, 薬剤学, 58, 150, 150, 1998年03月05日
  日本語
• 薬物の生体内動態における構造相関(第43報) LECラットにおけるフェノールスルホンフタレインの腎排泄挙動
  藤本 道夫; 小林 道也; 菅原 満; 井関 健; 宮崎 勝巳, 日本薬学会年会要旨集, 118年会, 4, 36, 36, 1998年03月
  (公社)日本薬学会, 日本語
• 高アンモニア血症治療薬フェニル酢酸製剤の生体内動態
  馬渕 朋美; 板垣 文雄; 橋本 あきら; 岸野 吏志; 菅原 満; 井関 健; 宮崎 勝巳; 郡 修徳; 長坂 博範; 窪田 満, 日本薬学会年会要旨集, 118年会, 4, 150, 150, 1998年03月
  (公社)日本薬学会, 日本語
• 薬物の生体内動態における構造相関(第42報) トリエンチンの尿中排泄におけるスペルミン輸送担体の寄与
  藤崎 博子; 小林 道也; 菅原 満; 井関 健; 宮崎 勝巳, 日本薬学会年会要旨集, 118年会, 4, 36, 36, 1998年03月
  (公社)日本薬学会, 日本語
• 薬物の生体内動態における構造相関(第44報) 難水溶性薬物の消化管吸収予測
  菅原 満; 古居 奈歩; 小林 道也; 井関 健; 宮崎 勝巳, 日本薬学会年会要旨集, 118年会, 4, 7, 7, 1998年03月
  (公社)日本薬学会, 日本語
• 薬物の生体内動態における構造相関(第45報) 薬物の消化管吸収に及ぼす膜表面電位の影響
  黒澤 恵; 菅原 満; 井関 健; 宮崎 勝巳, 日本薬学会年会要旨集, 118年会, 4, 7, 7, 1998年03月
  (公社)日本薬学会, 日本語
• 最近の文献情報より 薬物相互作用に関する文献情報（6）
  小林道也; 平野 剛; 菅原 満; 宮崎勝巳, 日病薬誌, 34, 1559, 1561, 1998年
• 最近の文献情報より 薬物相互作用に関する文献情報（4）
  菅原 満; 岸野吏志; 小林道也; 宮崎勝巳, 日病薬誌, 34, 969, 971, 1998年
• 最近の文献情報より 薬物相互作用に関する文献情報（3）
  平野 剛; 菅原 満; 岸野吏志; 宮崎勝巳, 日病薬誌, 34, 669, 671, 1998年
• 最近の文献情報より 薬物相互作用に関する文献情報（2）
  平野 剛; 小林道也; 菅原 満; 宮崎勝巳, 日病薬誌, 34, 347, 349, 1998年
• ペプチド輸送担体の再構築と構造解析
  米村 一洋; 神谷 あや子; 菅原 満; 井関 健; 宮崎 勝巳, 薬物動態 = Xenobiotic metabolism and disposition, 12, 195, 195, 1997年10月09日
  日本語
• 薬物の生体内動態における構造相関(第40報) 物理化学的測定値を用いた薬物の消化管吸収予測式の構築
  菅原 満, 日本薬学会年会要旨集, 117年会, 4, 13, 13, 1997年03月
  (公社)日本薬学会, 日本語
• EXCRETION MECHANISM OF POLYAMINE DRUGS FROM THE KIDNEY
  小林 道也; 藤崎 博子; 菅原 満; 井関 健; 宮崎 勝巳, 薬物動態, 12, 76, 77, 1997年
  The mechanism of renal excretion of polyamine drugs has been investigated in vivo and in vitro. Trientine clearance (CLtri) in the rat was significantly faster than creatinine clearance (CLcr). However, CLtri decreased to almost the same level as the CLcr when trientine and the same number of moles of copper ions were administered simultaneously to the rat. To clarify this active excretion system for trientine, the uptake of trientine and spermine, a physiological polyamine, was investigated using the rat renal proximal tubular brush-border membrane vesicles (BBMV). An outwardly directed Na⁺ gradient remarkably enhanced the uptake of these polyamine compounds, however, it did not affect the uptake of trientine-Cu complex. The Na⁺-dependent uptake of [³H]spermine was completely inhibited by spermine, trientine and tetraethylenepentamine. On the contrary, physiological polyamines (putrescine and spermidine) which have 2 or 3 amino-groups, and aminoglycoside antibiotics which have 4 or 5 cationic amines, did not affect the uptake of spermine in the presence of an outward Na⁺ gradient. These results suggest that the mechanism contribute to the renal tubular secretion of spermine is a Na⁺/spermine antiport system, and this transporter recognizes the straight-chain polyamine drug which has more than 4 amino-groups in its molecule., The Japanese Society for the Study of Xenobiotics, 英語
• Effect of cationic drugs on Na⁺-dependent carrier mediated transport and its evaluation
  加藤 雅也; 菅原 満; 小林 道也; 井関 健; 宮崎 勝巳, 薬物動態, 12, 74, 75, 1997年
  We investigated the effect of cationic drugs on carrier mediated transport using in vitro and in situ techniques. The initial uptake of glucose, alanine and glutamic acid by rat intestinal brush border membrane vesicles(BBMV) was distinctly inhibited by imipramine in the presence of Na⁺ gradient, but not inhibited in the absence of Na⁺ gradient. This result indicates that imipramine inhibited carrier mediated transport. Imipramine exhibited competitive inhibition with respect to Na⁺ concentration, while exhibited non-competitive inhibition with respect to glutamic acid concentration. This finding suggests that imipramine affected carrier mediated transport by competitive inhibition to Na⁺ binding site of the carrier. On the other hand, in situ single pass perfusion method showed that absorption of alanine was also inhibited by imipramine and other cationic drugs in the presence of Na⁺, but not inhibited in the absence of Na⁺. This result is agreement with that of BBMV study. The inhibition of carrier mediated alanine transport by cationic drugs in BBMV corresponded to that in situ. There was a relatively good correlationship between the BBMV study and in situ perfusion study in the inhibitory effects., The Japanese Society for the Study of Xenobiotics, 英語
• 薬物の物理化学的測定値による新規消化管吸収予測法の検討
  武隈 洋; 菅原 満; 山田 晴美; 小林 道也; 井関 健; 宮崎 勝巳, 薬物動態 = Xenobiotic metabolism and disposition, 11, S108, S109, 1996年09月20日
  A predicting method for the intestinal absorption of drugs by measuring their physicochemical properties such as organic solvent / buffer partition coefficient, molecular volume (molecular weight), hydrogen bonding and diffusion rate across silicone membrane was investigated. A poor correlation was observed between absorption rate from intestinal lumen and organic solvent / buffer partition coefficient of tested drugs. On the contrary, good regression coefficient (R = 0.801) was obtained when the three factors (molecular weight, hydrogen bonding, and permeation rate across silicone membrane) were used. On the other hand, the excellent regression was observed when the drugs were classified into anionic, cationic, and neutral groups. These results suggest that the permeation rate across silicone membrane, molecular weight, and hydrogen bonding are valuable measures for predicting the absorption behavior of drugs. Moreover, an additional parameter which reflects the effect of the molecular charge will be necessary., The Japanese Society for the Study of Xenobiotics, 日本語
• 薬物の生体内動態における構造相関(第36報) グルタミン酸の小腸刷子縁膜透過に及ぼすカチオン型薬物の影響
  菅原 満; 加藤 雅也; 小林 道也; 井関 健; 宮崎 勝巳, 日本薬学会年会要旨集, 116年会, 4, 38, 38, 1996年03月
  (公社)日本薬学会, 日本語
• 薬物の生体内動態における構造相関(第34報) ポリアミン類のラット腎刷子縁膜透過機構
  小林 道也; 田辺 亮; 菅原 満; 井関 健; 宮崎 勝巳, 日本薬学会年会要旨集, 116年会, 4, 46, 46, 1996年03月
  (公社)日本薬学会, 日本語
• 薬物の生体内動態における構造相関(第35報) ラット腎セフチブテン輸送担体の再構成
  菊地 崇行; Naasani Imad; 菅原 満; 井関 健; 宮崎 勝巳, 日本薬学会年会要旨集, 116年会, 4, 46, 46, 1996年03月
  (公社)日本薬学会, 日本語
• アニオン型薬物の消化管吸収予測式の構築 物理化学的測定値によるsimulation
  菅原 満, 薬物動態, 10, Suppl., 317, 317, 1995年10月
  (一社)日本薬物動態学会, 日本語
• 薬物の生体内動態における構造相関 (第30報) スパルフロキサシンの小腸刷子縁膜透過に及ぼす膜表面電位の効果
  辻華里; 平野剛; 宮崎正三; 高田昌彦; 菅原満; 井関健; 宮崎勝巳, 日本薬学会年会要旨集, 115th, Pt 4, 102, 1995年03月
  日本語
• イオン性薬物の小腸刷子縁膜透過におよぼす膜表面電位の影響
  菅原 満, 薬物動態, 9, Suppl., 62, 65, 1994年10月
  (一社)日本薬物動態学会, 日本語
• キノロン系抗菌剤の消化管吸収および腎排せつ機構
  平野剛; 宮崎正三; 高田昌彦; 菅原満; 井関健; 宮崎勝巳, 薬物動態, 9, Suppl, S110-S113, 113, 1994年10月
  Transport mechanisms of intestinal absorption and renal excretion for new-quinolone antibactrial agents were investigated. The absorption of enoxacin (ENX) from rat jejunal loop exhibited a pH-dependent profile. The greater absorption at acidic pH of medium was observed, and ciprofloxacin (CPFX) reduced the ENX plasma concentration after simultaeously oral administration to rat. In the uptake experiments by the intestinal brush-border membrane vesicles (BBMV), initial rate and time-course of ENX and sparfioxacin (SPFX) were significantly dependent on the pH of medium (pH5.5 > pH7.5), and CPFX inhibited compleately the pH dependent uptake of ENX. The ion diffusion potential affected the uptake of these drugs by the intestinal BBMV. On the other hand, ENX uptake by the renal BBMV was contributed by not only the ionic diffusion potential but also the cation-H⁺ antiport system of organic cation secretion., The Japanese Society for the Study of Xenobiotics, 日本語
• The Transport Mechanism of an Organic Cation, Disopyramide, by Brush-Border Membranes. : Comparison Between Renal Cortex and Small Intestine of the Rat.
  TAKAHASHI YASUSHI; ITOH TATSUYA; KOBAYASHI MICHIYA; SUGAWARA MITSURU; SAITOH HIROSHI; ISEKI KEN; MIYAZAKI KATSUMI; MIYAZAKI SHOZO; TAKADA MASAHIKO; KAWASHIMA YOSHIAKI, 岐阜藥科大學紀要, 43, 84, 84, 1994年06月30日
  岐阜薬科大学, 英語
• EFFECT OF MEMBRANE SURFACE POTENTIAL ON THE PERMEATION OF IONIC DRUGS THROUGH THE INTESTINAL BRUSH-BORDER MEMBRANE
  菅原 満; 小林 道也; 井関 健; 宮崎 勝巳, 薬物動態, 9, 62, 65, 1994年
  The effect of membrane surface potential on the permeation of ionic compounds through the intestinal brush-border membrane was investigated using uptake experiments by brush-border membrane vesicles (BBMV) and large unilamellar vesicles (LUV). The uptake of anionic compounds (ceftibuten, cefixime, benzylpenicillin etc.) was decreased with increase of membrane surface negativity. On the other hand, the uptake of a cationic compound, tryptamine, was increased with increase of surface negativity. The uptake of these ionic compounds was well correlated with membrane surface potential of BBMV and LUV monitored by ANS. These results suggest that the permeation of ionic compounds through the intestinal brush-border membrane is dependent on the membrane surface potential. The mechanism of inhibitory effect on the uptake among these Ionic compounds was also examined from the viewpoint of changes in the membrane surface potential. The inhibitory effect of tetracaine and imipramine on the uptake of tryptamine was well correlated with changes in the membrane surface potential induced by these organic cations. Similar relation was observed in the inhibitory effect of flufenamic acid on the uptake of cefixime. These results suggest that changes in the membrane surface potential contribute to the inhibitory effect on the uptake of these Ionic compounds., The Japanese Society for the Study of Xenobiotics, 英語
• MECHANISM OF POLYAMINES TRANSPORT BY RAT INTESTINAL EPITHELIAL CELL MEMBRANE
  小林 道也; 菅原 満; 井関 健; 宮崎 勝巳, 薬物動態, 8, 743, 746, 1993年
  The uptake characteristics of polyamines have been investigated using rat intestinal brush-border membrane vesicles (BBMV). The uptake of these polyamines into BBMV was high and the order of uptake activity was spermine > spermidine > putrescine, and the medium pH affected remarkably the uptake of polyamines (pH 7.5 > pH 5.5). We have also examined the binding behavior of polyamines to liposome, and the similar phenomenon such as uptake activity and pH-dependency was observed. An inward Na⁺ gradient did not stimulate the initial uptake of all polyamines. The uptake rate of spermine and spermidine were saturable (Km = 30.4 and 148.1 μM, respectively), but putrescine was not saturable up to 8 mM. Spermine competitively inhibited the uptake rate of spermidine (Ki = 33.8 NM), while putrescine inhibited spermidine non-competitively (Ki = 3.28 mM). However, intravesicular spermine exhibited no trans-stimulation effect on the uptake of spermine and spermidine. Therefore, the polyamines were considered to be taken up via a passive diffusion mechanism rather than the carrier-mediated systems. The interaction between polyamine and inner-layer acidic phospholipids of BBMV might play an important role as a driving force of the polyamine uptake mechanism. Furthermore, the uptake mechanism of polyamine was different from cationic compounds because valinomycin-induced potassium diffusion potential (inside negative) did not affect the uptake of polyamines., The Japanese Society for the Study of Xenobiotics, 英語
• 薬物の生体内動態における構造相関(第1報) β-ラクタム系抗生物質の消化管吸収機構
  菅原 満, 日本薬学会年会要旨集, 111年会, 4, 137, 137, 1991年03月
  (公社)日本薬学会, 日本語
• βラクタム系抗生物質の小腸刷子縁膜透過性
  菅原 満, 日本薬学会年会要旨集, 109年会, 2, 76, 76, 1989年03月
  (公社)日本薬学会, 日本語